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Abstract 
Mutation or aberrant expression of protein kinase domains can lead to the 
development of a variety of cancers, which is why these proteins have become the 
focus of many clinical therapies.  ~10% of the human kinome have been classified as 
pseudokinases, because they lack at least one of the highly conserved motifs that 
were originally used to help define the protein kinase superfamily. Due to these 
deviations from the normal situation, pseudokinases were originally predicted to be 
catalytically inactive, often based solely upon bioinformatic sequence alignment 
evidence. However, the discovery of pseudokinases that can hydrolyze or bind to 
ATP either at, or below, the nucleotide concentrations typically found in cells, 
suggests that each pseudokinase requires a thorough and individual biochemical 
analysis using a combination of techniques in order to reveal its biological function.  
Trib2 and NOK are two pseudokinases that contain a highly atypical ‘DFG’ metal 
ion binding motif, when compared to canonical kinase domains, and both are 
implicated in a variety of human cancers. Trib2 is predicted to be a Ser/Thr 
pseudokinase and is very closely related to the Trib1 and Trib3 pseudokinases in 
humans, and to the Tribbles pseudokinase that was originally characterized in the 
model fruit fly Drosophila Melanogaster. Along with an E3-ligase, Trib2 is required 
to target the tumor-suppressing transcription factor C/EBP for degradation in cells. 
The results presented in this thesis include the first demonstration of a Mg
2+
 ion-
independent ATP binding and autophosphorylation function for Trib2 in vitro. 
NOK is a pseudokinase that exhibits similarity to the RPTK sub-family, however it 
does not have a detectable ligand-binding domain, but does contain a putative 
transmembrane domain that lies adjacent to the pseudokinase domain. 
Overexpression of NOK mRNA has been observed in a variety of cancers, but its 
mode of action is still unclear. I describe in this thesis that NOK localizes to the 
nuclear membrane of cells and contains a localization sequence that resembles the 
EGFR Nuclear Localization Sequence, which translocates to the nucleus via the 
Inner Nuclear Membrane. 
Work described in this thesis also describes the development of tools to pave the way 
for future cellular analysis of both Trib2 and NOK, which will reveal whether these 
pseudokinases could be exciting, and novel drug targets in human diseases. 
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CHAPTER 1. Introduction  
1.1 Protein Kinases 
Kinase domains transfer the terminal phosphate group from a donor (usually 
ATP, rarely GTP) to a protein-based substrate and this can transduce an extracellular 
signal towards the nucleus by the propagation of a kinase cascade, e.g. the MAPK 
pathway (Figure 1.1A). There are a variety of substrates that can be phosphorylated, 
and protein kinases, of which there are 518 in the human protein kinome (Manning 
et al., 2002), are by far the best studied class of kinase. To elicit a cellular response, 
protein kinases usually hydrolyse the gamma phosphate from ATP and transfer it to 
a substrate residue, which changes its charge and structure (Vulpetti and Bosotti, 
2004).  To perform this function, a set of motifs that are conserved throughout the 
human kinome have evolved and the presence of these motifs in polypeptides 
classifies them as kinase domains. On the other hand, protein phosphatases act to 
hydrolyse the phosphorylated amino acid, reverting the protein substrate to an 
alcohol (OH) group and releasing a phosphate group (PO4
3-
, Figure 1.1B). In 
addition to modification of alcoholic side chains on proteins, lipids are also 
phosphorylated by related kinases termed lipid kinases, e.g. PI3 kinase (Foster et al., 
2003, Cheek et al., 2005) or sphingosine kinase (Plano et al., 2014).  Modification of 
sugars by phosphorylation is also common, e.g. glucokinase phosphorylates glucose 
(Peter et al., 2011). The structure of human protein kinase domains has been 
analysed using a variety of approaches, including X-ray crystallography and NMR 
spectroscopy (Shin et al., 2011, Toms et al., 2013). 
Protein kinase domains are bilobal in structure, with a small ‘N-lobe’, which 
comprises a -sheet that consists of 5 anti-parallel strands and an important helix 
termed the -C helix, which together form the ATP-binding surface, whilst the 
predominantly  helical C-lobe consists of the residues directly involved in catalysis. 
The active site, where ATP and the protein substrate binds, is located in a cleft 
between the two domains, with the motifs that are critical for stabilizing ATP and 
hydrolyzing the phosphate group lining the surface of the cleft (Figure 1.2A) 
(Hantschel and Superti-Furga, 2004, Hanks and Hunter, 1995, Manning et al., 2002). 
 21 
 
The best understood motifs that are conserved throughout the human kinome, 
which together define the protein kinase domain are, from N- to C-terminus, a 
glycine-rich loop, a conserved lysine in the 3 sheet, a conserved glutamate within 
the C helix, a catalytic loop, a magnesium ion binding loop, (Figure 1.2B) and an 
Asp residue in the otherwise hydrophobic F helix (Figure 1.2A). 
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Figure 1.1 Protein kinases phosphorylate substrates and trigger kinase cascades A) 
A cartoon of the ERK pathway stimulated by the binding of a growth factor (GF) to a 
monomeric RPTK, which dimerises and stimulates trans-receptor autophosphorylation, 
causing interacting proteins to bind, which activates further intracellular proteins and 
kinases, propagating the signal into the cell and often towards the nucleus. B) A simplified 
diagram showing the opposing functions of protein kinases and phosphatases. 
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Figure 1.2 Conserved kinase residues annotated on the kinase domain of EGFR A) 
The EGFR kinase domain (PDB ID 1M14) with the glycine-rich loop highlighted in blue, the 
3 motif highlighted in cyan, the conserved glutamate residue in the C helix in green, the 
catalytic loop in yellow, the magnesium ion binding residue in orange and the Asp of the F 
helix in red. The activation loop situated between the DFG and APE motifs is marked by the 
arrow and the helices and sheets are numbered accordingly B) A comparison of the 
conserved kinase domain motifs for the two canonical kinases PKA and EGFR, and the 
three pseudokinases HER3 STRADand VRK3. The conserved residues are highlighted in 
red and the secondary structures represented above the sequences. Beta sheets are a 
green arrow and helices are pink cylinders.  
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1.2.1. The glycine-rich loop  
The consensus sequence of GxGxxG forms part of a -turn- motif between 
the 1 and 2 strands, with the second Gly residue considered to be the most 
important for functional ATP binding. The purpose of the glycine-rich loop is to 
bind and expose the -phosphate of ATP to the solvent for catalysis. The glycine-rich 
loop is inherently flexible and the presence of the Gly residues minimizes steric 
hindrance so that the loop can clamp down on ATP, placing the gamma phosphate in 
an accessible position for phosphotransfer. The flexibility of the loop also enables 
hydrogen bonds to form between the backbone and ATP, orientating it in the binding 
pocket. By correctly orientating ATP, the glycine-rich loop can control the rate of 
phosphotransfer and directly affect ATP affinity (Barouch-Bentov et al., 2009, 
Scheeff et al., 2009, Taylor and Kornev, 2010). 
1.2.2 The 3 motif conserved lysine  
A positively charged Lys residue that is conserved in the 3 sheet of 
canonical kinases coordinates the α and β phosphate groups of ATP, which stabilizes 
and correctly aligns ATP (Hanks and Hunter, 1995). Mutation of this Lys to Arg, or 
more effectively, an uncharged side chain reduces the activity of many protein 
kinases (Iyer et al., 2005b), and is often used to create inactive protein kinase 
mutants. The hydrophobic motif, in which the conserved Lys is typically located 
(VAIK) also stabilises the adenine ring of ATP (Taylor and Kornev, 2010), however, 
it has been hypothesised that the lysine might be involved with catalysis rather than 
ATP binding because a 3 lysine mutation in pp56lck could still bind to ATP but 
transfer of the phosphate group to a substrate was impaired (Carrera et al., 1993). 
Currently, the lysine residue is thought to be involved in an ionic interaction with 
ATP in most protein kinases (Adams, 2001), in addition to the formation of a critical 
salt bridge (see below). 
1.2.3 A conserved glutamate in the C helix 
The C helix of many kinase domains contains a conserved glutamate residue, 
which forms a salt-bridge with the conserved 3 Lys residue only when the kinase is 
in a catalytically active conformation. This alignment of residues also aids the 
correct positioning of the ATP into the correct orientation for catalysis (Huse and 
Kuriyan, 2002, Taylor and Kornev, 2011).  The conserved Glu residue is present in 
most, but not all, kinases with catalytic activity, although its precise position in the 
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N-terminal C helix varies, and it is not embedded in a specific amino acid motif, 
making it hard to identify specifically using bioinformatics. 
1.2.4 The catalytic loop 
The motif that contains the amino acid residues HxDxxxxN is termed the 
catalytic loop. The Asp residue in this motif acts as the catalytic base and accepts a 
proton from the OH group of the protein substrate phosphate acceptor group 
(typically Tyr/Ser/Thr) (Huse and Kuriyan, 2002). The catalytic Asp is, in part, 
orientated by the Asn at the end of the motif, which also helps to coordinate one or 
two Mg
2+
 ions in collaboration with the DFG motif (see below). Mutations in the 
Asn residue have historically been used to create inactive kinases, often by mutating 
the residue to Ala, since the divalent cation(s) also stabilise the highly negative 
charge of the three ATP phosphate groups and loss of this interaction abolishes 
kinase activity (Hanks and Hunter, 1995). In addition, the His that begins the motif 
(HxD) makes hydrophobic contacts between the Phe from the DFG motif (and builds 
the hydrophobic spine of active kinases) and also interacts with the DFG Asp 
(Kornev et al., 2006). Finally, the ‘x’ residue in the HxD motif is often an Arg, 
especially in active kinases that are regulated by phosphorylation, since it interacts 
with phosphorylated amino acids in the activation loop (Bayliss et al., 2012). 
1.2.5 The magnesium ion binding loop or ‘DFG’ motif 
The main role of the Mg
2+
 ion binding loop, which is also termed the DFG 
motif, is to coordinate a second Mg
2+
 ion, which has the same role as the first bound 
by the Asn described above, to stabilize the negatively charged phosphates of ATP. 
Mutation of the Asp in the DFG motif to either Asn or Ala (both uncharged and 
unable to bind metals), is perhaps the best way to inactivate canonical protein 
kinases, which usually require ATP/Mg complexes for activity (Haydon et al., 
2003).  In addition, the conserved Phe in the DFG motif also makes hydrophobic 
contacts with the residues in the catalytic loop, and helps to position the αC helix 
correctly to stimulate formation of the Lys-Glu salt bridge (Kannan and Neuwald, 
2005). The Gly of DFG helps facilitate the correct positioning of the Asp of the DFG 
motif, explaining the very strong conservation of the complete DFG motif in most 
active kinases. When the kinase is in an inactive conformation, a hydrogen bond 
between the Gly and the Asp is disrupted and the Asp can move by as much as 140˚ 
without steric hindrance and in this position is unable to coordinate magnesium ions 
(Kornev et al., 2006). Rotational movement of the kinase domain is a way of 
 26 
 
switching the kinase from an inactive conformation to an active one. The ‘DFG-in’ 
conformation, when the Phe is placed in the ATP binding pocket, is typically the 
conformation found in an ‘active’ kinase, whereas an ‘inactive’ kinase, ‘DFG-out’ 
conformation does not have the Phe residue within the ATP binding site, but it has 
been “flipped” out (Taylor and Kornev, 2010, Xu et al., 2011, D'Abramo et al., 
2014). 
1.2.6 The F helix 
The Regulatory (Reg) spine of the kinase domain is made up of hydrophobic 
amino acids that are not related in sequence, but form a column-type structure in 
three dimensions (Taylor and Kornev, 2010). The Reg spine is anchored to the N 
terminus of the hydrophobic F-helix, whilst the Catalytic (Cat) spine terminates at 
the C terminus of the F-helix. The spines constitute hydrophobic spatial motifs and 
the Reg spine can be assembled or disassembled by varying the flexibility of the αC 
helix and activation loop. The Cat spine is formed from the Ala residue in the VAIK 
motif in the β3 sheet and this interacts with the adenine ring of ATP which forms 
part of the Cat spine.  The catalytic loop is kept rigid by its interactions with the F-
helix.  The F helix contains only one charged Asp residue, and this interacts with 
the backbone of the catalytic loop. The F-helix and the two spines coordinate and 
connect the different segments of the kinase and are therefore key during activation 
and inactivation cycles undergone by the kinase domain (Taylor and Kornev, 2010, 
Kornev et al., 2008). 
1.2 Common phosphate acceptor residues of protein substrates 
The most widely studied protein kinases phosphorylate either tyrosine (Tyr) 
or serine and threonine (Ser/Thr) residues, or Ser, Thr and Tyr residues (dual-
specificity kinases) (Douville et al., 1994), although there are examples of kinases 
that phosphorylate arginine or histidine residues as substrates in vitro, these are not 
closely related to the eukaryotic protein kinases (Cheek et al., 2002).  The diverse 
loops on the surface of the kinase are what provides the conserved fold with its 
different substrate specificities (Taylor and Radzioandzelm, 1994).  For example, 
simple analysis of the catalytic loop sequences from human kinases can be used to 
help determine whether phosphorylation substrates are likely to be Tyr residues or 
Ser/Thr residues. The catalytic motif of tyrosine kinases have the common consensus 
sequence of RDx(A/R)A(A/R)N, whilst Ser/Thr kinases often possess an RDxKxxN 
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motif, which also resembles the consensus motif of dual-specificity kinases  
(Okamoto et al., 2014, Hanks et al., 1988, Lindberg et al., 1992). 
1.3  Kinase domain activation 
There are a variety of methods that kinases use to become fully active. 
cAMP-dependent protein kinase (PKA), which is termed an ‘RD kinase,’ due to the 
Arg residue that is adjacent to the catalytic Asp in the HRD motif, is activated by the 
phosphorylation of a Thr197 residue located within its activation loop. The 
activation loop is a highly flexible loop that is situated between the two tripeptide 
sequences DFG and APE in catalytic subdomain VII and VIII, and a key site of 
phosphoregulation. Following phosphorylation of Thr197, the phosphate group 
coordinates the C helix (His 87), the Catalytic loop (Arg165), the 9 sheet (Lys189) 
and the activation loop (Thr195) and the Km for ATP decreases 7 fold (Steichen et 
al., 2010), reflecting the appearance of the active conformation.  
Tyrosine kinases are also activated by phosphorylation. For example, both 
the Fibroblast Growth Factor Receptor (FGFR) and Insulin-like Growth Factor 
Receptors autophosphorylate following dimerisation of the receptor domains. The 
autophosphorylation relieves the inhibition caused by the activation loop, which 
occludes the active site for the protein substrate to bind to (Lemmon and 
Schlessinger, 2010).  PDGFR family member, c-Kit is inhibited by its 
juxtamembrane domain, not its activation loop. It is not phosphorylation of a Tyr 
residue in the activation loop of c-Kit that destabilises the autoinhibitory interactions 
but instead the phosphorylation of 14-22 Tyr residues in the c-Kit juxtamembrane 
domain, the kinase insert domain (a variable length of sequence between the αC and 
αD helices in the C-terminal domain found in many RPTKs), the C-terminal domain 
and the activation loop (DiNitto et al., 2010, Lemmon and Schlessinger, 2010). It is 
not one phosphorylation event that causes this dynamic shift, as observed for FGFR, 
but a combination of phosphorylation events that together causes activation. The 
equivalent residue in c-Kit (Y823) to the FGFR activating tyrosine is 
phosphorylated, but only after the kinase has been 90% activated by phosphorylation 
elsewhere. 
Kinase domains can also be autoinhibited, not by occlusion of the substrate 
binding site with the C-terminal tail (a region outside the catalytic domain), but 
through binding interactions that lock the protein into an inactive conformation. For 
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example, the tyrosine kinase Src has an SH2 group that binds to phosphorylated 
Tyr527, which is phosphorylated by Csk. An SH3 group in the C-terminal tail of Src 
binds to a polyproline type-II helix which is located between the kinase domain and 
the SH2. This positions the αC helix in a conformation where a salt bridge cannot 
form between the conserved C-helix Glu residue and the 3 sheet conserved Lys, 
and so ATP is incorrectly orientated. The SH2 interaction with phosphotyrosine 
stabilizes this conformation (Hubbard, 1999). 
 Other kinases require the presence of separately encoded interacting proteins 
to attain full catalytic activity along with phosphorylation.  Cyclin-dependent kinases 
for instance, require a specific cyclin protein to become activated. In cells, 
monomeric CDK2 is inactive and requires cyclin E at the G1/S transition and cyclin 
A throughout S phase for activity. CDK2 activity is inhibited by phosphorylation of 
either Tyr15 or Thr14 by Wee1 and this is independent of cyclin status, whereas the 
activating phosphorylation of Thr 160, in the activation loop, requires the presence 
of the cognate cyclin molecule. However, the phosphorylated complex is inactive 
until the inhibitory phosphates at either Thr14 or Tyr15 are removed by the CDC25 
phosphatases (Bartova et al., 2004). 
Another protein that requires the presence of an additional protein to achieve 
full catalytic activity is Aurora A. Phosphorylation of Aurora A Thr288 in the 
activation loop is crucial for catalytic activity (Bayliss et al., 2003), however 
catalytic activity is increased in vitro following TPX2 binding (Eyers et al., 2003) 
with the presence of TPX2 and phosphorylation of Thr288 acting synergistically to 
activate Aurora A (Dodson and Bayliss, 2012). The phosphorylated activation 
segment of Aurora A lies in an inactive conformation when TPX2 is absent and 
binding to TPX2 induces a 10 Å shift of the phosphorylated Thr288 from an exposed 
to a buried position, which prevents dephosphorylation of the activating phosphate 
group by protein phosphatases (Bayliss et al., 2003). 
Other kinases however, such as the EGFR family, do not employ 
phosphorylation-mediated switches for catalytic activation but are moved into an 
active conformation by allosteric interactions following asymmetrical dimerisation 
after EGF binding. The juxtamembrane domains of each EGFR member of the dimer 
form a ‘juxtamembrane latch’ between the C-terminal half of the juxtamembrane 
segment (JM-B) from the ‘receiver kinase’ N-lobe to the ‘activator kinase’ C-
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terminal lobe along with short anti-parallel helices forming by both the activator and 
receiver JM-A segments (N-terminal sections of the juxtamembrane domains) that 
link to the C terminal sides of the dimeric transmembrane helices. Extracellular 
ligand binding induced dimerisation stabilizes the helical JM-A dimer, which in turn 
stabilizes the kinase domain dimer, activating the kinase domain. Ligand-
independent activation by alternative dimers can be prevented by the C-terminal tails 
inhibiting the formation of the ‘juxtamembrane latch’ creating a dimer of inactive 
kinase domains (Jura et al., 2009a). 
1.4 Protein kinases and cancer 
Most tumors appear after more than one genetic mutation has accumulated in 
a cell.   However, a single mutation in a gene that encodes a protein kinase domain 
can significantly increase the oncogenicity of the cells by either promoting cell 
proliferation or reducing tumour suppressor function (Tsatsanis and Spandidos, 
2000). A few of the many kinases implicated in human cancers are briefly described 
below. 
ErbB2 is a Receptor Protein Tyrosine Kinase that is overexpressed in ~30% 
breast cancers and these often have poor clinical outcomes, with overexpression of 
ErbB2 implicated in increased metastasis of tumors and therapeutic resistance (Yu 
and Hung, 2000). The extracellular portion of ErbB2, whose kinase activity is 
regulated in conjunction with the pseudokinase ErbB3 (HER3, see below) is a target 
for the therapeutic antibody Herceptin (Nahta and Esteva, 2006). 
The fusion protein BCR-Abl drives the development of chronic myelogenous 
leukemia (CML). The fusion is caused by the translocation of the Abl locus on 
chromosome 9 to the BCR locus on chromosome 22, t(9;22)(q34;q11) (Cilloni and 
Saglio, 2012). This fusion halts the translocation of BCR-Abl to the nucleus and 
prevents Abl induced apoptosis (Vigneri and Wang, 2001). The fusion kinase 
initiates downstream proliferative pathways by being in a constitutively active 
conformation and so phosphorylates more substrates and also increasing 
autophosphorylation, which subsequently recruits more adapter molecules leading to 
feed-forward activation (Salesse and Verfaillie, 2002). 
 BRAF is a Ser/Thr kinase that lies at the head of the ERK signaling pathway 
(Figure 1.1A) and phosphorylates the dual-specificity kinases MEK1/2, which in 
turn activates ERK1/2 by phosphorylation on Tyr and Thr residues.  Multiple ERK 
targets are known, and include other kinases and transcriptional programmes 
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associated with proliferation. Inappropriate regulation of this pathway can trigger the 
onset of tumourigenesis, due to uncontrolled cell growth and/or lack of apoptosis. 
Ninety percent of BRAF mutations that drive cancers occur in the residue Val 600, 
which is commonly mutated to a glutamate in melanoma patients (Qin et al., 2012). 
This can increase its activation 500 fold, causing constitutive downstream activation 
of the MEK/ERK even in the absence of extracellular signals (Cantwell-Dorris et al., 
2011). This example of kinase activation by mutation vividly illustrates how subtle 
changes in the composition of kinase catalytic domains can change their activity so 
markedly, and not surprisingly, these mutant kinases are excellent drug targets. 
1.5  Protein kinases as drug targets 
Small molecules that target kinases have become a major research focus for 
developing new cancer therapeutics, with ~150 being developed for clinical 
exploitiaton (Fabbro et al., 2012).  Small molecules that target the ATP binding 
pocket can be classified as either Type I or Type II inhibitors. Type I inhibitors bind 
to the ATP binding site when it is in an ‘active’ conformation and the DFG motif can 
coordinate a magnesium ion and the Phe places the C helix and activation loop into 
a position primed for catalysis (Fabbro et al., 2012). The inhibitor mimics the 
binding of the adenine ring of ATP by forming between 1-3 hydrogen bonds with the 
hinge region residues (Zhang et al., 2009, Liu and Gray, 2006). Dasatinib is a type I 
inhibitor, which binds to the ATP binding site of the active Abl kinase domain. The 
aminothyazole of Dasatinib sits into the space that is normally occupied by the ATP 
adenine ring, whilst two hydrogen bonds form between Dasatinib and Met318 (one 
to the carbonyl oxygen and one to the amide nitrogen), whilst another hydrogen bond 
forms between the oxygen hydroxyl oxygen from the Thr315 sidechain (Tokarski et 
al., 2006) which is the Abl gatekeeper residue (Weisberg et al., 2010), and Dasatinib 
can bind to the majority of Abl mutants apart from the Abl T315I gatekeeper residue 
mutation (Tokarski et al., 2006). 
Another example of an inhibitor that binds to BCR-Abl is Imatinib 
(Glivec/Gleevec), which in 2001 was the first kinase inhibitor to be clinically 
approved. Imatinib is a Type II inhibitor that can only bind to the ATP active site 
and gain access to the adjacent hydrophobic pocket when the DFG motif is in an 
‘inactive’ conformation (DFG-out) (Treiber and Shah, 2013, Kufareva and Abagyan, 
2008). Hydrogen bonds formed between Imatinib and the hinge region Met318 
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backbone NH, the gatekeeper Thr315 side-chain hydroxyl, the C helix Glu286 and 
the backbone Asp381 from the DFG motif. Ile360 and His361 make contacts with 
the tail of imatinib and the pyrimidine ring forms -stacking interactions with the P-
loop Tyr253 and the DFG Phe382. Hydrophobic residues are exposed following the 
movement of the DFG motif into the ‘out’ conformation and the benzamide group of 
Imatinib sits in this pocket (Blanc et al., 2013), preventing kinase activation and 
activity. 
1.6  Protein pseudokinases 
Pseudokinases are so called because they lack one or more of the motifs 
discussed above that are generally conserved throughout kinase domains, and which 
are found in nearly all catalytically active protein kinases (Manning et al., 2002). 
Approximately 10% of the human kinome are termed pseudokinases, with 
approximately 50 being documented (Eyers and Murphy, 2013, Reiterer et al., 
2014). When their locations are highlighted on the human kinome phylogenetic tree, 
it can be seen that each of the ~7 major subfamilies of kinases contains at least 1 
pseudokinase (Boudeau et al., 2006). This suggests that pseudokinases evolved 
independently from one another and explains why different pseudokinases have 
evolved deviations in the different motifs that are associated with ATP binding and 
catalysis (Manning et al., 2002, Boudeau et al., 2006).    
Pseudokinases were initially predicted to be ‘catalytically inactive’ because 
they lacked either the 3-sheet Lys residue, the catalytic Asp of the catalytic loop, or 
the Asp residue located within the DFG motif that usually binds a magnesium ion 
(Boudeau et al., 2006). Depending upon their polypeptide sequence, pseudokinases 
were grouped as either modulators of other catalytic domains, which included 
proteins that contained a pseudokinase domain alongside a second ‘active’ domain 
(such as the JAK kinases), or if the pseudokinases retained a high similarity to a 
protein kinase domain, then they were grouped together. A final group consisted of 
polypeptides that all had a lower sequence similarity to canonical protein kinases, 
and were considered to be inactive based on this difference (Manning et al., 2002). 
Following initial annotation and analysis of the human genome in 2001, the 
human kinome was loosely divided into kinases and pseudokinases in 2002 
(Manning et al., 2002). However, additional sub-groups of pseudokinases have 
recently been added, based on further sets of experimentally-identifiable criteria. For 
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example, pseudokinases have been grouped together depending upon which of the 
important catalytic residues they lack, either individually, or in combination, 
amongst the DFG Asp, HxD catalytic Asp, and the conserved Lys in the 3 sheet 
(Boudeau et al., 2006).  Throughout the eukaryotic protein kinome, each of these 
motifs are highly conserved but the conservation does vary slightly amongst known 
active kinases, with the Lys in the 3 ‘VAIK’ motif conserved amongst 98% of 
canonical kinases, but the catalytic Asp being present in a slightly smaller proportion 
of kinases (93%) and leaving only 3% of the eukaryotic kinome having evolved a 
non-classical DFG metal- binding Asp residue (Kannan et al., 2007). Table 1.1 
summarizes the human complement of pseudokinases and the sequence deviations 
found upon comparison with typical kinases (Eyers and Murphy, 2013). 
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Pseudokinase Motif(s) Mutated Pseudokinase Motif(s) Mutated 
Consensus DFG Consensus 3 K/HXD/DFG 
CASK GFG EphA10 H/HRG/GFG 
PTK7 ALG EphB6 Q/HRS/RLG 
SgK223 NFL NRBP1 N/HGN/SVA 
SgK269 NFS NRBP2 N/HGN/SVW 
SgK495 NFC SCYL1 F/HNN/GLD 
NOK GLG SCYL2 F/HGN/GFD 
RSKL1 YFS SCYL3 F/HNN/GME 
RSKL2 YFG SgK196 S/TRV/NFS 
Titin EFG STRADa R/HRS/GLR 
Trib1 SLE TBCK N/HRA/KFG 
Trib2 SLE TRRAP M/LNR/YFR 
Trib3 NLE 
Consensus HXD 
ANP HGN 
ANP HGS 
HSER HGR 
CYGD HGR 
CYGF HGR 
HER3 HRN 
ILK RHA 
IRAK3 CQS 
JAK1 (JH2) HGN 
JAK2 (JH2) HGN 
JAK3 (JH2) HGN 
TYK2 (JH2) HGN 
PSKH2 HRN 
SgK071 HRN 
SgK396 HGS 
VACMKL HRN 
Consensus 3 K 
WNK C 
KSR1 R 
KSR2 R 
Consensus 3 K/HXD 
GCN2 Y/HKV 
PXK S/YGH 
Consensus 3 K/DFG 
ULK L/NFC 
Consensus HXD/DFG 
IRAK2 HSN/HPM 
MLKL HGK/GFE 
SgK307 HRS/NLE 
Table 1.1 A summary of the human pseudokinases and their deviant motifs A compilation of 
human pseudokinases grouped by their non-canonical kinase motifs (adapted from (Eyers and 
Murphy, 2013)).  
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Following biochemical and structural studies, it became apparent that some 
pseudokinases were actually catalytically active, and able to transfer phosphate from 
ATP to a substrate at a rate above background levels detected with non-kinase 
proteins, or that of canonical protein kinases that had been inactivated by mutation 
(Eyers and Murphy, 2013). Moreover, during the past twenty years a selection of 
pseudokinases have been shown to bind to ATP but have so far not demonstrated the 
ability to transfer the gamma phosphate group to a substrate in the conditions tested, 
whilst some have been proven to lack ATP binding altogether (Scheeff et al., 2009). 
Therefore, a new pseudokinase grouping system was suggested by Zeqiraj and van 
Aalten in 2010, which segregated pseudokinases into one of four groups. Group 1, 
predicted pseudokinases, pseudokinases for which there is currently no structural or 
biochemical evidence that can help define whether they are able to bind ATP. Group 
2, pseudokinases, this group contains pseudokinases that cannot bind to ATP, or 
which do bind ATP (often weakly), but for which no catalytic activity has been 
determined. Group 3, for ‘low activity pseudokinases,’ which are pseudokinases that 
do phosphorylate a substrate but whose activity is much lower than that of typical 
kinases, and Group 4 ‘active pseudokinases’ are pseudokinases that are catalytically 
active, with high activity comparable to classically-active kinases even though they 
lack the ‘full’ complement of canonical kinase domain residues (Zeqiraj and van 
Aalten, 2010). Although this classification is useful, it does not really separate 
kinases based on their intrinsic ability to regulate a cellular function dependent on 
nucleotide binding, and places pseudokinases that can and cannot bind ATP into the 
same grouping. Recently, a fluorescence based thermal denaturation assay was 
utilized to further stratify pseudokinase domains into 4 groups based upon their 
nucleotide and cation-binding abilities. According to this nomenclature, Class 1 
pseudokinases do not bind to either a nucleotide or divalent cations, Class 2 
pseudokinases bind to nucleotides, whilst Class 3 bind to divalent cations (but not 
detectably to nucleotides). Finally, Class 4 pseudokinases, on the other hand, 
demonstrate the ability to bind to both nucleotides and divalent cations (i.e. 
Mg
2+/
ATP), similar to the conventional protein kinases (Murphy et al., 2014b).  
As more biochemical and structural evidence concerning ATP binding and 
catalytic activity is generated, the ‘classes’ that the pseudokinases have been 
somewhat arbitrarily grouped into will undoubtedly alter depending upon the type 
(and nature) of the evidence obtained. Current classifications for a selection of 
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pseudokinases and the supporting evidence based on the current literature have been 
summarized in Table 1.2.  
There are a variety of methods discussed in the literature that have been used to 
detect ATP binding. Structural methods, such as X-ray crystallography, initially 
require high concentrations of protein and the identification of appropriate buffers 
that facilitate the formation of protein crystals. Radiometric kinase assays are highly 
sensitive but require the use of radioactive nuclides (Lilienthal et al., 2010) and 
require the covalent incorporation of the -phosphate for detection, and as discussed 
previously, pseudokinases such as STRAD (Zeqiraj et al., 2009b), bind but do not 
hydrolyse ATP and therefore radioactive assays are not always suitable. One 
alternative method utilises fluorescent ATP analogues such as 2',3'-O-(2,4,6-
Trinitrophenyl)ATP (TNP-ATP) or 2'(3')-O-(N-methylanthraniloyl)ATP (mant-
ATP). When either of these analogues enters a hydrophobic environment (such as an 
ATP binding pocket), the fluorescence increases (Lucet et al., 2013), allowing for 
easy detection. Alongside DAP, these ligands have been used for the analysis of the 
nucleotide binding properties of the pseudokinases STRAD (Zeqiraj et al., 2009a, 
Zeqiraj et al., 2009b), CASK (Mukherjee et al., 2008), JAK2 (Ungureanu et al., 
2011) and HER3 (Shi et al., 2010). However, following the analysis of the binding 
affinities of a variety of nucleotide binding proteins with TNP-ATP, including to the 
histidine kinase CheA (Stewart et al., 1998), it was revealed that some (non-kinase) 
proteins bind to TNP-ATP with an affinity that is 1-3 orders of magnitude greater 
than ATP (Hiratsuka, 2003, Weber and Senior, 1997, Murphy et al., 2014b, Bilwes 
et al., 2001).  ATP can also be immobilized upon an agarose or Sepharose affinity 
matrix, and these pull-down experiments using purified protein are relatively simple 
and inexpensive to perform. ROP5 (T. gondii) and HSER (GUCY2C) were both 
identified as ATP binding pseudokinases using this method (Reese and Boothroyd, 
2011, Jaleel et al., 2006).  The pseudokinase ILK can also bind to ATP and this has 
been demonstrated not only by using an ATP affinity matrix (Becher et al., 2013) 
but also by isothermal titration calorimetry (ITC) (Fukuda et al., 2009). ITC 
confirmed that human MLKL could bind to ATP, and the Kd value determined in this 
experiment was comparable to the value obtained by differential scanning 
fluorimetry (DSF) (Murphy et al., 2014b). One limitation for ITC compared to DSF 
is the need for large amounts of purified protein, but for DSF only 2-5 g protein is 
required, and providing the kinase/pseudokinase of interest is the major species in 
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the assay mixture then the signal is not affected (Murphy et al., 2014b). This 
technique is also applicable to rapid, high throughput screening by using either 96 or 
384 well plates (Murphy et al., 2014b, Niesen et al., 2007, Lucet et al., 2013).      
In the next section, I discuss the available literature on pseudokinases, which 
includes members of the Tribbles pseudokinase family and the NOK pseudokinase, 
which are the subject of this thesis. 
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Pseudokinase 
nomenclature 
Evidence in the literature for ATP 
binding/hydrolysis? 
Pseudokinase 
class 
Pseudokinase 
group 
CASK  
Yes, crystal structure and phosphorylation (Mukherjee et al., 
2008) 
Class 2 
Low activity 
pseudokinase  
EphB6  Yes, binds to ATP (+GTP) (Murphy et al., 2014b)  Class 2 Pseudokinase  
ErbB3  
Yes, phosphorylation and crystal structure with ATP mimetic 
(Shi et al., 2010) 
Class 4 
Low activity 
pseudokinsae  
GCN2  
No thermal protective effect imparted by ATP  (Murphy et al., 
2014b) 
Class 1 Pseudokinase  
GUCY2C/HSER  Yes, binds to ATP-agarose (Jaleel et al., 2006) Class 2 Pseudokinase  
ILK  Yes, binds ATP but is not hydrolysed (Fukuda et al., 2009) Class 2 Pseudokinase  
IRAK2  
Possible autophosphorylation (Wesche et al., 1999)but queried 
(Pauls et al., 2013), binds ATP and cation (Murphy et al., 
2014b)  
Class 4 Pseudokinase  
IRAK3  
Possible autophosphorylation (Wesche et al., 1999) but queried 
(Pauls et al., 2013) 
Class 1 Pseudokinase  
JAK1 JH2 
No autophosphorylation detected and structural study suggests 
activation loop blocks phosphoacceptor (Toms et al., 2013) but 
binds ATP and divalent cation (Murphy et al., 2014b) 
Class 4 Pseudokinase  
JAK2 JH2  Yes, autophosphorylates (Ungureanu et al., 2011)  Class 4 
Low activity 
pseudokinase  
KSR1  
Yes, binds ATP and suggestion it can phosphorylate MEK (Hu 
et al., 2011a) 
Class 4 
Low activity 
pseudokinase  
KSR2  
Yes, phosphorylation of MEK1 and crystal structure bound to 
ATP (Brennan et al., 2011) 
Class 4 
Low activity 
pseudokinase  
MLKL  
Binds to ATP but is catalytically inactive (Murphy et al., 
2014a)  
Class 2 Pseudokinase  
NRBP1  Does not detectably bind to ATP/ions (Murphy et al., 2014b)  Class 1 Pseudokinase  
PEAK1/SgK269  
Binds to divalent cations only (Murphy et al., 2014b), 
contrasting catalytic behavior reported (Kelber et al., 2012) 
Class 3 Pseudokinase  
PTK7  
Not catalytically active (murine) when assayed in vitro (Jung et 
al., 2004). Does not bind ATP/ions (Murphy et al., 2014b) 
Class 1 Pseudokinase  
RYK  
Catalytically inactive (Hovens et al., 1992). Does not bind 
ATP/ions (Murphy et al., 2014b)  
Class 1 Pseudokinase  
SCYL1  
No detectable ion or nucleotide binding ability (Murphy et al., 
2014b) 
Class 1 Pseudokinase  
SgK071  Binds to ATP + divalent cations  (Murphy et al., 2014b) Class 4 Pseudokinase  
SgK196  
Yes, phosphorylates O-mannose (Yoshida-Moriguchi et al., 
2013) 
Class 4 
Low activity 
pseudokinase  
SgK223/Pragmin  No detectable ATP  or cation interaction (Murphy et al., 2014b) Class 1 Pseudokinase  
SgK495  
Yes, binds ATP in absence of divalent cations (Chapter 4). Not 
catalytically active  
Class 2 Pseudokinase  
STRAD Yes, structurally shown to bind to ATP (Zeqiraj et al., 2009b) Class 2 Pseudokinase  
Trib2  
Yes, autophosphorylates and binds to ATP in the absence of 
divalent cations (Chapters 3 and 4)  
Class 2 
Low activity 
pseudokinase  
Trib3  Yes, evidence for autophosphorylation (Chapter 3)  Class 2 
Low activity 
pseudokinase  
TYK2  
ATP binding not detected (Murphy et al., 2014b), but a crystal 
structure of TYK2 pseudokinase domain bound to an ATP 
competitive inhibitor has been deposited in PDB (3ZON)  
Class 1 Pseudokinase  
ULK4  
Binds to ATP in the absence of divalent cations (Murphy et al., 
2014b). Catalytic behavior unknown  
Class 2 Pseudokinase  
VRK3  
No, crystal structure shows ATP cannot access binding pocket 
(Scheeff et al., 2009) 
Class 1 Pseudokinase  
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1.7 Pseudokinases act in a variety of ways to alter cell signaling 
Following a recent review of pseudokinase (and pseudophosphatase) biology 
(Reiterer et al., 2014), and the implications of these physiological and disease 
functions, mechanistic effects that pseudokinases might employ have been 
summarized into 5 distinct categories and it has been suggested that all 
pseudokinases function in at least one of these roles: 
 Modulator: Regulates activity of a partner kinase by dimerisation and allostery. 
 Competitor: Binds to the substrates of canonical kinases reducing the free 
concentration of substrate available for a reaction. 
 Spatial anchor: When the pseudokinase is localized to a particular subcellular 
compartment, it binds to a ‘substrate’ and effectively traps it in this location. 
 Integrator: Many pseudokinases contain more than one functional domain and so can 
act as scaffolds, which bring substrates from one pathway into close proximity with 
the components from another pathway or substrates for a neighboring domain, 
initiating a new signaling cascade (Figure 1.3). 
 Activator: Pseudokinase is catalytically active, and can drive a signaling pathway. 
 
  
  
Table 1.2 A summary of the ATP binding properties of individual pseudokinase 
domains. The pseudokinases have been arranged in alphabetical order and the classes, 
described by Murphy and colleagues (Murphy et al., 2014b) and by Zeqiraj and van Aalten 
(Zeqiraj and van Aalten, 2010) based on experimental evidence reported in the literature 
describing  the presence or absence of ATP binding using recognized reliable assays, 
listed.  
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  ATP ADP
Downstream 
signaling
Pseudokinase
Active kinase
Inactive 
kinase
Substrate 1
Substrate 2
Cell and 
nucleus
A
B
C
D
Modulator
Competitor
Spatial anchor
Integrator
Substrate
P
E Activator
Figure 1.3 Four mechanisms employed by pseudokinases that might modulate a 
cell signaling pathway without transferring a phosphate group to a substrate A-D) 
Illustrative examples of the different ways pseudokinases might mediate or perturb the 
signaling processes in a cell, any one of which might still be regulated by ATP binding.  E) 
The fifth category shows the pseudokinase acting as a catalytic kinase, hydrolyzing ATP 
and transferring the phosphate group to a protein substrate. Adapted from Reiterer et al., 
2014. 
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1.8  CASK 
CASK (Calcium and Calmodulin-activated Serine-threonine Kinase) is a 
pseudokinase that does not have either of the kinase domain canonical divalent 
cation binding residues (DFG or N) and so was originally termed a pseudokinase, 
when the meaning of pseudokinase was meant to be interpreted to suggest a 
complete lack of catalytic activity, even though, in most cases, this had yet to be 
experimentally tested (Manning et al., 2002). In CASK, the canonical kinase 
catalytic motif Asn is replaced with a Cys residue, and the magnesium ion binding 
Asp residue located in the ‘DFG’ motif of typical kinases is swapped for a Gly 
(Mukherjee et al., 2010, Mukherjee et al., 2008). CASK has 44% sequence 
homology with the related (active) kinase CAMKII and in addition to the mutations 
discussed above, His145 is present in the catalytic motif of CASK whereas the 
‘classical’ CAMK related proteins have a Glu. In addition CASK Pro22 is an Ala 
residue in CAMK proteins, with both amino acids lining the nucleotide-binding 
pocket. (Mukherjee et al., 2010). In a very important finding, CASK was shown to 
autophosphorylate weakly and to directly phosphorylate the substrate neurexin-1 in 
vitro, suggesting that it belonged to the low activity pseudokinase group (Zeqiraj and 
van Aalten, 2010). However, because of its weak affinity for ATP (Km[ATP] 
measured at 0.563 mM), its thermal stability was not increased in the presence of 
ATP when analysed in a fluorescence-based assay (Table 1), which has become a 
standard technique in the field to help understand isolated pseudokinase domain 
binding to ligands such as ATP (Scheeff et al., 2009, Murphy et al., 2014b). This has 
now led to CASK being designated as a group 1 pseudokinase: ‘Does not bind 
detectably bind to nucleotides or cations’ in a very recent study (Murphy et al., 
2014b), despite biochemical evidence to the contrary when a radioactive isotope 
(
32
P) or a fluorescent reporter (TNP-ATP) was employed to evaluate ATP binding to 
CASK by a separate group (Mukherjee et al., 2010). This issue aptly demonstrates 
the requirement of a combination of methods to resolve whether a pseudokinase is 
catalytically active or can bind to ATP in vitro and does not even begin to address 
the biological relevance of CASK signaling potential in cells.  
In a second remarkable finding, and unlike all other active kinases that have 
been tested, the catalytic activity of CASK was inhibited in the presence of metal 
ions, which are nearly always added in kinase assays alongside ATP, and no metal 
ions have been detected in crystallographic structures, including those bound to an 
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ATP-mimetic, which contain a sodium ion at this site (Mukherjee et al., 2008). 
However, metal-dependent inhibition can be relieved by multiple ‘back’ mutations to 
absent Mg
2+
 ion binding residues in the pseudokinase domain. To achieve this, the 
Cys in the catalytic loop was mutated back to an Asn and the Gly in the ‘DFG’ motif 
was mutated to the canonical Asp (GFG becomes DFG). Other residues that align 
with the most closely related active kinase (CAMKII) were also reverted, so that the 
CASK His residue in the catalytic motif was mutated to the CAMKII Glu, and a Pro 
in the CASK Gly Rich loop was mutated to an Ala. When all of these residues were 
mutated simultaneously, the rate of CASK autophosphorylation was stimulated 
enormously, and the enzyme was no longer inhibited in the presence of Mg
2+
 ions 
(Mukherjee et al., 2010).  The only known CASK substrates are itself (an 
autophosphorylation site within the catalytic domain) as well as the synaptic protein 
neurexin-1, with which it is thought to co-localise in the nerve terminals of neurons.  
Structural analysis revealed that the catalytic domain of CASK crystallized in 
an active conformation, and the ATP binding site was not occluded by residue side 
chains (Mukherjee et al., 2008), consistent with its detectable phosphotransferase 
activity. These studies, alongside several others discussed below, demonstrated that 
pseudokinases have the ability to be catalytically active in some cases, and this work 
has stimulated the pseudokinase field to move ahead with the analysis of many other 
pseudokinases, with the realization that each separate pseudokinase needs to be 
functionally evaluated in vitro and in cells prior to its classification as either inert or 
‘devoid of activity.’   
1.9 ErbB3 
The Receptor Protein Tyrosine Kinase (RPTK)-related pseudokinase HER3 
(ErbB3) has evolved an uncharged Asn amino acid instead of a putative catalytic 
Asp residue in its unusual ‘HRD’ motif, and also possesses a His residue in the C 
helix in the region where the canonical Lys-interacting Glu residue might be 
expected to be present. HER3 is closely related to the ErbB family of RPTKs, of 
which there are four members, including model active kinases such as EGFR and 
ErbB2, which phosphorylate proteins containing Tyr residues. 
Interestingly, despite not having the catalytic Asp residue or the conserved 
Glu, as part of its catalytic domain, HER3 has demonstrated weak 
phosphotransferase activity in vitro (approximately 1/1000
th
 the activity of the 
closely related EGFR when assayed side-by-side) (Shi et al., 2010) and so HER3 
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was re-classified as a ‘low activity pseudokinase’ (Zeqiraj and van Aalten, 2010). 
Crystal structures of HER3 show that it resembles an ‘inactive’ tyrosine kinase 
conformation (Jura et al., 2009b, Shi et al., 2010), however, despite this HER3 
binds ATP with high affinity (Shi et al., 2010), and in cells can activate a ‘trans-
receptor’ partner as part of a heterodimer (e.g. other ErbB family members). 
Whether ATP binding is required for HER3 cellular function is not known, but in 
the presence of the clinically approved kinase inhibitor Bosutinib, a drug that binds 
strongly to the ATP-binding pocket of HER3 (Kd ~1 nM) (Davis et al., 2011), the 
trans-activation of EGFR actually increases because the presence of the small 
molecule increased the binding affinity of the dimer constituents (Littlefield et al., 
2014). This suggests that small molecules that mimic the ATP site of this 
pseudokinase will not necessarily function as inhibitors, and might actually be 
allosteric activators depending upon the binding mode (Klaus et al., 2013). 
For kinase-driven phosphoryl transfer, the conserved kinase catalytic Asp 
(corresponding to the Asn in HER3 pseudokinase) extracts the proton from the 
substrate Tyr OH group, which facilitates nucleophilic attack of the phosphate 
group by the Tyr O
-
 substrate acceptor. HER3 must therefore utilize a different 
pathway, or residue, for phosphoryl transfer because it does not possess the Asp 
residue. It has been suggested that HER3 transfers the labile proton of the phenolic 
tyrosine to the O1γ and then to O2β oxygens of ATP, and that phosphoryl 
transference occurs concurrently with this step (Shi et al., 2010).  
1.10 STRADα 
STRADα (Ste-20-related adaptor protein) is a pseudokinase that has a 
partially conserved Gly-rich loop, but does not contain the canonical 3 Lys, the 
catalytic Asp or magnesium binding Asn in the catalytic motif, nor the magnesium 
ion binding Asp residue in the DFG motif. Instead the respective residues in 
vertebrate STRADα homologues are Arg, Ser, His and Gly (Zeqiraj et al., 2009b). 
Despite these major differences (compared to the residues observed in standard 
kinase domains), STRAD can bind with high affinity to ATP, a process that is 
stimulated by the auxiliary protein MO25 (Zeqiraj et al., 2009b), but there has 
been no evidence presented that it is catalytically active, indeed no ATP turnover 
has ever been detected by STRAD in vitro, and it is therefore listed as a member 
of the inactive pseudokinase group as defined by Zeqiraj and van Aalten 2010., but 
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because it can bind to nucleotides it has also been re-classed recently by Murphy 
and colleagues as a group 2 pseudokinase (Murphy et al., 2014b).  
STRAD binds to the active kinase LKB1 and the scaffolding protein 
MO25 with a 1:1:1 stoichiometry.  Following binding, the conformation of LKB1 
alters and it becomes activated independently of phosphorylation. STRADα is in an 
active/closed conformation when it binds to LKB1.  The activation loop of LKB1 is 
not phosphorylated, but the αC helix is rotated akin to that of an active kinase, which 
allows the typical salt bridge to form between the conserved Glu and 3-Lys. Both 
MO25 and STRADα are required for this event (Zeqiraj et al., 2009a). STRAD is 
therefore an example of a pseudokinase that modulates the activity of an independent 
protein kinase, and by association the downstream pathways controlled by LKB1 
(Lizcano et al., 2004) by an allosteric interaction driven by ATP (and metal) binding, 
rather than by direct substrate phosphorylation. 
1.11 The ‘With No Lysine’ (WNK) family of kinases 
The WNK family comprises four kinases (WNK1-4), none of which contain 
the conserved lysine situated in the 3 ‘VAIK’ motif that coordinates the - and  
phosphates of ATP in model protein kinases. However, the WNK kinases are 
catalytically active (Lenertz et al., 2005) and are members of the ‘Active 
Pseudokinase’ grouping (Zeqiraj and van Aalten, 2010). The terminal residue in the 
glycine-rich loop is normally a Gly in kinases, however, for the WNK family it is a 
Lys residue and this performs the same role as the ‘missing’ Lys residue in the 
VAIK motif (Verissimo and Jordan, 2001, Xu et al., 2000).  Remarkably, the 
molecular basis for the absence of the Lys in the VAIK motif has recently been 
revealed by the publication of the structure of WNK1, which shows a chloride ion 
bound adjacent to the site that would normally be occupied by the lysine, stabilizing 
an inactive conformation and inhibiting WNK1 activation. This permits WNK1 
activity to be regulated by physiologically-relevant chloride ion sensing (Piala et al., 
2014). 
1.12 JAK2 JH2 pseudokinase domain 
STAT proteins can bind to cytokine receptors following JAK 
phosphorylation, which occurs in response to ligand binding. This activates the 
STATs, which are a series of transcription factors. There are four mammalian JAK-
containing polypeptides (JAK1-3 and Tyk2) and all contain related JAK homology 
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(JH) domains 1-7. The JH1 domain is an active canonical kinase domain but the 
‘JH2’ domain is a pseudokinase that lacks the catalytic Asp, possessing an invariant 
Asn residue instead in the JAKs. This led to the assumption that the pseudokinase 
domain of JAK kinases were catalytically inactive. However, Saharinen and 
colleagues demonstrated that JAK2 JH1 kinase activity was inhibited by the 
presence of the JAK2 JH2 (pseudokinase domain) (Saharinen et al., 2000) with the 
JH2 Cys618 residue that sits in a loop between the two N lobe β strands reduces the 
activity of the JH1 domain by restricting the conformational flexibility of the JH1 
activation loop by interacting with the JH1 residues Val1000 and Pro1002 (Lindauer 
et al., 2001).  Moreover, a mutation in the JAK2 JH2 domain next to this site 
(V617F) is a very common oncogenic driver in the bone marrow disorder 
polycythemia vera (Scott et al., 2007). Intriguingly, it has recently been 
demonstrated that the JH2 domain of JAK2 is actually catalytically active and 
autophosphorylates the JH2 residues Ser523 and Tyr570, indicating that the JH2 
domain is a dual specific kinase, the phosphorylation of Tyr residues by JH2 is 
however dependent upon prior Ser523 phosphorylation. Moreover, the 
phosphorylation of Ser523 or Tyr570 had an autoinhibitory effect upon the 
activation of the JAK2 JH1 domain and when either Ser523 or Tyr570 were mutated, 
the levels of JH1 activation loop phosphorylation increased (Ungureanu et al., 2011). 
1.13 VRK3 
VRK3, a pseudokinase of the Vaccinia Related Kinase (VRK) family, which 
has several paralogues in the human kinome (Scheeff et al., 2009). VRK3 contains a 
glycine-rich loop that consists of residues with much larger and acidic side chains 
than those found in active kinases, and that are required for ATP binding. Instead of 
the consensus GxGxxG, the sequence is TRDNQG in VRK3. These disrupt the 
interactions between ATP and the kinase by increasing the steric hindrance. In 
addition, the nucleotide binding site is, unusually, highly acidic in VRK3, which 
might repel, rather than stabilize, the negatively charged ATP co-factor in cells. This, 
and other mutations, clearly prevent VRK3 from binding ATP (and chemical 
analogues of ATP) and so it is the founding member of the Class 1 of pseudokinases 
that does not bind to ATP or cations (Murphy et al., 2014b) and a ‘catalytically 
inactive pseudokinase’ (Zeqiraj and van Aalten, 2010). Despite deviations from the 
catalytic domain of VRK3, the crystal structure of VRK3 strongly resembles the 
crystal structure of VRK2, with the retention of key VRK structural residues but not 
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catalytic residues, however, the activation loop and Gly-rich loop are much more 
rigid in the pseudokinase than its active counterpart (Scheeff et al., 2009), meaning 
that ATP is physically occluded from the catalytic site. 
1.14 KSR1/2 
KSR1 (kinase suppressor of RAS1) and KSR2 are pseudokinases that lack 
the highly conserved lysine in the kinase domain 3 sheet. KSR1 has recently 
confirmed to act as both as a catalytically ‘active’ pseudokinase and as a scaffolding 
protein for the ERK signaling pathway (Zhang et al., 2013).  To distinguish between 
the scaffolding functions of KSR1 and its intrinsic ATP-dependent activity, a KSR1 
mutant was generated that stabilized the ‘closed’ active conformation of the protein 
that could not bind ATP. In Ras-transformed cells, the induction of dimerisation 
between active B- and C-RAF by the presence of B-RAF specific inhibitors leads to 
the activation of C-RAF and the MEK/ERK pathway. Also, following treatment with 
PLX4720 (Vemurafenib), MEK/ERK signaling is induced in RAS-transformed cells, 
even though B/C-RAF dimers do not form. KSR1 was implicated in activating MEK 
via C-RAF because it forms dimers with both C and B-RAF. Following the 
induction of C-RAF/KSR1 dimers, by the addition of PLX4720 or GDC0879, MEK 
and ERK were activated (Hu et al., 2011a, Hatzivassiliou et al., 2010).  However, 
following mutation of KSR1 to a mutant (A587F) that could not bind ATP, but could 
still dimerise constitutively with C-RAF, downstream pathway activation was 
reduced, which indicates that the KSR1-mediated pathway activation was reliant 
upon ATP binding by the pseudokinase. Even more interestingly, in vitro kinase 
activity was detected when KSR1 and C-RAF were co-expressed and dimerisation 
was induced following the addition of 10 M PLX4720, and this activity could be 
traced by chemical genetics specifically to the pseudokinase protomer when a similar 
experiment was performed with the closely related KSR2 pseudokinase (Brennan et 
al., 2011). Furthermore, KSR1 immunoprecipitates were assayed in the presence of a 
C-RAF inhibitory concentration of PLX4720, and KSR1 phosphorylation of MEK 
was detected, but only when dimerisation of KSR1 and C-RAF had been induced, 
and the in vitro phosphorylation of MEK was not observed when the KSR1 ATP 
binding mutant (A587F) was assayed (Hu et al., 2011a). 
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1.15 MLKL 
Mixed lineage kinase domain-like (MLKL) has recently been analysed and 
revealed to be a catalytically ‘inactive’ pseudokinase with multiple biological roles. It 
not only lacks the G-rich loop, but also the two conserved Asp residues, one that 
typically acts as the catalytic base and one that binds a magnesium ion (Murphy et 
al., 2013, Murphy et al., 2014a). MLKL is required for TNF-induced necroptosis and 
acts downstream of the kinase RIP-3 in this process (Sun et al., 2012).  The thermal 
stability of MLKL in the presence or absence of ATP is markedly different, and 
confirms that despite a highly-degraded catalytic domain, this pseudokinase does 
indeed bind to the nucleotide with high affinity. Interestingly, the affinity of binding 
is reduced in the presence of divalent cations, contrary to the behavior of most 
‘standard’ kinases. To investigate this structurally, the crystal structure of MLKL was 
solved at a resolution of 1.7 Å, and confirmed that it retained the overall topology of 
a bilobial kinase domain. The crystal structure revealed that the only residue that 
could potentially block ATP from accessing the binding site was an Arg residue 
located in the Gly rich loop. It also confirmed that MLKL was in an ‘active’ 
conformation, with the 3 lysine coordinating a conserved Glu residue in the C 
helix. Consistently, the Glu from the GLE ‘substitution’ in the DFG motif was not in 
a position conducive for metal binding, which supported the finding that binding is 
metal-independent. The catalytic motif of MLKL contains an HGK, in place of the 
typical HRD motif. Lys 331 in this motif resides in the position of the canonical 
catalytic Asp and protrudes into the ATP binding cleft. Mutation of this Lys (K331N) 
reduced the affinity for ATP 3-fold, compared to the WT, indicating that the Lys 
might be involved in the coordination of ATP (Murphy et al., 2014a). This may be a 
similar situation to the WNK kinases, where a Lys residue had evolved in a different 
conserved motif (not the VAIK motif) to aid ATP binding, but unlike the WNKs, 
MLKL is catalytically inactive because the remaining motifs important for function 
are very highly degraded.  
1.16 Tribbles pseudokinases 
 The blastoderm in the Drosophila embryo develops by groups of cells 
progressing through mitosis in a coordinated and tightly regulated sequence of 
divisions.  These cells or ‘mitotic domains’ only proceed through mitosis after the 
String/CDC25 phosphatase is expressed. String removes inhibitory (Tyr 15) 
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phosphates on Drosophila CDK1, which relieves a block on G2 progression, with 
mitosis being initiated immediately (Figure 1.4A). The first domain to express String 
is the mesoderm, however in contrast to the other domains, this does not initiate 
mitosis immediately following String expression, but the cell cycle is halted until 
nine other domains have passed through the G2/M checkpoint. This pause in the cell 
cycle allows mesoderm invagination to occur by a controlled change in cell shape 
and mitotic progression disrupts this process (Seher and Leptin, 2000). Upon 
overexpression in the embryo, the Tribbles (Trbl) gene, which encodes a 
pseudokinase in flies lacking the canonical DFG motif, promotes the G2-phase of the 
cell cycle in wing imaginal disc cells and modulates the levels of String and Twine 
(a second CDK1 phosphatase) by targeting them for proteasomal degradation, thus 
decreasing protein levels and slowing mitotic progression. This allows the correct 
arrangement of cell morphologies prior to cell division, and loss of Tribbles 
underlies phenotypic defects in mitotic timing and its coordination with development 
(Mata et al., 2000). 
Trbl has 3 closely-related human homologues (Manning et al., 2002), and in 
flies also regulates the turnover of the human C/EBP transcription factor homolog 
termed slbo, which promotes migration of border cells in the Drosophila ovary 
(Rorth et al., 2000). In these cells, Trbl opposes slbo and halts border cell migration; 
the pseudokinase domain of Trbl is required for this phenotype. Mechanisticly, Trbl 
controls the levels of slbo by interacting with an E3 ligase and targeting slbo for 
proteasomal degradation. The ubiquitin hydrolase Ubp64 can stabilize slbo protein 
levels (Rorth et al., 2000, Masoner et al., 2013) (Figure 1.4B). 
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Figure 1.4 The biochemical function of Drosophila Trbl. A) A cartoon of the action of 
String (equivalent to CDC25 in yeast and vertebrates, which helps drive cells through 
mitosis by removing an inhibitory phosphorylation on CDK1. B) Trbl interacts with both 
String and slbo, targeting them for proteasomal degradation and thereby preventing M-
phase progression. 
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1.17 Trib2 
The major focus of this thesis is an analysis of the human pseudokinase 
Trib2 (also known as C5FW/SKIP2/SINK and TRB2). Bioinformatic analysis of the 
human Trib2 sequence predicted the presence of a kinase-domain fold between 
amino acid residues 64 and 308 (Simple Modular Architecture Research Tool), and 
further alignments with other vertebrate Trib2 orthologues (Figure 1.5 A) confirm an 
almost 100% identity between human Trib2 in the catalytic domain, in a region lying 
N-terminal to the kinase domain (termed 1-63) (Figure 1.5 B) and in the C-terminal 
region (termed 309-343) (Figure 1.5C). The predicted secondary structure elements 
of human Trib2 are shown beneath the protein sequence, with green arrows 
representing -sheets, and -helices depicted by red ovals. However, it should be 
noted that these are bioinformatic-based predictions and may not necessarily totally 
accurate because they rely upon comparisons with canonical kinases, and currently, 
there are no published structures of any Tribbles-related kinases to permit structural 
analysis of the kinase fold. 
The presence of the kinase-like domain in Trib2 led to its inclusion in the 
human kinome dendrogram, and its denotation as a pseudokinase (Figure 1.6 adapted 
from (Manning et al., 2002)). The dendrogram is a compilation of the 518 distinct, 
evolutionally-related protein kinases. On the same ‘evolutionary branch’ as Trib2 are 
the closely-related pseudokinases Trib1 (also termed TRB1, SKIP1, C8FW and 
GIG2) and Trib3 (also termed NIPK, SKIP3, SINK, TRB3 and LOC57761) and the 
more distant pseudokinase SgK495 (also termed SHIK and STK40). Trib2 location 
is highlighted in red, and it is most closely related to the CAMK and CGMC sub-
families of protein kinases, although it does not formally reside in either. 
An alignment of the full-length human pseudokinases Trib2, Trib1, Trib3, 
SgK495, the Drosophila orthologue Tribbles and the model active human kinase 
PKA (Figure 1.7) clearly demonstrates that the N-terminal and C-terminal segments 
of the Trib proteins are the most divergent. However, in the C-terminal regions of 
both Trib2, Trib1, Trib3 and Drosophila Tribbles there is a conserved sequence of 
amino acids [D/E/A]QxVP[D/E/A]. The presence of this sequence is known to 
facilitate the binding of an E3 ubiqutin ligase termed COP-1 to Trib2, Trib3 and 
Trib1 (Keeshan et al., 2010, Qi et al., 2006, Yokoyama et al., 2010). 
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Another protein-protein interaction sequence observed throughout the C-
terminal region of the Trib family, including Drosophila Tribbles, has been 
suggested to drive binding to MEK1, the major target of RAF in the ERK pathway 
(Figure 1.1A), and all 3 human Tribs have been shown to interact biochemically with 
this MAPKK in vitro. Indeed, following deletion of the IL(D/L)HPWF(F/L) binding 
motif, the interaction of Trib1 with MEK1 was abrogated (Yokoyama et al., 2010). 
Human Tribbles proteins are also reported to interact with other MAPKKs, including 
the JNK upstream kinases MKK4 and MKK7 (Eder et al., 2008, Kiss-Toth et al., 
2004). Through these interactions, the stability of MAPKKs can be controlled (Kiss-
Toth et al., 2004) and monocytic innate immune responses regulated, although as 
discussed in the literature, it still remains to be determined how the Tribbles family 
of proteins can alter the activity of its partner kinases at the molecular level (Eder et 
al., 2008). 
  
 51 
 
  
S
1
9
5
P
a
H
s
C
f
P
t
E
c
M
a
.m
A
m
B
t
O
c
M
u
. m
F
s
G
g
A
p
P
s
M
d
X
t
O
a
M
g
2
+
io
n
 b
in
d
in
g
 m
o
tif
P
a
H
s
C
f
P
t
E
c
M
a
.m
A
m
B
t
O
c
M
u
. m
F
s
G
g
A
p
P
s
M
d
X
t
O
a
K
9
0
F
1
3
0
K
1
8
0

3
m
o
ti
f
C
a
ta
ly
ti
c
 lo
o
p

3

C

2

D

E

6

7

F

4
/5

H

9

8

G
G
ly
c
in
e
 r
ic
h
 lo
o
p
A
6
4
1
8
7
3
0
8
1
8
6
M
E
K
1
 b
in
d
in
g
 
re
g
io
n
 52 
 
Pa
Hs
Cf
Pt
Ec
Ma.m
Am
Bt
Oc
Mu. m
Fs
Gg
Ap
Ps
Md
Xt
Oa
Pa
Hs
Cf
Pt
Ec
Ma.m
Am
Bt
Oc
Mu. m
Fs
Gg
Ap
Ps
Md
Xt
Oa
B
C
COP 1 binding 
sequence
1 63
343309
Figure 1.5 Trib2 amino acid conservation in vertebrates Alignments were performed in 
Jalview, using the Muscle alignment tool with the residues shaded using the Clustal colour 
scheme for clearer visualisation of levels of conservation. The secondary structure 
prediction was also performed in Jalview using the Jnet Secondary Structure Prediction tool 
(helices: red ovals, sheets: red arrows). Hs Homo sapiens, Pt Pan troglodytes, Pa Pongo 
abelii, Ma.m Macaca mulatta, Oc Oryctologus cuniculus, Mu. m Mus musculus, Bt Bos 
taurus,  Ec Equus caballus, Fs Felis silvestris, Am Ailuropoda melanoleuca, Cf Canis 
familiaris, Md Monodelphis domestica, Oa Ornithorhynchus anatinus, Xt Xenopus tropicalis, 
Ps Pelodiscus sinensis, Ap Anas platyrhinchos, Gg Gallus gallus. A) Trib2 catalytic domain. 
Numbered in relation to human Trib2 (catalytic domain between 64-308). B) Trib2 ‘N-
terminal domain’, labelled in relation to human Trib2 1-63 C) Trib2 ‘C-terminal domain’ 
numbered in relation to human Trib2 309-343. 
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Figure 1.6 The human kinome dendrogram. The human kinome (Illustration reproduced 
courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com) depicts the evolutionary 
relationship between proteins that contain the highly conserved kinase fold. The human 
Trib2 protein, closely flanked by its human homologues Trib1, Trib3 and the more distant 
SgK495, is marked by a red circle and is termed Trb2. NOK, labeled as SURTK106 in this 
figure, is highlighted by a blue circle. 
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Figure 1.7 Alignment of the human Trib orthologues. Full length (1-343) Trib2 (Uniprot 
Q92519), Trib1 (1-372 Uniprot Q96RU8), Trib3 (1-358, Uniprot Q96RU7) SgK495 (1-435, 
Uniprot Q8N2I9), and Drosophila melanogaster Trbl (1-484, Uniprot  Q9V3Z1) were 
aligned against the classical kinase PKA. The alignment was performed using the 
MUSCLE tool in JALVIEW and the secondary structure was predicted using the 
JNETPRED tool. The colours correspond to the CLUSTAL colour scheme.  
 
 55 
 
1.18 Predicted structure of Trib2 in three dimensions 
As of 2014, no structural coordinates for any of the Trib proteins have 
been deposited in the RCSB Protein Data Bank (PDB) or the Biological Magnetic 
Resonance Bank (BMRB).  One of the goals of this thesis is to generate high-quality 
pseudokinases that can be analysed using X-ray or NMR-based approaches, but until 
this is achieved, structural analysis is based largely on prediction. As shown in 
Figure 1.8A, a model of the Trib2 catalytic domain indicates that it does maintain (as 
is predicted by sequence analysis) the classical bilobal kinase fold, with the catalytic 
site at the interface of the N and C lobes. The conserved kinase domain residues are 
highlighted. The Trib2 residues that align with the glycine-rich loop (Figure 1.8 B) 
do not follow the consensus GxGxxG sequence, and are instead EGDHVF (blue). 
This sequence is predicted to be much more rigid because of increased steric 
hindrance caused by the presence bulkier residues and contains several acidic 
residues akin to the equivalent motif in the non-ATP binding pseudokinase VRK3 
(Scheeff et al., 2009). The 3 motif of Trib2, LVCK, consists of a canonical Lys 
(K90-cyan) preceded by hydrophobic residues that would normally pack against the 
adenine ring of ATP in canonical kinases  (Taylor and Kornev, 2010); this Lys 
normally coordinates the phosphate residues of ATP that are not transferred to 
substrate (- and -) and forms a salt bridge with the conserved glutamate in the -C 
helix. However, in Trib2, the predicted Trib2 Glu (E99-orange) that is nearest to the 
conserved Glu in PKA (E90) when sequences are compared (Figure 1.8), points 
away from the catalytic domain. The lack of conservation of Trib2 E99 with the 
other Trib family members suggests (but does not prove) that this Glu is not the 
residue that interacts with Lys 90, should one exist. The predicted ‘gatekeeper’ 
residue, which lies at the back of the ATP pocket, but is not involved in ATP 
binding, is a Phe in Trib2. F130 is coloured green and points into the ATP binding 
pocket between the two lobes of the kinase, where it controls access of adenine-
substituted kinase inhibitor mimetics in classical kinases. The gatekeeper residue is a 
Met in the closely related kinase CAMK1, a Met in the archetypal kinase PKA, and a 
Phe in the related CDK1 and CDK2 kinases. No human kinases have a Gly or Ala at 
this position (Garske et al., 2011), although the exploitation of the gatekeeper in 
chemical genetics will be discussed in Chapter 4 of this thesis. Trib2 has retained 
putative canonical Arg and catalytic Asp residues in the motif LRDLKLRK, 
however, the terminal lysine of this sequence and the serine in the SLE (DFG) motif, 
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are typically Asn and Asp in active kinases (Kannan and Taylor, 2008), and the 
importance of this atypical sequence in human Tribbles pseudokinases (as in 
Drosophila Tribbles)  is not yet understood.  
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  Figure 1.8 A model of the Trib2 catalytic domain, which retains the kinase fold. A) A 
predicted model structure of Trib2 visualised in Pymol, based on the crystal structure of 
p38 (PDB ID:1CM8) is shown in dark grey ribbons. The conserved kinase motifs have the 
sidechains displayed in ‘stick’ format and are colour coded. In the N lobe, the glycine-rich 
loop is blue and stretches from E71-F76 prior to the 2 sheet. The conserved lysine in the 
3 sheet (K90) is turquoise. The orange side chain in the C helix, points away from the 
catalytic domain (E99). This is the closest Trib2 Glu residue to the conserved Glu residue 
found throughout the canonical kinases (highlighted in orange in panel B).  The green Phe 
residue at 130 is the Trib2 gatekeeper residue and aligns with the classical kinase 
gatekeeper residues in the alignment below. L173-L180, which corresponds to the Trib2 
catalytic loop, highlighted in gold in the C lobe of the modelled kinase domain and is 
followed by the Mg
2+ 
binding loop (red). B) A MUSCLE alignment of Trib2 with the human 
Trib related proteins, Trib1, Trib3 and SgK495, as well as the pseudokinase CASK, that also 
lacks dthe metal ion binding residues (brown and red) like the Trib family and has 
demonstrated catalytic activity in vitro. The other proteins in this alignment include the 
canonical kinases CAMK1 and PKA, and also kinases CDK1 and CDK2 that, like Trib2 
possess a Phe ‘gatekeeper’ residue (green). 
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1.19 Trib2 is predicted to assemble Regulatory and Catalytic 
‘spines’ 
Upon alignment with the kinase domain of PKA (Figure 1.9 A), structural 
residues that constitute the Regulatory (red) and Catalytic spines (blue) (Taylor and 
Kornev, 2010) are highlighted and the corresponding Trib2 residues can be identified 
(Figure 1.9). The same residues were then highlighted on the 3D catalytic domain 
model of Trib2 and the known crystal structure of PKA (PDB 1ATP) (Figure 1.9 B). 
As discussed above, both ‘spines’ are anchored to the hydrophobic F helix in known 
kinases and pseudokinases. At its N terminus, the F-helix binds the Reg spine and at 
the C terminus binds the Cat spine of the kinase. The Regulatory (Reg spine) is a 
hydrophobic configuration of residues that controls the catalytic activity of the 
kinase domain because it is either assembled or disassembled by the mobility of the 
αC helix and activation loop, of which (PKA) Leu95 and Tyr164 are members. The 
Catalytic (Cat) spine is also very hydrophobic and is completed by the presence of 
the ATP adenine ring with which the Ala from the β-3 VAIK motif interacts.  The F-
helix forms the base of both spines to structurally organise and connect the different 
segments of the kinase together (Taylor and Kornev, 2010).  Despite deviations 
between the residues found in canonical kinase domains and Trib2, the Reg and Cat 
spines appear to remain intact when modelled and all but the conserved Asp located 
within the F-helix (PKA220/Trib2236) are hydrophobic, as observed for PKA. 
Mutations to spine residues can alter the behavior of a kinase. As discussed above, a 
catalytically inactive form of B-RAF that could allosterically activate ERK was 
generated by the Cat-spine mutation A481F. The Phe residue blocked catalytic 
activity by preventing ATP from binding in the ATP binding pocket, but locked the 
kinase domain in a constitutively active conformation, which activated the 
downstream pathway in a B-RAF ATP independent manner (Shaw et al., 2014). 
There is currently no evidence that any of the Tribbles-related (Trib-related) 
pseudokinases are able to bind to ATP or are catalytically active.  However, one 
published study indicated that following in vitro assay of immunoprecipitated Trib3 
from U2OS cell lysates, no autophosphorylation or phosphorylation of MBP,  
casein, or Histone H1 could be detected (Bowers et al., 2003), raising the possibility 
that Trib-related pseudokinases are indeed catalytically inactive. Moreover, the high 
degree of conservation observed within key areas of the catalytic domains of 
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vertebrate Trib-related proteins does indicate that they have an important function 
that has been selected for during molecular evolution.  
   
Figure 1.9 A comparison of the kinase core hydrophobic spines highlighted in a 
model of the Trib2 catalytic domain compared with PKA A) A MUSCLE alignment of the 
Trib2 and PKA catalytic domains with the catalytic spine residues highlighted in blue and the 
regulatory spine constituent residues highlighted in red. B) The residues that align with the 
PKA spine residues are annotated on the structural model of Trib2 (using the closest 
available kinase for which a structure is known; p38(PDB ID:1CM8) as a model) and 
displayed using Pymol. The catalytic spine is blue and the residues that comprise the 
catalytic spin are red. C) The corresponding PKA crystal structure (PDB ID:1ATP) with the 
annotated spines shown in the same colours. The PKA spine residues were obtained from 
Taylor et al., 2010 (Figure 3). 
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1.20 Trib2 is not essential for mouse development 
All individual homozygous “knock-out” mice for the Trib1, Trib2 and 
Trib3 genes are viable (Burkhardt et al., 2010, Okamoto et al., 2007, Takasato et al., 
2008) and following Trib3 knockout no clear phenotypic changes between the 
parameters tested could be found (Okamoto et al., 2007). Homozygous Trib2 knock-
out mice also demonstrated no developmental changes, with no significant 
differences observed between the litter sizes or incidence of premature death. As 
well as this, all organs appeared to develop normally and it was therefore concluded 
that Trib2 was not required for embryonic development or organogenesis (Takasato 
et al., 2008). Interestingly, elevated levels of ACC expression were observed in 
Trib1 knockout mice (Burkhardt et al., 2010). However, because of the marked 
similarities between the three Trib proteins, and lack of discernible phenotypes 
observed following individual knock-out, there might be some redundancy between 
each of the proteins. Creating multiple Trib knock out mice could help investigate 
this further, although discovery of specific small molecule regulators of Trib proteins 
would be even more useful. 
1.21 Trib2 is associated with COP1-mediated protein 
degradation 
Trib2 contains a COP1 (Constitutive Photomorphogenesis-1) binding 
domain as part of a motif in the C-terminus, and Trib2 binding to COP1 has been 
reported to be required for the degradation of the transcription factor C/EBP 
(Keeshan et al., 2010). The COP1 E3 ubiquitin ligase has a RING-finger motif, a 
coiled coil domain and seven WD40 repeats (Kato et al., 2008). Not only does Trib2 
bind to COP1 to degrade C/EBP, but Trib2 mediated degradation of CEBP/ has 
also been associated with two other E3 ubiquitin ligases, TrCP and TRIM21 in 
oncogenic environments (Wang et al., 2013b, Grandinetti et al., 2011). 
1.22 Trib2 binding to COP1 is required for C/EBP 
degradation and AML onset  
Trib2 was associated with the development of AML (acute myeloid 
leukemia) in mouse models. When mice were reconstituted with bone marrow cells 
that expressed Trib2, they died prematurely and displayed enlarged spleen and 
lymph nodes. Analysis of the bone marrow and blood sampled prior to death showed 
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that there was extensive involvement (greater than 80%) of myeloblasts and 
immature myelomonocytic cells, and because the proportion of the cellular 
population was greater than 20% blast cells, AML was diagnosed. The immature 
phenotype was further validated by flow cytometry (Keeshan et al., 2006). Further 
investigation of Trib2 induced AML, identified that HOXA9 worked synergystically 
with Trib2 in mice, advancing mortality from 152 and 169 days, respectively, to just 
79 days for the co-transduced mice (Keeshan et al., 2008). To ascertain which 
regions of the Trib2 polypeptide prevented the differentiation of granulocytes, a 
myeloid cell line, 32D, was engineered to express a variety of Trib2 protein 
truncations, including amino acids at the N-terminus, C-terminus or a combination of 
both. Fl Trib2 blocked G-CSF induced granulocyte differentiation and promoted the 
degradation of C/EBP. Cells expressing the N-terminal deletion variants (namely 
63, 55 or 32) also displayed this Trib2-driven blockade of cellular 
differentiation. However, cells expressing Trib2 that was mutated in the C-terminal 
domain or the kinase domain, or had the COP-1 binding site removed, were able to 
differentiate under these conditions unlike control cells expressing WT Trib2.   
Furthermore, degradation of C/EBP was impeded by the deletion of 
either the COP-1 binding site or a mutation within the kinase domain, whereas an N-
terminal mutant, which had a complete catalytic domain and total COP1 binding 
sequence integrity, could still reduce C/EBP protein levels. The N terminal deletion 
mutant of Trib2, and WT Trib2 could both promote serial replating of transduced 
cells, compared to the cells expressing the C-terminal or catalytic domain mutant 
Trib2. These cells lost the transformed phenotypes observed for the deleted N-
terminal or WT cells (Keeshan et al., 2010).  
Interestingly, mutation of the Trib2 D
326
QLVP
331
 sequence to an AQLAA 
(Trib3 also binds to COP1 via this sequence (Qi et al., 2006)), as well as a very 
subtle mutation of the conserved Lys in the catalytic motif (K177R, the analogous 
point mutation to Drosophila K266R (Grosshans and Wieschaus, 2000)) failed to 
provoke C/EBP degradation with the same efficiency as in WT Trib2 expressing 
cells, and cells expressing these mutations were unable to be serially replated. 
Critically, mice transplanted with cells expressing both HoxA9 and Trib2 COP1 
binding mutants survived for the same duration as mice transplanted with only 
HoxA9 cells. However, mice that had been transplanted with the N-terminal deletion 
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Trib2 expressing cells, had a latency period similar to that of WT Trib2 + HoxA9 (79 
±12 and 83± 3 days respectively) (Keeshan et al., 2010). This proved that the ability 
of Trib2 to mediate leukemogenesis was dependent upon its ability to bind to COP1 
and to degrade the putative tumor suppressor C/EBP (Figure 1.10).  
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Figure 1.10 The induction of AML by Trib2-mediated C/EBP degradation. A flow 
diagram showing how the putative tumour suppressor C/EBP is targeted for degradation 
by COP1 binding to Trib2, which stimulates the Ubiquitination of C/EBPand therefore 
targets it for proteasomal degradation, which presumably contributes to AML by a change 
in the transcriptional profile of the cell (Keeshan et al., 2010). A requirement for ATP 
binding and/or hydrolysis by Trib2 in this process in cells is unknown, as shown by the ‘?’ 
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In Trib2 leukemia samples, the expression of C/EBPp30 was high 
compared to the p42 isoform, a characteristic of AML (Keeshan et al., 2006). 
C/EBPp30 lacks the mitotic inhibitory, transactivation domain in the N-teminus of 
the protein and this domain inhibits the activation of the c-Myc promoter by E2F1.  
E2F1, 2, 3 and 4, but not E2F5 activated the Trib2 promoter and following 
overexpression of E2F1, Trib2 mRNA increased. Adjacent to the E2F1 binding sites 
in the Trib2 promoter a C/EBP binding site was detected, which both isoforms of 
C/EBP were predicted to bind. There was an inverse correlation between Trib2 
promoter activity and the levels of C/EBPp42 when cotransfected with E2F1. The 
opposite was observed when C/EBP p30 was co-transfected with E2F1, it increased 
Trib2 promoter activation raising the levels of Trib2 mRNA expression. In normal 
cells E2F1 is inhibited by the recruitment of C/EBPp42 on to the promoter region 
of Trib2, however when C/EBPp30 is in excess the levels of Trib2 mRNA increase, 
which indicates that the different C/EBP isoforms regulate the expression levels of 
Trib2 by modulating the promoter activities of E2F1. In AML samples derived from 
patients, high Trib2 and high E2F1 expression levels were apparent (Rishi et al., 
2014).   
Both Trib2 and Trib1 are overexpressed in AML and following 
transplantation of Trib1- or 2-expressing bone marrow cells, transplantable-AML 
was induced in mouse models. However, Trib3 expressing cell-transplants did not 
promote leukemogenesis, consistent with its inability to degrade C/EBP, and its 
lower binding ability, compared to Trib1 and 2. In domain swap experiments, when 
the Trib3 C-terminal domain was fused to the N/kinase domain of Trib1, C/EBP 
was degraded, however the Trib3 N- and catalytic domains bound to the Trib1 C-
terminal region could not degrade C/EBP. All three human Trib proteins could bind 
and degrade the fatty acid-synthetic enzyme acetyl CoA carboxylase (Dedhia et al., 
2010), which indicates redundancy of Trib proteins is tissue specific, and a report 
has recently described that following Trib1 knockdown in mice, the ACC-1 gene was 
upregulated, whereas in Trib1 overexpressing mice, it was downregulated 
(Burkhardt et al., 2010). It will be interesting to observe the double Trib2/1 knockout 
mouse, because both of these proteins, unlike the 3
rd
 member of the family Trib3, are 
thought to promote oncogenesis through the degradation of C/EBP. 
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1.23 Trib2 and ALL 
Trib2 is also associated with lymphoid associated leukaemia (T-ALL) and 
is regulated by the transmembrane receptor NOTCH1 following proteolytic 
cleavage. The levels of NOTCH1 protein are controlled by ubiquitination through 
FBXW7 (Wouters et al., 2007, Hannon et al., 2012, Keeshan et al., 2006). 
Interestingly, when samples from 60 paediatric ALL patients with either NOTCH1 
or FBX7W mutations were analysed, Trib2 expression was increased, with the 
highest expression seen in patients that have a mutation to the PEST domain of 
NOTCH1, which controls its rate of turnover. Trib2 was identified in particular 
subsets of ALL. Compared to controls, T-ALL that had a normal karyotype and pre 
B-ALL t(1:19) both expressed Trib2 to a significantly high level, however, pre B-
ALL t(12:21) in contrast had reduced Trib2 expression. In Trib2 high expressing 
ALL, other genes significantly expressed were associated with T-cell signaling and 
this indicates that the role of Trib2 could be involved with lineage determination of 
T/B cells (Hannon et al., 2012).  
1.24 Trib2 regulates the stability of C/EBP in NSCLC 
Trib2 mediated degradation of the transcription factor C/EBPhas also 
been associated with driving the development of non-small cell lung cancers 
(Grandinetti et al., 2011). NCI-H1650 lung cancer cells that had either been cultured 
as a monolayer or in non-adherent conditions (which increases their tumorigenesis 
abilities) were injected into NOD/SCID mice. By comparing the gene expression 
profiles of the tumors that formed in the mice derived from spheroids with tumors 
derived from the monolayer, Trib2 expression increased by as much as 76 fold. 
Furthermore, Trib2 was overexpressed in ~ 1/3
rd
 (20/68) of primary tumor samples 
tested. SNP analysis and qPCR identified that Trib2 gene amplification had occurred 
in 12% (8/68) of the tumors.  
Following shRNA knockdown in two different cell lines, cell 
proliferation of transformed cells and the ability to grow in non-adherent conditions 
was reduced, indicating that without Trib2 expression, the oncogenicity of the cells 
was hindered. This was confirmed further by the injection of NOD/SCID mice with 
either Trib2 shRNA expressing cancer cell lines, or controls. The Trib2-silenced 
cells failed to initiate tumor growth, in comparison, tumorigenesis was prevalent in 
mice that were injected with cells that still expressed Trib2. Following Trib2 
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depletion the levels of C/EBP rose. Cells that had higher C/EBP levels matured 
defined lineages. However, Trib2 expressing cells maintained an immature, 
undifferentiated phenotype. In primary tissues, it was confirmed that samples with a 
high Trib2 expression had low levels of C/EBP. TRIM 21 was the E3 ligase 
required for C/EBP degradation in lung tissues. Despite COP1 expression, it was 
not identified bound to Trib2, which indicates cell-specific E3-ligases are involed 
with Trib2-mediated C/EBPdegradation regulation by ubiquitination (Grandinetti 
et al., 2011). When A549 cells, a lung cancer cell line was transfected with either of 
the microRNAs miR511 or miR 1297 that target the 3’UTR of Trib2, the expression 
of Trib2 reduced and as a result of this levels of C/EBProse and the rate of 
proliferation decreased. A549 cells transfected with the miRNAs were transplanted 
into the mice. The tumors that developed were smaller than the control Trib2 
expressing tumors (Zhang et al., 2012). 
1.25 Trib2 levels are regulated by -TRCP and Smurf1 
Trib2 has been associated with the E3 ubiquitin ligases -TRCP and 
Smurf1 in liver cancer cells (Wang et al., 2013c, Qiao et al., 2013), however, in this 
instance C/EBP is not the intended target of degradation, but Trib2 itself.  Both of 
these ligases interact with Trib2 at the N-terminus of the protein in what has been 
termed the ‘Trib2 Degradation Domain’ (Trib2 1-5) (Qiao et al., 2013), however, the 
removal of the Trib2 C-terminus also reduced Trib2 interaction with -TRCP, albeit 
incompletely (Wang et al., 2013b).  Overexpression of -TRCP increased the 
ubiquitination of Trib2. Other -TRCP substrates include the protein PERIOD which 
contains a phosphodegron that has a phospho-Thr as the N-terminal residue in this 
motif (TSGSYS). Trib2 also has this motif but it has yet to be functionally analysed 
(Qiao et al., 2013) and it is not known if these Ser residues are phosphorylated.  
Interestingly, p70S6K phosphorylated Trib2 at Ser83, and this was recently shown to 
be required for Trib2 degradation by Smurf1 (Wang et al., 2013c). Consistently, 
when p70S6K is silenced, Trib2 is not targeted for degradation and the presence of 
Trib2 protects the oncogene YAP from -TRCP mediated degradation. An indication 
that Trib2 also regulates C/EBP in hepatic cancers was observed when the 
expression of the transcription factor increased following Trib2 knockdown (Wang 
et al., 2013c), which resembled data observed in lung tumors and AML (Keeshan et 
al., 2010, Grandinetti et al., 2011). The regulation of C/EBPwas independent of -
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TRCP. Interestingly, high C/EBP levels prevented the YAP-TEAD interaction, 
which is important for YAP mediated transcriptional activation. In this context, 
Trib2 acts as an apparent mediator, or ‘hub’ interlinking the three signaling 
pathways; Wnt, YAP, and C/EBP in liver tumorigenesis (Wang et al., 2013b). 
1.26 Trib2 regulates FOXO activity in malignant melanoma 
Trib2 was identified as a regulator of FOXO (forkhead/winged helix class 
O transcription factor) activity following a large-scale siRNA screen. When Trib2 
was knocked down, the activity of FOXO, a tumor suppressor, increased. Trib2 
mRNA expression was upregulated in 70% of matched skin cancer samples tested 
compared to normal, and all of these positive hits were from malignant melanomas. 
Further analysis observed the presence of overexpressed Trib2 mRNA in stage III/IV 
lesions, and immortalised lines derived from high grade skin malignancies also 
exhibited high levels of Trib2 mRNA, compared to ‘normal,’ non-cancerous cell 
lines. Moreover the expression level of Trib2 inversely correlated with the FOXO-
regulated protein, Bim, which is involved in apoptosis. Following knockdown of 
Trib2 in a melanoma cell line (G-361), the cells were less invasive than the control 
cells and growth was inhibited by cell-cell contact. Trib2 knockdown cells were 
transplanted into ZSCID mice and the tumors that formed in the absence of Trib2 
were on average smaller than the Trib2-expressing cells (Zanella et al., 2010). 
1.27 Mutational analysis of Trib2 confirms a cancer association 
Somatic cancer-driving mutations are commonly observed in kinases. 
Examples include BRAF V600E (He et al., 2013) and JAK2 V617F (Griner et al., 
2013). To identify pseudokinases that are potential drivers of cancer, we analyzed 
the total frequency of somatic mutations that occur in a multitude of independent 
samples (Bailey, Byrne and Eyers, In Press).  By mining the Catalogue of Somatic 
Mutations in Cancer database (COSMIC V.68), we identified the frequency of 
missense point mutations that occurred in each human pseudokinase domain. We 
assumed that if a somatic mutation occurred more than once in a pseudokinase 
domain then it potentially provides a survival advantage to the cell. The background 
(spontaneous) mutation rate was filtered by dividing the total number of missense 
point mutations by the protein length.  This created a very basic Mutation Rate (MR) 
for each (pseudo)kinase. An arbitrary cut-off value of 1.0 was employed, below 
which significance was assumed, and the greater the number of point mutations 
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detected in the analyzed samples, the smaller the MR value. This held true for the 
cancer-associated kinases BRAF, EGFR and JAK2, which had very low MR values, 
0.04, 0.02 and 0.03, respectively. Interestingly, several cancer-associated 
pseudokinases also had low MR values. The pseudokinases with the highest rate of 
mutation was HER3 (MR=0.66), which binds to ATP, exhibits vestigial kinase 
activity (see above) and has previously been identified to be mutated in 11% of 
gastric tumors sampled, and these mutations were capable of transforming normal 
epithelial cells, independent of ligand stimulation (Jaiswal et al., 2013). Excitingly, 
Trib2 also had a relatively low MR value of 0.88, and therefore was more highly 
mutated (in respect to its size) in selected tumor samples. Trib2 point mutations that 
have been identified in more than one cancer sample include D211N, R251W and 
R286Q. Both D211N (2 occurrences) and R251W (1 occurrence) have been 
identified following analysis of 781 large intestine carcinomas. Out of the 781 large 
intestince cancer samples analysed, Trib2 was mutated 10 times (1.28%) in total. 
Trib2 R251W was also detected in an endometrium carcinoma sample, as was Trib2 
R286Q and this Arg to Gln mutation also arose in both a breast cancer and a 
pancreatic cancer sample. In the database, there were 505 endometrium carncinomas 
sequenced and Trib2 was mutated in 6 of these (1.19%) whilst there were 905 
pancreatic carcinoma samples sequenced and Trib2 was mutated in only 2 of these 
samples (0.22%). Interestingly, out of 1220 central nervous system carcinoma 
samples there were no instances of mutant Trib2 proteins detected.  The total number 
of samples per tissue type that were analysed along with the number of samples that 
contained a mutated variant of Trib2 and the corresponding percentage are listed in 
Table A (Appendix), and future work might focus on detailing the effects of such 
mutations on Trib2 function. 
Other pseudokinases with high mutation rates include PSKH2 (MR=0.66), 
JAK3 (MR=0.81) and EphB6 (MR=0.87), although the mechanistic importance of 
these mutations remains unknown (Table 1.3).  
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Kinase/ 
Pseudokinase 
Nomenclature 
Uniprot 
ID 
Poly-
peptide 
(total 
amino 
acids) 
(pseudo) 
kinase 
domain 
boundaries 
Examples 
of enriched 
somatic 
mutations 
Mutation 
Rate (%) 
Normalised 
Mutation 
Rate (MR) 
BRAF P15056 766 457-717 
G469A, 
V600E 
19.4 0.04 
EGFR P00533 1210 712-979 
T790M, 
L858R 
9.7 0.12 
BubR1 O60566 1050 766-1050 
S913F, 
F996L 
0.52 2.02 
Ror1 Q01973 937 473-746 
F150L, 
G590R 
0.80 1.17 
RYK P34925 604 327-600 
R146C, 
R561Q 
0.23  2.62 
KSR1 Q81VT5 921 611-881 V676A 0.47  1.96 
KSR2 Q6VAB6 950 666-931 T778M 0.91  1.04 
WNK1 Q9H4A3 2382 221-479 I1172M 1.35 1.76 
WNK4 Q96J92 1243 174-432 R669W 0.61 2.04 
ErbB3/HER3 P21860 1342 709-966 
V438A, 
E928G 
2.04  0.66 
GUCY2A P16066 1061 528-805 
G541S, 
A887V 
0.82  1.29 
GUCY2B P20594 1047 513-786 E567K 0.68  1.54 
GUCY2C P25092 1073 489-749 
D509N, 
G944R 
0.90  1.19 
GUCY2D Q02846 1103 525-808 R331P 0.61  1.81 
GUCY2F P51841 1108 532-812 
R493H, 
R980L 
1.21  0.95 
ILK Q13418 452 193-446 
F342L, 
R349H 
0.45  1.00 
IRAK3 Q9Y616 596 165-452 
R267Q, 
D493N 
0.48 1.24 
JAK1 (JH2) P23458 1154 583-855 
V658F, 
R742H 
0.99  1.17 
JAK2 (JH2) O60674 1132 545-809 
K539L, 
V617F 
33.8  0.03 
JAK3 (JH2) P52333 1124 521-781 
A572T, 
R657Q 
1.39  0.81 
PSKH2 Q96QS6 385 63-320 
G312D, 
R338Q 
0.63  0.61 
SgK071 Q8NE28 680 28-297 
R198C, 
R246H 
0.38  1.79 
SgK396 Q9BXU1 1019 710-1019 
M804L, 
V860L 
1.32  0.77 
TYK2 (JH2) P29597 1187 589-875 
R565W, 
I684S 
0.87  1.36 
VACAMKL Q8NCB2 501 24-286 
G182R, 
S364T 
0.39  1.28 
CASK O14396 926 12-276 
R28Q, 
R489W 
0.52  1.78 
PTK7/CCK4 Q13308 1070 796-1066 
E743D, 
A933V 
0.63  1.70 
NOK Q6J9G0 422 114-384 
G313V, 
L316F 
0.43  0.98 
RSKL1 Q96S38 1066 794-1056 
G401S, 
E1022K 
0.79  1.35 
RSKL2 Q9Y6S9 572 145-539 - 0.26  2.20 
Titin Q8WZ42 34350 
32178-
32432 
- 12.8  2.68 
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Trib1 Q96RU8 372 94-338 
R178W, 
F371S 
0.32  1.16 
Trib2 Q92519 343 61-308 D211N 0.39  0.88 
Trib3 Q96RU7 358 68-316 R29H 0.32  1.12 
SgK223 Q86YV5 1402 976-1325 G758S 0.46  3.05 
SgK269 Q9H792 1746 1313-1675 
H611R, 
A1341V 
0.95  1.84 
SgK495 Q8N219 435 35-331 
V121A, 
M133V 
0.36  1.21 
GCN2 Q9P2K8 1649 296-539 H939Y 1.13  1.46 
SLOB Q32NE9 578 149-396 - 0.34  1.70 
PTK7 Q96C45 1275 4-280 
D295Y, 
C384Y 
0.78  1.63 
IRAK2 O43187 625 210-489 
V446M, 
G561K 
0.50  1.25 
MLKL Q8NB16 471 194-469 
E258K, 
G330E 
0.37 1.27 
SgK307 Q81WB6 1497 227-518 
R369C, 
E627K 
1.11 1.35 
STRAD Q9C0K7 418 58-369 
G155E, 
K356N 
0.24 1.75 
VRK3 Q8IV63 474 166-457 
S91F, 
R461C 
0.41 1.16 
EphA10 Q5JZY3 1008 645-900 
R150H, 
V1007M 
0.9  1.27 
EphB6 O15197 1021 670-919 
K154N, 
R719W  
1.17  0.87 
NRBP1 Q9UHY1 535 68-327 T421I 0.34  1.57 
NRBP2 Q9NSY0 501 38-306 - 0.13  3.85 
SCYL1 Q96KG9 808 14-314 
R271H, 
R368C 
0.34  2.38 
SCYL2/PACE
1 
Q6P3W7 933 32-327 
R301C, 
G355R 
0.76  1.23 
SCYL3 Q81ZE3 742 2-245 
R61C, 
K307E 
0.47  1.58 
SgK196 Q9H5K3 350 81-350 - 0.13  2.69 
STRAD Q7RTN6 431 69-379 - 0.21  2.05 
TBCK Q8TEA7 893 1-273 
R41C, 
F256L 
0.65  1.37 
TRRAP Q9Y485 3877 3514-3839 
S722F, 
R3486W 
2.75  1.41 
Table 1.3 Identifying potential cancer-driving pseudokinases. Data has been compiled from 
online resources (www.uniprot.org, www.kinase.com/kinbase and 
cancer.sanger.ac.uk/cancergenome/projects/cosmic). The mutation ratio (MR) of the canonical 
kinases BRAF and EFGR (bold), and a panel of pseudokinases were determined by normalizing 
the total frequency of somatic mutations to the length of the peptide. The MR of the BuBR1, 
Ror1 and RYK atypical kinases (italicized) were determined along with all human 
pseudokinases originally described during kinome annotaion. Trib2 is shown in red. The size of 
each pseudokinase-containing polypeptide, the position of the pseudokinase domain, the 
normalized mutation rate (polypeptide size divided by frequency (%) of samples in COSMIC 
v.68 containing a missense mutation, divided by 1000 for easy comparison) and examples of 
enriched mutations are listed in the table. Note that a lower MR indicates an increased average 
number of somatic mutations (normalized to polypeptide length), with enriched (≥2) mutations, 
many embedded in the pseudokinase domain, being noted where appropriate. 
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1.28 Trib2 and Inflammatory Bowel Disease 
Immunohistochemical staining of Trib2 in tissue samples of 
Inflammatory Bowel Disease (IBD) was reduced in inflamed epithelium compared to 
controls. By stimulating   the TLR receptors 2, 3, 5 and 9 with their cognate ligands, 
it was observed that the TLR5 activator flagellin increased the expression of Trib2 
mRNA 2 fold higher than controls and Trib2 upregulation was not observed 
following TLR5 knockdown. When Trib2 was knocked down by siRNA, the 
activation of NFB by flagellin-stimulated TLR5 was increased, and the levels of 
phospho-IKK and p65 also increased, whilst the levels of phosphorylated JNK 
and p-38 decreased. There were no changes detected to the activation levels of the 
MAPK/ERK pathway. Trib2 mediates NFB (p100/p52) activation by binding 
directly and reducing its phosphorylation. The Trib2 residues 158-177 were required 
for this effect (Wei et al., 2012). Incidentally this is part of the catalytic motif and 
the nature of the residue at position 177 has also been identified as important for 
COP1-mediated C/EBP degradation (Keeshan et al., 2010).  
1.29 Trib2 and Trib3 target multiple proteins for degradation 
In murine pre-adipocyte cell lines that overexpressed Trib2 or Trib3, the 
levels of C/EBPmRNA were reduced, indicating that Trib2/3 are required for 
modulation of C/EBPexpression. In contrast, the levels of C/EBP remained 
constant. As well as an observed decrease in C/EBP levels, the mRNA levels of a 
second transcription factor required for adipocyte differentiation, PPARwas also 
reduced. Despite both proteins reducing the levels of PPAR and C/EBP, Trib3 
(but not Trib2) blocked the phosphorylation of AKT, indicating that they operate 
using two distinct mechanisms. For example, Trib2 degrades LAP protein, a C/EBP 
isoform, but not LIP, another C/EBPisoform that lacks the transactivation domain. 
The degradation is prevented by treatment with the proteasome inhibitor MG132 
(Naiki et al., 2007, Han et al., 2009), which demonstrates that Trib2 mediated LAP 
levels are also regulated in a proteasome-dependent manner, although this does not 
require the Trib2 C-terminal region. Finally, Trib2 mediated LAP degradation 
prevented adipogensis (Naiki et al., 2007).  
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1.30 Trib2 autoantigens are linked to narcolepsy 
High levels of anti- Trib2 antibodies in the hypocretin producing neurons 
have been associated with the disease, narcolepsy. Three independent groups have 
noted this association in geographically distant cohorts: European, Northern 
American and Japanese (Cvetkovic-Lopes et al., 2010, Toyoda et al., 2010, 
Kawashima et al., 2010). However, the specificity or biological role of these 
antibodies has yet to elucidated (Lim and Scammell, 2010). As discussed in Chapter 
4, Oncomine analysis of differential Trib2 expression between cancer and non-
cancer tissues highlighted the brain as site of high Trib2 expression in a variety of 
brain tumors. The prevalence of Trib2 protein and Trib2 reactive antibodies in brain 
tissue associated diseases indicates that Trib2 expression here is deleterious to 
health. 
1.31 Trib2 autoantibodies associated with uveitis 
Trib2 auto antibodies have also been associated in uveitis, inflammation 
of the eye, and increased levels of Trib2 reactive auto antibodies were detected in 
30% of uveitis patients tested (Zhang et al., 2005b). Currently, to my knowledge, 
there have been no other correlations discovered between Trib2 and ocular tissues. 
1.32 Trib2 can inhibit MKK7 and MEK1 activity 
Both acetylated low density lipoprotein (AcLDL) and LPS-treated 
monocytes (THP-1 cell line) caused a reduction of Trib2 expression, and when both 
were added to monocytes at the same time, maximum IL8 production was 
stimulated. IL8 stimulates the MAPK and JNK pathways, and when Trib2 levels 
were knocked down, the IL8 stimulated MAPK and JNK pathways were further 
induced. Trib2 inhibits the MAPK pathway by binding to MKK7 and MEK1 through 
its pseudokinase domain. This effect is observed because exposure to AcLDL 
reduces the expression of Trib2, and this relieves the inhibitory effect on MEK1 and 
MKK7, causing LPS-stimulated THP-1 cells to increase the release of IL8. The 
inhibitory effect of Trib2 upon MKK7 and MEK1, which activate the JNK and 
MAPK pathways respectively, is by a direct, binding effect (Eder et al., 2008) 
mediated through the Trib2 sequence IL(D/L)HPWF(F/L), which is found in the 
pseudokinase domain between amino acids 302 and 308 in human Trib2, and is 
conserved in all vertebrate Trib2 homologues (Yokoyama et al., 2010). 
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1.33 Trib1 can hyperactivate the ERK pathway 
Trib1, like Trib2 can bind to MEK1, and it can also bind to the JNK-
specific activator MKK4 (Yokoyama et al., 2010), which Trib2 does not (Eder et al., 
2008). Following the binding of MEK1/MKK4 via the Trib C-terminal MEK1 
interaction sequence (ILLHPWF), ERK phosphorylation/activation was increased 
and this interaction was crucial for Trib1 mediated leukemogeneis in murine models. 
Trib1 mediated disease progression was accelerated when HoxA9/Meis1 was co-
expressed (Yokoyama et al., 2010, Jin et al., 2007), a similar synergistic effect was 
observed between Trib2 and HOXA9 (Keeshan et al., 2008). ERK phosphorylation 
increased in HeLa cells (non-bone marrow derived), and in bone marrow-leukemaia 
cells when HOXA9/Meis1 and Trib1 were coexpressed. A Trib1 mutant that loses 
the ability to bind MEK1 reduced the level of ERK phosphorylation. Only Trib1 that 
could bind to MEK1, when co-expressed with HOXA9 activated the MAPK 
pathway in the absence of IL3 (Jin et al., 2007, Yokoyama et al., 2010). This is in 
contrast to Trib2, which has an inhibitory effect on MAPK signaling following 
exposure to AcLDL in monocytic cells (Eder et al., 2008). Trib1 that was unable to 
bind to MEK1 could, however, still bind to C/EBP. However, when AML cells 
overexpressed both C/EBPand the Trib1 MEK1 binding mutant, the degradation of 
C/EBPp42, which is mediated by both Trib1 and Trib2 expressing leukemia cells 
(Keeshan et al., 2006), was reduced, demonstrating that C/EBP regulation by Trib1 
involved the MAPK pathway, although it is not thought that this is via 
phosphorylation of C/EBPSer21, an ERK1/2 phosphorylation substrate 
(Yokoyama et al., 2010). Finally, in trisomy-21 associated leukemias a Trib1 
mutation at R107 (R107L), has been observed. This mutation stimulated greater 
ERK1/2 phosphorylation in murine AML compared to WT upon cellular expression 
(Yokoyama et al., 2012).  
1.34 Trib1 and fatty liver disease 
Trib1 is implicated in oncogenic progression of AML, and is also 
strongly implicated in fatty disease of the liver. For example, Trib1 knockout mice 
had upregulated ACC expression levels (Burkhardt et al., 2010) and Trib1, along 
with other family members, could target ACC for COP1-mediated degradation 
(Dedhia et al., 2010), Trib1 has been associated with the development of 
(nonalcoholic) fatty liver disease (Kitamoto et al., 2014) and Trib1 heterozygous 
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knockout mice have an aberrant cytokine gene expression but are protected from 
obesity, intolerance to glucose and are insulin resistant, and by associating with the 
NFB RelA subunit, Trib1 is thought to promote proinflammatory cytokine 
production (Ostertag et al., 2010). 
1.35 Trib3 does not induce AML, but is a cancer-associated 
protein 
In vitro, Trib3 demonstrated an inability to degrade C/EBP and promote 
AML (Dedhia et al., 2010) however expression analysis in colorectal cancer showed 
that high Trib3 expression was observed in CRC cancers that had metastasised to the 
liver, lung, brain and bone, and the overall survival rate of high Trib3 expressing 
patients was low compared to the other groups. Following Trib3 siRNA knockdown 
in CRC cell lines there was a reduction in cell proliferation (Miyoshi et al., 2009). 
High Trib3 mRNA levels indicated a poor prognosis in breast cancers (particularly 
the triple negative phenotype) by association with the Unfolded Protein Response 
(UPR) PERK/ATF4/CHOP pathway (Wennemers et al., 2011b). In contrast, patients 
with high Trib3 protein expression in tumor samples had a longer mean overall 
survival compared to lower expressing tumors, although the detected protein levels 
did not correlate with the levels of Trib3 mRNA expression in breast cancer cell 
lines and patient samples. High Trib3 protein expression reduced the levels of cells 
that survived following hypoxic conditions but when Trib3 was knocked down, cells 
were more resistant to hypoxia. Typically, tumors that are tolerant to hypoxic 
conditions are more resistant to radiotherapy (Wennemers et al., 2011a, Rouschop et 
al., 2010). The deviations between Trib3 mRNA expression levels and Trib3 protein 
levels indicates that Trib3 is not just regulated at the level of transcription, but 
further translational regulatory events, possibly associated with hypoxia are required 
to modify the protein (Wennemers et al., 2011a). 
Overexpression of Trib3 inhibited the insulin-, but not nutrient- activation 
of AKT, mTOR and p70S6K, and in the livers of fed mice there was an increased 
level of glucose and insulin. On further analysis, the mice were insulin resistant.  
Trib3 inhibits Akt activation by binding to the unphosphorylated form (Matsushima 
et al., 2006).  Reduced Trib3 Akt activation, and ERK1/2 phosphorylation has also 
been identified in other studies (Liu et al., 2010, Kiss-Toth et al., 2004)  
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1.36 C/EBP regulation is evolutionary conserved in Trib proteins 
Drosophila Tribbles (Trbl), the founding member of the Tribbles 
pseudokinases is also involved in regulating the turnover of the fly C/EBP homolog: 
slbo. Slbo is required for the migration of border cells in the ovary of Drosophila 
(Rorth et al., 2000). In the border cells Slbo and Trbl have opposing activities and 
the kinase domain of Trbl is required for halting border cell migration. Following 
individual mutations to the 3 motif (FCLR to FCLA), the catalytic Asp (to Asn) 
and to the Mg
2+
 ion binding loop, showed that, the FLCA mutant and the Mg
2+
 
binding mutants behaved like the Tribbles-associated phenotype, but WT-mediated 
border cell migration pause was attenuated upon expression of the catalytic Asp 
mutant. This mutant also had a reduced ability to bind slbo, and suggests that the 
catalytic motif is functionally important for slbo degradation, which is mediated by 
an E3 ubiquitin ligase (Rorth et al., 2000, Masoner et al., 2013). In Drosophila, 
String/CDC25 is required for the mitotic progression  of  the cells in the blastoderm 
through the G2/M checkpoint (Seher and Leptin, 2000), and a loss of function 
mutation to String in the imaginal disc cells slows the G2 phase, causing cells to 
increase in size, akin to the phenotype observed from Trbl overexpression. When 
Trbl and String were overexpressed together, a normal phenotype was observed, 
which indicated that String and Trbl opposed each other and Trbl regulated 
String/CDC25 levels by degradation and this delayed mitosis, allowing gastrulation 
to complete (Mata et al., 2000). A K266R mutation which is located in the catalytic 
loop of Trbl does not cause any phenotypic changes in the progression of cells 
through the cell cycle when compared to WT and it indicates that whilst the catalytic 
loop is important for Slbo binding, it is not the relevant binding site for 
String/CDC25 (Grosshans and Wieschaus, 2000). 
1.37 SgK495 is required for lung development in murine 
embryos 
In contrast to Trib1, 2 and 3 knockout mice, which are all viable and born 
at normal Mendelian ratios, the related pseudokinase SgK495 knockout (STK40
-/-
) 
mice die within 12 hours of birth and exhibit a reduced body weight and size. Their 
determined cause of death was a failure to initiate breathing. Analysis of the lungs of 
SgK495 (-/-) mice showed that lung development was severely stunted. The small 
lobes contained fissures and displayed many of the phenotypes associated with 
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immature lungs, which included an increased glycogen level. Heterozygous mice 
with one functional copy of the gene (STK40
+/-
) did not demonstrate any obvious 
phenotypic changes from their WT littermates (+/+). Analysis of gene expression 
changes following STK40 homozygous deletion has highlighted a panel of genes that 
were significantly altered, and these included the genes FGF-18, FGF-1, Shh, Wnt2 
and interestingly, C/EBP which are known to be important for lung development 
(Yu et al., 2013).  SgK495 expression in mouse embryonic stem cells (ESCs) is 
inhibited by the transcription factor Oct4, when Oct4 is depleted SgK495 levels rise. 
SgK495 is able to signal through the MAPK pathway and activates ERK1/2 by 
interacting with RCN2, a Ca
2+
 binding protein to induce embryonic stem cell 
differentiation into the extraembryonic endoderm (ExEn) lineage (Li et al., 2010). 
Conversely, overexpression of other Tribbles-related proteins, drive cells into an 
undifferentiated or more immature state, an example being Trib2 overexpression in 
lung tissues (Grandinetti et al., 2011).  
As described above, Trib2 is an important regulator of multiple, 
divergent, signaling pathways associated with proliferation, cell size and disease, 
which includes the classical MAPK pathway, the JNK pathway, the HIPPO/YAP 
pathway, and the Wnt signaling pathway. There is clear evidence that Trib2, and 
other closely related Trib family members target specific proteins for degradation, 
and that aberrant regulation of this process is strongly associated with cancers, 
especially for Trib2 and Trib1, which can both appear to regulate the stability of the 
transcription faction C/EBP. However, it is as yet unclear whether the Tribbles 
proteins, which have all evolved a pseudokinase domain, can act catalytically to 
phosphorylate protein substrates, or whether they function in cells as ‘inert’ 
scaffolding proteins, whose role is to bring together various signaling complexes. 
  
 77 
 
1.38 NOK (Novel Oncogene with Kinase domain) 
NOK (Novel Oncogene with Kinase domain)/SuRTK106 Sugen Receptor 
Tyrosine Kinase 106)/STYK1 (Serine Threonine Tyrosine Kinase1), is a 
pseudokinase whose analysis constitutes Chapter 5 of this thesis. NOK, like the 
pseudokinases ErBb3 (HER3), PTK7, Ror1, Ror2, Ryk and NOK contains a 
(predicted) single-pass transmembrane domain found between residues 26-49 
(Figure 5.2) in its N-terminal region and an intracellular pseudokinase domain 
(Mendrola et al., 2013). NOK is a 422 amino acid polypeptide whose pseudokinase 
domain contains a partially conserved glycine-rich loop with the (CSGSCG), a 
canonical 3 motif which has the conserved lysine (K147) important for typical 
kinase coordination of the- and - phosphates of ATP. A ‘complete’ (canonical) 
catalytic motif is present in vertebrate NOK polypeptides, which contains the 
putative catalytic Asp residue and the Mg
2+
 ion-binding Asn at the end of the loop. 
The second metal-binding residue, the Asp of the DFG motif, is changed to a Gly in 
NOK, suggesting that NOK will not be able to phosphorylate substrates in a 
metal/ATP-dependent manner. These deviations from canonical kinase domains are 
conserved throughout NOK vertebrates, including in Xenopus tropicalis, which 
despite containing a canonical GxGxxG motif in the glycine loop, still lacks a 
canonical ‘DFG’ motif (Figure 1.11 B). Rather like the Trib-related pseudokinases, 
the presence of these unusual motifs has cast doubt upon the ability of NOK to bind 
to ATP or to phosphorylate a substrate protein, and the mechanism by which NOK 
signals in cells remains unknown.  
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  Figure 1.11 NOK vertebrates lack the canonical DFG motif. A) A cartoon of the NOK 
polypeptide domain structure with the predicted transmembrane and pseudokinase 
domains highlighted, along with the conserved Tyr residues Y327 and Y356. B) An 
alignment of human 98-335, with vertebrate NOK polypeptides, which contains conserved 
kinase domain residues performed in Jalview, using the Muscle alignment tool with the 
residues shaded in the Clustal colour scheme. Hs Homo sapiens, Pa Pongo abelii, Ma.m  
Macaca mulatta, Cj Callithrix jacchus, Oc Oryctologus cuniculus, Mu. M Mus musculus, Ec 
Equus caballus, Bt Bos taurus, Ss Sus scrofa, Fc Felis catus, Cf Canis familiaris, Am 
Ailuropoda melanoleuca, Xt Xenopus tropicalis. 
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1.39 NOK catalytic activity has not been demonstrated 
convincingly 
There is currently no clear and conclusive evidence confirming whether 
NOK is an active kinase or a pseudokinase, and whether it autophosphorylates or can 
phosphorylate an exogenous substrate, perhaps including a canonical receptor 
tyrosine kinase. Although there are suggestions that it is catalytically active, the 
supporting Figures in several papers do not adequately control for potential protein 
kinase contaminants in the assay (Chen et al., 2005b, Chung et al., 2009).  There is 
further evidence to suggest that an EPOR/NOK-transmembrane-and-intracellular 
domain artificial fusion protein that ‘dimerises’ and ‘autophosphorylates’ is 
constitutively active (Liu et al., 2004).  The fusion protein consists of the NOK 
transmembrane (TM) and intracellular domain attached to the extracellular domain 
of the mouse erythropoietin receptor.  Human NOK does not contain such a receptor 
domain and so any activity observed by this fusion protein may not be reconstituted 
in vivo in a wild-type configuration and cellular environment, because it may not be 
able to receive any ligand stimulation. Potentially, NOK could be constitutively 
active in the absence of a bound ligand, or dimerise with another receptor that binds 
ligands, autophosphorylating NOK Tyr residues, in a similar fashion to 
ErbB2/ErbB3 (HER3) receptor heterodimer activity (Citri et al., 2003). 
1.40 NOK activates the Akt and MAPK pathways 
Despite questions relating to its catalytic activity, the NOK pseudokinase has 
been implicated in both the Akt and MAPK pathways in cell-based studies. NOK 
physically interacts with Akt and in doing so, the phosphorylation of Akt-308 (the 
PDK1-activating site in Akt) increases, which leads to an increase in activity and 
downstream GSK3 phosphorylation on Ser9 (Li et al., 2012). Phosphorylation at 
Ser9 by Akt reduces GSK3 activity by approximately 50%, but because GSK3 is 
constitutively active, this is sufficient to trigger changes in GSK3-dependent 
signaling (Cross et al., 1995). NOK has also been reported to activate the MAPK 
pathway and interestingly, this activation was increased further following removal of 
the putative NOK transmembrane domain, indication that the presence of this TM 
domain might regulate the ability of NOK to activate signaling pathways, or lead to 
constitutive NOK activation (Li et al., 2009). Another example of NOK 
autoinhibiting the ability to activate the ERK pathway was observed following 
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mutation of Y417F, a tyrosine located within the C-terminal tail of NOK. When this 
residue was mutated to Phe, cellular proliferation increased, accompanied by 
increased levels of phosphorylated ERK and STAT1 (Li et al., 2007). Altogether, 
these studies indicate that NOK has evolved a variety of mechanisms to regulate its 
activity, perhaps suggesting that if these are deregulated there could be detrimental 
consequences in terms of normal cell control pathways. 
1.41 NOK is implicated in cancer progression 
Evidence of aberrant activation of the NOK-mediated MAPK and other 
signaling pathways is revealed by the reported oncogenic association of NOK 
expression in cancers, which led to it being given the name NOK, which I have 
employed in this thesis.  For example, BaF3 cells expressing NOK were 
subcutaneously injected into nude mice and this induced tumor formation and 
subsequent metastasis in a variety of organs distant from the point of injection, 
including the spleen, liver, kidney and skeletal muscle. The life span of NOK-
expressing mice was reduced to just 30 days from the time of injection. Further 
analysis of the BaF3-NOK cells demonstrated that both the PI3K and MAPK 
pathways had been activated (Liu et al., 2004), which is consistent with an anti-
apoptotic, proliferative effect. Interestingly, NOK-mediated tumorigenesis could be 
prevented by mutation of either Y327 or Y356. These corresponding Tyr residues in 
FGFR1 (Y701 and Y724), which are conserved in a variety of RPTKs, are required 
for FRS2-mediated ERK activation (Chen et al., 2005b).  The association of NOK 
with human cancers has been observed by analysis of mRNA levels in patient 
samples. For example, elevated NOK mRNA was observed in 16/20 acute leukaemia 
patients and following chemotherapy, the amount of NOK mRNA detected reduced 
(Kondoh et al., 2009). Other tumor types where NOK mRNA expression has been 
detected are lung (Amachika et al., 2007), ovarian (Jackson et al., 2009), prostate  
(Chung et al., 2009) and  breast (Kimbro et al., 2008). Interestingly, NOK 
subcellular localization has been reported in both the cytoplasm (Liu et al., 2004, Li 
et al., 2009), and in internalised EGFR-containing endosomes (Ding et al., 2012), 
although the function of its transmembrane domain in localization has not been 
investigated. 
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1.42 Aims of this Thesis 
The thesis is divided into two major experimental sections. In order to help 
understand the biochemistry of Trib2 and the related human pseudokinases Trib3 and 
SgK495, I devoted the majority of my studies to analyzing these three 
pseudokinases, which are described in Chapters 3 and 4. 
The major aims of this part of my project were to:  
 Optimize the purification of recombinant, soluble human Trib2 and Trib3 
 Develop a protocol that would permit the purification of large quantities of 
Trib2 sufficient for biochemical analysis and crystallization studies 
 Identify whether Trib2 and/or Trib3 pseudokinase domains are catalytically 
 active in vitro 
 Analyse the metal ion sensitivity of Trib2  
 Adapt a fluorescence based assay for Trib2 ligand-binding analysis 
 Discover ligands that can bind to Trib2  
 Generate tools to facilitate translation of recombinant Trib2 biochemical 
work into human cell models 
 Identify novel binding partners of Trib2 in model human cells. 
In addition, I was interested in understanding the biological function of a 
separate pseudokinase that, like Tribbles pseudokinases, lacks a canonical ‘DFG’ 
motif. The putative tyrosine kinase-like pseudokinase termed NOK has demonstrated 
the ability to alter several signaling pathways when overexpressed. However very 
little is known about its cellular role or its biochemical functions and to improve our 
understanding of this interesting cancer-associated pseudokinase, I have begun to 
evaluate its function (Chapter 5). The goals of this work were: 
 Generate inducible NOK-expressing human cell lines  
 Determine the subcellular localization of NOK by microscopy 
 Identify signaling sequences in the polypeptide that might target NOK in 
cells 
 Determine whether NOK pseudokinase domain mutants affect downstream 
      signaling pathways 
 Identify optimum expression conditions for expression and purification of 
      recombinant tagged versions of NOK 
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CHAPTER 2. Materials and 
Methods 
2.1 Chemicals and Reagents 
All chemicals (unless otherwise stated) were purchased from either Melford 
or Sigma and were of the highest quality available. The pET Ek/LIC vectors were 
purchased from Novagen and the Flp-In T-REx system including parental cells and 
plasmids were purchased from Invitrogen. The pGEx-6P-1 vector containing 
C/EBP was a kind gift from K. Keeshan. All restriction enzymes used were from 
New England Biolabs as was the Deep Vent polymerase. Taq polymerase was 
sourced from Invitrogen, KOD polymerase was from Novagen.  All buffers were 
made using RO (reverse osmosis) water and filter sterilized or autoclaved. 
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2.2 Antibodies described in this thesis 
 
Antibody 
Dilution 
for 
Western 
Blotting 
Dilution 
for IF 
Species Source 
Anti-Myc 
(9E10) 
1:5000 1:200 Mouse CR-UK 
Anti FLAG M2 1:5000 1:200 Mouse Sigma 
Anti Trib2 1:200 NT Rat Si Biologics 
Anti NOK 1:1000 NT Rabbit Abcam 
Anti phospho 
Ser10 Histone 
H3 
1:1000 NT Rabbit Upstate 
Anti p44/42 
(ERK1/2) 
1:1000 NT Rabbit Cell Signaling technology 
Anti phospho-
p44/42 
(phospho 
ERK1/2) 
1:1000 NT Mouse Cell Signaling Technology 
Anti 
Phosphotyrosine 
A4310 
1:5000 NT Mouse Millipore 
Anti polyHis-
HRP 
1:10,000 NT Mouse Sigma 
Anti Lamin B1 NT 1:10,000  Abcam 
Anti TAT-1 
Tubulin 
1:10,000 NT Mouse CRUK 
 
  Table 2.1 Primary antibodies used in this thesis. A list of the primary antibodies used 
for western blotting and immunofluorescence throughout this thesis. NT=Not Tested 
 85 
 
The corresponding mouse HRP conjugated secondary antibody was purchased 
from Cell Signaling, and the rat HRP antibody was obtained from SI Biologics. The 
secondary antibodies for immunofluorescence were conjugated to the fluorophorore 
(either FITC or Cy3) as determined in the experiment. 
2.3 Plasmid vectors 
The Ligation Independent Cloning (LIC) system (Haun et al., 1992) was 
employed to clone full length Trib2, Trib3, SgK495, Aurora A, NOK 98-422, NOK 
98-415, and NOK 98-400 cDNA from appropriate templates into the pET-30Ek/LIC 
vector (Novagen), which leads to the expression of an N-terminal fusion protein 
containing 43 amino acids, a 6His tag, and an enterokinase cleavage site immediately 
adjacent to the cDNA. NOK and CASK were cloned into pET-41Ek/LIC vector 
(Novagen), which encodes a GST and 6His tag N-terminal to the cDNA, whilst 
Trib2 and NOK 98-422 were cloned into the baculoviral expression plasmid pBAC-
2cp Ek/LIC (Novagen), which encodes an N-terminal 6His tagged fusion protein. 
Following ligation, the plasmids were transformed into the E. coli strain ‘NovaBlue’ 
(GigaSingle size) and plasmids were purified from single colonies that had been 
expanded overnight in 3 ml LB that contained Kanamycin (50 g/ml), using a 
QIAprep Spin Miniprep kit according to manufacturer’s instructions (Qiagen). 
Correct ligation and transformation were confirmed by restriction digestion of the 
plasmid and/or automated DNA sequencing using the dye-terminator method 
(University of Sheffield, DNA Sequencing core facility). Each DNA sequencing 
reaction required ~0.5 g of plasmid DNA and employed appropriate primers to 
generate between 500 and 1200 bp of readable sequence.  
pET-30Ek/LIC and pET-41Ek/LIC vectors were employed for the expression of 
recombinant proteins with N-terminal 6His or dual N-terminal GST-6His affinity 
tags respectively, following transformation into the BL21(DE3)pLysS (Novagen) 
strain of E. coli. Successful transformants were selected on LB-Agar plates that 
contained the antibiotic Kanamycin (50 μg/ml). The following three vectors were 
selected for, following successful transformation on LB-agar plates containing 
Carbenicillin (100 g/ml). LB (Melford) was made as directed by the manufacturer 
and autoclaved for 15 minutes at 121°C. 
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The pBAC-2cp Ek/LIC (Novagen) vector was used for baculoviral protein 
synthesis of either 6His tagged NOK or 6His tagged Trib2 in Sf9 cells derived from 
Spodoptera frugiperda pupal ovarian tissue.  
Recombinant C/EBP was supplied in the bacterial GST-fusion vector pGEx-
6P-1 (kind gift from Dr K. Keeshan) and was transformed into BL21(DE3)pLysS 
prior to expression as described below. 
Inducible isogenic expression of FLAG tagged Trib2, or FLAG tagged or 
Myc tagged NOK was facilitated following the transfection of the vector 
pcDNA5/FRT/TO (Invitrogen) that contained either the Trib2 or the NOK gene into 
human Flp-In T-REx cell lines, which were selected, and maintained, using 
appropriate antibiotics (Scutt et al., 2009). 
2.4 Primer design 
To clone the amplified cDNA into epitope fusion bacterial expression 
plasmids, the primers used were designed for Ligation Independent Cloning and 
generated overhangs that were complementary to the Ek/LIC plasmids used 
(sequences are underlined in Tables 2.2 A and B).  The reverse primers were also 
engineered to have an additional STOP codon immediately after the cDNA (BOLD) 
The PCR primers for the cloning of NOK or Trib2 into BamHI-NotI digested 
pcDNA5/FRT/TO, encoded a BamHI site (GGATCC) 5’ to the N-terminus of the 
insert, or a NotI (GCGGCCGC) recognition sequence 3’ to the insert, which 
facilitated vector ligation (Restriction sites are underlined with a dashed line in 
Tables 2.2 A and B). 
Site-directed mutagenesis required the primers shaded in Tables 2.2 A and B. 
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Description Direction Primer Sequence 5’ – 3’
LIC end + TRB2 N 
terminus
Forward GACGACGACAAGATGAACATACACAGGTCTACC
TRB2 C-Terminus + 
LIC ends
Reverse GAGGAGAAGCCCGGTTCAGTTAAAGAAAGGGTCC
BamHI +TRB2 Forward GGGGATCCATGAACATACACAGGTCTACCC
NotI +C-Terminal 
TRB2+FLAG tag
Reverse
GCGGCCGCTCACTTGTCATCGTCGTCCTTGTAGTCCATGTTAAAGAAA
GGGTCCAAGTTCTC
K90A Forward GGAGAGGAGCTGGTGTGCGCGGTGTTTGATATCAGCTGC
K90A Reverse GCAGCTGATATCAAACACCGCGCACACCAGCTCCTCTCC
K90M Forward GGAGAGGAGCTGGTGTGCATGGTGTTTGATATCAGCTGC
K90M Reverse GCAGCTGATATCAAACACCTTGCACACCAGCTCCTCTCC
K90R Forward GGAGAGGAGCTGGTGTGCAGGGTGTTTGATATCAGCTGC
K90R Reverse GCAGCTGATATCAAACACCCTGCACACCAGCTCCTCTCC
K180N Forward CGGGACCTCAAGCTGCGGAACTTCATCTTTAAGGACGAAG
K180N Reverse CTTCGTCCTTAAAGATGAAGTTCCGCAGCTTGAGGTCCCG
S195D L196F E197G Forward CTCGGGTCAAGCTGGAAGACTTCGGAGACGCCTACATTCTGCGG
S195D L196F E197G Reverse CCGCAGAATGTAGGCGTCTCCGAAGTCTTCCAGCTTGACCCGAG
K177A Forward CTGGTGCTGCGGGACCTCGCGCTGCGGAAATTCATCTTT
K177A Reverse AAAGATGAATTTCCGCAGCGCGAGGTCCCGCAGCACCAC
F129A Forward GAGACCAAAGCCTATGTGGCCTTTGAGCGAAGCTATGGG
F129A Reverse CCCATAGCTTCGCTCAAAGGCCACATAGGCTTTGGTCTC
F129G Forward GAGACCAAAGCCTATGTGGGCTTTGAGCGAAGCTATGGG
F129G Reverse CCCATAGCTTCGCTCAAAGCCCACATAGGCTTTGGTCTC
F130A Forward ACCAAAGCCTATGTGTTCGCTGAGCGAAGCTATGGGGAC
F130A Reverse GTCCCCATAGCTTCGCTCAGCGAACACATAGGCTTTGGT
F130G Forward ACCAAAGCCTATGTGTTCGGTGAGCGAAGCTATGGGGAC
F130G Reverse GTCCCCATAGCTTCGCTCACCGAACACATAGGCTTTGGT
A
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Table 2.2 Primers used for the generation of constructs used in this thesis. The 
sequences of the primers used for the amplification/mutation of A) Trib2-containing 
plasmids or B) NOK containing plasmids are listed in the table. The shaded primers 
were used for site-directed mutagenesis of the template cDNA, whereas the primers 
used for LIC cloning, have the required LIC sequences and these are in italics. The C-
terminal LIC primers encode an extra STOP codon (bold). The restriction digestion 
recognition sequences (BAMHI and NOTI) are underlined with a dashed line and the 
sequences that encode the Myc (EQKLISEEDL) or FLAG epitope tags (DYKDDDDK) 
are underlined with a solid line.   
Description Direction Primer Sequence 5’ – 3’
NOK Residue 98 + 
LIC ends
Forward GACGACGACAAGATGGCTACCACACCTGCCCTGGCTAAGC
NOK C-Terminus 
+ LIC ends
Reverse GAGGAGAAGCCCGGTTCAAAGCATGCTATAGTTG
NOK C-Terminus 
Δ residues 401-
422 + LIC ends
Reverse GAGGAGAAGCCCGGTTCATACCACCAACTCTGGTACTTGTAACAC
NOK C-Terminus 
Δ residues 416-
422 + LIC ends
Reverse GAGGAGAAGCCCGGTTCAGAGGCTCTCCACTCTGATGCC
BamHI + Myc Tag 
N-terminal NOK
Forward
GGATCCATGGAACAAAAACTTATTTCTGAAGAAGATCTGATGGGCATG
ACACGGATGCTCCTG
NotI +C-Terminal 
NOK
Reverse GCGGCCGCTCAAAGCATGCTATAGTTGTAG
BamHI +NOK N-
Terminus
Forward GGGGATCCATGGGCATGACACGGATGCTCCTG
NOK + FLAG + 
Stop+ NotI
Reverse
GCGGCCGCTGACTTGTCATCGTCGTCCTTGTAGTCCATAAGCATGCTA
TAGTTGTAG
NOK BamHI Forward GCAGATGTCTGGTCTTTTGGCATCCTGCTCTATGAGATG
NOK BamHI Reverse CATCTCATAGAGCAGGATGCCAAAAGACCAGACATCTGC
R377A Forward CCCTCACCTAGAGAGCTGGCCTTGCGCCTAGAAGCTGCC
R377A Reverse GGCAGCTTCTAGGCGCAAGGCCAGCTCTCTAGGTGAGGG
R379A Forward CACCTAGAGAGCTGCGCTTGGCCCTAGAAGCTGCCATTAAAAC
R379A Reverse GTTTTAATGGCAGCTTCTAGGGCCAAGCGCAGCTCTCTAGGTG
K147M Forward GCCCAAGAGTGTTATTCTCATGGCTTTAAAAGAACCAG
K147M Reverse CTGGTTCTTTTAAAGCCATGAGAATAACACTCTTGGGC
G269D AND
L270F
Forward CTCACTGCTAACATCTGTGACTTCGGCCTGGCTTATGAACTTTAC
G269D AND
L270F
Reverse GTAAACTTCATAAGCCAGGCCGAAGTCACAGAGCTTAGCAGTGAG
B
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2.5 PCR cycling parameters used to generate LIC-compatible 
ends 
Reaction Mixture: 
~100 ng DNA template cloned in a plasmid 
1 μl Forward Primer (1 mg/ml stock, contains GAC GAC GAC AAC AAG ATG 
added to the cDNA sequence for LIC cloning, with the underlined ATG 
corresponding to the first Met residue) 
1 μl Reverse Primer (1 mg/ml stock contains GAG GAG AAG CCC GGT TCA 
sequence for LIC cloning, with TCA encoding the reverse orientation stop codon 
TAG) 
1 μl Deep Vent DNA Polymerase (2000 U/ml) 
5 μl 10x ThermoPol Reaction Buffer (NEB) 
5 μl 10x dNTP mixture (Final concentration 50 M dATP, dTTP, dCTP, dGTP)  
H2O to a total of 50 μl 
PCR Cycle Parameters: 
Hot Start  94°C 
94°C 30s 
55°C 60s 30 cycles 
72°C 240s 
72°C 10 min 
Hold  4°C 
2.6 PCR products for blunt-end ligation into pCR2.1-TOPO 
vector using an overhanging adenine and Topoisomerase I 
(‘TOPO’ cloning) 
>100 ng Template 
1 μl Forward Primer (1 mg/ml stock) (containing a BamHI sequence) 
1 μl Reverse Primer (1mg/ml stock) (containing a NotI sequence) 
1 μl Taq DNA Polymerase (5U/μl) (Invitrogen) 
5 μl 10x PCR Buffer 
1.5 μl 50mM MgCl2 (Final concentration 10 mM Mg
2+
 ions) 
5 μl 10x dNTP mixture (Final concentration 50 M each dATP, dTTP, dCTP, 
dGTP) 
H2O to a total of 50 μl 
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PCR Program: 
Hot Start 94°C 
94°C 30s 
55°C 60s 30 cycles 
72°C 240s 
72°C 10 min 
Hold 4°C 
2.7 Site-Directed Mutagenesis PCR procedure 
~100 ng Template 
1 μl Forward Primer (1mg/ml stock) 
1 μl Reverse Primer (1mg/ml stock) 
1 μl Deep Vent (NEB) polymerase (2000 U/ml) 
5 μl 10x ThermoPol Buffer (NEB) containing 10 mM Mg2+ ions 
5 μl 10x dNTP mixture (Final concentration 50 M of each dATP, dTTP, dCTP, 
dGTP) 
H2O to a total of 50 μl 
 
PCR Cycle Parameters: 
Hot Start  94°C 
95°C 30s 
50°C 60s 30 cycles 
68°C 18 min 
68°C 10 min 
Hold   4°C 
After PCR completion 20U DpnI was added to each PCR reaction tube and 
incubated for 1h at 37°C to fully digest double-stranded methylated DNA template.  
PCR products were checked by gel electrophoresis prior to transformation.  
2.8 Ligation-Independent Cloning (LIC) 
PCR products that contained LIC overhangs were gel purified and 0.2 pmol 
were treated with 0.6 μl T4 DNA polymerase (3000 U/ml) in the presence of DTT, 
dATP and T4 DNA polymerase buffer for 30 min at room temperature. The T4 DNA 
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polymerase was then heat-inactivated at 75°C for 20 min. The T4 polymerase 
treated, heat inactivated DNA fragments were incubated with the Ek/LIC vectors in a 
ratio of 5:1 for 5 minutes before 1 μl EDTA (1 mM) was added. After a 5 minute 
incubation, 2 μl of the annealed plasmid containing the LIC-PCR product was 
transformed into NovaBlue GigaSingle E. coli strain (endA1 hsdR17(rK12
– 
mK12
+
) 
supE44 thi-1 recA1 gyrA96 relA1 lac F'[proA
+
B
+ 
lacI
q
ZΔM15::Tn10 (Tc
R
)] > 1 × 
10
9
 cfu/µg). 
2.9 Vectors for generation of Tet-inducible stable human cell lines 
To engineer Tetracycline-controlled expression of tagged full length proteins 
in human Flp-In T-REx cell lines (commercially available HeLa and 293, 
Invitrogen), the host plasmid pcDNA5/FRT/TO was employed. 
N-terminal Myc epitope tagged NOK or C-terminal FLAG epitope tagged 
NOK or Trib2 constructs were amplified by PCR and a Bam HI site was added 5’ 
and a NotI restriction site was added 3’ to the construct DNA, which permitted rapid 
ligation and cloning. 
2.10 Cloning of cDNA in Human expression Vectors 
The pcDNA5/FRT/TO vector (100 ng/μl) was digested using the restriction 
enzymes BamHI (10U) and NotI (5U) (New England Biolabs).  
BamHI/NotI PCR products that had a single (non-template) A on the 3’ end 
(a by-product of using Taq-polymerase in the PCR reaction) were first cloned into 
the ‘general purpose’ pCR2.1-TOPO cloning vector (can be selected by either 
50g/ml Kanamycin or 100 g/ml Carbenicillin) using the TOPO-TA cloning kit 
(Invitrogen). The pCR2.1-TOPO was supplied linearized with a single 3’ T overhang 
and a covalently bound Topoisomerase I, which facilitated the ligation of the Taq 
amplified PCR products into the plasmid. The ligated plasmid was then transformed 
into chemically competent OneShot TOP10 E. coli cells following the protocol 
provided by the manufacturer (Invitrogen). The pCR2.1-TOPO vector containing the 
recombinant NOK/ Trib2 inserts were isolated using a QIAprep spin Miniprep kit 
(Qiagen) and the isolated DNA was then treated with BamHI (10U) and NotI (5U) 
restriction enzymes and gel purified using a QIAquick Gel Extraction kit (Qiagen). 
Purified BamHI and NotI digested DNA inserts were ligated into the BamHI, NotI 
treated pcDNA5/FRT/TO vector using 400U T4 DNA Ligase (New England 
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Biolabs) and a ratio of vector to insert 1:5, ensuring the T4 DNA ligase was not 
added to the reaction mixture before the inserts were added. To observe successful 
ligation, ligation products were subjected to gel electrophoresis as described in the 
agarose gel purification section after treatment with 10U BamHI to relieve 
supercoiling of the plasmid alongside the nicked pcDNA5/FRT/TO that had not had 
the cDNA ligated into it. By analysis of the differences in migrated distance during 
electrophoresis it was possible to predict whether the ligation had occurred correctly. 
This was confirmed by dye terminator sequencing following transformation of the 
plasmids into GigaBlue Singles or TOP10 strains of E. coli, which were expanded in 
3 ml selective LB overnight, and the plasmids isolated by using a QIA Spin 
Miniprep Kit (Qiagen) as described below and in the Manufacturer’s instructions. 
This procedure allowed for the insertion of FLAG-tagged Trib2 or NOK and Myc-
tagged NOK into this mammalian expression vector prior to generation of stable cell 
lines. 
The NOK template cDNA used in this procedure had already undergone 
mutagenic PCR using the ‘NOK BamHI’ primers listed in Table 2.2B and 
treatment with DpnI (as described below) to remove an internal BamHI site situated 
within its coding sequence, prior to amplification with BamHI/NotI NOK primers.  
2.11 Plasmid DNA preparation 
The plasmids from transformed GigaBlue singles, or TOP10 cells could be 
purified from 3 ml LB that had been inoculated with transformed cells 18 hours 
previously. The cells were pelleted by centrifugation and then were treated 
sequentially by the constituents of the QIA Spin Miniprep kit, as described in the 
Manufacturer’s instructions (Qiagen).  
2.12 Site-Directed Mutagenesis 
To specifically mutate a residue in Trib2 or NOK, primers were used that 
introduce specified mutation(s) into the Trib2 or NOK coding sequence, but do not 
affect the remaining sequence integrity of the plasmid. To remove the template 
DNA, DpnI (20U) was added to the reaction mixtures following PCR, which were 
incubated at 37°C for 1hr.  DpnI is able to distinguish between template DNA and 
PCR products due to purine methylation of the template DNA in the original host 
strain from which the plasmid was purified (Weiner and Costa, 1994). The PCR 
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products were then transformed into the NovaBlue GigaSingles strain of E. coli. The 
mutated plasmids were isolated using a QIA miniprep QuickSpin Kit (Qiagen) from 
one colony that had been expanded overnight in 3 ml LB. Successful mutagenesis 
was determined by dye terminator sequencing (University of Sheffield).  
2.13 Agarose gel Purification of DNA fragments 
After PCR amplification or digestion with restriction enzymes, the DNA 
products were isolated using electrophoresis in 0.8% (w/v) agarose gels (solid 
agarose was dissolved in 1x TAE in a microwave), which contained the intercalating 
DNA stain ethidium bromide (final concentration 5g/ml). The DNA was 
electrophoresed at a constant field strength of 6.7 Vcm
-1
 for ~45 min. The DNA was 
then viewed on a UV transilluminator and DNA migrating at the predicted size 
(when compared to a 1-10 kb DNA marker ladder, New England Biolabs) was 
extracted using the QIAquick Gel Extraction kit, as described in the manufacturer’s 
protocol (Qiagen). Briefly, this involved adding 900 μl QG buffer to the gel 
fragment which was melted by incubating the solution in a water bath at 50°C. After 
the gel had dissolved, 200 μl isopropanol was added and the solution was applied to 
the QIA quick spin column provided in the kit. Following centrifugation at 16162 x g 
for 1 minute the flow through was discarded. This process was repeated until all the 
solution had passed through the QIA quick spin column. To the column, 750 μl 
Buffer PE (containing ethanol) was added and the column was centrifuged as before. 
The flow through was discarded and a further 1 minute centrifugation step performed 
after 2 minutes later had elapsed. The DNA was eluted in 40 μl of sterile, distilled 
H2O that had been applied to the centre of the silica membrane in the column. After 
1 minute the DNA was spin-eluted and stored at -20°C and 4 l of the purified 
plasmid were re-examined by gel electrophoresis, and if the presence of the plasmid 
is visible by UV, a sample is sequenced and the remainder frozen at -20°C. 
2.14 General protocol for chemical transformation of E. coli. 
Approximately 20 ng of plasmid DNA containing Trib2/NOK constructs 
were added to 50 μl aliquots of Novablue Gigasingles (for plasmid generation) or 10 
μl BL21(DE3)pLysS (for protein expression) strains of competent E. coli cells and 
incubated on ice for 30 minutes. The mixtures were then transferred to a 42°C water 
bath for a 30s heat shock and immediately placed back on ice for a further 2 min. 
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Two hundered of pre-warmed (37°C) SOC media (2% tryptone, 0.5% yeast extract, 
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) was 
added to the transformation mixture and incubated for 2 hours in a heated shaker at 
37°C. The mixtures were plated onto pre-warmed Luria-Bertani (LB) media and agar 
plates that contained antibiotics for selection. The plates were incubated for 18 h at 
37°C. Upon growth of colonies, individual clones were picked and expanded in 3ml 
of selective LB broth at 37°C for 18 h. Plasmids were purified from Novablue 
Gigasingles using the QIAprep spin Miniprep kit and stored at -20°C or protein was 
expressed from the BL21(DE3)pLysS cells. Glycerol stocks were created by adding 
glycerol (to a final concentration of 15% v/v) to the transformed cells in LB broth 
and stored at -80°C. 
2.15 Optimising protein expression in BL21 (DE3) pLysS E. coli 
strain 
Trib2 expression: 
Two autoclaved 2 litre flasks containing 1 litre sterile LB (supplemented with 
50 g/ml filtered kanamycin) was inoculated with 500 l of an overnight culture of 
E. coli BL21(DE3)plysS that had been transformed with pET-30 Ek/LIC Trib2. The 
flasks were incubated at 37°C whilst rotating at 1 x g. When the A600nm reached 0.8, 
protein expression in both flasks was induced by the addition of sterile Isopropyl-1-
thio-β-D-galactosidase (IPTG) at a final concentration of 0.5 mM.  
One flask was incubated for 3 hours at 37°C, whilst the other was incubated for 18 
hours at 18°C. The cells were pelleted and lysed as described below. Induction for 
18 hours at 18°C was routinely used when expressing pET-30 Ek/LIC Trib2, Trib3, 
SgK495, STRAD, pET-41 Ek/LIC CASK and C/EBP pGEX-6P-1 
NOK expression: 
Three mililitres of autoclaved LB broth supplemented with Kanamycin (50 
μg/ml) was inoculated with BL21(DE3)pLysS strains transformed with either pET-
30Ek/LIC or pET-41Ek/LIC vectors ligated to NOK DNA corresponding to residues 
98-400, 98-415 or 98-422 in sterile 15 ml Falcon tubes. To induce protein expression 
IPTG was added in a sterile environment, once the cells reached mid-log phase 
(A600nm 0.8) and the cultures were incubated at 37°C for 3 h or 18°C for 18 h. 
Subsequently, the cultures were centrifuged at 21036 x g for 20 min.  The media was 
discarded and the cell pellet resuspended in sodium dodecyl sulphate (SDS) sample 
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buffer (5x SDS sample buffer: 10% SDS, 10mM β-mercaptoethanol, 20% glycerol, 
0.2M Tris 6.8, 0.05% Bromophenol Blue.). The proteins were boiled for 5-8 min and 
then resolved using SDS-PAGE (See SDS-PAGE below). 
2.16 Lysis of E. coli cells 
Two litres of autoclaved LB were inoculated from -80°C glycerol stocks of 
His tagged Trib2, Trib3, Aurora A, SgK495, STRAD GST-His tagged CASK and 
GST C/EBPtransformedBL21(DE3)pLysS and incubated at 37°C, 1 x g, until the 
A600nm reached 0.8 at which point a sample was taken and stored at -20°C. 
Recombinant protein expression was induced by the addition of 0.5 mM IPTG and 
the flasks were incubated for a further 18 hours at 18°C on a shaking platform. 
To purify 6His-tagged proteins, the cells were pelleted and ice-cold lysis 
buffer (50 mM Tris-HCl pH 7.4, 300 mM NaCl, 0.1% Triton X-100, 10 mM 
imidazole, 1 mM DTT, 0.1mM Na-vanadate, 10 mM NaF, 10 mM -
glycerophosphate, 100 nM okadaic acid and a cOmplete protease inhibitor cocktail 
tablet (Roche)) added. The cells suspended in the lysis buffer were then sonicated for 
10s intervals on ice at an amplitude of 11 microns using a 3 mm exponential 
microprobe attached to a MSE Soniprep 150 plus motor unit. After sonication, the 
samples were centrifuged at 4°C for 30 min at 5525 x g to pellet unwanted cellular 
debris and a 200 μl supernatant sample was collected and stored at -20°C. The 
soluble cell lysate was purified by IMAC (described below) 
NOK: A single colony in BL21(DE3)pLysS E. coli strain was picked using a 
sterile tip and used to inoculate 3 ml liquid LB supplemented with Kanamycin (50 
μg/ml). After the OD reached 0.8 a sample was frozen and IPTG added to the 
remaining culture. After incubation with IPTG for the appropriate time, the cells 
were pelleted and whole cell lysates generated by the addition of 2 x SDS PAGE 
loading buffer, which were sonicated and the proteins resolved by SDS-PAGE, along 
with the uninduced fractions. 
2.17 Lysis of Sf9 cell pellets  
Cell pellets (~2x10
9
 cells) (supplied by Dr Edward Mackenzie, University of 
Manchester) expressing His tagged NOK catalytic domain (98-422) or His tagged 
full length Trib2 (1-343) were lysed in cell lysis buffer (50 mM Tris pH 7.4, 300 mM 
NaCl, 1 mM DTT, 10 mM imidazole, 0.1 mM Na-vanadate, 0.1 mM NaF, 10 mM -
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glycerophosphate pH 7.4, 100 nM okadaic acid, 0.1% Triton X-100, 1 x cOmplete 
protease inhibitor tablet) and sonicated 6 times for 20 seconds followed by three 20 
second pauses on ice. The lysate was cleared of insoluble matter by centrifugation 
and was then incubated with TALON resin (described below). 
2.18 Immobilised Metal Affinity Chromatography (IMAC) of 
recombinant His tagged proteins 
Following lysis of the bacterial cell pellet, which contains the endogenous 
and exogenous recombinant proteins, the cleared lysate was either applied to a 5 ml 
Ni Sepharose His Trap HP column (GE Healthcare) or TALON metal affinity resin 
(Clontech). The cleared lysate which contained either expressed His tagged Trib2, 
Trib3 SgK495, STRAD, Aurora A or GST-His CASK was applied to the Ni 
Sepharose resin that had been equilibrated in 5 column volumes of filtered, degassed 
wash buffer (50 mM Tris-HCl pH 7.4, 500 mM NaCl, 20 mM imidazole, 1mM 
DTT) using an Äkta FPLC system (GE Healthcare) as the pump and sample 
collector. Following injection of the lysate on to the resin, the column was washed 
with 5 column volumes of wash buffer and then 3 column volumes of elution buffer 
(50 mM Tris-HCl pH 7.4, 300 mM NaCl, 300 mM imidazole, 1 mM DTT, 10% 
glycerol). Throughout the washing and elution process 500 l fractions were 
collected by a Frac-920 (GE Healthcare), prior to the washing step 1.5 ml fractions 
of the flowthrough were collected. All fractions were immediately transferred to ice. 
The fractions that corresponded to the peak on the elution profile (monitored by the 
absorbance at A280nm) were analysed by SDS-PAGE. 
Bacterial NOK expressing cell lysates and Sf9 lysates containing expressed 
Trib2 or NOK proteins were applied to wash buffer-equilibrated TALON (cobalt 
conjugated) metal affinity resin. The columns containing the resin and lysate were 
incubated for 2 hours at 4°C on a see-saw rocker. The lysate was then drained into a 
collection tube and the resin washed with a total of 40 column volumes of wash 
buffer (50 mM Tris-HCl pH 7.4, 500 mM NaCl, 20 mM imidazole, 1mM DTT), 
which was collected and then six column volumes of elution buffer (50 mM Tris-
HCl pH 7.4, 300 mM NaCl, 300 mM imidazole, 1 mM DTT, 10% glycerol) was 
added and this was collected in 0.5 ml fractions, all performed on ice. The presence 
of eluted protein was checked by observing a colour change by adding 5 l to 495 l 
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Coomassie Plus Protein Assay Reagent (Thermo Scientific Pierce) and all eluted 
fractions were resolved by SDS-PAGE.  
Unless the proteins were purified further by gel filtration, the fractions that 
contained the eluted tagged recombinant protein were pooled and dialysed into 
(described in Chapter 3, buffer A) 50 mM Tris pH 7.4, 150 mM NaCl, 1 mM DTT 
10% glycerol or (buffer B) 20 mM bicine pH 9.0, 100 mM NaCl, 1 mM DTT, 10% 
glycerol, the buffer was replaced after the initial 30 minutes and aliquots were snap 
frozen in liquid nitrogen then stored at -80°C. Unless stated, all Trib2 preparations 
were dialysed into buffer B. 
The Trib2 protein yield obtained by purification from TALON resin and Ni 
Sepharose was comparable and therefore Ni Sepharose in combination with the Äkta 
FPLC was routinely used for rapid purification of Trib2 recombinant protein by 
IMAC. 
2.19 Purification of GST-C/EBP 
Following cell lysis of bacterial cells expressing GST-C/EBP(as described 
above) the cleared lysate was slowly re-circulated through the 1ml GSTrap column 
(equilibrated in wash buffer prior to lysate addition) (GE Healthcare) packed with 
Glutathione Sepharose High Performance resin for 2 hours at 4°C. The column was 
then washed with 30 column volumes of wash buffer (described above) and GST-
C/EBP was eluted by the addition of 10 mM reduced glutathione in 50 mM Tris pH 
8.0, 5 mM DTT. Fractions (500 l) were collected and proteins detected by SDS 
PAGE. Fractions that contained GST-C/EBP were pooled and dialysed into 20 mM 
bicine (pH 9.0), 100 mM NaCl, 1mM DTT and 10% (v/v) glycerol. 
2.20 Molecular Weight Gel Filtration Standard curve 
2 mg/ml Blue Dextran, 10 mg/ml albumin, 5 mg/ml alcohol dehydrogenase, 
4 mg/ml -amylase,  3 mg/ml carbonic anhydrase and 2 mg/ml cytochrome c protein 
standards were dissolved  in 500 l IMAC elution buffer and analysed on a 
Superdex200 10/300 gel filtration column (GE Healthcare). The proteins were eluted 
from the gel filtration column in 20 mM bicine pH 9.0, 100 mM NaCl, 10% glycerol, 
1 mM DTT. The column elution volumes (Ve) were measured from the centre of the 
peaks and the Ve/Vo value derived, where Vo is the void volume (2 mg/ml Blue 
Dextran). The MW for each protein were plotted on a semi-log (Linear X-axis, log-
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scale Y-axis) graph as a function of the Ve/Vo values and the line of best fit plotted. 
This allowed estimation of the molecular mass of proteins that eluted in a known 
volume, and is discussed further in Chapter 3. 
2.21 Size exclusion chromatography of Trib2 for buffer exchange 
and purification 
IMAC-purified Trib2 at a concentration of 2 mg/ml or higher (no more than a 
1 ml volume was applied at any one time to prevent the peaks broadening and 
reducing the separation between constituent proteins), was applied to an equilibrated 
(20 mM bicine pH 9.0, 100 mM NaCl, 1 mM DTT, 10% glycerol) Superdex 200 
10/300 GL gel filtration column (GE Healthcare) attached to an Äkta FPLC. The 
protein was loaded on to the column and eluted in the buffer used for equilibration at 
a flow rate of 0.5 ml/min or lower depending upon the detected pressure. If the 
pressure reached 1.5 MPa, then the flow rate was reduced. The molecular weight of 
the eluted proteins could be estimated by comparing their elution volume with 
reference to the Molecular Weight standards (Chapter 3). The fractions were 
subjected to SDS PAGE analysis. To prevent aggregation on the column, monomeric 
Trib2 can only be obtained by including 10% glycerol in the buffer. Size exclusion 
not only facilitates a buffer exchange but also permits the isolation of purified 
soluble proteins in native complexes. 
2.22 Mass Spectrometry analysis for Trib2 MW determination 
Electrospray ionisation mass spectrometry (ESI-MS) was performed using a 
Waters Q-TOF Global and a nano-electro spray, on gel filtered Trib2 that eluted in 
the volume of the monomeric species. BSA was used as a standard and the data 
deconvoluted using MAXENT1 software (Waters) by Dr. Claire Eyers (University 
of Liverpool). 
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2.23 Bradford Assay 
 
 
 
 
 
 
 
 
 
 
 
An Albumin protein standard (2mg/ml) (Thermo Scientific) was diluted to 
various concentrations (ranging from 0 – 1 mg/ml) in Coomassie Plus Protein Assay 
Reagent (Thermo Scientific), using the method of Bradford (Bradford, 1976). The 
A595nm absorbance levels of samples were measured relative to the blank (no BSA) 
and a standard curve plotted to allow estimation of the protein concentration for any 
unknown sample. 
To determine sample protein concentrations, 5 l of sample was added to 495 
l of Coomassie Plus Protein Assay Reagent and the A595nm value was recorded after 
shaking for 5 seconds. The concentration of protein was then calculated by 
comparison with the standard curve. 
An alternative (non-Coomassie based) method that can be used to measure 
Trib2 concentration is to measure the absorbance at 280 nm by using a Nanodrop 
device and the equation Concentration (M) = Absorbance at A280nm / Molar 
Extinction coefficient (His tagged Trib2 Molar extinction coefficient assuming all 
disulphide bonds are reduced is 0.629). This technique was used to estimate Trib2 
concentration for NMR analysis alongside a very basic calculation that A280nm of 1.0 
≈ 1 mg/ml soluble protein. 
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Figure 2.1 Bradford Assay Standard Curve for determination of protein 
concentration. At 595 nm the optical density of BSA concentrations incubated with the 
Coomassie based reagent were determined and a standard curve generated. A linear 
increase in absorbance at concentrations up to 1.0 mg/ml was determined  
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2.24 SDS PAGE. 
Following protein concentration determination, equal (or unknown) amounts 
of proteins were denatured in 5x SDS sample buffer to a final concentration of 2% 
SDS and boiled for 5 minutes before being resolved using SDS Polyacrylamide Gel 
Electrophoresis. Each sample was run on 12% (or 15% if proteins below 20 kDa 
were analysed) polyacrylamide gels for 65 minutes (or until the dye front had exited 
the base of the gel) in an electric field strength of 20 Vcm
-1
 in running buffer (25mM 
Tris, 190mM glycine, 0.1% SDS). Known amounts of BSA standard were run 
alongside the samples in polyacrylamide gels.  After electrophoresis was complete, 
the resolving gel was placed into Coomassie stain (0.2% Brilliant blue R-250, 7.5% 
acetic acid, 50% methanol) and left for up to 1 h on a See-Saw Rocker for the gel to 
become fully stained.  The non-specific Coomassie stained regions were then 
removed, leaving visible bands of protein by washing the gel for 12 hours in multiple 
changes of destain buffer (7.5% acetic acid, 50% methanol). 
2.25 Western Blotting 
Samples were resolved by SDS-PAGE electrophoresis but upon completion 
instead of placing the gel into Coomassie strain it was placed into a cassette along 
with nitrocellulose membrane (Whatman Protran) to transfer the protein from the gel 
to a solid membrane support. A gel was run as described for SDS-PAGE. The 
cassettes containing the membranes were then placed into a tank containing transfer 
buffer (25mM Tris, 190mM glycine, 0.1% SDS, 20% methanol) and the voltages set 
for protein transference at either 80V for 2 hours  (at 4°C) or at 20 V for 10 hours. 
The membranes were then placed in block (5% non-fat milk (Marvel) in TBS-T) for 
30 minutes and incubated for 12 hours at 4°C with primary antibody at various 
dilutions in 5% non-fat milk in TBS-T or 5% BSA in TBS-T depending upon which 
primary antibody was employed (see Table 2.1). The membranes were washed 3 
times in TBS-T and the secondary antibody, also diluted to a specific concentration 
(usually 1/5000 dilution in 5% non-fat milk TBS-T) and added for one hour at room 
temperature. The membranes were then washed a further 3 times in TBS-T and 
placed into a developing cassette. ECL (Amersham) developing agent was added to 
the membranes in accordance with the manufacturer’s protocol and films were 
exposed and developed. 
 101 
 
The BSA standards used for Coomassie stained gels were replaced by 
positive controls that could be detected with the desired antibody. 
2.26 Preparation of working stocks of 32P-ATP 
ATP (adenosine 5'-triphosphate, tetra(triethylammonium) salt in 10mM 
Tricine (pH 7.6)) that was 32P-labelled, was supplied by Perkin Elmer in volumes of 
35 l (5 mCi), and had an activity equivalent to ~140 Ci/ml at the ‘activity’ date. 
For pseudokinase assays, generally 995 l of 10 mM ATP was added to 5 l of 32P-
ATP radionucleotide giving a 10 x working stock solution at ~700 Ci/ml.   In most 
experiments, a final concentration of ATP of 1 mM was used per assay, and the final 
volume of each assay was 30 l, meaning that 3 l of the radiolabelled 10x working 
stock of ATP was added; this equates to ~2.3 Ci 32P ATP per assay. Prior to 
addition of the radionucleotide, the 10 mM stock of ATP was adjusted to pH 9.0. 
Note, the half-life of 
32
P is ~14.3 days, and so the ratio of 
32
P ATP was adjusted as 
the stock solution decayed. 
2.27 In vitro kinase assays 
Either 250 pmoles of bacterially expressed pseudokinase, or 250 pmoles 
Trib2 WT (Sf9) in 20 mM bicine pH 9.0, 100 mM NaCl, 1 mM DTT, 10% glycerol 
was incubated with 1 mM ATP (2.2 Ci 32P ATP), 10 mM of the appropriate 
divalent cation or 2 mM EDTA (as required) and various concentrations of protein 
substrates (as required) in a total volume of 30 l. Each condition was performed in 
duplicate. For each assay the following concentration of substrates were tested: -
Caesin 1 mg/ml, MBP 0.5 mg/ml, Histones (H1, H2A, H2B, H3 and H4) 1mg/ml, 
GST-C/EBP
For NOK (Sf9) assays, the required volume of lysate to equal 1 g protein 
was incubated with either 10 mM Mg
2+
, 10 mM Mn
2+
 or no cation and 1 mM ATP, 
both unlabelled and labeled (as described above for the Trib2 assays). When assayed 
with unlabelled ATP, the protein was transferred by western blotting to membrane 
for phosphotyrosine analysis. 
The ATP was added immediately prior to the start of the assays which were 
staggered to allow for termination at the stipulated timepoint. The assays were 
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performed at 30°C whilst on a temperature-controlled Eppendorf shaking platform. 
The reactions were terminated by the addition of 5x SDS loading buffer and heated 
at 95°C for 5 minutes. A sample of each terminated assay (25 l) was loaded into 
12% SDS PAGE gels (a 15% gel was employed if low molecular weight kinase 
substrates were assayed) and the proteins resolved for 65 minutes at 20 Vcm
-1
. 
Subsequently, proteins were visualized by staining with Coomassie Blue and 
following destaining of the gels, were dried onto blotting paper using a slab gel drier 
(SCIE-PLAS) for 2 hours at 80°C (or < 3 hours for 15% gels, it is worth noting that 
these times are extended if multiple gels are dried at the same time). The gels were 
then placed into a cassette that contained a reflector screen and were taken to the 
dark room where, under red light, an X-ray film was placed on top for analysis by 
autoradiography. The cassette was transferred to the -80°C freezer and left for a 
minimum of 48 hours, during which time the film becomes blackened as a function 
of 
32
P decay. The films were subsequently developed and fixed following standard 
procedures. For phosphorimage analysis, a phosphorscreen was placed over the top 
of the gels for ~12 hours, and 
32
P decay detected by photo-stimulated luminescence 
on a Fuji FLA-3000 phosphorimager. Data was analysed with ImageReader 
Software. The values obtained following phosphorimage analysis were averaged and 
plotted graphically using GraphPad Prism6 software. 
2.28 Differential Scanning Fluorimetry analysis of Trib2 
To determine the extent of folding of recombinant Trib2 after expression in 
E. coli, 5 M of purified Trib2 was mixed, or boiled for 5 minutes and then mixed, 
with Sypro Orange dye of unknown final concentration. Prior to addition, the dye 
(supplied as a ‘5000 x’ solution by Invitrogen) was diluted 1:40 in 20 mM bicine 
(pH 9.0), 100 mM NaCl, 1 mM DTT to create a 10 x working stock solution (as used 
to analyse kinases previously (Eathiraj et al., 2011)). The total volume of each 
reaction was made up to 25 l in buffer B (see IMAC purification) and for each 
reaction, master mixes sufficient for assays to be performed in triplicate were made. 
The solutions were thoroughly mixed and 25 l dispensed into individual wells of a 
96 well plate along with a buffer-dye solution that did not contain protein for a 
blank. The plates were sealed by optical adhesive covers to prevent sample 
evaporation and centrifuged for 15 seconds at room temperature. They were then 
placed into a real time PCR machine (Applied Biosystems StepOne Plus) for thermal 
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analysis. The temperature range was set between 25°C and 90°C and the temperature 
increased at a rate of 0.3°C/minute. The data was collected by the StepOne Software 
v2.1 and using a combination of Microsoft Excel and GraphPad Prism 6, the 
detected fluorescence readings for each temperature increment were averaged and 
thermal denaturation curves generated. 
To analyse ATP binding to proteins, 5 M Trib2 or Aurora A was incubated 
with increasing concentrations of ATP (pH 9.0) from 10x working stock solutions 
and mixed with Sypro Orange dye as described previously. From the generated 
thermal denaturation curves, the Tm was determined by the fitting of the Boltzmann 
equation (Y=Bottom+(Top-Bottom)/(1+exp((V50-X)/Slope)) with the V50 value 
equating to the Tm of the unfolding protein GraphPad Prism). Ligand binding was 
determined when the Tm was >2°C higher than protein in the absence of ligand 
Following the identification of Trib2 divalent cation sensitivity in the in vitro 
kinase assays, either magnesium ions or EDTA were added to reaction mixtures of 5 
M Trib2 and 1 mM ATP at final concentrations of 10 mM and 2 mM respectively 
and DSF performed as previously described. 
A range of concentrations of the ATP-competitive kinase ligand DAP (N′2′-
(4-aminomethyl-phenyl)-5-fluoro-N′4′-phenyl-pyrimidine-2,4-diamine, 
dianilinopyrimidine), obtained from SYNKINASE, (Murphy et al., 2014b) which 
had been reconstituted in 100% DMSO to a concentration of 20 mM, was further 
diluted to create 10x working stock solutions. The 10x DAP (in 20% DMSO) 
solutions were added to 5 M Trib2 or Aurora A and Sypro Orange Dye (final 
DMSO concentration 2%) and Tm values were compared to protein plus a 2% 
DMSO control. 
Either 5 M Trib2, Trib2 F130A, F130G in 20 mM bicine pH 9.0, 100 mM 
NaCl, 1 mM DTT, 10 % glycerol were incubated with 250 M bulky PP1 analogues 
(unless otherwise stated for a titration experiment) that were supplied as a 10 mM 
stock solutions dissolved in 100% DMSO (kind gift of Professor Kevan Shokat, 
UCSF). The final concentration of DMSO was 2.5% and the Tm values were 
compared to the Tm of the proteins without inhibitor but containing 2.5% DMSO as 
solvent. 
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2.29 Measuring the intrinsic fluorescence and static light scattering 
of Trib2 during a thermal ramp 
To determine the Tm of Trib2 by detecting the intrinsic fluorescence, or the 
Tagg by analysis of the static light scattering, 1 g (~2.5 M) Trib2, Trib2 mutants, or 
Aurora A were either mixed with ATP ± 2 mM EDTA/10 mM Mg2+or incubated with 
a series of compounds, including CZ 30 and HxJ 42, which were aliquoted into glass 
microcuvette arrays in triplicate (9l volume). The samples were placed into the 
Optim2 device and excited with both 266 nm and 473 nm lasers for 1000 ms (1s) 
during a thermal ramp which increased by 0.3°C increments, from 15°C (starting)  to 
95°C (ending) on an Optim2 system (Avacta Analyticals). The 266 nm laser was 
used to measure the thermal stability (reported as Tm) of the proteins whilst 
concurrent measurements of protein aggregation (reported as Tagg) by static light 
scattering were performed by analysis of data captured by the 473 nm laser. The first 
derivative was fitted to the detected intrinsic fluorescence curves (266 nm) and the 
Tm was identified. The Tagg (Aggregation Onset Temperature) was identified 
following static light scattering analysis and was determined at the temperature that 
gave 10% of the maximum detected signal detected by the 473 nm laser. Average Tm 
and Tagg values were calculated and Tm measurements (for ligands) for each 
protein were plotted using GraphPad Prism6. 
2.30 Purification and initial crystallization trials with recombinant 
Trib2 
Full length His tagged Trib2 was purified from two litres of E. coli as 
previously described through a two step procedure, Ni-IMAC purification followed 
by gel filtration chromatography. Trib2 was eluted from the Superdex200 column 
10/300 in 20 mM bicine (pH 9.0), 100 mM NaCl, 1 mM DTT, 10% glycerol. The 
fractions that contained protein were resolved by SDS PAGE and the fractions that 
contained Trib2 and eluted in the volume predicted for monomeric Trib2 were 
concentrated to 10 mg/ml by centrifugation using a Vivaspin 2 (10 kDa MWCO) 
concentrator column (GE Healthcare). The concentration was determined using 
Coomassie based methods and confirmed by the absorbance at 280 nm. Using a 
Screenmaker 96+8 liquid handling system, 100 nl of protein was transferred to each 
sitting drop crystallography well and mixed with 100 nl of the reservoir buffer 
dispensed into that well.  Seven, 96 well plates were set up for crystallography trials. 
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After dispensing the protein, buffer and reservoir, the trays were heat sealed with an 
adhesive optical cover and centrifuged for 20 seconds and then placed on a dark 
shelf away from any vibrations at room temperature. The plates were checked on 
days 3 and 5 post trial initiation and then at least once every two weeks to identify 
crystal formations. The seven buffer screens used were Wizard 1 and 2 (Emerald 
Biosystems), ‘Pact premier’ (moleculardimensions.com), JCSG-plus 
(moleculardimensions.com), Morpheus (moleculardimensions.com), PEGRx1 and 2 
(Hampton Research), Crystal Screen 1 and 2 (Hampton Research) and Cryo 1 and 2 
(Emerald Biosystems). 
2.31 Generation of 15N-labeled Trib2 for NMR analysis 
Trib2 expression was induced by the addition of IPTG for 18 hours at 18°C, 
when two litres of media inoculated with pET30 EK/LIC Trib2 transformed E. coli 
(full length) had reached an A600nm of 0.8. The Trib2 had been grown in M9 minimal 
media. Flasks containing 14.6 g Na2PO4 (anhydrous), 5.4 g KH2PO4 (anhydrous), 1g 
15
N labeled NH4Cl and H2O (RO) made up to 1 litre were autoclaved for 15 minutes 
at 121°C and following this, to each 1 litre flask 2 g glucose was added along with 
20 ml of 0.1 M MgSO4, 2.5 mM CaCl2, 0.75 mM MnCl2, 0.25 mM FeSO4 that had 
been filter sterilized.  
After incubation at 18°C for 18 hours, the cells were pelleted and harvested 
as previously described. Trib2 was purified by Ni-IMAC, which was followed by gel 
filtration through a Superdex200 10/300 GL column and then anion exchange 
chromatography through a MonoQ 5/50 (GE Healthcare) column.  
Coomassie staining of gel filtered 
15
N Trib2 revealed the presence of 
contaminants in the sample. To remove these minor contaminants, and therefore 
provide a homogenous Trib2 sample for 
15
N-HQSC NMR, gel filtered Trib2 was 
applied to a MonoQ 5/50 GL (GE Healthcare) column equilibrated in 20 mM bicine 
pH 9.0, 100 mM NaCl, 1 mM DTT 10% glycerol. Following loading of protein on to 
the column, the concentration of NaCl was increased linearly to a final volume of 10 
ml up to a concentration of 1000 mM. The location of the eluted Trib2 was observed 
by referring to the elution profile and SDS-PAGE, and the concentration of NaCl 
that eluted Trib2 from the MonoQ column was deduced by referring to the gradient.  
Trib2 was transferred to a suitable NMR buffer (20 mM Tris pH 7.4, 50 mM NaCl, 1 
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mM DTT) by buffer exchange through a NAP-10 column, and was then analysed by 
15
N-HSQC NMR on a Bruker 800 MHz solution state NMR for 12 hours after being 
supplemented with 10% D2O. 
2.32 Maintenance and growth of Adherent Human Cell Lines 
Flp-In T-REx-HeLa cells (Invitrogen) or Flp-In T-REx-293 human 
embryonic kidney cells (Invitrogen) were grown in Dulbecco’s Modified Eagle’s 
medium (DMEM) that contained 10% Foetal Calf Serum (FCS) that had been filter 
sterilized to prevent contamination and 50,000U Penicillin and 50,000 g 
Streptomycin (Gibco) added, along with the following selective, sterile-filtered 
antibiotics: Pre-transfected (parental) Hela Flp-In T-REx cells: Blasticidin (Melford) 
4 μg/ml, Zeocin 50 μg/ml (Invitrogen). After transfection:  HeLa Flp-In T-REx cells 
were maintained in: Blasticidin 4 μg/ml, Hygromycin B (Invitrogen) 200 μg/ml, final 
concentrations. 
Flp-In T-REx 293 cells were cultured in similar conditions to the Flp-In T-
REx HeLa cells described above, however, the selective antibiotics used were as 
follows: Pre-transfected (parental) cells: Zeocin 100 g/ml, Blasticidin 15 g/ml. 
After transfection: Blasticidin 15 g/ml, Hygromycin B 150 g/ml. 
The cells were cultured at 37°C in a 5% CO2 atmosphere and were passaged 
approximately every 3 days in a lamina flow hood after trypsinolysis in 
trypsin/EDTA (versine) and cell counting. 
Zeocin selects for the pFRT/lacZeo vector that contains an integrated FRT (Flp 
recombination Target) site. Following cotransfection of a Flp recombinase (pOG44) 
and pcDNA5/FRT/TO vector containing Trib2/NOK, the pOG44 expresses the Flp 
Recombinase and homologously recombines the FRT sites in pFRT/lacZeo and 
pcDNA5/FRT/TO.  The cells, which were previously resistant to Zeocin are 
sensitised, but become resistant to Hygromycin B (the resistance gene in 
pcDNA5/FRT/TO). The pcDNA6/TR, which encodes the Tet repressor gene, is 
selected for and maintained by the constant presence of Blasticidin.  
2.33 Growth of suspension human cell lines 
THP-1 (a suspension monocytic cell line) was cultured in RPMI, 
supplemented with Penecillin and Streptomycin, 10% low endotoxin FCS, 1% L-
glutamine and 0.2 mM -mercaptoethanol. Cells were maintained at 37°C and 5% 
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CO2 and to maintain exponential growth, the cells were passaged when the 
concentration was ~ 8 x10
5
 cells/ml.  
2.34 Human Cell Transfection with double stranded DNA plasmids 
HeLa Flp-In T-REx parental cells were cultured to 80-90% confluency, 
washed 3 times with Phoshate Buffered Saline (PBS) and standard transfection 
protocols were followed. Briefly, for stable cell lines, 1 μg pcDNA5/FRT/TO- 
Trib2/NOK and 9 μg pOG44 (this 1:9 was suggested in the suppliers manual and 
pOG44 Flp recombinase expression vector is required for stable integration of 
transfectants), were combined in a sterile microcentrifuge tube and a volume of 
Lipofectamine appropriate for the size of flask or dish used was added (as described 
in the Lipofectamine 2000 manual). After 5 minutes, 50 μl of serum-free DMEM 
was added to this mixture and was left for 30 minutes in the lamina-flow hood. The 
parental cells for transfection were washed three times with PBS and had 2ml serum-
free DMEM dispensed onto them. The contents of the microcentrifuge tubes were 
added to the plate/flask containing the cells for transfection and these were incubated 
for 3-5h at 37°C in 5% CO2. Then 10 ml of serum containing DMEM was added to 
the transfections. Selective media was added 24h later.  Expression of the Flp 
recombinase mediates ligation of the plasmid sequence into a pre-defined site of the 
genome. Tetracycline (sterile-filtered stock solution was 1mg/ml in 70% EtOH) was 
added at a final concentration of 1 g/ml to induce the expression of the recombinant 
protein in the stably transfected cells, and this was confirmed by western blotting. 
2.35 Human Cell Lysis 
Mammalian cell lysis buffer (1% Triton x-100 or 0.1% Triton x-100, 100 
mM NaCl, 10 mM Tris pH 7.4, 10 mM β-glycerophosphate pH 7.5, 1 mM EDTA pH 
8, 1 mM EGTA pH 8, 1 x protease inhibitor tablet, 100 nM okadaic acid, 10 mM 
NaF, 0.5 mM Na orthovanadate, the latter three are protein phosphatase inhibitors) 
was added to cells after they had been trypsinised and the trypsin neutralized by the 
addition of growth media containing 10% FCS. To prevent re-attachment, the cells 
were immediately pelleted by gentle microcentifugation at 1000 x g 18°C, to prevent 
premature cell lysis. The media was discarded and the pellet gently washed in PBS 
and pelleted 3 times in succession. The pellet was then resuspended in ice cold cell 
lysis buffer and left for 20 min on ice with occasional agitiation. The solution was 
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then centrifuged at 20,000 x g in a refrigerated centrifuge at 4°C for 20 min. The 
supernatant fraction (soluble after Triton x-100 extraction) was left on ice or stored 
at -20°C whilst the pellet was resuspended in 2 x SDS Lysis buffer and then boiled 
for 10 min prior to SDS-PAGE. 
2.36 Generation of antibody raised against recombinant Trib2 
To detect endogenous, untagged NOK as well as exogenous and recombinant 
Trib2, a new antibody was raised in rats using recombinant His-tagged human Trib2 
as immunogen, in collaboration with SI Biologics. Samples of sera were tested from 
each rat to test for an immune response directed against Trib2 (assessed by ELISA). 
Following successful reactivity, the sera was collected and purified. CnBr-activated 
Sepharose (GE Healthcare) was first coupled to recombinant His-tagged Trib2 by 
swelling the 1g resin (swells to ~ 3.5 ml) in 200 ml 1 mM HCl for 1 hour. The resin 
was then washed using a vacuum pump and 0.22 m nitrocellulose membrane with a 
further 200 ml 1 mM HCl followed by 200 ml Coupling Buffer (100 mM NaHCO3 
pH8.3, 500 mM NaCl) and 5 mg lyophilized recombinant full length His- Trib2 was 
dissolved in 5 ml Coupling Buffer. The resin was centrifuged and resuspended in the 
Coupling Buffer dissolved 5 ml His- Trib2 and incubated for 2 hours on a see-saw 
rocker.  The resin was then gently washed with 5 gel volumes Coupling buffer and 
then incubated in 20 ml Blocking buffer (100 mM Tris-HCl pH 8.0) for 2 hours. 
Following a further wash with 20 ml Coupling buffer, 4 rounds of alternating 10 ml 
of Cycle buffer 1 (100 mM acetic acid pH 4.0, 500 mM NaCl) and Cycle buffer 2 
(100 mM Tris-HCl pH 8.0, 500 mM NaCl) commenced and then washed with 20 ml 
PBS and stored in a 1:1 ratio with PBS. Two milliliters of the antiserum was then 
added to 1 ml of the Trib2 conjugated Sepharose slurry (bead volume 500 l) packed 
into a BioRad Econo-Pac chromatography column and incubated for 1 hour. The 
flow through was then collected and the resin washed with 100 ml PBS. The Trib2 
reactive antibodies were eluted by the addition of 4 ml Elution Buffer (100 mM 
glycine pH 2.5), and ~500 l was collected in each microfuge collection tube that 
contained 100 l Neutralisation buffer (1M Tris-HCl pH 8.0) and fractions tested by 
western blotting for Trib2 immunoreactivity. Antibodies were stored at either 4°C or 
-20°C prior to analysis. 
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2.37 Immunoprecipitation (IP) of endogenous Trib2 from THP-1 
cells 
Approximately 30x10
6
 THP-1 cells were washed and pelleted by 
centrifugation and then lysed in 1 ml lysis buffer as described above. Twenty 
microlitres was saved and snap frozen. The remaining lysate was split into two 
aliquots, one of which was incubated with 10 l (~2 g antibody) of the rat anti-
human Trib2 antibody and rotated end-over-end for 3 hours at 4°C.  10 l G-
Sepharose beads (equilibrated in cell lysis buffer) were added to both aliquots of cell 
lysate (+/- antibody) and left rotating overnight at 4°C. The Sepharose resin was 
pelleted by gentle centrifugation (~1000 x g) for 2 minutes at 4°C and the 
supernatant extracted (using a gel loading pipette tip to minimize disruption to the 
pellet), which was snap frozen stored at -20°C. The pellet was then washed 3 times 
with cell lysis buffer. The first wash was in cell lysis buffer that had an increased 
NaCl concentration of 500 mM. Following the final washing step, the pellet was 
resuspended in 50l 2x SDS loading buffer and boiled. Samples of the input, 
supernatant and IP (+/- antibody) were resolved by SDS PAGE and western blotted 
using the same Trib2 antibody to identify the presence of Trib2 in the IP. 
2.38 Immunoprecipitation of overexpressed FLAG-tagged Trib2 
from Flp-In T-REx-293 cells for mass spectrometric analysis 
Twenty, 15 cm dishes were seeded with Flp-In T-REx-293 cells. Upon 
reaching 80-90% confluency, half of the plates were treated with tetracycline to 
induce FLAG tagged Trib2 protein expression. Twenty four hours later both control 
and Tet-induced plates were trypsinised, washed in PBS three times following 
trypsin neutralisation, pelleted and then lysed in 1 ml (total) lysis buffer (on ice) with 
regular agitation to ensure complete cell lysis. Following removal of insoluble matter 
by centrifugation, the lysates were incubated with 50l FLAG M2 conjugated 
agarose beads (Sigma) that had been equilibrated in cell lysis buffer in 2 ml (round 
bottomed) Eppendorf tubes, which were rotated overnight at 4°C. The beads were 
pelleted and washed 3 times in 15 ml cell lysis buffer. Following this, 10 l 5mg/ml 
3xFLAG peptide (Sigma) was diluted in 150 l ice cold PBS and added to each 
pellet to elute the FLAG-tagged Trib2. This was kept on ice for 30 minutes with 
regular agitation. Both immunoprecipitations (+/- tetracycline) were centrifuged and 
the eluate saved. Samples from each step (input, elution and supernatant) were 
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immunoblotted and the remaining immunoprecipitations were analysed by LC-
MS/MS mass spectrometry (Synapt HDMS quadrupole-time-of-flight Mass 
Spectrometer, Waters) by Ms. Alice Wadkin at the University of Manchester. The 
samples were desalted and applied to a nano-ESI source with a PicoTip emitter (New 
Objective, Woburn, MA,USA) at 300 nl/min. The data was acquired by both MS
E 
and DDA experiments, which was analysed and putative interacting Trib2 partners 
were identified by the online software MASCOT (Matrix Science) matching peptide 
ion fragments with the Swissprot database. The proteins that were identified in both 
of the methods are described in Chapter 4. 
2.39 siRNA transfection of NOK Flp-In T-REx-HeLa cells 
Cells were grown to ~70% confluency and transfected as described in the 
transfection reagent protocol with either 200 pmoles of a NOK targeted pool 
consisting of equimolar amounts of 4 NOK targeting siRNA oligonucleotides or 200 
pmoles of a non-coding siRNA pool (On target Plus, Thermo scientific 
(Dharmacon)) dissolved in RNase free sterile H2O using Lipofectamine 2000 as the 
transfection reagent. The siRNA treated and control cells were lysed 48 hours post 
transfection. Lysates were generated as previously described and Trib2 protein levels 
determined by western blotting. 
The NOK target sequences of each constituent of the siRNA pool are: 
siRNA1: CCCAGUAGCUGCACACAUA 
siRNA2: GGUGGUACCUGAACUGUAU 
siRNA3: GAUUAGGCCUGGCUUAUGA 
siRNA4: GAAAAGCUGCCACUCUAUA 
2.40 Immunofluorescence of Fixed Human Cells 
Stably transfected Flp-In T-REx cells (1 x 10
5
 cells) were seeded into wells 
of a 6 well plate that contained sterile glass coverslips. Protein expression was 
induced by the addition of tetracycline (1g/ml) for 18 hours once the cells had 
reached ~80 % confluency. The cells on the coverslips were fixed in 2.5 ml 3.7% 
PFA (paraformaldehyde) for 20 minutes and then washed 3 times in PBS and placed 
in a blocking solution of 0.1 M glycine (pH 8.5) for 5 min. Cells were washed again 
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then permeablised in 0.1% Triton X-100 in PBS for 4 min, and a further 2 washes 
performed. The appropriate primary antibody, at the optimal concentration (antibody 
diluted in PBS, Table 2.1) was added and incubated for 60 minutes. The cells were 
then washed 3 times in PBS and 15 μl of FITC- or Cy-3- conjugated secondary 
antibodies diluted 1/20 in PBS were added and left in the dark for 30 min. The cells 
were again washed 3 times in PBS before 1 μg/ml DAPI (4',6-diamidino-2-
phenylindole) solution in PBS was added and left for 5 min in the dark. The cells 
were washed 3 times and placed face down upon a droplet of Vectashield Mounting 
Medium that rested on a microscope slide and the edges were sealed with nail 
varnish. Images were captured on a Nikon Eclipse T200 inverted microscope 
(Melville). A 200 metal arc lamp (Prior Scientific) and a Hamamatsu Orca ER 
camera were used to obtain images through a 60x oil immersion objective lens. 
Volocity software version 6.1.1 (Improvision) was used to overlay the captured 
images. 
2.41 Nocodazole exposure (cell arrest at metaphase/anaphase 
boundary) 
HeLa cell lines transfected with Myc-tagged full length NOK in the 
pcDNA5/FRT/TO vector were split into 4 T-75 flasks, and two of these were 
supplemented with tetracycline (1 μg/ml). All 4 flasks were grown until >90% 
confluent. Once the cells had reached >90% confluency, nocodazole, (0.2 μg/ml) 
was added to each ± Tet T-75 flask. The cells were then incubated for 12 hours at 
37°C in a 5% CO2 atmosphere before harvesting, including the floating cells.  The 
cells were washed 3 times in 10ml of PBS, but not discarded. One millilitre trypsin 
was then added to the flasks and left for 5 min at 37°C in a 5% CO2 atmosphere. 
This was then added to the post-wash PBS and spun to pellet the cells. The 
supernatant was discarded. The cell pellet was washed and resuspended in PBS and 
re-pelleted. This was repeated twice more. After the final wash step the cell pellet 
was resuspended in Cell Lysis Buffer containing 1% Triton X-100, and left for 20 
min on ice. The microcentrifuge tubes were then spun for a further 20 min at 4°C in 
a refrigerated centrifuge.  Protein concentration was quantified by Bradford Assay, 
whilst the Triton X-100 insoluble pellet was resuspended in 100 μl 1x SDS Buffer 
and boiled for 10 min. Equal amounts of supernatant (typically 30 l) were analysed 
by 15% SDS-PAGE, after boiling in 1/5 volume of 5X SDS loading buffer, 
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alongside the resuspended pellets, and including a ladder of pre-stained protein 
markers. The gel was transferred for 10 h at 18V onto Nitrocellulose membrane. The 
membrane was cut at 25 kDa, the membrane containing proteins of size <25 kDa 
was probed for phospho-Histone H3 Ser 10, whilst the >25 kDa proteins were 
probed for Myc-tagged NOK for 18 hours. Subsequently, the membranes were then 
washed 3 times in TBS-T and exposed to secondary antibodies diluted in 5% milk-
TBS-T for 1h at RT. The membranes were then exposed to ECL reagents as 
described in the western blotting section (above). 
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CHAPTER 3. Biochemical analysis 
of recombinant human Trib2 
Human Tribbles 2 (Trib2), a human homologue of the Drosophila Tribbles 
protein, is a pseudokinase linked to a multitude of human diseases, and is 
consistently overexpressed in a variety of cancers. Trib2 is also termed Hs.155418, 
GS3955, TRIB2 and TRB2, but will be referred to as Trib2 throughout this thesis. As 
demonstrated by Keeshan and colleagues, an intact catalytic domain and a COP1-
binding DQLVP motif (part of the C-terminal 18 amino acids) in Trib2 are required 
for oncogenic transformation in vitro, and the degradation of C/EBP requires the 
recruitment of both Trib2 and a specific Ubiquitin E3 ligase, either COP1 in blood 
malignancies or TRIM21 in solid lung tumors (Keeshan et al., 2010, Grandinetti et 
al., 2011).  The mechanism by which Trib2 specifically controls C/EBP 
degradation has yet to be elucidated, and whether Trib2 binds ATP and/or is a 
catalytically-active pseudokinase remains unknown. 
The deduced protein sequence of Trib2 suggests that the polypeptide contains 
a eukaryotic protein kinase (ePK) domain located between amino acids 64-308. The 
kinase domain of Trib2, is however, non-canonical because several invariant amino 
acid residues that are usually involved in the alignment of metals and ATP and that 
catalyze phosphoryl transfer in classical kinases (Hanks and Hunter, 1995) are absent 
(Chapter 1). Specifically, the metal-binding DFG and Asn motifs are missing in all 
vertebrate Trib2 homologues (Figure 1.1). This observation originally led to the 
classification of the human Tribbles-related proteins Trib1, Trib2, Trib3 and SgK495 
as pseudokinases (Manning et al., 2002). 
Recently, pseudokinases including the tyrosine kinase HER3 (Jura et al., 
2009a, Shi et al., 2010), the pseudokinase-containing JH2 domain of JAK2 
(Ungureanu et al., 2011), and the CAMK family member CASK (Mukherjee et al., 
2008) have demonstrated the ability to both bind and hydrolyse ATP, albeit with 
reduced specific activity compared to typical protein kinases. In contrast, the 
pseudokinase VRK3 is unable to bind to ATP and is thus unable to transfer 
phosphate groups to substrates (Scheeff et al., 2009). In between these extremes lies 
STRAD, a pseudokinase that can bind, but is unable to hydrolyse, ATP in vitro 
(Zeqiraj et al., 2009b). 
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To determine whether Trib2 can hydrolyse ATP and phosphorylate a 
substrate, obtaining a yield of pure Trib2 sufficient for biochemical assays is a 
prerequisite.  One benefit of using E. coli as a source of recombinant human Trib2 is 
that all kinases present in the bacterium are prokaryotic, and only a few members of 
the bacterial kinome are known to autophosphorylate or to phosphorylate non-
specific substrates. Examples include DnaK, the nucleotide diphosphate kinase and 
Era, a GTPase (Macek et al., 2008). However, in order to determine whether Trib2 
can bind ATP and/or phosphorylate substrate proteins, a general control for 
background kinase contamination was generated, in which lysine 90 in the 3 sheet 
of the kinase N-lobe was mutated to an uncharged residue. The corresponding 
mutation in many kinases reduces, and usually abolishes, detectable catalytic activity 
(Iyer et al., 2005b) and therefore the experiments detailed in this chapter are 
performed alongside a series of Trib2 ‘3 lysine’ point mutants, including K90M.  
Results 
3.1 Affinity purification of recombinant human Trib2 from E. coli 
Flasks inoculated with the E. coli strain BL21(DE3)pLysS that had been 
transformed with Trib2 containing IPTG-inducible pET-30 Ek/LIC were incubated at 
37°C (1 x g) until the A600nm reached 0.8 (mid-log phase) as described in Chapter 2. 
To identify conditions for optimal Trib2 expression, induction with (0.5 mM) IPTG 
was performed at 37°C or 18°C, for 3 and 18 h respectively. Following induction, 
His-tagged Trib2 in the cleared bacterial lysate was captured on immobilized Ni-
Sepharose resin (5 ml HisTrapHP), washed, and then eluted with a buffer containing 
300 mM imidazole. The eluted proteins were distinguished on chromatograms by 
their absorbance at a wavelength 280 nm (left panels of 3.1 A and B). To visualize 
proteins by SDS-PAGE, they were resolved and the fractions that contained the 
highest levels of Trib2, which ran as a single band ~45 kDa (judged by Coomassie 
staining and immunoblotting) were pooled. Of the conditions tested, maximum Trib2 
expression was observed following induction at 18°C for 18 h, as judged by SDS-
PAGE. As such all E. coli derived human Trib2 proteins, unless otherwise stated, 
were expressed under these conditions. Final yields of purified WT and mutant Trib2 
protein are listed in Table 3.1. 
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Of interest, two additional high molecular weight proteins migrating at a size 
different to Trib2 were observed following IMAC of recombinant proteins from 
bacterial sources (Figure 3.1, arrowed). The ratio of these bacterial proteins to the 
over-expressed tagged protein varies between one purification and another, despite 
an attempt to follow identical protocols and by using the same glycerol stocks.  To 
identify these proteins, they were separated by SDS-PAGE and excised after staining 
and destaining. Mass spectrometry (performed by Alice Wadkin, University of 
Manchester) identified the proteins as GroEL (57 kDa CH60_ECO24) and DnaK (69 
kDa, DNAK_ECOH5) which are two common contaminants of IMAC-purified 
proteins from E. coli (Bolanos-Garcia and Davies, 2006). Since these are unlikely to 
be physiological Trib2-binding proteins, perhaps interacting with partially folded 
Trib2, or interacting directly with the resin, they were later successfully removed by 
further rounds of purification.  
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Figure 3.1 A comparison of experimental conditions assessed for recombinant His-
tagged Trib2 expression in BL21(DE3)pLysS competent E. coli. Protein expression 
was induced for either (A) 3 hours at 37°C or (B) 18 hours at 18°C and purified by nickel 
ion affinity chromatography. Left panel: The elution of Trib2 was observed by absorbance 
changes on the chromatogram (blue line). The position where the imidazole concentration 
was raised to 300 mM has been labelled as have the fractions that correspond to the gels 
on the right. Right hand panel: SDS-PAGE of the fractions eluted from the Ni-Sepharose 
resin along with samples from the uninduced and induced total cell lysates and 4 g BSA 
protein standard. The protein was stained with coomassie stain. Trib2 and the 
contaminating proteins are labelled and the fraction numbers correspond to the fraction 
numbers on the chromatogram.  
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Protein 
Soluble Trib2 yield  
(mg Trib 2 / litre of LB) 
Trib2 WT 2 
Trib2 K90M 1.3 
Trib2 K90A 1.0 
Trib2 K90R 1.5 
Trib2 DFG K180N 1.0 
Trib2 F130A 2.5 
Trib2 F130G 2.5 
Table 3.1 Yields of His-tagged Trib2 obtained following elution from Ni-Sepharose 
and dialysis. The average yield of Trib2 WT and mutants purified from 1 litre of LB 
induced at 18°C for 18 hours and dialysed into 20 mM bicine pH 9.0, 100 mM NaCl, 1 
mM DTT, 10% (v/v) glycerol are listed.  
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3.2 Purified recombinant WT Trib2 transitions to an unfolded 
state when heated 
Biochemical analysis of Trib2 function requires the purified recombinant 
human protein to be appropriately folded, which is often challenging in prokaryotic 
organisms that lack the fine-tuning pathways normally associated with eukaryotic 
protein expression. One method to determine if Trib2 is folded is to subject it to 
Differential Scanning Fluorimetry (DSF). This technique involves incubating a 
protein with a hydrophobic fluorescent dye such as Sypro Orange. In an aqueous 
environment the dye is strongly quenched, but over the course of a ‘DSF assay’ the 
temperature is raised incrementally, causing the protein to gradually unfold and 
denature, thus exposing buried hydrophobic residues. Binding of these hydrophobic 
surfaces by Sypro Orange results in an increase of fluorescence emission and when 
the detected fluorescence is plotted as a function of temperature, thermal 
denaturation curves can be produced that describe the behavior of the protein as it 
unfolds (Niesen et al., 2007). 
To evaluate whether Trib2 was appropriately folded after expression in 
bacteria, DSF was performed in duplicate, on affinity purified Trib2 or on Trib2 that 
had been denatured by heating for 5 minutes at 95°C. The fluorescence emitted at 
each temperature interval was recorded, averaged and used to generate thermal 
denaturation curves (Figure 3.2). The blue line (non-denatured Trib2) had a melting 
curve consistent with the profile of a folded protein unlike the red line (denatured 
Trib2) which resembled an unfolded protein (Uniewicz et al., 2012). This 
demonstrated that bacterially expressed Trib2 was in a folded conformation 
following IMAC purification. 
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Figure 3.2 His-tagged Trib2 exhibits a thermal denaturation profile typical of a 
folded protein. DSF was performed on 5 μM Trib2, either denatured by heating for 5 
minutes at 95°C (red line), or without heating (blue line). For each condition, the 
average fluorescence intensities from the triplicate assays were normalised and plotted 
as a function of temperature. The Tm value of the average thermal denaturation profile 
has been annotated.  
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3.3  Trib2 solubility can be improved following buffer optimisation 
Trib2 exhibited signs of aggregation and precipitation following IMAC 
purification, which is in agreement with Vedadi et al., (2006) who previously 
observed Trib2 instability in solution. However, this study identified 20 mM bicine, 
100 mM NaCl, 1mM DTT and 10% glycerol as a buffer that greatly improved the 
stability of the purified recombinant Trib2 catalytic domain. We therefore 
investigated whether the same buffer conditions could stabilize full length human 
Trib2 purified from bacteria.  
Affinity purified Trib2 was either dialysed into a buffer used routinely in our 
lab for IMAC purification of kinases (buffer A, 50 mM Tris pH 7.4, 150 mM NaCl, 
1 mM DTT, 10% glycerol) or into the buffer optimized by Vedadi and colleagues 
(buffer B, 20 mM bicine pH 9.0, 100 mM NaCl, 1 mM DTT, 10% glycerol).  
Following dialysis, white insoluble protein aggregation was observed in the 
dialysis tubing that contained Trib2 equilibrated in buffer A, whilst no aggregation 
was detected in the buffer B dialysed sample. To investigate the yield of soluble 
protein, insoluble protein aggregates were removed by rapid centrifugation and the 
soluble protein concentration was determined by Bradford Assay. The findings are 
summarized in Table 3.2A, along with SDS-PAGE analysis (Figure 3.3A). When 
Trib2 was concentrated by centrifugation using a Vivaspin 2 (10 kDa MWCO) 
centrifugal concentrator, Trib2 in buffer A only reached 6 mg/ml, whilst Trib2 in 
buffer B could be concentrated in excess of 10 mg/ml without protein aggregation. 
A mutation to the conserved lysine located within the 3 sheet of the kinase N-
lobe (K72 in the model Ser/Thr kinase PKA) reduces the catalytic activity of most 
kinases (Iyer et al., 2005b), and a mutation was also generated for Trib2. Trib2 
K90M was also soluble in buffer B, and following dialysis no white insoluble 
aggregation was observed. After centrifugation, the concentration of Trib2 and Trib2 
K90M dialysed into buffer B at pH 9.0 or pH 8.0 was determined (Table 3.2 B) and 
the samples resolved by SDS-PAGE (Figure 3.3 B).  Consistently, a lower yield of 
Trib2 K90M was obtained compared to WT from E. coli. The concentrations of both 
Trib2 K90M and Trib2 remain higher following dialysis into buffer B at pH 9.0 
compared to pH 8.0 (Table 3.2B), suggesting increased stability at a higher pH. To 
confirm that this was the case, Trib2 was dialysed into buffer B at pH 7.4 and pH 
9.0, which resulted in more soluble protein at the higher pH (Table 3.2C). 
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Furthermore, following a single freeze thaw cycle, approximately half the protein at 
pH 7.4 was lost compared to Trib2 at pH 9.0 which still contained ~85% of soluble 
Trib2. Unless otherwise stated, buffer B was employed for all future Trib2 
purification procedures from E. coli. 
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Figure 3.3 Optimising experimental conditions for maximising Trib2 solubility. A) 
Trib2 was purified by IMAC and the peak fractions containing the eluted Trib2 were 
pooled then samples of the pool were dialysed in either buffer A (50 mM Tris pH 7.4, 
150 mM NaCl, 1 mM DTT, 10% glycerol) or buffer B (20 mM bicine pH 9.0, 100 mM 
NaCl, 1 mM DTT 10% glycerol) and subjected to SDS-PAGE where 20 l of the 
predialysed sample (lane 1) was resolved alongside the same volume of Trib2 dialysed  
in to buffer A or buffer B (lanes 2 and 3 respectively). The remaining dialysed Trib2 
samples were concentrated by centrifugation in a Vivaspin2 column and resolved by 
SDS-PAGE (lane 4 = buffer A, lane 5 = buffer B). Lane 6 contained 4 g of a BSA 
standard. The protein was observed by coomassie staining. B) Trib2 K90M (lanes 1-3) 
and Trib2 WT (lanes 4-6) were purified concurrently under identical conditions and 
dialysed into either buffer B at pH 8, or buffer B pH 9 and 20 l samples subjected to 
SDS-PAGE.  The concentrations of the purified proteins are noted in Tables 3.2 A and 
B. 
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Following 
IMAC 
Following
dialysis  
into 
buffer A
Following
dialysis  
into 
buffer  B
Buffer A 
dialysed Trib2
after centrifugal 
concentration
Buffer B dialysed 
Trib2 after 
centrifugal 
concentration
Trib2
concentration 
μg/μl
6.4 2.1 6.2 6.0 13.2
Trib2 WT
Following 
IMAC
Following 
dialysis into 
buffer B 
(pH 7.4)
Following 
dialysis 
into buffer 
B (pH 9.0) 
Frozen and 
thawed Trib2
(buffer at pH 
7.4)
Frozen and 
thawed  Trib2
(buffer at pH
9.0)
Trib2
concentration 
μg/μl
2.6 1.3 2.4 1.15 2.2
Trib2 K90M Trib2 WT
Following
IMAC
Following 
dialysis into 
buffer B (pH 
8.0)
Following 
dialysis 
into 
buffer B 
(pH 9.0)
Following
IMAC
Following 
dialysis 
into buffer 
B (pH 8.0)
Following 
dialysis 
into buffer 
B (pH 9.0)
Trib2
concentration 
μg/μl
0.8 0.65 0.72 2.2 1.8 2.2
A
B
C
   
Table 3.2 Summary tables for Trib2 solubility optimisation. Concentrations of the 
dialysed proteins in Figure 3.3 were determined by Bradford analysis at 595 nm. A) The 
concentrations of Trib2 dialysed into buffer A and buffer B are noted. The concentration of 
each sample of Trib2 in either buffer A or buffer B is also recored following centrifugal 
concentration using a Vivaspin 2 column, until the protein concentration remained constant. 
B) The concentrations of Trib2 K90M and Trib2 WT purified by IMAC are listed and the 
concentrations following dialysis into buffer B, either at pH 8.0 or pH 9.0. C) Trib2 WT was 
purified using IMAC and the pooled fractions were dialysed into buffer B at either pH 7.4 or 
pH 9.0. The concentration before dialysis and after dialysis was noted and and the fractions 
were snap-frozen in liquid nitrogen. Following one freeze thaw cycle, the concentrations of 
the proteins were also measured, to assess the effects of storage at -80°C. 
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3.4  Affinity purified Trib2 is catalytically active 
The ability of the Trib2 pseudokinase domain to transfer the-phosphate 
from ATP to a protein substrate has yet to be demonstrated, and many pseudokinases 
are known to be catalytically inactive when analysed in vitro towards exogenous 
substrates, meaning that other approaches are needed to analyse their biochemical 
functions (Murphy et al., 2014b) (Riterer et al., 2014 (TCB In press)). To analyse 
Trib2 catalytic potential, the fractions that contained Trib2 that eluted from the Ni-
Sepharose column (see chromatogram in Figure 3.4 A) were assayed for 
autophosphorylation in the presence of 1 mM ATP (2.25 Ci 32P ATP) (Figure 3.4 
B and Figure 3.4 C) to identify whether any detectable activity was associated with 
Trib2. Trib2, like the pseudokinase CASK, whose kinase activity was inhibited by 
divalent cations (Mukherjee et al., 2008), does not have a divalent cation-binding 
asparagine residue located in the catalytic motif, nor a magnesium ion binding 
‘DFG’ motif in kinase subdomain VII (Trib2 has SLE instead), and so magnesium 
ions were not added to the reaction mixture.  
As shown in Figure 3.4 B, 250 pmoles of affinity purified Trib2 from each of 
the fractions that corresponded to the protein peak on the chromatogram (Figure 3.4 
A) were assayed in duplicate for 30 minutes in the absence of any divalent cation.  
Another preparation of Trib2 was affinity purified and the protein in the peak 
fractions were assayed alongside the fractions that eluted either side of the peak 
(Figure 3.4 C).  
In both of these assays it was interesting to observe that the pseudokinase 
Trib2 had become autophosphorylated, meaning 
32
P was incorporated directly into 
Trib2. Trib2 that eluted in the fractions that corresponded to the centre of the peak 
autophosphorylated to a greater extent than Trib2 towards the peak shoulders, 
perhaps indicating that the protein in the shoulders of the peaks was more 
aggregated. 
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Figure 3.4 Isolating the catalytically active fractions of Trib2 following Ni IMAC A) The 
absorbance peak observed on the chromatogram indicated the fractions that contained protein 
following IMAC chromatography. B) Trib2 (250 pmoles, ~11.75 g) from fractions 41-44 were 
assayed in duplicate for 30 minutes at 30°C on a shaking platform with 2 mM EDTA and 1 mM 
ATP (2.2 Ci -
32
P ATP). The reactions were stopped by the addition of 5 x SDS loading 
buffer and 25 l of each assay were resolved by SDS-PAGE. The protein was stained with 
coomassie stain and the gels were dried and treated to autoradiography. C) In duplicate, 250 
pmoles of fractions 38-48 were assayed on a shaking platform for 30 minutes. The individual 
fractions were assayed alongside 100 pmoles Trib2 WT (Pool) that had been purified 
previously and dialysed into buffer B, 25 l of the reaction mixtures were subjected to SDS-
PAGE and subjected to autoradiography. 
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3.5  Isolation of Monomeric Trib2 
As discussed in Section 3.3, affinity purified Trib2 is very prone to 
aggregation. Importantly, gel filtration (often termed size-exclusion) 
chromatography can be employed to separate aggregated Trib2 away from 
appropriately folded Trib2, which interacts with the column and elutes in a native 
complex. Gel filtration separates the proteins by molecular weight, in non-denaturing 
conditions (Stellwagen, 1990) and permits further Trib2 purification.  
Prior to gel filtration of Trib2 using a Superdex 200 10/300 column (GE 
Healthcare), purified protein standards of varying molecular weights were dissolved 
in standard IMAC elution buffer, and then applied to the column, permitting a 
standard curve to be generated (Figure 3.6B) (as described in Chapter 2). The elution 
volumes of each standard are determined by direct reference to this chromatogram 
(Figure 3.5 and summarised in Table 3.3 A).  Following gel filtration, the Ve values 
of the chromatograph peaks (Figure 3.6 A) were divided by the Vo of Blue Dextran. 
The apparent molecular weight was estimated by applying these values (summarised 
in Table 3.3B) to the molecular weight standard curve (Figure 3.6 B).  The predicted 
molecular weight of monomeric Trib2 with a 6His tag is 43524 Da (ExPASy 
ProtParam). The Ve of peak 3 predicts a protein of ~45 kDa, (Figure 3.6A and Table 
3.3 B), which indicates the presence of monomeric Trib2 in these fractions. The 
protein was confirmed by SDS-PAGE (Figure 3.6 C) and western blotting as Trib2. 
The fractions labelled in red (Fig 3.6 C) were snap frozen in liquid nitrogen and 
stored at -80°C prior to analysis. Trib2 that eluted in a lower Ve (higher MW in non-
denaturing conditions) such as detected in peak 2 (Figure 3.6), could potentially be 
aggregated or disulphide bonded oligomers. To determine whether Trib2 remained 
monomeric following freeze-thaw procedures, purified Trib2 was applied to a gel 
filtration column as described above. The elution profile (Figure 3.7 A) confirmed 
that several fractions contained a protein that eluted in the Ve (14.7 ml) that was 
expected for monomeric Trib2, and SDS PAGE confirmed that Trib2 was present in 
these fractions (Figure 3.7 B). Higher MW contaminants were separated from the 
protein that eluted in a volume predicted for monomeric Trib2. These Trib2-
containing fractions were pooled, freeze-thawed, and the protein was again applied 
to the gel filtration column. Analysis of the chromatogram (Figure 3.8 C) shows that 
after gel filtration the Trib2 conformational equilibrium mainly favored monomeric 
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Trib2, rather than a transition to the higher MW forms of the protein observed 
following affinity chromatography.  
 
   
Figure 3.5 Gel filtration of Molecular Weight protein standards. Albumin 10 mg/ml, 5 mg/ml 
alcohol dehydrogenase, 4 mg/ml -amylase,  3 mg/ml carbonic anhydrase, 2 mg/ml 
cytochrome c protein standards  were dissolved  in 500 l elution buffer (containing 300 mM 
imidazole, see Materials and Methods) and subjected to gel filtration in 20 mM bicine pH 9.0, 
100 mM NaCl, 10% glycerol, 1 mM DTT. The elution volumes (Ve) were measured from the 
centre of the peaks (recorded in Table 3.3A) and the Ve/Vo value derived, where Vo is the void 
volume (2 mg/ml Blue dextran). These values were used to generate a standard ‘curve’ for this 
Superdex 200 10/300 gel filtration column (Figure 3.6B).  
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Figure 3.6 A population of Trib2 elutes from a gel filtration column in a volume that 
corresponds to the Ve predicted for monomeric Trib2 A) Trib2 (1 mg) that had been 
purified by IMAC chromatography was applied to a Superdex 200 10/300 gel filtration 
column and the elution volumes of each peak were recorded. B) The Ve/Vo ratio was 
determined for each peak by dividing the Ve values with the Vo from Blue Dextran. The 
MW of the proteins in each absorbance peak were inferred by refering to the MW protein 
standard curve. C) SDS-PAGE was used to resolve 20 l of the collected fractions along 
with 4 g of a BSA standard. The fractions that eluted in the predicted Ve for monomeric 
Trib2 (peak 3 fractions 23-26 Ve = 14.7ml) were pooled (red font).  Predicted MWs for 
each peak are summarised in Table 3.3B. 
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MW kDa Vo ml Ve ml Ve/Vo
Blue Dextran 2000 8.25
β Amylase 200 11.39 1.38
Alcohol 
Dehydrogenase
150 12.27 1.48
Albumin 66 13.43 1.63
Carbonic 
Anhydrase
29 15.86 1.94
Cytochrome c 12.4 17.63 2.12
Vo 
ml
Ve ml Ve/Vo
Interpolated MW from 
standard curve
kDa
Blue dextran 8.25
Absorbance peaks Ve ml Ve/Vo
1 7.9 0.96 1024
2 9.96 1.2 407
3 14.68 1.77 45
4 20.58 2.5 2
A
B
  
Table 3.3 Summary of Ve values interpolated MW of following gel filtration  of 
protein standards and Trib2 A) The MW of each standard (10 mg/ml abumin, 5 mg/ml 
alcohol dehydrogenase, 4 mg/ml -amylase, 3 mg/ml carbonic anhydrase, 2 mg/ml 
cytochrome c) dissolved in 500 l IMAC elution buffer is listed along with the elution 
volume (Ve) of each protein measured from the middle of the corresponding protein peak 
following elution from the Superdex 200 10/300 gel filtration column and the elution 
volume of Blue Dextran (Vo). B) 1 mg Trib2 was applied to the gel filtration column and 
the Ve/Vo for each of the peaks determined. The MW of protein eluted in these peaks was 
estimated from the standard curve (Figure 3.6 B) 
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Figure 3.7 The majority of Trib2 retains a monomeric elution profile with further gel 
filtration A) IMAC purified Trib2 was applied to the Superdex 200 10/300 gel filtration column 
and the protein eluted in buffer B (500 l). The elution volume of the main peak was 
determined and 20 l fractions were resolved by SDS-PAGE (B). The protein was stained with 
coomassie stain and lanes 19 and 20 (red font) corresponded to the fractions that had a Ve 
representative of monomeric Trib2 (Ve 14.7). These were pooled together and 20 l resolved 
alongside (Pool). The pooled protein (fractions 19 and 20) was snap frozen in liquid nitrogen 
then thawed and C) gel filtered again. Interestingly, the majority of the protein eluted again as 
a sharp peak of Ve ~14.7 ml. 
 
 131 
 
To confirm that the purified protein was Trib2, and further investigate its 
native sequence, Mass Spectrometry analysis (ESI-MS) of gel filtered Trib2 (Figure 
3.8) was employed. This revealed that Trib2 had an intact average mass of 43,582 
Da, compared to a predicted MW of 43,524 Da (ProtParam) and an estimated 
molecular mass after gel filtration interpolated from the standard curve of ~45,500 
Da (Figure 3.6 B). Together, these data confirm the predominance of monomeric, 
non-covalently modified Trib2 in these preparations.  
3.6  Trib2 purified by gel filtration still autophosphorylates in 
vitro 
  Gel filtered Trib2 was subjected to an in vitro kinase assay to determine 
whether it could still autophosphorylate (Figure 3.9A) as previously demonstrated 
for IMAC-purified Trib2 (Figure 3.4).  Fractions of Trib2 that were predicted to be 
monomeric (fractions 19 and 20, Ve 14.6 ml) were subjected to an in vitro kinase 
assay in the presence of 1 mM ATP (2.25 Ci 32P ATP per assay) in the absence of 
divalent cations. As shown in Figure 3.9B, Trib2 was still able to autophosphorylate 
after separation from the higher molecular weight contaminants that were present 
after affinity purification.  Autophosphorylation was visualised by autoradiography, 
which detected the presence of the radiolabelled phosphate that had been 
incorporated by Trib2 during the in vitro kinase assay. The active kinase Aurora A 
(tagged with the same N-terminal His tag and isolated in an identical fashion from E. 
coli) was also assayed as a positive control in the presence of Mg
2+
, and affinity 
purified Trib2 autophosphorylated in the absence of magnesium ions as previously 
demonstrated (Figure 3.4).  The fractions that contained monomeric Trib2 were 
pooled and assayed (Figure 3.9 C). The time-dependent increase of the signal 
intensity was indicative of autophosphorylation and confirmed that Trib2 hydrolysed 
ATP and incorporated the released -phosphate rather than non-specifically binding 
to it in the gel.  
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Figure 3.8 Exact MW of gel filtered Trib2 was determined by Mass Spectrometry. An 
intact average mass of Trib2 was calculated using a Waters Qtof Global by nanoES. A MW 
of 43582 Da compared to the predicted 43524 Da was obtained by ESI-MS analysis, using 
BSA (average mass 66432.96 Da) as a standard (performed by Dr Claire Eyers, University 
of Liverpool).  
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Figure 3.9 Trib2 autophosphorylated after gel filtration A) Gel filtration chromatogram of 
IMAC purified Trib2 eluted into buffer B. The fractions collected are numbered and the fractions 
that eluted in 14.6 ml buffer, the predicted elution volume of monomeric Trib2 are highlighted in 
red font (fractions 19 and 20)  B) The gel filtered Trib2 (from A) was subjected to an in vitro 
kinase assay and resolved by SDS-PAGE. Fractions 19 and 20, highlighted in red, were the 
fractions that eluted from the gel filtration column (panel A) in a volume (14.6 ml) that was 
expected for monomeric Trib2. Alongside the assays of the fractions, 250 pmoles of a Trib2 
control (purified previously by IMAC) and 25 pmoles Aurora A were also assayed and resolved 
by SDS-PAGE. The protein was stained by coomassie stain (top panel) and autorads show the 
presence of incorporated radiolabelled phosphate in the protein (bottom panel).  C) The fractions 
19 and 20 (eluted in a volume predicted for monomeric Trib2) were pooled together and 250 
pmoles were assayed in the same manner as in Figure 3.9 B. The assays were terminated at the 
stated time by the addition of 5 x SDS PAGE loading buffer and heating. They were then treated 
to SDS-PAGE analysis and the protein stained with coomassie stain (top panel).  The gels were 
dried and subjected to autoradiography (bottom panel shows the autorads and the signals 
correspond to protein containing radiolabelled phosphate). 
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3.7  Trib2 autophosphorylation is decreased by mutation of 
classical invariant kinase residues in the Trib2 catalytic domain. 
With the discovery that the Trib2 has an intrinsic ability to autophosphorylate, 
its mechanistic biochemistry was investigated further. It is standard practice in the 
field (Carrera et al., 1993, Iyer et al., 2005a), for the conserved lysine in the 3 motif 
of classical kinases (PKA K72, corresponding to Trib2 K90) to be mutated in an 
attempt to create a kinase domain with a reduced level of catalytic activity.  To 
verify whether the Trib2 pseudokinase domain is catalytically active through a 
conventional mechanism that involves amino acids in stereotypical positions in the 
kinase, affinity purified Trib2, and the Trib2 mutants K90M and K177A were 
incubated with radiolabelled 32P ATP. Trib2 K90M contained a mutation to the 
lysine that is conserved throughout the 3 motifs of ‘classical’ human kinases. This 
coordinates the - and - phosphates of ATP in the kinase active site, facilitating the 
catalytic hydrolysis of the -phosphate.  Trib2 K177A is a mutation to a lysine 
located within the catalytic motif. Previous studies identified that following a 
mutation to K177, the stability in cells and oncogenic transforming capability of 
cells expressing K177A and levels of C/EBPdegradation were reduced, compared 
to WT Trib2-expressing cells (Keeshan et al., 2010). As shown in Figure 3.10 A, 250 
pmoles Trib2 autophosphorylated in a readily detectable manner but this was 
markedly reduced when Trib2 K90M (Figure 3.10 B) or Trib2 K177A (Figure 3.10 
C) were assayed alongside. The positive control for these experiments was 25 
pmoles of the active kinase Aurora A (Figure 3.10 D) and 250 pmoles of the point 
mutant Aurora A D274N (Figure 3.10 E), which is a mutation to the magnesium ion 
binding Asp in the DFG motif that prevents metal binding, were assayed for 60 
minutes. This experiment demonstrated that the D274N mutation in the catalytic 
domain of Aurora A kinase reduced catalytic activity (assessed by 
autophosphorylation) to a level lower than that present in Trib2. However, 10-fold 
less active WT Aurora A was assayed alongside Trib2, yet despite this, Aurora A 
autophosphorylated to a greater extent than Trib2 (determined by visual analysis of 
the autorad intensities), which indicated that Trib2 catalytic activity is rather low 
when compared directly to an active kinase. 
To quantify the difference in catalytic activities of Trib2 and mutant Trib2 
proteins, an in vitro kinase assay was performed (Figure 3.11). The gels were 
subjected to autoradiography (Figure 3.11 A) and radioactivity was quantified by 
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normalizing the density of each signal to the coomassie stained protein using the 
ImageJ software. A representative gel is shown in Figure 3.11 A, with the 
normalized, averaged values plotted in Figure 3.11 B, which clearly displays the 
increased ability of WT Trib2 to incorporate the radiolabelled phosphate compared 
to the pseudokinase domain-mutated proteins. 
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Figure 3.10 Catalytic domain mutations reduce Trib2 autophosphorylation. A, B, C) 
Trib2 WT, K90M and K177A (250 pmoles, 11.75 g) were incubated with 2 mM EDTA and 
1 mM ATP (2.25 μCi -
32
P ATP) for the stated time in duplicate. The assays were stopped 
by the addition of 5 x SDS loading buffer, boiled for 5 minutes and samples run on 12% 
polyacrylamide gels. The protein was stained with coomassie stain and dried (top panels). 
The gels were subjected to autoradiography (bottom panels). D) 25 pmoles Aurora A WT 
and E) 250 pmoles Aurora A D274N were incubated with 10 mM Mg
2+
 and 1 mM ATP for 
60 minutes. At which point the assays were terminated as in A-C. 
 137 
 
 
  
Trib2
50
50
37
37
WT K90M K177A
32P-Trib2
A
B
n=2
T
r i
b
2
 W
T
T
r i
b
2
 K
9
0
M
T
r i
b
2
 K
1
7
7
A
 
0 .0 0
0 .2 5
0 .5 0
0 .7 5
1 .0 0
1 .2 5
R
e
la
ti
v
e
 d
e
n
s
it
o
m
e
tr
y
Figure 3.11 Trib2 K90M and K177A autophosphorylate to a lesser extent than WT 
Trib2. A) In duplicate, 250 pmoles Trib2 WT, K90M and K177A were assayed in vitro for 
30 minutes. The gel containing the stained protein (top panel) was subjected to 
autoradiography (bottom panel). B) The stained protein from A and signals in the 
autoradiograms were quantified by densitometry using imageJ software. The 
32
P signals 
were normalised to the protein (approximated by densitometry of the coomassie stained 
protein in the gels). The averaged signals for the two experiments that were performed 
with different preparations of protein (in duplicate) were plotted in the bar chart along with 
the standard deviation. 
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3.8  Analysis of K90 Trib2 mutants 
K90M Trib2 demonstrated a reduced ability to autophosphorylate when 
compared to WT Trib2 (Figure 3.12). The autoradiograms demonstrate that WT 
Trib2 incorporated the hydrolysed radiolabelled phosphate to a greater extent than 
K90M over the course of the assay and this was quantified by phosphorimage 
analysis. Two other K90 mutants, Trib2 K90A and Trib2 K90R, were therefore 
assayed in the same manner, to see whether the effect was true for a variety of K90 
mutants or was specific to K90M. 
Trib2 (Figure 3.13 A), K90A Trib2 (Figure 3.13 B) or K90R Trib2 (Figure 
3.13 C) were assayed as above (250 pmoles), in the presence of 1 mM ATP (2.25 
Ci 32P ATP) and the reactions were stopped in SDS sample buffer at the indicated 
time points. Trib2 autophosphorylation increased in a time-dependent manner. 
However, mutating K90 to Ala (Trib2 K90A) where the charged lysine is mutated to 
an uncharged Ala, led to the abrogation of autophosphorylation. Conversely, K90R 
Trib2, in which Lys was mutated to a similarly positively charged Arg residue, 
remained catalytically active and was able to autophosphorylate to a similar degree 
as WT Trib2 
3.9 Trib2 cannot phosphorylate common exogenous kinase 
substrates 
Most kinases autophosphorylate weakly due to dimerisation, especially at 
high protein concentrations, but nearly all function to phosphorylate specific 
substrate proteins to trigger downstream signaling pathways, examples being 
members of the MAPK cascade. Analysing substrate phosphorylation would be 
advantageous for elucidating the biochemical activity of Trib2 because it would 
allow for the possibility of examining phosphorylation using techniques other than 
autoradiography of radiolabelled proteins after SDS-PAGE, which can be a very 
slow procedure (up to a week) when analyzing pseudokinases that have low levels 
of catalytic activity, such as Trib2. One technique that could be adopted for Trib2 
assays requires discovery of a substrate that has a net positive charge. When such 
substrates are phosphorylated and applied to negatively charged P81 
phosphocellulose paper (Glass et al., 1978) the rate of phosphorylation can be 
quantified using a liquid scintillation counter. 3 types of classical protein 
substrates, two of which are amenable to the p81 phosphocellulose procedure, 
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were therefore tested for phosphorylation by Trib2. These are a range of Histone 
proteins (H1, H2A, H2B, H3 and H4), Myelin Basic Protein (MBP) and alpha 
casein (Figure 3.14). However, despite being phosphorylated by the active kinase 
Aurora A, there was no observable phosphorylation of any of these substrates by 
Trib2. A high background signal was detected for the histone proteins even in the 
absence of Trib2, which indicated that the high concentration and specific activity 
of the ATP used had caused a false-positive signal.  
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Figure 3.12 Trib2 autophosphorylates to a greater extent than the 3 Lysine mutant 
K90M   A) Trib2 and Trib2 K90M were assayed in the presence of 1 mM radiolabelled ATP 
and 20 mM EDTA, The assays (in duplicate) were stopped by the addition of 5 x SDS 
loading buffer at the stated timepoints, boiled for 5 minutes and samples run on 12% 
polyacrylamide gels. The protein was stained with coomassie stain and autophosphorylation 
observed on X-ray film.  B) The autophosphorylation was quantified using a 
phosphorimager. The values corresponding to each timepoint were averaged and plotted in 
GraphPad Prism 6, along with the standard deviation values. 
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Figure 3.13 Trib2 K90R retains residual catalytic activity unlike Trib2 K90A. A) 
Trib2 WT, B) Trib2 K90A and C) Trib2 K90R (250 pmoles), were incubated at 30 °C 
on a shaking platform for the given time in the presence of 2 mM EDTA and 1 mM 
ATP (2.25 μCi -
32
P ATP). The assays were terminated and the protein in the assays 
resolved by SDS-PAGE. The protein was stained (top panels of A, B and C) and gels 
were dried and treated to autoradiography, where the film was exposed to the stained 
and dried SDS-PAGE gels containing the radioactive samples for 48 hours (lower 
panels). 
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Figure 3.14 Trib2 WT does not phosphorylate 3 commonly used kinase exogenous 
substrates. Trib2 (250 pmoles)  or  25 pmoles Aurora A were assayed  in the presence of 
either mixed histones, alpha-casein or Myelin Basic Protein, and with 1 mM ATP (2.2 Ci 

32
P ATP) and ‘cofactor’ (either 2 mM EDTA or 10 mM Mg
2+
) . The substrates were also 
incubated with ATP but without any additional kinase present. 250 pmoles BSA was 
assayed alongside. The assay duration was 30 minutes. The assays were terminated by 
the addition of loading buffer containing SDS and then heated for 5 minutes. The protein 
was observed by coomassie staining of the SDS-PAGE resolved assays (top panel) and 
the incorporated phosphate was observed on the corresponding autorads (lower panel). 
BSA (250 pmoles), was used as a negative control and assayed in the same manner as 
Trib2 and Aurora A. 
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3.10 Trib2 does not phosphorylate GST-C/EBPin in vitro kinase 
assays 
No evidence of Trib2 catalytic activity directed towards several exogenous 
substrates was observed in vitro, although Trib2 can autophosphorylate in these 
assays. In cellular systems Trib2 interacts with the E3 Ubiquitin ligases COP1 and 
TRIM21 and this then targets the transcription factor C/EBP for degradation, 
although other proteins such as acetyl CoA carboxylase are also substrates in HeLa 
cells (Dedhia et al., 2010). All members of this complex are required to actively 
target C/EBP for degradation (Keeshan et al., 2010). To identify whether C/EBP 
is a substrate for Trib2 phosphorylation in the absence of COP1, recombinant GST-
C/EBP(a kind gift from Dr. Karen Keeshan, University of Glasgow) 
wasexpressed in BL21(DE3)pLysS and purified as described in Chapter 2 (Figure 
3.15 A). To assay for substrate phosphorylation, GST-C/EBP was incubated at a 
1:1 molar ratio with 250 pmoles of Trib2 in the presence of 1 mM ATP (2.25 Ci 
P ATP) for 30 minutes. Under these assay conditions, Trib2 did not phosphorylate 
GST-C/EBP, whereas GST-C/EBPwhich contains two potential (weak) Aurora 
A phosphorylation consensus sequences (RxS) (Ferrari et al., 2005), was 
phosphorylated detectably in the presence of Aurora A and magnesium ions (Figure 
3.15B). Interestingly, Trib2 autophosphorylation was partially reduced in the 
presence of GST-C/EBP compared to when C/EBP is absent, but this was not 
investigated further. These findings suggest that GST-C/EBPis not a direct 
substrate for Trib2-mediated phosphorylation. 
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Figure 3.15 Trib2 does not phosphorylate GST-C/EBP A) Twenty microlitres of the 
fractions collected following IMAC purification of GST-C/EBP were resolved on 12% SDS-
PAGE gels alongsdide 10 l induced lysate. The protein was stained with coomassie stain and 
fractions 5 and 6 were pooled together. B) Trib2 WT or K90M (250 pmoles), or 25 pmoles 
Aurora A WT, were incubated with/without 250 pmoles of GST-C/EBPand radiolabeled ATP 
(2.2 Ci 
32
P ATP) at 30 °C on a shaking platform for 30 minutes. The assays were stopped by 
the addition of loading buffer, boiled, subjected to SDS-PAGE (15% SDS-PAGE gels) and the 
protein stained with coomassie stain (top panel of B). The gels were dried and an X-ray film 
placed over the film. The incorporated radiolabelled phosphate was then observed on the film 
(lower panel of B). 
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3.11 Trib2 autophosphorylation is inhibited by divalent cations in 
vitro 
In data described so far, Trib2 has demonstrated the unusual ability of 
autophosphorylation in the absence of Mg
2+ 
ions, which were not added to the 
reaction mixture because, Trib2 does not possess the metal ion-binding residues 
that are observed in active kinases. Most of these kinases require the presence of 
divalent metal ions to phosphorylate substrates. However, one recent study with 
the pseudokinase CASK is a notable exception (Mukherjee et al., 2010). Similar 
to CASK, Trib2 can autophosphorylate in the absence of Mg
2+
 ions (Figure 
3.16). Remarkably, autophosphorylation is actually inhibited in the presence of 
10 mM Mg
2+
 and Mn
2+
 ions, as judged by the reduced intensities of the 
autophosphorylated proteins on an autoradiogram (Fig 3.16 A) Trib2 K90M 
residual activity is also sensitive to divalent cation addition (Figure 3.16 B). 
Trib2 was inhibited by Mg
2+ 
ions in a concentration-dependent manner with 
inhibition observed at as low as 5 mM Mg
2+
 (Fig 3.16 C). It is difficult to judge 
whether Trib2 autophosphorylation is inhibited to an even greater extent by the 
Mg
2+
 concentration exceeding 10 mM, because when in vitro assays were 
performed in the presence of 50 mM Mg
2+
, the solubility and/or stability of 
Trib2 decreased markedly, as observed by SDS-PAGE (Figure 3.16 C) 
Intriguingly, the level of Trib2 autophosphorylation was affected to 
varying degrees by different divalent cations (Figure 3.17). Ni
2+
 and Zn
2+ 
(ZnAc2), inhibited Trib2 autophosphorylation to a similar extent as Mg
2+
. Whilst 
the addition of several other divalent cations, including Cd
2+
, Cu
2+
, Co
2+
, Ca
2+
 
and Zn
2+
 (ZnCl2), also appeared to reduce Trib2 autophosphorylation, this may 
well have been the result of decreased Trib2 solubility in the assay, as judged by 
the reduced amount of Coomassie-stained Trib2 present.  
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Figure 3.16 Trib2 autophosphorylation is inhibited by Mg
2+ 
and Mn
2+ 
ions. A) Trib2 
WT and B) Trib2 K90M (250 pmoles) were assayed in the presence of 1 mM ATP at 
30°C for 30 minutes with either no additional ions (0) or 10 mM Mg
2+
 or Mn
2+
 as 
indicated above the respective lanes of the SDS-PAGE gels. The protein was stained by 
coomassie stain (top panels) and the Trib2 incorporation of 
32
P was detected by 
autoradiography after termination of the assay and SDS PAGE (bottom panels). CASK 
(250 pmoles) was assayed as a positive control with no additional divalent cations 
added. C) Twenty minute radiometric assays of 250 pmoles Trib2 WT in the absence of 
(0), or presence of the indicated concentrations of Mg
2+
 or 2 mM EDTA. The protein was 
resolved by SDS-PAGE, and stained using coomassie (top panel). The gels were dried 
and subjected to autoradiography (bottom panel) to observe the incorporated 
radiolabelled phosphate.  
 
 147 
 
N
o
 io
n
M
g
2
+
M
n
2
+
N
i 2
+
C
d
2
+
C
u
2
+
C
o
2
+
S
r
2
+
C
a
2
+
Z
n
 A
c
2
Z
n
 C
l2
E
D
T
A
Trib2 WT
10 mM metal ion
32P Trib2 WT
50
50
37
37
50
50
37
37
N
o
 io
n
M
g
2
+
M
n
2
+
N
i 2
+
C
d
2
+
C
u
2
+
C
o
2
+
S
r
2
+
C
a
2
+
Z
n
 A
c
2
Z
n
 C
l2
E
D
T
A
Trib2 WT
10 mM metal ion
32P Trib2 WT
 
 
  
Figure 3.17 Trib2 is differentially sensitive to distinct divalent cations. Trib2 WT 
(250 pmoles) was assayed either in the absence or presence of the 10 mM divalent 
cation listed, or 2 mM EDTA for 30 minutes in duplicate. Added to the reaction mixture 
was 1 mM 
32
P ATP (2.2 Ci ATP). The reactions were terminated upon addition of SDS 
loading buffer and the samples were boiled for 5 minutes. The samples were then 
subjected to SDS-PAGE and upon completion, the duplicate gels were coomassie 
stained to visualise the protein (top segment of each of the duplicate experiments). After 
gel drying, 
32
P incorporation was detected by autoradiography on X-ray film (lower 
segments). 
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3.12 CASK autophosphorylates under assay conditions adapted for 
Trib2 autophosphorylation 
CASK is a catalytically active pseudokinase that is inhibited by divalent 
cations (Mukherjee et al., 2008). As demonstrated in Figure 3.18A, Trib2 and 
GST-His CASK that were purified using identical procedures and dialysed into 
identical 20 mM bicine pH 9.0, 100 mM NaCl, 1 mM DTT 10% glycerol 
buffers, were assayed in the absence of divalent cations. Trib2 
autophosphorylation increased during the assay in a similar fashion to GST-His 
CASK, as reported previously (Mukherjee et al., 2008) (Figure 3.18A). This 
clearly shows that under the assay conditions used for Trib2 
autophosphorylation, a pseudokinase with reported catalytic activity can also 
autophosphorylate. Of note, no signal was detected on the autoradiogram when a 
non-pseudokinase control (250 pmoles BSA) was assayed, confirming an 
enzymatic role of the pseudokinases. 
3.13 Can Trib2 biochemical function be changed by mutagenesis? 
In an attempt to subvert the catalytic behaviour of Trib2 from a very low 
activity, metal-inhibited pseudokinase to one that more closely resembles a 
typical active kinase, Trib2 residues K180 and S195, L196 and E197 were 
mutated to the equivalent canonical Mg
2+
 binding residues find in classical 
kinases (PKA DFG motif; D184, F185, G186) (Trib2 S195D, L196F, E197G 
and K180N). As previously observed, Trib2 WT demonstrated optimal activity 
in the absence of divalent cations. Trib2 K180N, and Trib2 ‘DFG’, a Trib2 triple 
mutant (S195D L196F E197G), were still able to weakly autophosphorylate in 
the absence of divalent cations, but their activity was not augmented by Mg
2+
, or 
Mn
2+
. Simultaneous insertion of both of these motifs to produce a Trib2 DFG 
K180N quadruple mutant resulted in no detectible autophosphorylation (Figure 
3.18B), showing that mutagenesis had not successfully activated Trib2 under 
these conditions. Consistently, no signal was observed for BSA, a non-kinase 
secreted protein that was employed as a negative control. 
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Figure 3.18 Trib2 divalent metal inhibition cannot be removed by mutating the metal 
binding residues to canonical kinase residues.  A) Trib2 (250 pmoles) were 
radiometrically assayed for the allocated time, alongside 250 pmoles GST-CASK and 250 
pmoles BSA (60 minutes) in the absence of Mg
2+ 
ions. B) Mutant Trib2 proteins containing 
the classical kinase Mg
2+ 
binding residues were generated (DFG and DFGK180N) and 250 
pmoles were subjected to radiometric kinase assay for 30 minutes in the presence of either 
2 mM EDTA or 10 mM of the divalent cations as listed. GST-tagged CASK and BSA (250 
pmoles) were used as autophosphorylation controls. The assays were terminated and the 
protein resolved by SDS-PAGE. The stained protein (top panels of A and B) were 
subjected to autoradiography and the incorporated 
32
P visualised on X-ray film (bottom 
panels). 
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3.14 Purification of recombinant human Trib2 from eukaryotic 
cells 
Some human protein kinases are inactive, or less active, when isolated from 
E. coli. For example, a study performed by (Zhang et al., 2004) identified lower 
levels of activity for the C subunit of PKA when purified from E. coli compared to 
a eukaryotic source (Sf9 cells).  This suggests that eukaryotic factors may be 
required for the production of a fully functional enzyme. Furthermore, it is well-
known that human kinases purified in prokaryotic expression systems will lack the 
upstream regulators that often activate them, an example being the members of the 
MAPK family, which are sequentially phosphorylated and activated as part of kinase 
cascades (Khokhlatchev et al., 1997). 
To analyse the catalytic behavior of Trib2 expressed in a eukaryotic cell type, 
Sf9 cells, derived from the pupal ovarian tissue of Spodoptera frugiperda, were 
transfected with Trib2-pBAC2cp plasmid, and transformants selected. Expression 
levels of recombinant 6His- Trib2 WT, K90M or DFGK180N mutants present in Sf9 
cell lysates are shown in Figure 3.19. Note that the expression levels of Trib2 WT 
and DFGK180N are much higher than the expression of the K90M mutant. In order 
to assay Trib2, Trib2 WT was partially purified from the lysate of ~2x10
9
 Sf9 cells 
using TALON metal affinity resin (described in Chapter 2). Eluted fractions that 
contained Trib2 (2, 3 and 4, Fig 3.20A) were pooled. Five microlitres of each of the 
fractions, and 5 l of pooled fractions were subjected to an in vitro kinase assay for 
30 minutes (Figure 3.20 B), in the presence of either 10 mM Mg
2+
 or 2 mM EDTA. 
In the presence of Mg
2+
, there were multiple signals observed on the gel 
autoradiogram (Figure 3.20 B) at both the molecular weight previously established 
for Trib2 autophosphorylation and at much higher molecular weights.  In the absence 
of Mg
2+
 ions, a much fainter signal was detected at the size of monomeric Sf9-
derived human Trib2, and the higher molecular weight signals were no longer 
visible. This indicated that many of these bands were the phosphorylation products 
of classical, magnesium-dependent, kinases. The recombinant Trib2 derived from 
Sf9 cells was dialysed into either buffer A or buffer B (described in Chapter 2) in 
case the buffer affected the solubility of the protein as observed previously for 
recombinant Trib2, which is stabilized in buffer B, and 250 pmoles of the pooled 
fractions of Sf9-derived human Trib2 were assayed either in the presence or absence 
of Mg
2+ 
ions (Figure 3.20 C). In the absence of magnesium, weak 
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autophosphorylation of Trib2 from Sf9 cells was observed, consistent with findings 
with bacterially-expressed Trib2. In the presence of magnesium ions, there were a 
number of higher molecular weight phosphorylation contaminants and also an 
intense signal detected at the appropriate size of Trib2. However, this band is likely 
to be caused by the Sf9 contaminant kinases phosphorylating Trib2, and these 
contaminants have been the cause of a variety of pseudokinases being attributed 
catalytic activity when none exists, an example being the inactive pseudokinase Titin 
(Bogomolovas et al., 2014).  Aside from the bacterial (E. coli) and eukaryotic (Sf9) 
protein sources described above, recombinant or endogenous Trib2 could be 
obtained from mammalian cell lines  by immunoprecipitation. One advantage of 
using mammalian cell lines for protein production instead of insect lines is their 
ability to perform more complex protein glycosylation, which could be required for 
correct protein trafficking, folding or substrate interactions (Kost et al., 2005). As 
with the other cell types, when assays are performed, the correct controls, including a 
‘kinase-inert’ mutant must be used because pseudokinases such as BUBR1, when 
immunoprecipitated and assayed, initially appeared to be catalytically active. 
However, mutation to the catalytic residues did not alter the substrate 
phosphorylation and so it was concluded that the originally observed 
phosphorylation originated from co-purifying proteins rather than BUBR1 itself 
(Suijkerbuijk et al., 2012). To ensure the observed autophosphorylation of Sf9 
derived JAK2 was not caused by a contaminating kinase, assays were performed 
using in vitro translated JH2 (cell-free system), which supported the intrinsic 
catalytic activity of the insect JH2 protein and demonstrated that it was not caused by 
copurified kinase(s) (Ungureanu et al., 2011).   
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Figure 3.19 Expression of Trib2 WT and mutants in Sf9 cells. Trib2 K90M, Trib2 WT, 
and Trib2 DFGK180N expressing Sf9 cells were lysed and protein was immunoblotted 
with an anti-His antibody (Sigma, mouse monoclonal) along with an untransfected cell 
lysate and a 6His tagged control lysate.  Eddie Mackenzie, University of Manchester. 
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Figure 3.20 Purification of Trib2 from Sf9 cells. A) Fractions (1-9) eluted from TALON 
resin and 4 μg BSA were resolved by SDS-PAGE and the protein stained with coomassie 
stain. B) Protein from each individual fraction (2-5 from panel A), or the pool of fractions 2-5 
(5 μg) were assayed with either 10 mM Mg
2+ 
or 2 mM EDTA. The protein was observed after 
SDS-PAGE by coomassie staining (top panel). The incorporated labelled phosphate was 
observed by autoradiography (bottom panel). Signals detected >75 kDa are annotated 
‘Higher MW contaminants.’ C) Following dialysis in to either 20 mM bicine pH9.0, 100 mM 
NaCl, 1 mM DTT, 10% glycerol (pH9) or 50 mM Tris, 150 mM NaCl, 1 mM DTT 10% 
glycerol (pH 7.4), 250 pmoles Trib2 derived from E. coli or Sf9 cells were assayed in the 
presence or absence of metal ions and 1 mM ATP (2.2 Ci  
32
P ATP) and the SDS-PAGE 
resolved and coomassie stained protein (top panel) was subjected to autoradiography.  
Signals observed on the autorads at MWs that are higher than expected for Trib2 have been 
labelled ‘Higher MW contaminants.’ 
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To isolate a homogenous population of monomeric recombinant Trib2 
derived from Sf9 cells, affinity purified Sf9 Trib2 was applied to a Superdex 200 
10/300 gel filtration column. The absorbance peaks (Figure 3.21 A) identified a 
series of proteins with different Ve values. Elution fractions 17-19 contained Trib2, 
as judged by SDS-PAGE and by immunoblotting with antibodies directed against the 
6His tag (Figure 3.21 B and C) and had elution volumes indicative of the monomeric 
species (as discussed in Section 3.5).  
Trib2 containing fractions were pooled and 250 pmoles were assayed without 
divalent cations to observe any Trib2 catalytic activity that was not caused by 
contaminating kinases, alongside Trib2 WT purified from E. coli. As shown, Trib2 
autophosphorylation increased over time. This indicated that Trib2 from both Sf9 
cells and E. coli cells are able to hydrolyse ATP in the absence of divalent cations, 
albeit the signal for E. coli derived human Trib2 is more intense than that from Sf9 
(Figure 3.22). This means that in the assay conditions used, the incorporation of 
radiolabelled phosphate by bacterial Trib2 was higher than the incorporation by Sf9 
Trib2. 
As mentioned previously, these experiments are likely to contain 
contaminating eukaryotic kinases and their substrates, which contribute to the strong 
signal seen when ATP and cations are added. To control for this, the assays should 
be performed in tandem with a Trib2 K90M mutant purified from Sf9 cells. 
However, the soluble protein yield of this mutant was far too low for accurate 
biochemical assays to be performed and therefore the intense signal seen at ~45kDa 
in Figure 3.20 in the presence of 10 mM magnesium ions, cannot be classed as Trib2 
autophosphorylation unless this signal reduces in assays that contain protein has 
been purified further and the assays are controlled by a ‘kinase-dead’ control 
(K90M). This signal is therefore more than likely a by-product of eukaryotic kinase 
contamination.  With regards to the faint time-dependent phosphorylation observed 
in Figure 3.22, this is much more likely to be bona fide Trib2 autophosphorylating 
activity because divalent cations are absent in this assay, however until the issue of 
kinase contamination has been fully explored and controlled for, using Sf9 cells as a 
source of Trib2 for biochemical analysis cannot be recommended. 
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Figure 3.21 Gel filtration of Sf9 Trib2 reveals a fraction that elutes at the predicted 
volume expected for monomeric Trib2A) IMAC eluate containing Sf9 derived Trib2 was gel 
filtered into buffer B (20 mM bicine, 100 mM NaCl, 1mM DTT, 10% glycerol). The elution 
volumes of the peaks were determined and the peak fractions (17-19) that correspond to the 
predicted MW of monomeric Trib2 were isolated (Ve 14.6 ml). B) Twenty microlitres of select 
fractions were subjected to SDS-PAGE and the protein stained with coomassie stain. The 
fraction numbers in red (17-19) correspond to the peak with a predicted MW of monomeric 
Trib2. C) One hundred nanograms of Trib2 WT purified from E. coli was resolved by 
electrophoresis in a polyacrylamide gel alongside 2 l fractions 17, 18 and 19. The protein 
was transferred to nitrocellulose membrane by western blotting and the membrane probed 
with -His HRP conjugated antibody.   
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Figure 3.22 Sf9 Trib2 demonstrates very low levels of autophosphorylation. Gel filtered 
Sf9 or E. coli derived Trib2 (250 pmoles) were assayed in the presence of 2 mM EDTA and 1 
mM ATP (2.25 μCi 
32
P ATP). The assays were stopped by the addition of 5 x SDS loading 
buffer at the stated timepoint, heated for 5 minutes at 95°C and samples run on 12% 
polyacrylamide gels. The protein was stained with coomassie stain and the gels subjected to 
autoradiography, and the 
32
P incorporated visualised on the X-ray film.   
 
 157 
 
3.15 Trib3, a closely related protein to Trib2, also 
autophosphorylates in the absence of magnesium ions 
Trib2 is one of the four human Tribbles related proteins, which are 
pseudokinases that lack the magnesium ion binding residues present in canonical 
kinases. To determine whether Trib3 can also autophosphorylate in the absence of 
magnesium ions after isolation from E. coli, full-length Trib3 and a 3 lysine mutant 
K97M (corresponding to Trib2 K90M) were expressed in E. coli and purified in an 
identical fashion to Trib2 and Trib2 K90M. Trib2 WT and K90M, and Trib3 WT and 
K97M were assayed in duplicate for 30 minutes in the absence of divalent cations. 
As shown in Figure 3.23, both Trib2 and Trib3 exhibited the ability to 
autophosphorylate in vitro, in contrast to the K90M (Trib2) or K97M (Trib3) 3 
lysine mutant controls. 
3.16 The Trib-related protein SgK495 does not autophosphorylate 
under the experimental conditions validated for Trib2/3. 
The Trib related protein SgK495, has a highly degraded kinase-fold, with 
amino acid alignment showing that it does not have a typical glycine-rich loop in the 
pseudokinase domain, lacks a lysine residue in the 3 sheet of classical kinases, and 
lacks the ‘DFG’ metal ion binding motif. However, the catalytic aspartate located 
within the catalytic loop of kinases is present in SgK495, along with an asparagine, 
which is the terminal residue of this motif and, in classical kinases, interacts with a 
Mg
2+ 
ion. SgK495, unlike Trib 1, 2 and 3, has a canonical glycine-rich loop located 
N terminal to the pseudokinase domain. Whether this is involved in binding ATP has 
yet to be determined because no crystal structures or biochemical analyses of 
SgK495 have been published. STRAD, was also assayed here, and is a 
pseudokinase that has demonstrated the ability to bind to ATP but not hydrolyse nor 
incorporate the phosphate (Zeqiraj et al., 2009b).  His-tagged Trib2, Trib2 K90A, 
Trib2 K90R, SgK495 and STRAD were purified from BL21(DE3)pLysS 
competent E. coli by IMAC. Following dialysis, Trib2 (Figure 3.24 A), Trib2 K90A 
(Figure 3.24 B), Trib2 K90R (Figure 3.24 C), SgK495 (Figure 3.24 D) and STRAD 
(Figure 3.24 E) were assayed in duplicate. The upper panels in Figures 3.24 A-E 
show the Coomassie-stained protein and the lower panels are the corresponding 
autoradiography films. The average signals from each duplicate timepoint were 
quantified by phosphorimaging and plotted in GraphPad Prism6 (Figure 3.24 F). As 
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previously observed, Trib2 WT and Trib2 K90R autophosphorylation increased 
during the assay (Figure 3.24 A and C respectively), whereas very low 
autophosphorylation was observed for Trib2 K90A (Figure 3.24 B). Neither SgK495, 
nor STRAD exhibited detectable autophosphorylation. 
  
Figure 3.23 Trib3 autophosphorylates in the absence of Mg
2+ 
ions. Trib2 WT and 
K90M, and Trib3 WT and K97M (250 pmoles) were assayed in the presence of 2 mM 
EDTA and 1 mM ATP (2.25 μCi -
32
P ATP) for 30 minutes.  The reactions were stopped 
by the addition of 5 x SDS loading buffer and samples were resolved by SDS-PAGE. The 
protein was coomassie stained (top panel) and phosphate incorporation was observed by 
autoradiography (middle panel). Loading was determined by the coomassie stained gel 
and immunoblotting 5 μl of each assay using an His antibody (bottom panel). 
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Figure 3.24 SgK495, a Trib-related protein does not demonstrate autocatalytic 
activity. Radiometric kinase assays of 250 pmoles A) Trib2 WT, B) K90A Trib2, C) K90R 
Trib2, D) SgK495 and the inactive pseudokinase E) GST-STRAD were carried out in 
duplicate over a time period of 60 minutes, with assays terminated at intermittent time 
periods. Samples were subjected to SDS-PAGE (top panels) and autoradiography (lower 
panels). F) The signals were then quantified by phosphorimager and average values plotted 
in GraphPad Prism 6 along with the standard deviation for each point.  
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3.17 Purification of Trib2 for X-Ray Crystallographic analysis 
There are currently no available structural co-ordinates for any of the Trib 
related proteins (www.sgc.ox.ac.uk and www.pdb.ed.ac.uk). A crystal structure of 
Trib2 will be vital to observe the accessibility of the ATP binding site and identify 
how ATP and ligand binding sites might be manipulated for development of Trib2-
specific inhibitors.  
This lab recently used pET30 Ek/LIC to express and purify, then solve the 
structure of the canonical kinase Mps1 (Chu et al., 2008). To purify high-quality, 
high concentration protein for this purpose, Trib2 was affinity purified and the Trib2-
containing fractions were pooled and applied to the Superdex 200 10/300 gel 
filtration column and eluted in 20 mM bicine pH 9.0, 10 mM NaCl, 1 mM DTT, 
10% glycerol. The protein in the fractions that correspond to the peaks on the 
chromatogram (Figure 3.25 A) were resolved by SDS-PAGE (Figure 3.25 B) and 
fractions that eluted in the volume predicted for monomeric Trib2 (Ve 14.6 ml), 22-
25, were pooled and concentrated by centrifugation using a Vivaspin 2 (10 kDa 
MWCO) concentrator to 10 mg/ml. Ten micrograms was resolved by SDS-PAGE 
and the presence of a single coomassie stained band highlights the purity of the 
sample, alongside 8 g BSA standard (Figure 3.25 C). 
Trib2 (100 nl per well) was mechanically transferred (described in Chapter 2) 
to 7, 96 well sitting drop crystallography trays, into which 100 nl of the buffers from 
the crystal screens listed in Chapter 2, were added. The trays were sealed and left at 
room temperature to facilitate crystal formation. The buffers added were from the 
crystal screening buffer libraries listed in Chapter 2. The trays were sealed and left at 
room temperature to facilitate crystal formation and observed regularly. Trib2 
formed aggregates in many of the conditions but did not form any crystals (Figure 
3.26 A-D). 
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Figure 3.25 Purification of Trib2 for X-Ray crystallography trials. A) Affinity purified 
Trib2 was gel filtered into 20 mM bicine, 100 mM NaCl, 1 mM DTT and 10% glycerol and 
the fractions collected. Peaks in the absorbance spectrum (blue line) were used to 
identify the fractions in which protein was eluted. The peak that contains protein which 
eluted in 14.6 ml buffer (expected volume for elution of Trib2 monomer) B) Twenty 
microlitres of the fractions (16-27) were resolved by SDS-PAGE and the protein was 
observed by coomassie stain. The fractions that eluted in the Ve that corresponded to the 
predicted MW of monomeric Trib2 (22-25) were pooled together and the protein was 
concentrated to 10 mg/ml using a Vivaspin2 centrifugal column. C) One microlitre of Trib2 
was resolved by SDS-PAGE and coomassie stained alongside 8 g BSA standard.  
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Figure 3.26 Trib2 aggregation was observed in crystal trials.  Images demonstrating 
the high levels of protein aggregation observed in the sitting drop crystal trials. One 
hundred nanolitres of TRB2 (10 mg/ml) was added to 100 nl A) 10% (w/v) PEG-3000, 
0.1 M imidazole pH 8.0, Li2SO4, .B) 1.0 M K/Na tartrate, 0.1 M imidazole, pH 8.0, 0.1 M 
NaCl, C) 15% (v/v) ethanol, 0.1 M imidazole pH 8.0, 0.1 M MgCl2.  Images were 
captured on a Leica M795 microscope using a KL1500 LCD lightsource with a 60 x 
objective. 
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3.18  Purification of 15N-labelled Trib2 for 2D NMR 
Another method that could determine Trib2 structural features is 2D 
15
N-
HSQC NMR. NMR can be used to determine the structure of macromolecules, with 
the number of protein structures deposited into the online RCSB Protein Data Bank 
structural database at this present time that have been solved using solution NMR 
being in excess of 10,000, some 10-fold less than for X-ray crystallography, for 
which 100,000 structures have now been deposited in the PDB resource. For 
successful NMR spectroscopy, the backbone amine groups require labeling with 
15
N, 
whose nucleus contains an odd mass number, and integral spin value of 1/2. In the 
15
N-HSQC spectra, a signal for each 
1
H-
15
N covalent bond is detected. This process 
occurs in solution and is non-denaturing. By comparing the peaks before and after 
the addition of a ligand, the spectra can be used to identify whether binding occurred. 
To incorporate radiolabeled 
15
N atoms into the Trib2 backbone, the protein has to be 
expressed in E. coli that has been grown in minimal media supplemented with 
15
N 
ammonium sulphate. Prior to expression in labeled media, it needed to be determined 
whether Trib2 was expressed in E. coli grown in 1 L minimal media (M9). Once an 
A600nm 0.8 was reached, Trib2 expression was induced with 0.5mM IPTG at 18°C for 
18 h. The cells were harvested and Trib2 purified by elution from a 5 ml HisTrap. 
The fractions were resolved by SDS-PAGE, which confirmed the presence of Trib2 
(Figure 3.27 A). 
Following successful Trib2 expression in minimal media, Trib2 was 
expressed (as above) in 2 L of minimal media supplemented with radiolabeled 
15
N 
ammonium sulphate (Figure 3.27 B and C). Monomeric Trib2 was isolated as 
previously described (Figure 3.27 D). When analysed by coomassie stain (Figure 
3.27 E), the fractions that contained monomeric Trib2 also had protein contaminants 
present and to ensure the sample was homogenous for NMR analysis, anion 
exchange chromatography using a MonoQ 5/50 column was performed and Trib2 
eluted in 20 mM bicine pH 9.0, 460 mM NaCl, 1 mM DTT, 10% glycerol (Figure 
3.27F), SDS-PAGE confirmed the presence of purified Trib2 (Figure 3.27 G) The 
Trib2 containing fractions were then pooled (fractions numbered in red) and 
subjected to buffer exchange in a NAP-10 column to transfer Trib2 into an NMR-
suitable buffer (20 mM Tris pH 7.4, 50 mM NaCl, 1 mM DTT) and analysed by 
15
N-
HSQC by Dr. I. Barsukov, University of Liverpool, on a 800 MHz Bruker solution 
state NMR machine. 
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3.19 15N-HSQC spectrum indicates that recombinant human Trib2 
generates a spectrum consistent with a folded protein in 
solution 
The spectrum obtained following 
15
N-HSQC of recombinant Trib2 showed a 
broad distribution of non-uniform signals. Each signal corresponded to a covalently 
bonded 
15
N atom and 
1
H atom and was plotted on the spectrum, determined by their 
respective chemical shift values.  When proteins are folded, the chemical 
environment that each covalently bonded 
15
N amide-Hydrogen pair occupies is 
different. This means that each amide-proton pair exhibits a different chemical shift 
than other amide-protons throughout the protein, providing a broad spectrum of 
signals as observed in Figure 3.28. If, on the other hand, the protein was unfolded, 
then the chemical environment that each amide proton occupies and by association, 
the chemical shift of each proton, will be similar to one another because they all are 
exposed to buffer. This is indicated by a narrow 
15
N-HSQC spectrum (Kwan et al., 
2011).  The concentration of Trib2 used in this experiment (~1mg/ml) was too low to 
determine any other features other than protein ‘foldedness.’ Ideally, with a higher 
concentration of Trib2, NMR will be a very useful tool for not only determining 
structural components of Trib2 but for observing ligand and inhibitor interactions. 
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Figure 3.27 Purification of 
15
N-labelled Trib2 for NMR analysis To determine whether 
Trib2 could be expressed using ‘minimal media’, lysate from E. coli that expressed Trib2 in 
A) One litre minimal (unlabelled) media was subjected to IMAC and the eluted fractions 
treated to SDS-PAGE analysis alongside 8 g BSA. The protein was visualised by 
coomassie stain. Trib2 is located between 37 kDa and 50 kDa. B) The fractions containing 
eluted IMAC purified 
15
N labelled Trib2 after application of a 300 mM imidazole containing 
elution buffer, could be identified by analysis of the absorbance profile. C) Fractions (20 l) 
from the elution of 
15
N labelled Trib2 B (29-38), were resolved in a 12% SDS-PAGE gel 
along with 5 l of the uninduced lysate and induced lysate. D) Following IMAC, the pooled 
15
N labelled Trib2 (red fractions in C, 35-38) was gel filtered and the elution volumes were 
determined by analysis of the absorbance spectrum. The peak Ve values are labelled. E) 
The peak fractions from D were treated to SDS-PAGE and protein visualised by 
coomassie stain. The fractions that corresponded to monomeric 
15
N labelled Trib2 were 
pooled (Ve 14.8, fractions 22-25) and passed through a F) MonoQ Anion exchange 
column, where 
15
N labelled Trib2 eluted in 460 mM NaCl. G) The eluted protein was 
resolved by gel electrophoresis and the fractions that contained the highest concentration 
of 
15
N labelled Trib2 were pooled (62-64). 
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15N
1H
Figure 3.28 
15
N-HSQC Spectra of Recombinant Trib2. Purified 
15
N labelled Trib2 
(Figure 3.27G) was supplemented with 10% D2O and was loaded into a Bruker 800 MHz 
solution state NMR machine for 12 hours. Each point on the spectra corresponded to a 
15
N 
atom that is covalently bonded to a 
1
H atom and the location of the points are ascertained 
by the chemical shift values for each of the constituent atoms. The chemical shift values 
for 
1
H atoms are determined by referring to the X-axis, and the Y-axis corresponds to the 
15
N chemical shift values. 
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3.20  Discussion  
The work presented in this chapter describes a robust protocol for the 
purification of E. coli derived full length recombinant human Trib2 in sufficient 
yields to perform careful biochemical analyses using monomeric, soluble protein. 
Trib2 was most stable in a slightly alkaline pH buffer, specifically 20 mM bicine pH 
9.0, 100 mM NaCl, 1 mM DTT and 10% glycerol, allowing protein concentrations in 
excess of 10 mg/ml to be obtained without evidence of protein precipitation. 
Recombinant aggregation of Trib2 catalytic domain was previously evaluated by 
Vedadi et al., (2006), who reported that the catalytic domain of Trib2 was most 
stable in a buffer containing 20 mM bicine at pH 9.0 (Vedadi et al., 2006). 
Monomeric preparations of Trib2 were successfully separated from higher molecular 
weight Trib2 aggregates and contaminant proteins by a combination of gel filtration 
and anion exchange chromatography. The presence of folded and monomeric Trib2 
was then confirmed by a combination of DSF, MS and NMR.  
Excitingly, when recombinant Trib2 was assayed in the presence of 
radiolabelled ATP, it autophosphorylated, although this was weak when compared to 
the active kinase Aurora A. Trib2 autophosphorylation, observed by autoradiography 
and quantified by phosphorimage analysis, was consistently higher than the 3 lysine 
mutants K90M and K90A. Reduced catalytic activity by mutation of the 3 
conserved lysine in classical kinases has been observed previously for PKA (PKA 
72) (Iyer et al., 2005a) and it is known that this Lys interacts not only with the - 
and - phosphates of ATP assisting with the correct orientation of ATP in the 
binding site but it can also form a salt bridge with the conserved Glu residue in the 
C helix (Glu91 PKA), helping to maintain the kinase domain in an active 
conformation (Scheeff and Bourne, 2005). Intriguingly, it is difficult to identify a 
conserved Glu residue in the Trib2 sequence, which has a short predicted C helix 
(Chapter 1). Interestingly, the Trib2 mutant K90R was able to autophosphorylate to a 
similar level as Trib2 WT despite the mutation and so, it could be possible that in 
Trib2 this mutation is tolerated more than in PKA, where K72R has a markedly 
reduced catalytic activity (Iyer et al., 2005a). However, K90R equivalent mutations 
have been shown to lead to preservation of activity in other active kinases, such as 
Aurora A, where ~10% of WT activity is maintained by mutation of the equivalent 
lysine and mutation of the DFG motif to AFG is necessary to abolish activity 
completely (Haydon et al., 2003). To confirm that the detected signals are caused by 
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Trib2 autophosphorylation, the assayed proteins could be treated with a phosphatase 
(e.g. lambda phosphatases) to demonstrate that the labelled phosphate can be 
removed enzymatically. Assays should also be performed with the Trib2 catalytic 
Asp (D175) mutants D175N or D175A. The expectation is that the 
autophosphorylation levels would be reduced compared to WT, albeit there is a 
possibility the activity may not be completely abrogated, because HER3 and JAK2 
are catalytically active pseudokinases that possess an Asn residue in this position, 
and mutation of this Asp in EGFR to Asn still facilitates (low-efficiency) 
phosphotransfer (Shi et al., 2010, Ungureanu et al., 2011). The mutation of the 
catalytic Asp in CASK (D141A) did not reduce the level of autophosphorylation 
(Mukherjee et al., 2008, Supplementary Figure 5), as mentioned below. 
The presence of K177 in the catalytic loop helps place the Trib2 
pseudokinase domain into the Ser/Thr (rather than Tyr) kinase sub-family (Hanks 
and Hunter, 1995). Mutation of K177 to an Arg residue results in depleted C/EBP 
degradation in cells that also become unable to form colonies in an assay measuring 
cell transformation, compared to WT (Keeshan et al., 2010).  When Trib2 K177 was 
mutated to Ala, to abolish a positive charge at this position, it displayed reduced 
autophosphorylation compared to Trib2 WT, possibly because the mutation has 
altered the ability of Trib2 to recognize the substrate recognition/dimerisation 
sequence, or because it affects the ability of Trib2 to either bind to ATP or 
autophosphorylate. This could suggest that Trib2 catalytic activity may be linked to 
the oncogenic progression of Trib2 driven cancers and highlights the catalytic 
domain of Trib2 as a new potential target for small molecule inhibition. 
Interestingly, no other phosphorylated Trib2 substrates (should they exist) 
have been reported in the literature. Neither standard exogenous protein kinase 
substrates such as Histones nor the known Trib2-regulated protein GST-C/EBP 
were phosphorylated by Trib2 under the conditions adopted for in vitro kinase 
assays. One simple possibility is that Trib2 does not need to phosphorylate proteins 
for biological function. Furthermore, Trib2 might not only be a protein 
pseudokinase, but also phosphorylate non-protein molecular substrates.  For 
example, the pseudokinase SgK196, has recently been shown to phosphorylate the 6-
position of O-mannose (Yoshida-Moriguchi et al., 2013). 
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Autophosphorylation of Trib2 occurred in the absence of divalent cations 
including Mg
2+
, which classical kinases appear to require for catalytic activity (Waas 
et al., 2004), and intriguingly bacterially-expressed Trib2 autophosphorylation was 
inhibited in the presence of divalent cations, although this was less marked for Sf9-
expressed Trib2 preparations, which may also be contaminated with other kinases 
that co-purify with Trib2. Magnesium ion independent autophosphorylation has only 
been identified for one other member of the human kinome, the pseudokinase 
CASK, which like Trib2, does not have canonical magnesium ion binding residues. 
However, mutation of classical inactivating residues (3 Lys K41A or the Catalytic 
Asp D141A) did not alter CASK’s ability to autophosphorylate, but a CASK double 
mutation; S24D V26L selected following structural analysis of the ATP-binding 
pocket, did reduce autophosphorylation and phosphorylation of neurexin-1. 
(Mukherjee et al., 2008). CASK can be converted to a kinase that behaves similarly 
to a classical Mg
2+
 ion stimulated  kinase, by mutation of 4 residues in the ATP 
binding pocket; 2 of which align with the classical kinase magnesium binding 
residues and 2 of which are conserved throughout CaM-Kinases but are not found in 
CASK (Mukherjee et al., 2010). However, mutating the residues in Trib2 that align 
to the canonical Mg
2+
 binding residues of classical kinases, did not confer on Trib2 
increased Mg
2+ 
dependent autophosphorylation, suggesting that other (unknown) 
residues are present in Trib2 that prevent metal-dependent ATP hydrolysis. 
Furthermore, abrogation of WT-levels of autophosphorylation for the Trib2 DFG 
K180N tetra-point mutation was observed, which was likely to be a result of protein 
denaturation (See Chapter 4 for further details). It has been postulated that CASK, 
which phosphorylates neurexin-1 and is a pseudokinase that is also inhibited by 
divalent cations, could be regulated by surges of divalent cations caused by synaptic 
activity in neurons, with levels of CASK activity highest during the development of 
neurons and then decreasing following neuronal maturity and the activation of 
signaling to the synapses (Mukherjee et al., 2008). Whether anything similar occurs 
with Trib2 will be investigated in the future in human cell models, as will the 
potential regulatory functions of other metal cations, some of which appear to 
stimulate or inhibit Trib2 in vitro (Figure 3.17).    
Sf9-expressed human Trib2 was also purified to identify whether a 
eukaryotic expression system was required for higher levels of Trib2 activity to be 
revealed. There was a large amount of kinase background ‘noise’ present in the 
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assays of partially purified Trib2 from Sf9 cells assayed in the presence of Mg
2+
, and 
I speculate that non-specific kinases could be the cause of the phosphorylation 
detected at the size of Trib2 on the radiolabelled gels. Sf9 Trib2 appeared to 
autophosphorylate in the absence of Mg
2+
 ions (canonical protein kinases should be 
almost completely inactive in these conditions) however, the detected signals were 
weaker than for the same amount of Trib2 derived from E. coli. This could mean that 
Trib2 derived from Sf9 cells is catalytically inert and the faint signal is residual 
activity from other kinases, or it is not folded correctly and autophosphorylates at a 
lower level or favors substrate phosphorylation rather than favoring 
autophosphorylation. Whatever the cause may be, until the assays are performed in 
tandem with Trib2 K90M protein expressed in eukaryotic cells, it is impossible to 
determine whether the signal detected for Trib2 WT derived from Sf9 cells is truly 
autophosphorylation. However, the expression of the K90M mutant was 
considerably lower than the WT protein (Figure 3.19). It could be that the ability of 
Trib2 to bind ATP or autophosphorylate stabilizes the nascent protein. Because of 
the difficulty obtaining Sf9 expressed Trib2 K90M there was insufficient protein 
available for comparable kinase assays, and the data showing hyperactivity of Trib2 
from Sf9 cells in the presence of Mg
2+
 ions be judged preliminary. 
The Trib2 related pseudokinase, Trib3, also demonstrated 
autophosphorylation in the absence of Mg
2+
 ions. To confirm that this was intrinsic 
to the Trib3 pseudokinase, I showed that autophosphorylation occurred to a greater 
extent in Trib3 when compared to the 3 lysine mutant (Trib3 K97M).  This 
indicated that a conserved magnesium-independent mechanism is likely to exist 
throughout this family, which perhaps enables Tribbles proteins to bind ATP and 
transfer the gamma phosphate to itself as part of a regulatory mechanism. However, 
this finding suggests that the inability of Trib3 to drive AML in animal models, or to 
degrade C/EBP (but not ACC) in vitro, is unlikely to be due to an inability to bind 
ATP or to weakly autophosphorylate (Dedhia et al., 2010). 
SgK495, a more distantly related Tribbles pseudokinase, did not 
autophosphorylate under the assay conditions tested, but the SgK495 pseudokinase 
domain is much more degraded than Trib1-3, although intriguingly it does have at 
least one canonical glycine-rich loop located very close to the N-terminus of the 
pseudokinase domain. Assayed alongside SgK495 was the pseudokinase 
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STRADwhich did not autophosphorylate under any conditions, consistent with 
previous work by other groups showing that STRAD cannot autophosphorylate, 
despite binding to ATP with relatively high affinity (Zeqiraj et al., 2009b).  
Trib2 autophosphorylation has yet to be examined in cell lines and no direct 
phosphorylation substrates other than Trib2 itself have been identified. Magnesium 
independent autophosphorylation is an interesting observation for recombinant Trib2 
in vitro, because magnesium is present in cells with a concentration flux of 5 – 30 
mM (Waas et al., 2004) and as demonstrated in this Chapter, Trib2 was inhibited in 
the presence of 5 mM Mg
2+
, and so the ability of Trib2 to bind to ATP in vivo needs 
to be determined along with a structure of Trib2 bound to ATP for a full 
understanding of the mechanism and function of Trib2 autophosphorylation. 
However, due to the aggregation-prone nature of Trib2 at high concentrations, our 
attempts to produce crystals for X-Ray analysis have thus far been unsuccessful. 
Screening Trib2 in a variety of buffer conditions has so far failed to yield any protein 
crystals for X-ray analysis, with aggregation being the main constituent of the 
majority of wells.  
Another method used to investigate the structural properties of Trib2 was 
15
N-HSQC NMR, which demonstrated that purified Trib2 was in a folded 
conformation. Future analysis of Trib2 using this technique will focus upon 
identifying the residues on the spectra which would not only facilitate the generation 
of a Trib2 structure, but because NMR allows the protein to remain in solution, it 
permits the observation of structural dynamics that could enable the identification of 
residues that undergo a conformational change when a ligand binds or residues that 
are in close proximity to the ligand i.e. the ligand binding surfaces or pockets. 
3.21 Conclusion 
Human Trib2 expressed in E. coli demonstrates the ability to hydrolyse ATP 
and auto-incorporate the released phosphate in a metal ion-sensitive manner. This 
poses some very interesting questions about Trib2. If Trib2 can bind to ATP using a 
different mechanism than utilized by classical kinases, which require the presence of 
Mg
2+
 ions and ATP binding, and given its documented importance for the 
transformation of cells and progression of the oncogenic phenotype, then this might 
make the pseudokinase domain of Trib2 an exciting and novel drug target, with the 
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unique catalytic domain providing an opportunity to develop a specific Trib2 
targeting therapeutic molecule. 
Chapter 4 describes the development of some specific tools required to 
investigate interaction of Trib2 with ATP in vitro and in a cellular environment. 
These will be essential to determine whether the pseudokinase domain of Trib2 can 
be specifically targeted by small molecules.  
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CHAPTER 4. Biophysical and 
cellular analysis of Trib2 
4.1 Introduction 
In Chapter 3, I demonstrated that recombinant Trib2 was capable of in vitro 
autophosphorylation, despite lacking the metal ion binding residues conserved in 
nearly all canonical protein kinases. This autophosphorylation event was inhibited by 
several different divalent cations, an effect currently described for only 3 members 
of the human kinome; CASK (Mukherjee et al., 2008), Trib2 and Trib3 (Chapter 3). 
It has been reported that an intact ATP binding site is essential for Trib2-mediated 
C/EBP degradation and Trib2-driven oncogenesis (Keeshan et al., 2010, Liang et 
al., 2013, Lohan and Keeshan, 2013). If ATP binding by Trib2 mediates the 
observed phenotypes of Trib2-overexpressing cells (Lohan and Keeshan, 2013, 
Grandinetti et al., 2011), then this would make the ATP binding site of this 
pseudokinase a novel therapeutic target, especially if overexpression of Trib2, which 
is linked to ubiquitination and transcription factor turnover, could be blocked by 
compounds binding in the ATP site. To investigate the impact of Trib2-mediated 
ATP binding both in vitro and in intact cells, several new strategies must be 
developed. These include new methodologies and tools to develop screens to identify 
small molecules that directly target Trib2, the identification of its cellular interacting 
partners and the generation of Trib2 overexpressing cell-lines. 
 
Results 
4.2 DSF can be exploited to identify ATP binding to a purified 
pseudokinase domain 
To permit transfer of the gamma phosphate group from ATP to an amino acid 
on a substrate, protein kinases must first bind to ATP, usually in the presence of a 
divalent cation. The cellular concentration of ATP lies in the low (1-5 mM) range 
(Huang et al., 2003, Traut, 1994). However, different kinases have different 
affinities for ATP in the presence of different substrates, for instance in the presence 
of artificial in vitro peptide substrates, Chk1 has a Km[ATP] of 1.4 M, but the 
Km[ATP] for MuSK (Muscle-specific kinase) is much higher at 380 M (Knight and 
Shokat, 2005) while cellular kinases interact with metals and nucleotides with Km 
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values ranging from low micromolar to low millimolar, representing some three 
orders of mangnitude of affinities (Becher et al., 2013). Since Trib2 is capable of 
weak autophosphorylation, it must also bind to ATP, although the affinity is 
presumably relatively low since incubation of recombinant Trib2 with sub-
millimolar (~0.2 mM) concentrations of ATP does not elicit marked thermal 
stabilization, although fluctuations above control levels are evident (Murphy et al., 
2014b). Several non-enzymatic methods for detecting ATP binding have been 
described, including direct and indirect approaches for measuring changes in 
fluorescence. For example, ligand binding to a protein can be detected by observing 
an increase of protein thermal stability (folding vs. unfolding), and, by association, a 
Tm (melting temperature) can be calculated (Celej et al., 2003). DSF (Differential 
Scanning Fluorimetry) is a technique that determines the Tm of a protein by 
measuring the increased fluorescence intensity emitted by an exogenous dye that is 
added to the reaction mixture. The fluorescence intensity, when plotted as a function 
of temperature, generates a thermal denaturation curve that can be used to determine 
the Tm of essentially any folded protein. The Tm of a protein can increase markedly 
when a ligand is bound and so the protein is said to be ‘thermally stabilized’. This is 
observed experimentally by the melting curve shifting to the right (increased 
temperature) when plotted on the graphical X axis. In general, the higher the change 
in melting temperature (Tm), the stronger the binding affinity for the ligand 
(Bullock et al., 2005), although cut-offs are relatively arbitrary for minimum and 
maximum detectable Tm’s, and some ligands may produce less effect than others. 
In terms of nucleotide, metal and ligand binding to single domain kinases, 
pseudokinases or bromodomains (which interact with acetylated lysine residues), 
several in vitro experimental procedures have recently been published that take 
advantage of DSF to evaluate ligand binding (Scheeff et al., 2009, Murphy et al., 
2013, Krishna et al., 2013, Filippakopoulos et al., 2010).  
To uncover if the binding of ATP to Trib2 can be detected using this assay 
format, and to extend a previous independent analysis employing Trib2 in a DSF-
based assay performed in a collaboration that used a rather low ATP concentration  
(200 M) that is not representative of the intracellular environment (Murphy et al., 
2014b), I analysed the ability of Trib2 to interact with several ligands.  
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A previous analysis of Trib2 formed part of a screen that established the 
binding abilities of a range of pseudokinases for ATP, GTP and divalent cations 
(Murphy et al., 2014b). Analysis of this data led to pseudokinases being classified 
into four groups, which depended upon their ability to bind ligands, as detected by 
DSF (Chapter 1). Briefly, class 1 pseudokinases demonstrated no detectable 
nucleotide or cation binding, class 2 pseudokinases demonstrated the ability to bind 
to a nucleotide in the absence of cations, whilst class 3 solely bound metal cations. 
Pseudokinases that bound nucleotides and cations were grouped together in class 4. 
Trib2 and CASK were both grouped into class 1 because neither had Tm values 
that exceeded the threshold for any of the ligands tested, which was ±3°C in this 
analysis (Murphy et al., 2014b). 
Sypro-orange based DSF was employed to analyse the pseudokinases Trib2 
and CASK, by comparing them to Aurora A, a kinase that is known to bind ATP 
with high affinity. As shown in Figure 4.1 A and 4.1 B, I was unable to detect a 
marked Tm for either of these pseudokinases in the presence of ATP, despite in 
vitro kinase assays and fluorescent ATP analogue studies demonstrating that CASK 
binds ATP with a measured Km[ATP] of 563 M (Mukherjee et al., 2008) and that 
both Trib2 and CASK can autophosphorylate in vitro (Chapter 3). In marked 
contrast, SgK495 (Figure 4.1 C), a highly degraded pseudokinase that was also 
grouped with the class 1 pseudokinases (Murphy et al., 2014b), exhibited 
concentration-dependent ATP binding. When the concentration of ATP increased, 
the thermal stability of SgK495 also increased, which, if confirmed, might place 
SgK495 into the pseudokinase class 2 (binds nucleotide but not metals). Importantly, 
as a positive control, DSF analysis was performed under identical conditions with 
the canonical kinase Aurora A, which has a known Km for ATP of ~10 M (Sloane 
et al., 2010), clearly showed that it is stabilized by >5°C in the presence of ATP and 
metal co-factor (Figure 4.1 D). 
4.3  A modified assay procedure permits Trib2 ATP binding to be 
detected by DSF 
In Chapter 3, my in vitro kinase assays demonstrated conclusively that Trib2 
catalytic activity was inhibited by Mg
2+ 
ions. The consensus Tm increase that 
validates ligand binding throughout the biological literature is ±2-3°C.  For example, 
ligands that potently inhibit the ATP binding site of MAP2K4 only impart a 
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detectable Tm value of 2°C or higher (Krishna et al., 2013). This same threshold 
was reported as the temperature increase that occured when ligands bind to a protein 
with M affinity, which might be expected for some, but not all, physiological 
ligands (Vedadi et al., 2006).  Indeed, a Tm increase of ~2°C is observed for the 
classical kinases VRK1 and VRK2 when incubated with ATP and magnesium ions 
and analysed by DSF. As a control, the VRK3 pseudokinase (which cannot bind a 
nucleotide due to amino acid blockade of the ATP site) was assayed alongside and 
was actually less stable in the presence of a nucleotide (Scheeff et al., 2009).  
Following addition of EDTA (a magnesium chelator) to the DSF reaction, 
ATP binding to Trib2 now became detectable (Figure 4.2 A), and the Trib2 Tm 
increased by ~ 2°C compared to the Tm of Trib2 with EDTA alone. Importantly, the 
Tm was >6°C when compared to Trib2 alone (no EDTA).  The melting temperature 
of Trib2 also increased in the presence of both ATP and magnesium together (but it 
was not stabilised as highly as Trib2 following ATP and EDTA addition) although 
the Tm was only 2.93°C compared to Trib2 in the absence of any additions. The 
melting curves for three mutations designed to reduce ATP binding, namely Trib2 
K90M (Figure 4.2 B), Trib2 K90A (Figure 4.2 C) and Trib2 K90R (Figure 4.2 D) 
did not show marked thermal stabilisation following addition of ATP, and are clearly 
different to WT Trib2, with decreases of essentially 100% binding for K90M, K90M 
and K90R calculated. Finally, the denaturation profile of Trib2 DFGK180N 
quadruple mutant resembled that of an unfolded protein  (Figure 4.2 E), in marked 
comparison to all other Trib2 proteins assayed (Uniewicz et al., 2012).  Consistently, 
this mutant did not autophosphorylate in vitro (Figure 3.18 B). In contrast, the 
control kinase Aurora A was stabilized in the presence of both ATP and Mg
2+
 
(Figure 4.2 F), consistent with its functioning as a canonical protein kinase.  
4.4 Trib2 does not bind detectably to the kinase inhibitor DAP 
Following the detection of ATP binding to Trib2 by DSF, which was 
expected given the ability of this pseudokinase to autophosphorylate weakly but 
reproducibly (Chapter 3), Trib2 and Aurora A ligand binding was investigated by 
incubation with the generic ATP competitive kinase inhibitor DAP (Figure 4.3), 
which has been shown to bind to 6 out of 32 (19%) of the pseudokinases towards 
which it has been tested, consistent with it being a general ATP-site ligand suitable 
for DSF analysis (Murphy et al., 2014b, Bantscheff et al., 2007). However, Trib2 did 
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not bind to DAP (Figure 4.3A) in agreement with the previous analysis by Murphy, 
although DAP binds to Aurora A in a concentration-dependent manner (Figure 4.3 
B). 
 178 
 
20 40 60 80
0
20
40
60
80
100
20 40 60 80
0
20
40
60
80
100
20 40 60 80
0
20
40
60
80
100
20 40 60 80
0
20
40
60
80
100
Temperature  C
N
o
rm
a
li
s
e
d
 
F
lu
o
re
s
c
e
n
c
e
(%
)
N
o
rm
a
li
s
e
d
 
F
lu
o
re
s
c
e
n
c
e
(%
)
N
o
rm
a
li
s
e
d
 
F
lu
o
re
s
c
e
n
c
e
(%
)
N
o
rm
a
li
s
e
d
 
F
lu
o
re
s
c
e
n
c
e
(%
)
5 mM ATP
2.5 mM ATP
1.25 mM ATP
0.625 mM ATP
0.3 mM ATP
Trib2 WT
0.45  0.2
0.09  0.2
0.13  0.5
0.38  0.6
0.23  0.6
 Tm  C 
0 mM ATP 0.00  0.5
5 mM ATP
2.5 mM ATP
1.25 mM ATP
0.625 mM ATP
0.3 mM ATP
CASK
0.35  0.6
0.49  0.3
0.45  0.3
0.01  0.3
0.16  0.5
 Tm  C 
0 mM ATP 0.00  0.6
5 mM ATP
2.5 mM ATP
1.25 mM ATP
0.625 mM ATP
0.3 mM ATP
Aurora A
8.55  1.7
9.76  3.0
9.85  2.1
9.25  2.0
7.97  1.6
 Tm  C 
0 mM ATP 0.00  0.4
5 mM ATP
2.5 mM ATP
1.25 mM ATP
0.625 mM ATP
0.3 mM ATP
SgK 495
3.84  0.62
2.27  0.69
1.45  0.69
1.08  0.47
0.59  0.61
 Tm  C 
0 mM ATP 0.00  0.42
BA
DC
n=3
-
-
-
100
80
60
40
20
0
80604020
100
80
60
40
20
0
80604020
Temperature  C
10
80
60
40
20
0
80604020
Temperature  C
100
80
60
40
20
0
80604020
Temperature  C
   
Figure 4.1 Sgk 495, a Trib family member is thermally stabilised by the presence of 
ATP A) Trib2 WT, B) CASK, C) SgK 495 or D) Aurora A (5 μM) were incubated with 
increasing concentrations of ATP (0-5 mM). In the presence of Sypro Orange, thermal 
denaturation profiles were generated by detecting the emitted fluorescence and melting 
temperatures were determined by applying the sigmoidal Boltzmann equation to the 
normalized denaturation curves. The Tm values were determined by subtracting the Tm for 
protein alone from the TM values in the presence of either ATP and/or cofactor. This was 
repeated 2 further times in triplicate and the average Tm values are listed ± the standard 
deviation for the 3 constituent experiments, alongside typical thermal denaturation curves. 
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Figure 4.2 ATP demonstrates a small protective effect on Trib2 in the presence of 
EDTA. Representative normalised denaturation curves and average Tm values with the 
standard deviation are listed for three independent experiments each performed in 
triplicate. A) Trib2 WT, B) K90M, C) K90A, D) K90R, E) DFGK180N or F) Aurora A (5 M) 
were incubated with either 10 mM MgCl2 (green or red) or 2 mM EDTA (purple or orange), 
with samples supplemented with 1 mM ATP (green and orange) and Sypro Orange dye 
added to all.  
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Figure 4.3 Trib2 does not bind the kinase inhibitor DAP. DSF was performed on 5 
M A) Trib2 and B) Aurora A with increasing concentrations of DAP. The average Tm 
values including the standard deviation values from 2 repeat experiments (performed in 
triplicate) are shown alongside the normalised denaturation curves representative of the 
experiments. 
 
Figure 4.4 Mutating the ‘gatekeeper’ residue of a protein kinase or a pseudokinase 
can increase the accessibility of the ATP binding site. A cartoon that depicts how a 
bulky inhibitor (e.g. an analogue of the kinase inhibitor PP1) cannot access the ATP 
binding site of a WT kinase but can enter the ATP-binding site of an enlarged (analogue-
sensitive) kinase. 
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4.5 Trib2 gatekeeper mutants specifically bind small molecule 
inhibitors 
A chemical genetic approach that might help elucidate the function of Trib2 
is to block the ATP binding site by employing cell permeable small molecule 
inhibitors and characterizing any phenotypic changes. Targeting a specific protein 
kinase in a cell is, however, inherently difficult because of the high degree of 
conservation shared between all kinase domains in the human kinome, and the 
promiscuity of small molecules developed to target them (Bantscheff et al., 2007, 
Davis et al., 2011). Within the human kinome, a conserved amino acid termed the 
‘gatekeeper’ residue occludes the binding of bulky kinase inhibitor analogues (e.g. 
PP1 analogues), since they cannot access a hydrophobic cavity located within the 
ATP binding pocket.  Most clinically approved kinase inhibitors target kinases with 
a small (Thr) gatekeeper residue, although only ~20% of the human kinome have 
evolved a Ser or Thr amino acid in this position. Interestingly, mutation of Thr to a 
more ‘bulky’ amino acid can cause drug resistance (e.g. The BCR-Abl T315I kinase 
is resistant to Imatinib and EGFR T790M is resistant to Erlotinib) (Alaimo et al., 
2005).  
No human kinase possesses the smallest amino acid side-chains (Gly or Ala) 
at this position (Liu et al., 1998, Alaimo et al., 2005) and following mutation to 
either of these residues, the enlarged ATP binding pockets of such ‘analogue-
sensitive’ gatekeeper kinases now possess the ability to specifically interact with 
bulky kinase inhibitor analogues (e.g. PP1 analogues such as Na-PP1 and NM-PP1), 
which have the enormous advantage of being unable to target the vast majority (but 
not all) WT kinase ATP binding sites (Figure 4.4) (Liu et al., 1998, Hengeveld et al., 
2012, Bain et al., 2007).  
The majority of the ‘CMGC’ family of kinases contain a phenylalanine 
gatekeeper residue (Huang et al., 2010), including all Tribbles family members, 
which are located between the CMCG family and CAMK divisons on the 
phylogenetic kinome ‘tree’ (Chapter 1). CDK2 is an example of a kinase that has a 
phenylalanine gatekeeper residue at this position, and following mutation of the 
CDK2 gatekeeper residue to Ala or Gly, the kinase domain can be specifically 
targeted by an ATP analogue, whilst maintaining its substrate and phosphorylation 
site specificity along with Km and Vmax values that are comparable to WT CDK2 
(Elphick et al., 2009). In addition, the gatekeeper residue of the pseudokinase KSR2 
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(T739) can be mutated to a small Gly residue, which permits it to bind to the bulky 
ATP analogue benzyl ATP and identify it as a direct activator of MEK (Brennan et 
al., 2011). However, this approach clearly does not work for all kinases, since the 
gatekeeper residue is involved in stabilizing the active kinase conformation (Garske 
et al., 2011) To build upon my initial work with Trib2, I therefore decided to test 
whether this pseudokinase was amenable to chemical genetics by generating 
‘analogue-sensitive’ gatekeeper Trib2 mutants.  
4.6 Purification of recombinant mutant Trib2 proteins (F130A or 
F130G) 
Trib2 gatekeeper mutants were expressed in E. coli and purified by IMAC 
(see Chapter 2). The column fractions that corresponded to Trib2, Trib2 F130A, 
Trib2 F130G (Figure 4.5 A, C and E) from a Ni-Sepharose column were analysed by 
SDS-PAGE on 12% polyacrylamide gels (Figure 4.5 B, D, F) to identify those that 
contained Trib2 and Trib2 point mutants; these were then pooled and dialysed into 
buffer B (Chapters 2 and 3).   
Since two phenylalanines (F129/F130) lie adjacent to each other in the ATP 
binding site of Trib2, and there is no crystal structure available to confirm if F129 or 
F130 are directly or functionally equivalent to the canonical gatekeeper residue, two 
‘gatekeeper -1 mutants’ (F129A/G) were also created for analysis.  If F130 was the 
gatekeeper residue then the F130A/G mutants might be predicted to bind specifically 
to bulky ATP-dependent kinase inhibitor analogues, whereas the F129A/G proteins 
would likely remain unaffected, since this amino acid equivalent does not interact 
with the region guarding the pocket in model kinases. However, although Trib2 
F129A and F129G mutants were synthesised at high levels in E. coli and could be 
observed following Coomassie staining, they were both completely insoluble after 
bacterial lysis, and were not observed in the Coomassie-stained gels following SDS-
PAGE, unlike Trib2, Trib2 F130A and Trib2 F130G, which were readily detected 
after purification from a soluble E. coli extract. 
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Figure 4.5 Trib2 F129A and F129G mutants are synthesised but present in the 
insoluble fraction. A-E) Left panel: The elution profile of recombinant Trib2 proteins WT, 
K90M, F130A, F130G, F129A and F129G were eluted from nickel Sepharose after the 
application of 300 mM imidazole elution buffer. Right panel: Protein resolved by SDS 
PAGE and stained with coomassie stain. U = Uninduced total cell lysate, I = Induced total 
cell lysate, following IPTG induction, F = Unbound protein in the flowthrough, Peak= 
Fractions corresponding to the peak observed on the elution profiles in the left hand 
panels. BSA (4 g) was resolved by SDS PAGE alongside the fractions eluted during 
affinity chromatography. 
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4.7  Identifying ligands that interact with Trib2 gatekeeper 
mutants 
In order to maximize the chances of discovering a Trib2 ligand, a panel of 30 
synthetic PP1-derived bulky inhibitors (kindly supplied by Professor Kevan Shokat, 
UCSF) were screened to look for candidates that could access the enlarged ATP 
binding site of the Trib2 analogue sensitive gatekeeper mutants. As shown in Figure 
4.6D, DSF identified two of these bulky PP1 analogues, which are termed CZ 30 and 
HxJ 42. CZ 30 markedly increased the thermal stability of Trib2 F130A and Trib2 
F130G by 20.53°C and 19.74°C respectively, whereas in the presence of HxJ 42 the 
Tm of F130A and F130G was 11.99°C and 9.39°C. Importantly, however the Tm 
of WT Trib2 was unaffected by the addition of either CZ 30 or HxJ 42 (Figure 4.6). 
This was consistent with the inhibitors binding to the ATP binding site of the 
analogue-sensitive Trib2 mutants with high specificity. In my initial screen, I 
measured the Tm for 5 M Trib2, F130A and F130G mutants in the presence of 250 
M of each inhibitor. As discussed above, I used a threshold Tm of >2°C to 
indicate an interaction. Along with CZ 30 and HxJ 42, Trib2 F130G (Figure 4.6 C) 
was also stabilized by ~ 7°C in the presence of CZ 24 (7.26°C), 3MB PP1 (7.95°C), 
CZ 89 (7.83°C), ZFZ 19 (7.59°C), and ZFZ 11 (7.96°C). However, only HxJ 42 and 
CZ 30, increased the Tm of both Trib2 F130A (11.99°C and 20.53°C respectively) 
(Figure 4.6 B) and F130G (9.39°C and 19.74°C respectively) (Figure 4.6 C) when 
compared to WT Trib2 (Figure 4.6 A), and these ligands were therefore employed 
for further analysis.  
Trib2 (Figure 4.7 A), Trib2 F130A and Trib2 F130G (Figure 4.7 B and C) 
were incubated with 250 M HxJ 42 in a further 3 separate experiments, each 
performed in duplicate. The melting curves of both Trib2 F130A and Trib2 F130G 
consistently shifted dramatically to the right in the presence of HxJ 42 compared to 
the DMSO vehicle control and the Tm increased on average by 15.18°C ± 3.7 for 
Trib2 F130A and 12.91°C ± 3.5 for Trib2 F130G. In contrast, CZ 24 does not 
increase the Tm of F130A, unlike the Tm of F130G, which is 5.3°C ± 3.4 higher 
than F130G in the presence of DMSO.  Trib2 F130G is stabilized by more of the 
bulky inhibitors tested in this panel than F130A, potentially because the Gly 
facilitated increased accessibility to the active site than Ala. 
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Trib2 (Figure 4.8A), Trib2 F130A (Figure 4.8B) and Trib2 F130G (Figure 4.8 C) 
were also incubated with CZ 30 in three separate experiments. The averaged Tm 
values for Trib2 in the presence of CZ 30 was 1.8°C ± 2.2 compared to Trib2 F130A 
and F130G, where the respective Tm compared to the DMSO controls were 16.7°C 
± 5.3 and 20.1°C ± 5.1. CZ 24, again increased the Tm of F130G but not F130A nor 
Trib2.  
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Figure 4.6 Trib2 gatekeeper mutant kinase domains can be targeted by bulky PP1 
derivatives. A) Trib2 WT, B) Trib2 F130A or C) Trib2 F130G were incubated with 250 M 
bumped PP1 kinase inhibitor analogues in triplicate. The fluorescence signals were 
normalised which generated the thermal denaturation profiles (left) and from these the 
average melting temperatures determined by application of the Boltzmann sigmoidal 
equation. The average Tm values were plotted in the bar charts on the right along with 
the standard deviation. D) Chemical structures of the PP1-related compounds HxJ 42 and 
CZ 30 were drawn using ChemBioDraw. 
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Figure 4.7 Trib2 F130 gatekeeper mutants can bind to the inhibitor HxJ 42, whilst WT Trib2 
is unaffected. Three separate DSF experiments were performed in duplicate on either A) Trib2 
WT B) Trib2 F130A or C) Trib2 F130G that were incubated with either DMSO, 250 M of the 
bulky PP1 kinase inhibitor HxJ 42 or CZ 24. Fluorescent denaturation curves were normalised 
and plotted (representative curves shown on the left). From these curves the Tm values were 
determined and averaged (right, ± SD shown alongside). 
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Figure 4.8 Trib2 F130A and F130G mutants bind to the PP1-related inhibitor CZ 30 In the 
presence of either DMSO, CZ 24 or CZ 30, A) Trib2 WT, B) Trib2 F130A and C) Trib2 F130G 
were thermally denatured and the detected fluorescence was averaged and normalised, which 
generated thermal denaturation curves. The curves observed in the left panels are 
representative of the three separate experiments. The Tm values from each curve were 
determined by applying the Bolztmann equation and then averaged. The average Tm values 
(± SD) are shown on the right. 
 
 189 
 
WT Trib2 does not bind to CZ 30, and this was confirmed by findings shown 
in Figure 4.9, where the Tm of Trib2 was not markedly increased in the presence of 
CZ 30.  Conversely, Trib2 F130G (Figure 4.9 B) exhibited a Tm of 27.7°C ± 1.6  in 
the presence of CZ 30 whereas the classical kinase Aurora A Tm was 8.7°C ± 0.04  
(Figure 4.9 C), which is ~20°C lower than the Tm of Trib2 F130G. In contrast, the 
Tm for SgK495 is 4.3°C ± 0.08 (Figure 4.9 D), although this represents a much 
lower binding affinity than Trib2 F130G. 
The CZ 30-related inhibitors CZ 28 and CZ 29 were incubated with Trib2 
and the Trib2 analog-sensitive mutant Trib2 F130A. As expected, Trib2 did not 
detectably bind to either CZ 30, CZ 28 or CZ 29 with the respective Tm values 
being below the 2°C threshold that I have adopted for these experiments (Figure 4.10 
A). The Tm Trib2 F130A increased by 19.41°C (Figure 4.10 B) when incubated 
with 250 M CZ 30, but this effect was not observed following the addition of 250 
M CZ 29 or CZ 28, and the Tm values were consistently below 2°C, TM 1.11 
and -0.96°C respectively. The melting profile of Trib2 F130A in the presence of CZ 
30 appeared to be biphasic, which can be observed when there are populations of 
both ligand-bound and apo-protein in the solution (Vivoli et al., 2014). 
The binding of CZ 30 to Trib2 F130A was not observed to be concentration 
dependent, because when assayed in the presence of 125 M or 25 M CZ 30, the 
Tm were not above the binding threshold.  
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Figure 4.9 CZ 30 increases the thermal stability of the Trib2 F130G more than the 
classical kinase, Aurora A, or the Trib related protein SgK495.In triplicate A) Trib2 WT, the 
analogue sensitive B) Trib2 F130G, C)  Aurora A and D) SgK495 were incubated with either 
DMSO or 250 M of the bulky PP1 kinase inhibitor CZ 30. Thermal denaturation profiles were 
generated by normalising the detected fluorescence signal. These curves were used to 
determine the Tm by the Boltzmann equation. The average Tm values of proteins in the 
presence of DMSO were subtracted from the Tm values of proteins in the presence of CZ30.  
The averaged Tm values are plotted in the right panels. 
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Figure 4.10 Compounds related to CZ 30 do not demonstrate similar binding 
interactions to F130A  Trib2 WT and B) Trib2 F130A (5 M) were incubated with either 
250 M, 125 M or 25 M of the bulky PP1 kinase inhibitors CZ 28, CZ 29, CZ 30 and CZ 
24, or DMSO and following DSF, thermal denaturation profiles were generated by 
normalising the detected fluorescence. The Boltzmann equation fitted to the curves provided 
the melting temperatures, and from these profiles the Tm values could be calculated and 
are listed below the denaturation curves. 
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4.8 Intrinsic fluorescence measurements readily detect Trib2 
ligand binding  
Not all proteins can be analysed using Sypro Orange dye (Niesen et al., 
2007), and it is possible that pseudokinases such as Trib2, which is rather unstable 
and prone to denaturation (Chapter 2) are not ideally suited to this dye-based 
approach.  Indeed, a quarter of soluble proteins subjected to DSF in a case study 
reported in the literature are not amenable to DSF because of the high fluorescence 
background caused by the dye binding to solvent-exposed hydrophobic pockets 
(Vedadi et al., 2010). To help negate the addition of an extrinsic fluoroprobe, the 
changing intensity of intrinsic fluorescence of a protein as it unfolds can also be 
measured, and changes in Tm invoked to infer ligand binding (Gaudet et al., 2010).  
As a protein melts, the hydrophobic, fluorescent Trp and (less-so) Phe 
residues residing in the protein interior gradually become more exposed to solvent. 
Therefore, the emitted fluorescence associated with the indole and phenyl moieties 
changes (usually increases) as a function of temperature. To evaluate the effects of 
ligands on Trib2 thermal stability, intrinsic fluorescence was measured using an 
Avacta Optim2 system. Typical fluorescence curves generated during each 
experiment are shown in Figure 4.11 A-D. The experiments in the right panels were 
supplemented with 1 mM ATP. The first derivative fitted to the curve (thin red line) 
from which the Tm was determined. The average Tm values from two separate 
experiments, with each condition being assayed in triplicate were used to ascertain 
Tm values, which are plotted on the chart showing the mean ± SD (Figure 4.11 E).  
Interestingly, the average Trib2 Tm in the presence of ATP was 3.6°C higher 
than Trib2 in the absence of ATP, suggesting that ATP binding to Trib2 can be 
detected using 1 mM nucleotide in the absence of metal ions. The thermal stability of 
Trib2 K90M and K90A mutants were also assessed alongside WT Trib2 and 
although the Tm for Trib2 K90M (Tm 1.6°C, 56% decrease) and K90A (Tm 
0.23°C 94% decrease) were detectable, neither was stabilized in the presence of ATP 
to the same extent as WT Trib2. As a control, the kinase Aurora A was stabilized in 
the presence of ATP with a Tm of 3°C, as assessed by this intrinsic fluorescence 
approach. The identification that the Trib2 WT ATP binding site is accessible to 
ATP will facilitate future development of inhibitors to this site that could prevent 
ATP from binding and therefore, potentially, block WT activity. 
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As shown in Figure 4.12, intrinsic fluorescence could also be used to detect 
an interaction between the Trib2 F130A and F130G point mutants and the bulky PP1 
analogues HxJ 42 and CZ 30, in agreement with my DSF analysis using Sypro 
orange dye. Consistently, HxJ 42 (Figure 4.12 A) increased the melting temperature 
of both F130A and F130G (Tm 2.7°C and Tm 3°C respectively) but destabilized 
WT Trib2 (Tm -0.32°C). Intriguingly, CZ 30 markedly increased the Tm of Trib2 
by 10.8°C (Figure 4.12 B), but this was 20°C lower than the Tm values for Trib2 
F130A (Tm 33.8°C) and F130G (Tm 38.6°C). Note that Trib2 F130A/G and WT 
were assayed on 2 independent experiments in duplicate, and the average Tm 
values are recorded here 
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Figure 4.11 ATP has a thermally protective effect on Trib2 WT when analysed 
using intrinsic protein fluorescence as a read-out. Representative figures of 
detected intrinsic fluorescence as Trib2 WT (A), K90M (B), K90A (C) and Aurora A (D), 
unfold ±1 mM ATP. Each condition was tested in triplicate. The red line is the detected 
fluorescence, whilst the blue line is the fitting of the first derivative. The centre of the first 
derivative peak corresponded to the Tm for the protein (black line).  The average Tm for 
each protein in each condition (+/- ATP) was determined and the average TM (°C) was 
plotted using the software GraphPad Prism6 (E). 
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Figure 4.12 Measuring the intrinsic fluorescence of Trib2 as it unfolds also 
demonstrated the pseudokinase domain is targetable by bulky PP1 analogues In 
duplicate, the average Tm for each protein in each condition A) +/- HxJ 42 or B) +/- CZ 30 
was determined detecting the intrinsic fluorescence and fitting the first derivative to the 
obtained curve. The average TM (°C) values were determined from the two experiments 
along with the standard deviation and plotted in the tables (blue = Trib2 WT, red = F130A, 
green = F130G).  
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4.9 The Trib2 Gatekeeper mutants F130A and F130G 
autophosphorylate weakly 
DSF assays revealed two bulky PP1 analogues (CZ 30 and HxJ 42) that 
markedly increased the melting temperatures of both the F130A and F130G Trib2 
mutants, but not WT Trib2. This suggested that they bound specifically to the ATP 
binding site of the analogue- sensitive mutants and will be useful for probing the 
function of appropriately mutated Trib2. However, it is well known that gatekeeper 
mutations can sometimes lead to a loss of intrinsic kinase activity in protein kinases 
(Oh et al., 2007, Hengeveld et al., 2012).  To examine if this was also the case for 
Trib2, the rate of autophosphorylation for each mutant was analysed in vitro. Trib2 
(Figure 4.13 A), Trib2 K90M (Figure 4.13 B), Trib2 F130A (Figure 4.13 C) and 
Trib2 F130G (Figure 4.13 D) were subjected to an in vitro kinase assay to determine 
whether the mutant proteins could hydrolyse ATP as efficiently as the WT 
pseudokinase in vitro. As presented in Figure 4.13A and B, WT Trib2 
autophosphorylation was readily detected, in contrast to Trib2 K90M, which exhibits 
much lower levels of autophosphorylation. Interestingly, Trib2 F130A (Figure 4.13 
C) and F130G (Figure 4.13 D) mutants also exhibited very low levels of 
autophosphorylation, which were similar to K90M Trib2, indicating a defect in the 
ability to bind or hydrolyse ATP. To quantify the incorporation of the hydrolysed 
phosphate, SDS-PAGE gels that contained immobilized, assayed Trib2 were 
analysed by phosphorimager (top panels in Figure 4.13 A-D). The duplicate signals 
were averaged (Figure 4.14 A), and plotted using GraphPad Prism6 software, which 
confirmed that both F130A and F130G Trib2 can only autophosphorylate weakly in 
vitro in the presence of 1 mM ATP. To evaluate whether this marked decrease in 
autophosphorylation by F130A and F130G Trib2 was mirrored by a change in ATP 
affinity, intrinsic fluorescence during thermal unfolding in the presence and absence 
of ATP was measured. This confirmed that although F130A and F130G Trib2 
gatekeeper mutant Tm values increased when ATP was added (Tm ~1°C), this was 
below the 2°C threshold that suggests strong ligand binding, a marked decrease from 
WT Trib2 (Tm ~4°C) yet a measurable increase from Trib2 K90M (Tm 0.1°C, 
Figure 4.14 B). 
4.10 Evaluation of Trib2 aggregation as a function of temperature  
An additional advantage of using the Avacta system to measure the intrinsic 
fluorescence of an unfolding protein is that protein aggregation can be monitored 
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simultaneously during the process of denaturation. Protein aggregation is detected by 
static light scattering at a wavelength of 266 nm. The temperature at which the 
scattered light signal was 10% of the final maximum is termed the Tagg, or 
Aggregation Onset Temperature.  The Tagg of WT Trib2 is 42.5°C (Figure 4.15A), 
whereas the Tagg for Trib2 K90M was 32.2°C (Figure 4.15 B), suggesting partial 
destabilization of this mutant in vitro. Interestingly, the aggregation of both Trib2 
F130A and F130G initiated at 29.8°C and 29.5°C respectively (Figure 4.15 C and 
D), suggesting that mutant Trib2 proteins are much more unstable and more prone to 
aggregation than either WT or K90M Trib2, which are themselves relatively 
unstable. In contrast, the average Tagg of Aurora A kinase is similar to Trib2 WT, at 
approximately 40°C (37.8°C).  
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Figure 4.13 Trib2 catalytic activity is abrogated by mutating the gatekeeper residue. 
Two millimolar EDTA and 1 mM ATP (2.25 μCi -
32
P ATP) were added to A) Trib2 WT, B) 
K90 M  and the gatekeeper mutants C) F130A and D) F130G. The assays were stopped by 
the addition of 5 x SDS loading buffer after the stated timepoint, boiled for 5 minutes and 
samples resolved on 12% polyacrylamide gels. The protein was stained with coomassie 
stain (top panels) and subjected to autoradiography (bottom panels).  
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Figure 4.14 Trib2 gatekeeper mutants autophosphorylate less than WT Trib2, but 
bind to ATP more so than Trib2 K90M.  A) The gels in Figure 4.13 were placed into a 
cassette with a phosphorimage screen for 24 hours. The detected signals for each 
timepoint were quantified and averaged with standard deviation error bars. B) Average 
Tm values were determined following the thermal unfolding and detection of intrinsic 
fluorescence of Trib2 (blue), Trib2 K90M (red), Trib2 F130A (green) and Trib2 F130G 
(purple) in the presence of and absence of 1 mM ATP in triplicate.  The Tm values were 
determined by the fitting of the first derivative to the detected intrinsic fluorescence curves 
and the Tm values from the 3 assays were averaged. The Tm was determined by 
subtracting the average Tm values for the protein that was not supplemented with ATP 
from the average Tm values of Trib2 in the presence of ATP. The Tm values were plotted 
in B using GraphPad Prism software. 
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Figure 4.15 Trib2 F130A and F130G aggregate at temperatures lower than the 
temperature used for in vitro kinase assays. The aggregation of A) Trib2 WT, B) 
K90M, C) F130A and D) F130G was measured on an Optim2 (Avacta) by detecting static 
light scattering (266 nm) as the temperature increased by 0.3°C/min. The Average Tagg 
was determined for each protein. Each experiment was performed in duplicate, and 
aggregation curves representative of each experiment shown. WT and K90M n=3, F130A 
and F130G n =2. 
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4.11 Generation of Isogenic Tet-inducible lines for cellular Trib2 
analysis  
The identification of two bulky inhibitors that bind to Trib2 F130A and 
F130G (but not WT Trib2) in vitro, raises the possibility that these compounds could 
be used to determine cellular phenotypes that are driven by Trib2 binding to ATP in 
cells, which might be important for signaling processes downstream of this 
pseudokinase. To make this approach a reality, human stable cell lines 
overexpressing either WT, F130A or F130G Trib2 were generated. This chemical 
biology approach was originally validated by employing matched pairs of v-Src or v-
Src I338G (gatekeeper mutant)-expressing NIH3T3 fibroblasts. Both lines displayed 
the attributes of Src-transformed cells; that is they had a rounded morphology with 
reduced contact inhibition of growth and could phosphorylate the v-Src substrate 
protein p36. However, following treatment with a bulky PP1-like inhibitor, the v-Src 
expressing cells maintained the transformed appearance and the ability to 
phosphorylate p36, but the morphology of v-Src I338G expressing cells reverted to 
an untransformed phenotype and phosphorylation of p36 was abrogated, which 
indicated that the bulky inhibitor specifically inhibited the v-Src I338G protein but 
not WT Src, or other kinases relevant to cell transformation present in these cell lines 
(Bishop et al., 1998).  
As introduced above, by following a similar approach, inhibition of the ATP 
binding site of Trib2 F130A and F130G gatekeeper mutants might permit the 
elucidation of phenotypes that are dependent upon the ATP binding site of Trib2. For 
instance, it has been demonstrated that cells expressing Trib2 with a mutated 
catalytic motif display reduced levels of C/EBP degradation and transformation 
ability despite still being able to bind COP-1, which indicated the integrity of the 
ATP binding motif (and potentially the ability to bind ATP directly) is important for 
Trib2 phenotypic effects (Keeshan et al., 2010). Therefore, by comparing changes in 
cellular behavior of Trib2 F130A/G cell lines and WT Trib2 cell lines in the presence 
of a bulky inhibitor, we might be able to validate if ATP binding by Trib2 is required 
for its oncogenicity, therefore opening up the ATP binding site of Trib2 as a 
therapeutically important drug target in AML and other cancers where it is 
overexpressed. In addition, such cell lines might be useful for validation of other 
ATP-dependent/independent functions of Trib2, which might include its own 
stability, and/or that of multiple downstream targets. 
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To this end, Flp-In T-REx HeLa cell lines were generated in which FLAG-
tagged full length Trib2, K90M, F130A or F130G Trib2 were expressed after the 
inducing agent Tetracycline (Tet) was added to the media. As shown in Figure 4.16, 
FLAG-tagged Trib2 proteins were detected following immunoblotting of soluble cell 
lysates that had been treated with Tet. No signal was observed in Tet-negative lanes, 
which suggested that the cell lines were truly inducible. Interestingly, the signal 
intensity detected for FLAG tagged Trib2 K90M (even when adjusted for the total 
amount of protein in the cells) was much lower than that WT Trib2, despite loading 
similar levels of alpha tubulin, which was employed as a loading control (Figure 
4.16, bottom panel). The expression levels of F130A and F130G were intermediate 
when compared to K90M and WT Trib2. As detailed above, both of the analogue-
sensitive Trib2 mutants were stabilized by ATP less than WT but more so than 
K90M Trib2 in vitro, which suggests that the ability of Trib2 to bind ATP correlates 
with the ATP turnover of Trib2 in vitro and mutant stability upon expression in 
human cells. 
4.12 Generation of a Trib2 antibody for analysis of Trib2 
expression 
In order to analyse the concentration of Trib2 in human cells, an anti- Trib2 
antibody was generated to compare endogenous levels of Trib2 with exogenous 
Trib2 in stable cell lines. To this end, an antibody was raised in rats against 
recombinant full length human Trib2 purified from E. coli. The Trib2 reactive 
antibody was purified from the rat sera using CnBr activated resin conjugated to 
recombinant Trib2 (Chapter 2). After Trib2 antibody isolation, cell lysates from 
inducible HeLa cells and 293 cells that overexpressed FLAG tagged Trib2 were 
resolved by SDS PAGE and transferred to nitrocellulose. This was then 
immunoblotted with the purified anti- Trib2 antibody, and overexpressed Trib2 was 
readily detected in the Tet-positive lanes at the apparent size as the FLAG-tagged 
Trib2 (compare Figure 4.16 and Figure 4.17). However, endogenous Trib2 could not 
be detected in either of these cell lines using this antibody, which demonstrated that 
the background levels of Trib2 were very low, and suggested that the levels of 
induced Trib2 are either much above the endogenous, or that Trib2 is not expressed 
in these cells.  Endogenous Trib2 has previously been reported in lysates isolated 
from the human monocytic leukaemia cell line THP-1 (Eder et al., 2008). To 
determine if this rat Trib2 antibody also recognized endogenous Trib2 in these cells, 
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Trib2 was first concentrated by immunoprecipitation (IP) from the lysate, and 
subsequently identified by western blotting using the same antibody (Figure 4.18). 
No equivalent signal was observed in the lane corresponding to the control IP, which 
was performed alongside the endogenous Trib2 IP, however the lysate was not 
incubated with purified Trib2 antibody prior to addition of G-Sepharose beads and so 
the Trib2 was isolated by the antibody and not by a non-specific interaction with the 
G-Sepharose beads. 
4.13 Trib2 expression in a variety of model cancer cell lines 
To evaluate the levels of Trib2 expression in a panel of cell lines with this 
new antibody, 13 different cancer cell extracts were probed with the anti- Trib2 
antibody. A densitometric approach, using ImageJ software, allowed an approximate 
comparison between the levels of Trib2 in each cell line, normalized to the alpha 
tubulin to identify cell lines that could be used for future analysis of endogenous 
Trib2 (Figure 4.19). The cell line in which the highest level of Trib2 was detected 
when normalized to alpha tubulin was the fetal lung fibroblast derived MRC5-VA 
line, followed by HCT116 (colorectal carcinoma). Interestingly, despite a lack of 
endogenous Trib2 observed in commercial Flp-In T-REx 293 cell lines (Figure 4.17), 
the HEK293 (human embryonic kidney, non cancer) lines obtained from the 
commercial supplier ATCC, expressed detectable levels of Trib2. Endogenous Trib2 
was also detected in the MDH2774 (ovarian cancer), RT112 and U2OS cell lines. In 
the SKOV3 (ovarian cancer), urothelial, RT4 (bladder cancer) and HeLa cell lines 
however, much lower levels of Trib2 were detected. The relative level of Trib2 in the 
MRC5-VA, HEK293 and HCT116 cell lines compared to the others, could make 
these lines particularly useful in future endogenous cell line analysis. Unfortunately, 
the current NCI-60 cell line proteome database lacks data concerning Trib2 protein 
expression (Moghaddas Gholami et al., 2013).  However, using the BioGPS online 
database (www.biogps.org) (Wu et al., 2009), the mRNA expression of the NCI-60 
cell lines is available and can be mined for data concerning Trib2 (dataset NCI60 on 
U133A) and this showed that the expression of Trib2 in HEK293 cells is higher than 
HeLa, SKOV3, DLD-1 and U2OS, which was a similar pattern to the protein 
expression observed in my analysis (MRC5-VA was not present in this dataset). 
Interestingly, the neuroblastoma cell line SH-SY5Y (retinoic acid treated) had the 
highest Trib2 mRNA expression out of all the cell lines in this data set and it would 
be interesting to test the Trib2 antibody on this cell line in the future. Initially, the 
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inability to detect endogenous Trib2 in the Flp-In T-REX 293 system using the Trib2 
antibody was intriguing, considering the high level observed in HEK293 cells. 
Further mining of this dataset highlighted that the Trib2 mRNA expression in the 
Flp-In T-REX 293 cells was considerably lower than in parental HEK293 cells, 
supporting the differences observed at the protein level (Wu et al., 2009). 
4.14 Trib2 expression in primary cancer samples  
Trib2 overexpression has been reported as a driver of lung cancers 
(Grandinetti et al., 2011), blood malignancies (Keeshan et al., 2010)  and melanomas 
(Zanella et al., 2010). Analysis of the Oncomine database (www.oncomine.org) 
confirms that Trib2 is also overexpressed in a multitude of brain tumour samples, 
including pilocytic Astrocytomas, where the Trib2 expression was increased by >7-
fold, and in glioblastomas where the fold increase was ~5 when compared to normal 
tissue (Table 4.1). Other cancers located in the head region also exhibited 
overexpression of Trib2 when compared to normal tissue. In addition, Trib2 mRNA 
expression in both the salivary gland adenoid cystic carcinoma and the oral cavity 
carcinoma samples had a fold increase of > 3. Follicular Lymphoma, a cancer of the 
lymphatic system, exhibited a 6-fold difference in mRNA expression compared to 
control. Trib2 overexpression has been implicated in another lymphatic cancer, T-
ALL (Hannon et al., 2012), and Trib2 overexpression in T-ALL was some 2.6-fold 
above control levels.   
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Figure 4.17 Purified Trib2 antibody detects recombinant Trib2 purified from E. coli 
and exogenous Trib2 expressed in induced human cell lysates Lysates from Flp-In 
T-Rex HeLa and 293 Flp-In T-REx cell lines that overexpressed FLAG tagged Trib2 were 
immunoblotted using a Trib2 polyclonal antibody generated in rats, which had been raised 
against recombinant full length human TRB2.  An - alpha tubulin antibody was used to 
establish similar loading in each lane 
 
Figure 4.16 Isogenic Trib2 over-expression in a Tet-inducible system. Stable Trib2 
WT and mutant overexpressing Flp-In T-Rex (HeLa and 293) cells were cultured in DMEM 
containing 10% FCS, PenStrep and selective antibiotics. Tetracycline was added to induce 
Trib2 expression.  Fifty micrograms of cell lysates were transferred to nitrocellulose 
membrane which was immunoblotted with a FLAG specific antibody to detect induced 
FLAG-Trib2 and the loading was determined by using an alpha tubulin antibody 
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Figure 4.18 Endogenous Trib2 isolated from THP-1 cells by immunoprecipitation. 
Endogenous human Trib2 was immunoprecipitated from an acute monocytic leukaemia 
cell line, THP-1. Twenty microlitres of lysate was resolved in the input lane of the SDS 
PAGE gel alongside the Trib2 IP and the control IP and samples of the supernatents 
(unbound fractions). These were immuno-blotted with -Trib2. The detected heavy and 
light chains of the antibody are labelled 
 
Figure 4.19 Endogenous Trib2 expression in a variety of cancer cell lines was 
examined. Thirteens cell lysates from a variety of cancers were immunoblotted with 
purified Trib2 antibody, alongside 500 ng His tagged Trib2 isolated from E. coli. To allow 
for an estimation of the relative total protein loaded in each cell line, alpha tubulin was 
also immunoblotted, which revealed very uneven protein loading. Densitometric analysis 
was performed using imageJ software, which following normalisation of the Trib2 bands to 
the corresponding alpha tubulin allowed approximate comparison of Trib2 protein levels in 
the different cell lines. 
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Cancer Fold change Oncomine Dataset 
Reference to 
Primary Study 
Cutaneous Melanoma 10.506 Talantov Melanoma 
(Talantov et al., 
2005) 
Pancreatic Ductal 
Adenocarcinoma 
Epithelia 
7.623 Grutzmann Pancreas 
(Grutzmann et al., 
2004) 
Pilocytic Astrocytoma 7.027 Gutmann Brain 
(Gutmann et al., 
2002) 
Follicular Lymphoma 6.120 
Rosenwald 
Multicancer 
(Rosenwald et al., 
2001) 
Follicular Lymphoma 5.812 Alizadeh Lymphoma 
(Alizadeh et al., 
2000) 
Glioblastoma 4.646 Shai Brain (Shai et al., 2003) 
Melanoma 4.581 Haqq Melanoma (Haqq et al., 2005) 
Fibrosarcoma 4.383 Detwiller Sarcoma 
(Detwiller et al., 
2005) 
Cutaneous Melanoma 4.305 Riker Melanoma (Riker et al., 2008) 
Desmoplastic 
Medulloblastoma 
3.931 Pomeroy Brain 
(Pomeroy et al., 
2002) 
Pancreatic Ductal 
Adenocarcinoma 
3.749 Badea Pancreas (Badea et al., 2008) 
Salivary gland Adenoid 
Cystic Carcinoma 
3.499 
FriersonHF Salivary-
gland 
(Frierson et al., 
2002) 
Pancreatic 
Adenocarcinoma 
3.323 Logsdon Pancreas 
(Logsdon et al., 
2003) 
Pancreatic Carcinoma 3.279 Segara Pancreas (Segara et al., 2005) 
Oral cavity Carcinoma 3.266 Pyeon Multi-cancer (Pyeon et al., 2007) 
Esophageal 
Adenocarcinoma 
3.088 Hao Esophagus (Hao et al., 2006) 
Anaplastic 
Oligodendroglioma 
3.010 French Brain (French et al., 2005) 
Angioimmunoblastic T-
cell Lymphoma 
2.603 Piccaluga Lymphoma 
(Piccaluga et al., 
2007) 
  
Table 4.1 Trib2 mRNA expression levels reported in the Oncomine database. 
Analysing Trib2 expression differences between normal and oncogenic tissues using the 
Oncomine database highlighted cancer samples that markedly overexpress Trib2. 
Cancerous tissues that expressed Trib2 at a higher level than compared to normal (p 
value= 0.05) are listed above, along with the names of the datasets which reported the 
data and the citations of the primary studies. 
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4.15 Trib2-interacting proteins identified by Mass Spectrometry  
To gain a better understanding of the functions of Trib2 in its natural cellular 
environment and to identify potential Trib2 substrate phosphorylation (including 
autophosphorylation) or ATP-binding dependent substrates, it is crucial to determine 
the function of Trib2 in cellular signaling pathways and how it interacts with other 
constituent members. For instance, it was previously determined that Trib2 inhibited 
TLR5-dependent NF-B activation, but it was only after MS/MS mass spectrometry 
was performed that the transcription factor NF-B was identified as a putative 
binding partner of Trib2 and from this it was possible to identify the binding site, 
which is reported to be located within the catalytic loop of Trib2 (Wei et al., 2012).  
To identify Trib2 interacting-proteins in a human cell line that is well-characterised 
and suitable for proteomics, FLAG-tagged Trib2 was immunoprecipitated from Flp-
In T-REx-293 Tet-inducible cells, with uninduced cells used as a negative control for 
background interaction. Following incubation of the lysates with M2 FLAG antibody 
conjugated beads FLAG-tagged Trib2 was competitively eluted following the 
addition of FLAG peptide. Samples of the IP and control were resolved by SDS-
PAGE and immunoblotted, which showed that FLAG- Trib2 had been successfully 
specifically purified from the induced lysate (Figure 4.20 A). All the proteins present 
in the Trib2 and control IPs were resolved by SDS PAGE and analysed by coomassie 
staining using a known amount of BSA as a control (Figure 4.20 B). The proteins in 
both the IP lane and control lane were subjected to in-gel digestion by the addition of 
trypsin and LC-MS/MS mass spectrometry (performed by Ms. Alice Wadkin, 
University of Manchester). The data was then analysed using MASCOT software. 
Proteins that interacted with Trib2 and were present only in the +Tet IP have been 
summarised in Table 4.2. The bands on the gel that were analysed are numbered 1-
11 (highlighted in the gel in Figure 4.20) and in Table 4.2 the number of the band 
where the peptides were identified are noted along with both the SwissProt identifier 
and the full name. The protein score is the sum of all the peptide ion scores and takes 
into account the size of the protein, number of peptides detected and the peptide 
score. The observed Mr is the molecular weight of the ion detected in the MS/MS 
spectra (these values include doubly charged ions, for instance). The molecular 
weight expected for the neutral compound, in its natural form (Mr(expt)) and the 
isotopic masses of the peptides (Mr(calc)) are also reported in the table. The peptide 
score is derived from the size of the peptide and how likely it is to fragment as 
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expected and is a score of how confident the peptide matches the predicted protein. 
A peptide score (above or equal to 20) indicates a detected peptide is likely to be a 
‘real’ match. The expected values are the number of matches with equal or better 
scores than the threshold in the database. The lower the expectation value, the more 
confidence there is that the protein has been detected in the sample. It is also worth 
noting how many peptide fragments for each protein have been detected; the more 
observed, the more likely the protein is to be present (Mascot database 
www.matrixscience.com). 
Amongst the proteins that coimmunoprecipitated with Trib2 was a canonical 
protein kinase STK38 (NDR1), which has constituent peptides that have scores 
greatly above 20, low expectation values and there are 7 matched peptides which is 
highly suggestive that it is a protein that interacts with Trib2 and it would be very 
interesting to perform the reciprocal immunoprecipitation to confirm this interaction.   
Another kinase that was detected was the metabolic regulator Creatine kinase (both 
kinases are highlighted in yellow in Table 4.2). In contrast to NDR1, it had only one 
peptide hit in the analysis, but this exhibited a relatively high peptide score. More 
than one peptide for each of the proteins calmodulin-regulated spectrin associated 
protein, protein arginine N-methyltransferase 5, nicotinamide 
phosphoribosyltransferase 5 were identified in the analysis. Only one, however, was 
identified for each of the 60s Ribosomal proteins L8 and L19, and Shroom 3, which 
were also recovered with FLAG-tagged Trib2 in Flp-In T-REx 293 cells.  
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Figure 4.20 Trib2 isolated by -FLAG immunoprecipitation Following FLAG 
immunoprecipitation of FLAG-Trib2 from inducible Flp-In T-Rex 293 cells (+/- Tet), A) the 
input, IP and supernatents were immunoblotted using an anti-FLAG antibody B) Forty 
microlitres of the eluted immunoprecipitation were resolved in an SDS-PAGE gel along 
with known amounts of BSA and stained with coomassie stain. The numbers refer to the 
bands in which the proteins in Table 4.2 were identified.  
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Band Protein Protein Name MW
Protein 
Score
Peptides Observed Mr (expt) Mr (calc)
Peptide 
Score
Expect
3
CAMP3 
HUMAN
Calmodulin regulated 
spectrin associated 
protein
135464 41 LSAALSSLQR 523.3734 1044.7322 1044.5927 8 7.9
SAFLQVQPR 523.383 1044.7514 1044.5716 41 0.0027
LSAALSSLQR + 
Deamidated (NQ)
523.8688 1045.723 1045.5767 9 8.3
8
STK38 
HUMAN
Serine/threonine protein 
kinase
54498 40 KETEFLR 922.5009 921.4936 921.492 12 5.3
IGAPGVEEIK 1012.57 1011.5627 1011.56 15 2.7
LGLEDFESLK 1150.6058 1149.5985 1149.5917 40 0.0091
ERPAAISIEIK 1226.7126 1225.7053 1225.703 21 0.63
DIKPDNLLLDSK 1370.7524 1369.7451 1369.7453 31 0.067
SNSFFEGVDWEHIR 1722.7955 1721.7882 1721.7798 2 58
VTLENFYSNLIAQHEER 2063.0266 2062.0193 2062.0119 12 5.5
8
ANM5 
HUMAN
Protein Arginine N-
Methyltransferase 5
73322 72 GPLVNASLR 463.8442 925.6738 925.5345 47 6.50E-04
YSQYQQAIYK 646.4155 1290.8164 1290.6244 46 0.0014
8
NAMPT 
HUMAN
Nicotinamide 
Phosphoribosyltransfer
ase 5
55772 54 VLEILGK 386.3092 770.6038 770.4902 39 0.0061
AVPEGFVIPR 542.8906 1083.7666 1083.6077 39 0.0043
9
KCRB 
HUMAN
Creatine Kinase B-Type 42902 40 VLTPELYAELR 652.4621 1302.9096 1302.7183 40 1.30E-03
10
RL8 
HUMAN
60s Ribosomal Protein 
L8
28235 53 AVVGVVAGGGR 471.3479 940.6812 940.5454 53 0.00018
11
RL19 
HUMAN
60s Ribosomal Protein 
L19
23565 75 LASSVLR 373.2847 744.5548 744.4494 36 0.036
LLADQAEAR 493.8366 985.6586 985.5192 72 4.80E-06
11
SHRM3 
HUMAN
Protein Shroom 3 218321 36 SSPATADKR 466.822 931.6294 931.4723 36 2.40E-02
Table 4.2. A list of proteins that interact with FLAG-Trib2. The proteins listed were 
detected in the IP from lysate that had been exposed to Tetracycline aside from Trib2. The 
column titled ‘Band’ corresponds to the numbered bands highlighted in Figure 4.20. The 
proteins in this table were only observed in the IP from cells in which FLAG-Trib2 was 
overexpressed.  The peptides identified are listed along with the Swiss-Prot and full protein 
name, observed weight, expected mass and calculated mass. The peptide scores and 
expected values are also listed (mass spectrometry peformed by Ms. Alice Wadkin). Two 
kinases identified by this analysis are highlighted in yellow.  
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4.16  Discussion 
My prior biochemical analysis of recombinant Trib2 in Chapter 3 
demonstrated that Trib2 is a very low activity pseudokinase, similar to the 
pseudokinase CASK, which functions in neurons to regulate the substrate neurexin-1 
(Mukherjee et al., 2008). The finding that Trib2-mediated ATP hydrolysis can be 
abrogated by mutating known catalytic residues in the pseudokinase domain in vitro, 
along with evidence that an intact catalytic domain is required for Trib2 oncogenic 
transformation and C/EBP degradation (Keeshan et al., 2010) suggests that ATP 
binding to Trib2 could be a potential driver of the oncogenic behavior displayed by 
Trib2 overexpressing cells, including those highlighted in NSCLC (Grandinetti et 
al., 2011) and AML (Rishi et al., 2014). 
The aim of the work presented in this chapter was to develop an ATP-binding 
assay for Trib2, and to determine whether the Trib2 ATP binding site was targetable 
by small molecule inhibitors. In addition, I have begun to develop tools such as 
inducible Trib2 overexpressing cell lines that will help identify the roles of Trib2 
ATP-binding, autophosphorylation, overexpression, stability and Trib2 proteomics in 
cells. 
Recombinant Trib2 binds to ATP 
Data presented in this chapter prove unequivocally that Trib2 binds to ATP 
(Figures 4.2 and 4.11). One advantage of using DSF as a technique to identify 
ATP/ligand binding by a pseudokinase is that the thermal denaturation curves are 
only influenced by the main protein constituent of the reaction mixture and the 
results are not affected by the presence of low amounts of contaminating proteins 
(Murphy et al., 2014b), which have historically been problematic for in vitro kinase 
assays performed on pseudokinases. BUBR1 is an example of a pseudokinase that 
was initially deemed to be catalytically active following in vitro kinase assay 
analysis (Taylor et al., 1998), however the activity was later attributed to active 
kinases that had contaminated the BUBR1 sample when the pseudokinase was 
isolated by immunoprecipitation (Suijkerbuijk et al., 2012). A similar case is true for 
ILK, which demonstrated catalytic activity and could phosphorylate MBP as well as 
cellular substrates (Hannigan et al., 1996) and when key residues in the catalytic 
domain were mutated, the observed phosphorylation was reduced (Persad et al., 
2001). However, it was later shown that ILK is not catalytically active, but that the 
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mutations reduced the interactions with ILK binding partners including -parvin and 
-parvin (Attwell et al., 2003, Yamaji et al., 2001, Lange et al., 2009) and a crystal 
structure confirmed instead that ILK is a catalytically inactive pseudokinase that 
binds to ATP with high affinity (Fukuda et al., 2009). 
In addition, other advantages of DSF to determine ATP/ligand binding 
include the requirement of only 2-5 M of purified pseudokinase  (Lucet et al., 
2013) in a volume of 25 l, and the use of a relatively basic thermocycler for thermal 
control and signal detection, allowing analysis in 96-well plates, which facilitates the 
analysis of multiple ligands and conditions at any one time and a rapid turnover of 
results. Indeed, DSF data-set could be obtained 90 minutes after the initiation of the 
assay, in marked contrast to 
32
P-based experiments, with a time-to-analysis of almost 
a week in some cases, due to the very low levels of ATP hydrolysis and limits to the 
amount of 
32
P ATP that can be utilised. 
Published thermal shift assays previously performed on His-tagged Trib2 
isolated using our pET30-based Trib2 plasmid and purification procedures (Murphy 
et al., 2014b) demonstrated that there was no interaction between Trib2 and 200 M 
ATP, or any other potential ligands tested. The same results were obtained for CASK 
at 200 M ATP, consistent with previous biochemical and structural work 
highlighting CASK’s ability to bind to ATP in the very high M range (Mukherjee 
et al., 2008). This led to both proteins being classified as ‘Group 1 pseudokinases: 
Devoid of detectable nucleotide and cation binding.’ These results were reproduced 
and are shown in Figure 4.1. Surprisingly, I found that SgK495 was also able to bind 
to ATP in our assay, despite having an ATP binding site with low sequence 
conservation compared to canonical kinases. Interestingly, there is no observable 
canonical Gly-rich loop in the predicted pseudokinase domain of SgK495, however 
there is a canonical GXGXXG motif located N-terminal to the typical start of the 
catalytic domain, and it will be interesting to assess if this is involved in ATP 
binding. There is also no typical lysine residue in the 3 motif when the sequence is 
aligned with Trib2 and PKA (Chapter 1) but SgK495 does have an intact catalytic 
motif, HRDLKLGN, with the magnesium chelating Asn present, although it also 
lacks the magnesium-binding Asp in the DFG motif (NFC) similar to Trib1, Trib2 
and Trib3. Murphy and colleagues recently classified SgK495 as a group 1 
pseudokinase that did not bind to nucleotides or divalent cations (Murphy et al., 
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2014). However, the only concentration of ATP assessed in this screen was 200 M, 
and in Figure 4.1, a Tm of >1°C only occurs when SgK495 is incubated with an 
ATP concentration in excess of 625 M. This demonstrated that to accurately 
determine whether a pseudokinase has the biochemical ability to bind to ATP, DSF 
should be employed using multiple concentrations of ATP, and by combining the 
data with site-directed mutagenesis of the ATP-binding site. In vitro kinase assays 
(Figure 3.25 D) have thus far provided no evidence that SgK495 is catalytically 
capable of hydrolysing ATP, but in this thesis, I provide some evidence that it can 
bind to ATP in vitro.  There is still the potential that a substrate for SgK495 
phosphorylation has yet to be discovered, but until one is found, SgK495 
demonstrates the properties attributed to Class 2 pseudokinases that are defined by 
Murphy et al., 2014 as being able bind to ATP in the absence of cations. In the 
future, it will be important to test whether mutations in potential SgK495 ATP 
binding residues, such as either of the Gly-rich sequences (GAGETS (9-14) or 
GSGISG (21-25)) in the SgK495 N-terminus or amino acids in the canonical 
catalytic loop (H195-N202), decrease binding of this pseudokinase to ATP. A 3D 
structure is ideally required to decipher how SgK495 folds and and whether it adopts 
a classical kinase fold and if so, how it binds to ATP. For example, it has recently 
been demonstrated that SgK495 complexed to RCN2 is able to activate the 
ERK/MAPK pathway required for maturation of murine lung tissues (Yu et al., 
2013), but whether ATP binding by SgK495 is required for this process has yet to be 
determined. Another member of the class 2 group of pseudokinases is the well 
studied pseudokinase STRAD, which modulates the activity of the classical kinase 
LKB1 through ATP binding but not hydrolysis (Zeqiraj et al., 2009a), and it is 
possible that SgK495 has a similar kinase-activating function in human cells.  
DSF analysis of Trib2 and other pseudokinases 
Interestingly, when DSF reactions were supplemented with 2 mM EDTA 
(Figure 4.2), replicating the conditions used in the in vitro kinase assays described in 
Chapter 3, Trib2 was stabilized by ATP, unlike any of the K90 Trib2 point mutants. 
Interestingly, when analysed by DSF, K90R behaved much more like K90M and 
K90A, and its thermal stability did not increase under these conditions, despite 
demonstrating the ability to autophosphorylate efficiently in Chapter 3. The presence 
of 10 mM Mg
2+
 ions and ATP increased the Tm of Trib2 (Figure 4.2 A), but not as 
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markedly as EDTA and ATP, again supporting the in vitro kinase data presented in 
Chapter 3, which showed Trib2 autophosphorylation occurred in the presence of 
divalent cations, but that this level of autophosphorylation was less than in their 
absence. DSF has indicated that the reason for this reduction is that Trib2 in the 
presence of magnesium and ATP has a lower Tm than for Trib2 in the presence of 
EDTA and ATP; therefore on the basis that there is a positive correlation between 
the Tm and the affinity of a protein for a ligand (Bullock et al., 2005), Trib2 has a 
lower affinity for ATP when Mg
2+
 is present.   The thermal protective effect that 
ATP imparted upon Trib2, was indicative of ligand binding. I therefore suggest that 
Trib2 should be moved from characterization as a class 1 pseudokinase (Murphy et 
al., 2014b), where members did not demonstrate nucleotide or cation binding, and 
securely placed into class 2. Although when Trib2 was assayed by Murphy et al., it 
was not thermally stabilized by ATP, its Tm was lower than 40°C and this is also 
observed in the data presented in this thesis. Murphy et al., also noted that the 
majority of kinases that had a low melting temperature were Class 4 proteins that 
bind ATP, compared to Class 1 proteins whose Tm were generally  >40°C and they 
suggest this low melting temperature indicates that there is a higher degree of 
flexibility between the N and C lobe because in the absence of a ligand, the ATP 
binding site is more open and that it could be the binding of ATP by Class 2 or 4 
pseudokinases that increases the rigidity of the kinase domain and provides the 
structural integrity required to perform its function, such as acting as a protein 
scaffold for instance (Murphy et al., 2014b). 
DSF was also useful for explaining why Trib2 DFGK180N did not 
autophosphorylate in vitro (Chapter 3). Analysis of this quadruple point mutant by 
DSF (Figure 4.2 E) revealed that it was already unfolded prior to the thermal 
ramping step (Uniewicz et al., 2012) and this is entirely consistent with the inability 
of the mutant protein to autophosphorylate in the presence or absence of metal ions 
(Chapter 3). In the future, it will be important to try and generate a constitutive 
active ‘back’ mutation of Trib2 to evaluate what its potential biological role might be 
when unhindered by a low affinity for ATP.  In addition, it is important to note that 
at the low millimolar ATP concentrations found in the cell, which might fluctuate in 
subcellular regions, Trib2 is likely to interact with ATP, meaning that a nucleotide-
binding function is theoretically possible, and biologically quite likely.  
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An additional technique, which used a similar principle to DSF, determined 
the Tm of a protein by measuring changes of intrinsic fluorescence as it unfolded, 
which negated the need for an extrinsic fluorescent dye. Analysis of Trib2 melting 
temperatures derived from intrinsic fluorescence thermal denaturation curves 
identified that the thermal stability of Trib2 increased markedly in the presence of 1 
mM ATP (Figure 4.11 E).  The Tm for Trib2 is 2°C higher than for Trib2 K90M 
and > 3°C higher than Trib2 K90A. Neither of these Trib2 3 motif lysine mutants 
autophosphorylated to the same extent as Trib2 (Chapter 3).  The lower Tm values 
for the Trib2 K90 mutants compared to WT in the presence of ATP indicated that 
mutating this residue in Trib2 affected the affinity of Trib2 for ATP (Bullock et al., 
2005), and supported the decreased catalytic activity observed following in vitro 
kinase assays (Chapter 3). Had time permitted, bacterially-expressed Trib2 K177A 
and Trib3 alongside K97M Trib3 would also have been assayed by DSF to uncover 
their ATP binding properties. It will be very interesting to ascertain whether K177A 
could bind to ATP, because it would indicate whether the reduced 
autophosphorylation (Chapter 3) was caused by a reduced affinity for ATP or direct 
inhibition of the catalytic phosphotransfer mechanism, and a mutation at this 
position (K177R) has demonstrated a reduced ability to degrade C/EBPin 
conjunction with COP1, and then initiate Trib2 mediated AML in mouse models 
(Keeshan et al., 2010).  Further evaluation of the Trib3 ATP binding site by DSF 
would further validate the Mg

 independent autophosphorylation observed for Trib3 
(Chapter 3) and help drive the initiation of Trib3 ligand binding studies to identify 
whether ATP-binding is critical for the degradation of COP-1 mediated degradation 
of substrates such as Acetyl CoA Carboxylase (Dedhia et al., 2010).    
DSF was also used to investigate the accessibility of the Trib2 ATP binding 
site to kinase inhibitors. DAP (N′2′-(4-aminomethyl-phenyl)-5-fluoro-N′4′-phenyl-
pyrimidine-2,4-diamine), a generic kinase inhibitor did not bind to Trib2 in thermal 
shift assays when used at a concentration of 40 M when previously tested (Murphy 
et al., 2014b). In Figure 4.3, Trib2 was incubated with a variety of DAP 
concentrations, ranging up to 400 M, and even at this high concentration, no 
thermal protective effect was conferred onto Trib2.  The highly active kinase Aurora 
A was, however, stabilized by DAP in a concentration-dependent manner.  Despite 
the discovery that Trib2 could bind to and hydrolyse ATP, and that the pseudokinase 
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domain of Trib2 was required for Trib2-mediated oncogenesis (Keeshan et al., 
2010), it is still unclear whether ATP binding by Trib2 is essential for C/EBP 
degradation and the transformation of cells. To investigate this, small molecule 
inhibitors that target the ATP binding site of Trib2 might now be employed, although 
it would also be most useful to construct cell lines of the immune lineage in which to 
test this where there is a confirmed phenotype for Trib2 over-expressing cells.  
Increasing the size of the ATP binding pocket, by reducing the size of the 
gatekeeper residue, enables access of bulky small molecules that previously could 
not have entered because of size constraints. These have previously been used to 
elucidate the activities of dozens of canonical kinases beginning with Src (Liu et al., 
1998) and extending to CDK2 (Elphick et al., 2009), and have also recently been 
employed to identify direct substrates of pseudokinase phosphorylation. An example 
of this was the discovery that MEK1 is directly phosphorylated by KSR2, in an in 
vitro kinase assay. The bulky ATP analogue N6-phenethyl ATPS was incubated 
with both WT KSR2 and KSR2 T739G, which contains a mutated gatekeeper 
residue, creating a kinase domain with an enlarged ATP binding pocket. 
Phosphorylation of MEK1 was only observed in the assays containing the T739G 
mutated KSR2 and not WT KSR2  (Brennan et al., 2011). Another advantage of 
using this chemical genetic technique in the drug discovery process was that the 
manipulation of the gatekeeper residue can also be used in cell-based and in vivo 
model systems because the small molecule inhibitors are cell permeable and have 
low toxicity in mice (Shokat and Velleca, 2002). 
Analysis of Trib2 gatekeeper mutants as tools for examining Trib2 
biology 
Trib2 gatekeeper mutants F130A and F130G were purified from E. coli and 
facilitated the identification of bulky small molecules that targeted the (predicted) 
enlarged ATP binding sites of the mutants. DSF enabled a fast and relatively 
economical method of identifying ligands that interacted with the mutant Trib2 
kinase domains. If the addition of an inhibitor from the panel of 30 that were tested 
caused Trib2, Trib2 F130A or F130G aggregation, then the inhibitor was not 
included in Figure 4.6. From the remaining 7 ligands, two increased the Tm of both 
the gatekeeper mutants but did not affect the Tm of Trib2. Further analysis by DSF 
and detection of intrinsic fluorescence showed that these two inhibitors (HxJ 42 and 
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CZ 30) stabilized Trib2 F130A and F130G but did not affect Trib2, nor was the 
stability of Aurora A or SgK495 increased to the same extent.  Closely related 
analogs of the biphenyl-PP1 analogue CZ 30; CZ 28 and CZ 29, did not stabilize the 
gatekeeper mutants, and the reason for this is not currently known. 
Following the discovery of two bulky analogues that specifically interacted 
with recombinant F130A and F130G, isogenic inducible stable human cell lines, 
expressed FLAG tagged Trib2, K90M, F130A and F130G were generated that could 
facilitate the future identification of cellular phenotypes that change following 
application of inhibitors that interacted with the ATP binding sites of gatekeeper 
mutants and could help determine whether specifically targeting the ATP binding 
site of Trib2 would be therapeutically advantageous. The HeLa Flp-In T-REx and 
293 Flp-In T-REx inducible cell lines express low levels of endogenous Trib2 that 
are not detectable with the purified Trib2 antibody. However, endogenous Trib2 was 
detected in a variety of oncogenic cell lines, including in the human colon 
adenocarcinoma cell line HCT116, which when the levels of total protein loaded 
were taken into account, had the highest amount of Trib2 detected by western blot 
(Figure 4.19). HCT116 cells overexpress the oncogenic protein YAP which is a 
downstream target of the Hippo signaling pathway (Wang et al., 2013d) and in 
hepatocarcinoma cells (HCCs), Trib2 stabilises YAP by interacting with TrCP, an 
E3 ligase, and the presence of Trib2 is crucial for the cells transformative phenotype 
(Wang et al., 2013b). To identify whether Trib2 is an oncogenic driver in the 
HCT116 cell line, as in the HCCs, the cells could be treated with Trib2 siRNA and 
the levels of apoptosis and colony formation analysed. Endogenous Trib2 can also be 
detected in HeLa and HEK293 cells, unlike the Flp-In T-REx variants, which 
indicates that the Flp-In T-REx cell lines would be a good model to study 
overexpressed Trib2 WT and mutants without significant background endogenous 
Trib2 contamination, but if required, the ‘normal’ well-characterised HeLa or 
HEK293 cells can be utilized to study Trib2 endogenously. 
Trib2 expression in patient samples was investigated by analysis of the 
Oncomine database, which looked at the fold changes between tumor samples and 
normal tissue from published studies. I focused on presenting Trib2-overexpressing 
samples because of the previous studies that reported the significance of Trib2 
overexpression in cancers (Grandinetti et al., 2011, Zanella et al., 2010, Rishi et al., 
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2014). The tissue sample that had the largest Trib2 expression change was in a 
melanoma sample, and it has been reported previously that Trib2 is overexpressed in 
melanoma, where it represses the tumor suppressor FOXO, and knockdown of Trib2 
in melanoma cells reduces the cell proliferation by reinstating contact-inhibition 
growth and also reduces the ability of cells to form colonies (Zanella et al., 2010). 
Noticeably, Oncomine highlighted a variety of tumors that overexpressed Trib2, 
were isolated from brain tissue. Interestingly, the level of ‘free’ ATP (ATP that is not 
complexed to Mg
2+
) is high in brain compared to other tissues. In normal brain tissue 
it was revealed that ~24% ATP was not complexed with magnesium, in contrast to 
muscle tissue where only ~4% of ATP was free (Taylor et al., 1991), and as shown 
in the in vitro kinase assays presented in Chapter 3, Trib2 catalytic activity is 
inhibited by magnesium ions and so, the brain could be a potential  in vivo site where 
Trib2 catalytic ATP binding is particularly important, and might well be 
oncogenically relevant.   
Interestingly, the amount of induced recombinant Trib2 K90M expressed in 
HeLa cells is much lower compared to WT Trib2, suggesting that it is more rapidly 
turned over, and this could be investigated further by employing proteasome 
inhibitors such as MG132 (Dedhia et al., 2010). A similar destabilisation has also 
been observed following expression of Trib2 K90M in E. coli and Sf9 cells, which 
potentially indicates that the ability of Trib2 to bind ATP affects the rate of Trib2 
turnover and stability. The amount of expressed FLAG-tagged Trib2, is also higher 
than Trib2 F130A and F130G. Consistently, ATP did provide a marginal thermo-
protective effect on F130A and F130G with an average Tm ~1°C (performed in 
triplicate), which despite not being above the 2°C threshold indicative of ligand 
binding, was higher than the Tm increase observed for Trib2 K90M, in the 
presence of ATP (Tm 0.1°C) but was lower than Trib2 (Tm 4°C). Despite these 
results hinting at a link between Trib2 stability and the ability to bind ATP, further 
work will be required before any biological relevance can be attached to this 
observation.   
Despite DSF indicating that Trib2 F130A and F130G were very slightly 
stabilized by the presence of ATP, when they were assayed in vitro, there was no 
evidence of autophosphorylation, perhaps because they were much less stable and 
didn’t interact as strongly.  Static light scattering analysis that was performed 
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concurrently with the detection of intrinsic fluorescence whilst Trib2 and the 
gatekeeper mutants were incubated with ATP, showed that at 30°C (the temperature 
of the in vitro kinase assays) Trib2 F130A and F130G were aggregating. In both 
cases, the Tagg (onset of aggregation temperature) was ~29°C, whereas Trib2 K90M 
aggregated at a temperature above 30°C, so aggregation was not the likely reason for 
the lower activity observed by the K90M mutant. To categorically determine 
whether the Trib2, Trib2 F130A and Trib2 F130G mutants expressed in cell lines can 
bind to ATP, they could be FLAG-immunoprecipitated and subjected to an in vitro 
kinase assay alongside Trib2 K90M as a control, using autophosphorylation or 
phosphorylation of Trib2 K90M as a substrate.  
Reduced catalytic activity of the gatekeeper mutants is not unique to Trib2 
but has been observed for ~30% of the kinases that have been tested so far 
(Hengeveld et al., 2012). It has been suggested that mutating the gatekeeper residue 
could disrupt the hydrophobic spine of the kinase fold and reduce its stability 
(Garske et al., 2011).  Aurora B is an example of such a kinase where a Gly or Ala 
mutation to the gatekeeper Leu residue (L154G/A) abrogates catalytic activity. 
However, a second site mutation (H250Y) reinstates WT-like phosphorylation to 
gatekeeper mutated proteins (Hengeveld et al., 2012). The Syk tyrosine kinase is 
also unable to tolerate a gatekeeper mutation and Syk mutants have reduced catalytic 
activity. By aligning Syk with Src, which remained catalytically active following 
mutation of the gatekeeper residue, it was noticed that residues in close contact with 
the Src gatekeeper residue (T338) are Gln and Leu whereas in Syk, the 
corresponding residues are Arg425 and Met426 (Syk gatekeeper residue M442). The 
catalytic activity of the R425Q M426L M442A Syk mutant increased compared to 
M442A alone. However, these secondary mutations did not increase the catalytic 
activity of Syk M442G (Oh et al., 2007). 
A strategy to identify second site mutations that reinstate the catalytic activity 
of gatekeeper mutant kinases has been identified and concluded that mutating a 
residue located within the 3 middle  sheets of the N-lobe of the kinase to a branched 
amino acid, did not reduce the space opened up in the ATP binding domain brought 
about by the mutated gatekeeper residue but restabilized the N lobe of the kinase 
domain and increased the catalytic activity of the analog sensitive mutants, and these 
could still bind to the bulky analogues (Zhang et al., 2005a).  Structural and 
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sequence analysis of tolerant gatekeeper mutant kinases identified that a valine was 
often present (c-Src V284), and alignment of Cdc5, which is intolerant to mutation 
of the gatekeeper, has a Cys residue at this position. In budding yeast, when Cdc5 is 
doubly mutated, with C96V and either L158A or L158G, the yeast are viable, unlike 
when the gatekeeper is the sole mutation (Zhang et al., 2005a). Alignment of Trib2 
with c-Src has indicated that the aligned residue is also a valine (V75 Trib2), so this 
is not the position to locate a ‘second-site’ mutation in Trib2 and further analysis of 
the sequence, and ideally a structure (when available) is required to help predict 
where a mutation should be placed to increase tolerance of a gatekeeper mutation. 
 
Irreversible kinase inhibitors: 
Another method that creates an analogue-sensitive gatekeeper mutant kinase 
without increasing the size of the ATP binding pocket (and potentially prevents 
catalytic spine disruption) is the mutation of the gatekeeper residue to a cysteine, 
which can then be targeted by electrophilic small molecules, which covalently bind 
to the protein. Initial work was performed on Src, and although no second site 
mutations in the N lobe were required to maintain catalytic activity, screens to 
identify new reactive compounds needed to be performed (Garske et al., 2011).  If 
F130C Trib2 displays similar stability, ligand binding and catalytic activity as WT 
Trib2, then DSF could be used to identify electrophilic inhibitors that bind to F130C 
Trib2, but not WT Trib2.  Additionally, Cys residues are present in over 200 ATP-
binding sites in the kinome (Zhang et al., 2009, Liu et al., 2013) and these could be 
exploited, or Cys residues introduced, into Trib2 so that ligands specifically targeting 
a Cys residue can be developed.   
Recent analysis of the catalytically active pseudokinase HER3 (Shi et al., 
2010), a member of the EGFR family, has revealed that upon binding to the ATP-
competitive inhibitor Bosutinib, the binding affinity of HER3 for EGFR, which it 
activates allosterically, increases. This therefore predicts, and was recently validated 
in vitro, that Bosutinib ‘inhibition’ actually increases HER3-mediated downstream 
signaling rather than reducing it. A similar property has been observed for the kinase 
BRAF. The MAPK pathways in cells expressing an oncogenic form of BRAF 
(BRAF V600E), were blocked following the addition of ATP-competitive RAF 
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inhibitors. However, in B-RAF WT cells, the ‘inhibitors’ trigger MEK/ERK 
phosphorylation (Hatzivassiliou et al., 2010, Claus et al., 2013). This means that 
following inhibitor treatment of Trib2 (or any kinase domain) the downstream 
signaling pathways must be fully evaluated to ensure the catalytic activity of the 
targeted protein, or allosterically-regulated binding partners are not inadvertently 
activated when the goal was inhibition (as might be the case in Trib2-driven 
cancers). 
The Trib2 interactome: 
Although I did not confirm the interaction between Trib2 and a number of 
binding partners, it is interesting to speculate what the role of these interactions 
might be if confirmed. An interesting protein that coimmunoprecipitated with Trib2 
was STK38, more commonly known as NDR1, which is a key kinase in the Hippo 
pathway and controls cell size and proliferation through the transcription factor 
YAP. Interestingly, Trib2 has recently been shown to interact with the E3 ligase 
TrCP, and this interaction increases the stability of YAP in liver cells. Moreover, 
YAP transcriptional activity is inhibited by CEBP/ in liver cancer cells, and Trib2 
relieves this repression by targeting CEBP/ for degradation (Wang et al., 2013b). 
Interestingly, NDR1 (STK38) can phosphorylate YAP in vitro, although there is, so 
far, no evidence of YAP phosphorylation by NDR1 in cell lines (Hao et al., 2008). 
The consensus sequence of NDR1 phosphorylation identified by Hao et al., is also 
conserved throughout the AGC kinase family, of which p70S6K is a member. 
Intriguingly, p70S6K decreased Trib2 stability via phosphorylation of serine 83 
(Wang et al., 2013c).  The NDR1 phosphorylation consensus sequence observed in 
YAP,  H V R A H S
127
 (H x H/R/K x x S /T) (Hao et al., 2008) is partially conserved 
surrounding Ser 83 in Trib2: A V H L H S
83
, with the only deviation being the initial 
Ala residue. To determine whether Trib2 S83 is phosphorylated by NDR1, the 
stability of Trib2 could be assessed following transfection of NDR1 siRNA or 
mutation of Trib2 S83.  It would also be interesting to examine whether the activity 
of NDR1 or the transcriptional activity of YAP was altered in Trib2 K90M 
overexpressing cells compared to WT because this could indicate whether the 
binding of ATP by Trib2 influences Trib2 phosphorylation by NDR1, and if so this 
could potentially be disrupted by the exposure of either HxJ 42 or CZ 30 to F130A 
or F130G Trib2 overexpressing cell lines.  Interestingly, Shroom3, another putative 
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binding partner of Trib2 identified in Table 4.1, recruits Rho kinases to apical cell 
junctions (Nishimura and Takeichi, 2008) and Rho kinases are also constituents of 
the AGC kinase family (Pearce et al., 2010). Creatine Kinase also 
coimmunoprecipitated with Trib2. It catalyses the reversible phospho transfer from 
ATP to creatine (Dzeja and Terzic, 2003), and has been predicted to interact with 
C/EBP (Hu et al., 2011b), which has previously been immunoprecipitated with 
Trib2 from HEK293 cells (Naiki et al., 2007).  The relevance of this link is worthy 
of further investigation. Finally, Protein Arginine N-Methyltransferase 5 
(ANM5/PRMT5) was also identified by Mass Spectrometry following FLAG 
immunoprecipitation of Trib2. ANM5 interacts with other protein kinases and 
modulates their behaviour, including the activity of EGFR, where it methylates 
Arg1175, which stimulates the transautophosphorylation of Tyr1173 (Hsu et al., 
2011). JAK2 (Pollack et al., 1999) and JAK1, also interact with ANM5 which 
methylates and activates STAT6 (Igarashi et al., 2009).  
Several techniques described in this Chapter have allowed me to demonstrate 
unequivocally that Trib2 binds ATP, and that the ATP binding domain of engineered 
Trib2 mutants are targetable by small molecule inhibitors. Throughout the human 
kinome a large range of Km values for ATP and ligands have been reported (Knight 
and Shokat, 2005, Davis et al., 2011, Becher et al., 2013) and the catalytically active 
pseudokinase CASK has a reported ‘low’ affinity for ATP with a Km value 563 M 
(Mukherjee et al., 2008). The generation of Trib2 overexpressing cell lines, will 
allow specific targeting of the ATP binding domain by the identified bulky 
inhibitors, which could potentially isolate ATP dependent Trib2 driven phenotypes. 
One very interesting phenotype to be investigated in the future is the turnover of 
C/EBPwhich has been associated with the progression of AML. When Trib2 was 
overexpressed, the turnover of C/EBP increased and the protein level reduced. This 
caused increased cell transformation and reduced differentiation, which are 
characteristics of cancerous cells. The proteasomal turnover of C/EBP is dependent 
upon the integrity of the Trib2 catalytic motif, with cells that expressed the mutated 
Trib2 K177R protein displaying phenotypes that were less oncogenic (Keeshan et 
al., 2010). Recombinant Trib2 K177A produced in E. coli displayed a reduced 
ability to autophosphorylate (Chapter 3), however the ability for Trib2 K177A to 
bind ATP was not determined by DSF and ideally should be performed in the future. 
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These findings suggest that if direct ATP binding is required for Trib2-mediated 
oncogenesis, chemical genetic approaches that use analogue sensitive Trib2 mutants 
along with DSF, can be used to discover Trib2 ligands that might also be inhibitors, 
and therefore drug targets.  
In this Chapter, I have used different techniques to show that Trib2 does bind 
ATP and that the ATP binding site of Trib2 mutants can be targeted by small 
molecule analogues. This has demonstrated that the Trib2 ATP binding site is 
‘druggable’, and, to my knowledge, is the first identification of any small molecule 
ligand that can bind to Trib2.  Trib2 is not the only Tribbles pseudokinase that is 
implicated in disease progression, Trib3 is associated with a variety of diseases, 
including breast cancer (Wennemers et al., 2011b). In Chapter 3, Trib3 also 
demonstrated the ability to autophosphorylate and it would be very interesting to see 
whether DSF can identify ATP binding to Trib3, as it does for Trib2 and SgK495, 
which would indicate that this member of the Tribbles family also has an ATP 
binding pocket that could be targeted by ATP analogues. Further work is still 
required to fully validate the implication of ATP binding by Trib2 upon the 
oncogenicity of Trib2 overexpressing cells and to determine whether current 
‘gatekeeper’ mutants are active in a cellular environment, or whether further N lobe 
mutations or generating Trib2 F130C are required to reinstate ATP binding and 
catalytic activity. What can be appreciated by this work is that by combining 
techniques such as DSF and chemical genetics, the function of pseudokinases can 
begin to be elucidated along with the identification of druggable ATP binding sites 
and the discovery of new pseudokinase-targeted ligands. 
4.17  Conclusion 
Analysis of Trib2 by DSF enabled the first detection of ATP binding by 
Trib2 in an assay that is amenable for establishment of large scale Trib2 ligand and 
inhibitor screens. DSF is a particularly valuable technique for pseudokinase 
functional analysis, especially when used in tandem with in vitro kinase assays as 
performed here for Trib2. The advantages of following up in vitro kinase assays with 
DSF was observed following disappointing results with a Trib2 DFGK180N mutant, 
which was designed to ‘re-activate’ this kinase, making it a highly active, Mg2+-
dependent kinase. However, Trib2 DFGK180N did not autophosphorylate in the 
presence of ATP, but after analysis by DSF, it was apparent that the lack of 
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autophosphorylation was caused, at least in part, because the protein was unfolded 
prior to the assay. Using DSF as a technique to probe the accessibility of the Trib2 
ATP binding site has facilitated the initiation of inhibitor binding trials. Two bulky 
PP1 analogues that specifically bind to Trib2 F130A and F130G (but not Trib2) have 
so far been identified. In the future, cell lines overexpressing Trib2, Trib2 F130A or 
F130G can be exposed to the bulky inhibitors to determine whether inhibiting the 
ATP binding site causes perturbations to the downstream signalling pathways it has 
been implicated in regulating, including the analysis of changes to C/EBP stability, 
NF-B signalling, YAP/TEAD transcriptional activation, AKT activation and the 
MAPK pathway. 
By developing the tools and cell lines described in this chapter I have 
confirmed that Trib2 binds ATP in vitro, and facilitated the transition from 
recombinant in vitro functional assessment of Trib2 to identifying that the Trib2 ATP 
binding site is potentially targetable by small molecule inhibitors in cells. This work 
might lead to the identification of whether inhibiting ATP binding, or placing a 
ligand in the unusual Trib2 ‘nucleotide-binding site’ can alter the oncogenic 
behaviour displayed by Trib2-overexpressing cells in diseases such as AML, ALL, 
NSCLC and hepatic cancers. This will help determine whether the Trib2 ATP 
binding site would make a novel drug target, and because the Trib2 pseudokinase 
domain differs from the majority of the human kinome (does not have the Mg
2+
 
binding residues), the therapeutics developed have the potential to be highly specific. 
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CHAPTER 5. Analysis of NOK, a 
novel Receptor Protein Tyrosine 
Pseudokinase  
5.1 Introduction 
In Chapters 3 and 4 of this thesis, I demonstrated that like the pseudokinase 
CASK (Mukherjee et al., 2008), Trib2 and Trib3 could also weakly bind to ATP and 
autophosphorylate in the absence of divalent cations. Both CASK and Trib2 were 
originally defined as pseudokinases because they lack the Asp residue in the ‘DFG’ 
motif of the kinase domain. Consistently, CASK and Trib2 (but not Trib2 containing 
point mutations in the ATP-binding site) can still interact (weakly) with ATP when 
assayed using thermal stability assays, which suggests a potential reliance on 
nucleotide binding for cellular function. In the human kinome, seven other human 
pseudokinases do not contain a canonical DFG motif, but still retain other conserved 
residues that clearly define them as protein kinase domains. These residues are 
defined as the Asp residue in the catalytic loop and a conserved lysine in the 3 sheet 
of the N lobe kinase, which interacts with the - and - phosphates of ATP to 
facilitate nucleotide positioning and binding (Boudeau et al., 2006). The 
pseudokinases that contain a magnesium ion binding loop that deviate greatly from 
the canonical DFG motif are CCK4 (PTK7) (Figure 5.1C), SgK223, SgK269, NOK, 
Trib1, Trib2 (Figure 5.1 C), Trib3 and SgK495 (Eyers and Murphy, 2013). 
Interestingly, the pseudokinase Titin, which has a more conservative change in the 
canonical DFG motif (to EFG), has very recently been reported to be catalytically 
inactive (Bogomolovas et al., 2014). However, both Trib2 and Trib3 have 
demonstrated the ability to autophosphorylate in vitro, but only in the absence of 
divalent cations (Chapter 3), while SgK495, although unable to autophosphorylate 
under the conditions tested, appears to bind to ATP when analysed by DSF (Chapter 
4).  
A particularly interesting pseudokinase in which the DFG motif is mutated is 
NOK (Novel Oncogenic Kinase), which has also been termed STYK1 
(Serine/Threonine/Tyrosine Kinase 1) and SuRTK106 (Sugen Receptor Tyrosine 
Kinase 106). Analysis of the human, mouse and Xenopus tropicalis NOK amino acid 
sequences reveals a predicted transmembrane domain located between residues 26-
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49 in the N-terminus of NOK (human numbering, Figure 5.1A,B). Along with this 
putative hydrophobic transmembrane domain, the NOK gene also encodes a 
pseudokinase domain, and residing in this domain is a catalytic motif that closely 
resembles those observed in the tyrosine kinase sub-family, namely HxDxAARN 
(Figure 5.1C) (Kannan et al., 2007, Lemmon and Schlessinger, 2010, Mendrola et 
al., 2013). Specifically, NOK has also retained the canonical His, catalytic Asp, two 
Ala residues, an Arg and an Mg
2+
-coordinating Asn, all of which are typically found 
in the catalytic motif of tyrosine kinases. However, the magnesium-ion binding motif 
in the ‘DFG’ motif (which is also highlighted in Figure 5.1C), is highly atypical 
compared to those observed in canonical tyrosine kinases, because NOK has evolved 
a GLG sequence. As discussed previously, both the Asp and Phe residues in this 
motif are important for kinase activity, and NOK shares between 20-30% overall 
amino acid identity with the Platelet-Derived Growth Factor (PDGF) and Fibroblast 
Growth Factor Receptor Protein Tyrosine Kinase family members (Liu et al., 2004). 
Interestingly, however, NOK lacks a prominent extracellular domain, in marked 
contrast to other growth factor receptors linked to tyrosine kinases and no 
extracellular or intracellular ligand binding domains are predicted when the protein 
sequence is interrogated by bioinformatic or biochemical evaluation. 
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Figure 5.1 Bioinformatic analysis of NOK predicts a single pass transmembrane 
domain and an intracellular tyrosine kinase like-pseudokinase domain. A) TMPred 
output following analysis of all NOK residues (1-422) highlights the presence of a 
predicted single pass transmembrane domain, which lies between residues 26 and 49. 
Positive Y-axis values on the hydropathy plot represent predicted hydrophobic regions, 
whilst negative values are hydrophilic, and therefore are not predicted to form a 
transmembrane region. The X-axis represents the NOK residue number. B) TMHMM 
software predicts, as the TMPred software did in A, that the residues between 26-49 
form a membrane-spanning helix. Predicted transmembane regions are denoted with 
an arrow in A and B. C) The catalytic loops and DFG motifs of the pseudokinases NOK 
and PTK7, which both have a non-DFG metal ion binding Asp (red box) were aligned 
using MUSCLE software, using HER3 pseudokinase (which lacks the catalytic Asp) 
and the canonical active RPTKs EGFR, and FGFR3 for comparison. Abelson kinase 
(Abl) is a cytoplasmic TK, and also forms part of this analysis as does the Ser/Thr 
kinase PKA for comparative purposes. The consensus motifs emerging from the 
alignment is displayed underneath using Weblogo, a graphical representation of the 
amino acid multiple sequence alignment where the height of the amino acid is 
proportional to its relative conservation in a motif. 
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 NOK research remains in its infancy, with the majority of the literature 
focusing on the finding that NOK mRNA is commonly overexpressed in human 
tumors, including acute leukemia (Kondoh et al., 2009), ovarian (Jackson et al., 
2009), castration-resistant prostate (Chung et al., 2009), and breast cancers (Kimbro 
et al., 2008).  NOK has also been implicated in the metastatic progression of cancer 
cells (Liu et al., 2004).  Interestingly, a fusion between the extracellular domain of 
mouse erythropoietin receptor (EPOR) and the NOK-transmembrane-and-
intracellular domain, termed EPOR/NOK has been suggested to be ‘constitutively 
active’ leading to EPOR/NOK dimerisation and autophosphorylation of NOK (Liu et 
al., 2004). In a separate study by the same group, immunoprecipitated EPOR/NOK 
was assayed using an in vitro kinase assay, which demonstrated autophosphorylation 
of the fusion protein (Chen et al., 2005b). However, contamination by other kinases 
was neither controlled for, nor ruled out, although the fusion protein might well alter 
the conformation or behavior of NOK.  If NOK can bind to ATP, and if ATP binding 
is important for NOK-driven oncogenesis, then the ATP binding site of NOK might 
become a novel drug target in the future should cancer cells exhibit specific 
sensitivity to NOK ligands/inhibitors. Other RPTK ATP binding domains that have 
been successfully targeted in clinical trials include EGFR (Berardi et al., 2013), 
BCR-Abl (Zhang et al., 2010), c-Kit (Ashman and Griffith, 2013), SRC (Creedon 
and Brunton, 2012) and PDGFR (Michael et al., 2010), and because NOK 
overexpression has been implicated in a number of blood-borne and solid cancers, it 
is important to determine whether it too, can, be targeted with kinase ligands that 
might function as inhibitors in cells. As discussed in Chapters 3 and 4, approaches 
that combine elucidation of the cellular biology and biochemistry of pseudokinase 
are important to determine both function and potential ‘druggability.’ The results 
described in this Chapter represent some of the preliminary findings from my 
evaluation of human NOK. 
To identify cell lines that expressed detectable levels of NOK, a panel of 13 
cell lines (described in Chapter 4) were immunoblotted using a commercial NOK 
antibody (Figure 5.2). However, apart from the positive control lane, which 
contained recombinant GST-His NOK that had been expressed in E. coli and 
purified by IMAC, no NOK signal was detected following either a 10 minute or 60 
minute exposure, and this limited my ability to analyse endogenous NOK cellular 
behavior. To counter this potential problem, inducible cell lines that expressed 
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recombinant epitope-tagged NOK were therefore generated (Figure 5.3). In addition, 
a differential analysis of NOK expression in cancer samples compared to normal 
samples was undertaken using the Oncomine database (summarized in Table 5.1), 
which showed that NOK expression in cancer cell lines varied markedly. For 
example, superficial bladder cancer showed a 10-fold increase in NOK expression, 
while NOK expression in pancreatic, testicular, skin and ovarian carcinomas was ~5-
6 fold greater than normal tissues, whilst lung carcinoma NOK expression was four 
times higher than controls. NOK overexpression was also detected in renal cell 
carcinomas, at levels some 3 times higher than in normal kidney tissue. Elevated 
NOK mRNA expression has previously been reported in 92.3% (12/13) of lung 
tumor tissues analysed from a small cohort of patients and compared to samples 
from healthy patients. Moreover, in lung cancer tissues, NOK mRNA was detected 
in 97.6% (40/41) of the samples compared to normal tissue, where only 38% (5/13) 
of the samples stained positive for NOK mRNA (Amachika et al., 2007). Currently, 
and to my knowledge, there have been no reported associations between elevated 
NOK expression in either bladder or pancreatic carcinomas, and the four epithelial 
bladder cell lines analysed in this work did not reveal any detectable expression of 
NOK using a commercial antibody (Figure 5.2).  NOK mRNA was, however, 
undetectable by Northern blot analysis of normal pancreatic samples (Liu et al., 
2004), and this same group detected high levels of NOK mRNA expression in 
human 293T cells. However, when I probed HEK293 cell extracts with a NOK 
antibody, no immunoreactive band was detected by western blotting (Figure 5.2). 
Furthermore, NOK mRNA was reported by RT-PCR in a panel of ovarian cancer 
cell lines (including SkOv3), which expressed different forms of the Oestrogen 
receptor, and in a small sample study, malignant ovarian tissues stained strongly for 
NOK, whereas benign tissues were only weakly immunoreactive and no immune-
staining was observed in normal ovarian tissues (Jackson et al., 2009). All of these 
findings suggest that high levels of NOK mRNA, (but not necessarily NOK protein), 
are associated with cancer and that the cellular function of NOK requires further 
investigation. 
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Figure 5.2 Endogenous NOK was not detected in any of the cell lines tested. 
Thirteen cancer cell lines were lysed in 1% Triton X-100, and soluble lysates were 
immunoblotted with a NOK antibody. Five hundred nanograms GST-His tagged NOK was 
included as an antibody control and the relative loading was determined by a comparison 
of the levels of detected alpha-tubulin (same experiment as Figure 4.19). 
 
Table 5.1 A summary of NOK overexpression reported in the Oncomine database. 
NOK overexpression was examined by performing a ‘Cancer versus Normal‘ analysis. The 
tissues that had the highest fold change compared to normal (p=0.05) are listed using an 
arbitrary 3-fold change cut-off. The names of the datasets and primary study citations are 
listed. 
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5.2 Overexpression of epitope-tagged NOK in human cells 
To facilitate an analysis of NOK signaling in the model HeLa ovarian human 
cancer cell line, HeLa Flp-In T-REx parental cells were transfected with full-length 
human NOK cDNA cloned in the pcDNA5 FRT/TO vector that was individually 
tagged at either the C terminus with a FLAG epitope (predicted intracellular epitope 
tag) or at the N terminus with a Myc epitope (predicted extracellular epitope tag). 
The pseudokinase domain is located between amino acids 114 and 384, C-terminal 
to the putative transmembrane domain. After addition of Tetracycline (Tet), epitope 
tagged NOK protein expression was evaluated by western blotting and 
immunofluorescence. To test the expression and solubility of NOK after cell lysis, 
cell extracts were made by employing cell lysis buffer that contained either 0.1% 
Triton X-100 or 1% Triton X-100, which will vary the amount of membrane-bound 
proteins solubilised. Proteins were resolved by SDS-PAGE and transferred to 
nitrocellulose membrane. The membrane was then probed with commercial 
antibodies corresponding to each specific epitope tags.  
As shown in Figure 5.3 A, immunoblotting with anti-Myc antibody 
confirmed that Myc-tagged NOK and alpha tubulin (detected by an alpha tubulin 
reactive antibody used as a loading control) were both present in the ‘soluble’ (0.1% 
Triton) and ‘insoluble’ (0.1% Triton pellet resuspended in SDS) fractions. The 
inducibility of the system was confirmed because Myc-NOK was observed only in 
the lysates that had been prepared from cells treated with Tetracycline (Figure 5.3 
A). 
The proportion of full length NOK present in the soluble lysates was 
increased by lysing the Myc-tagged full length NOK expressing cells (Figure 5.3 B) 
and FLAG tagged full length NOK (Figure 5.3 C) expressing cells in a cell lysis 
buffer that consisted of 1% Triton X-100. The lysates and insoluble pellets were 
resolved by SDS-PAGE. The resulting signals observed following immunoblotting 
of the epitope tags, confirmed that by increasing the Triton X-100 concentration, the 
proportion of soluble NOK (and also alpha tubulin) increased. 
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Figure 5.3 Expression of epitope-tagged NOK in stably transfected HeLa Flp-In T-
REx cells. Myc tagged NOK expressing HeLa Flp-In T-REx cells were lysed in cell lysis 
buffer that contained either A) 0.1% Triton X-100 or B) 1% Triton X-100. The soluble and 
insoluble fractions were resolved by SDS PAGE and western blotted with an α-Myc 
antibody and the loading determined by analysis of alpha tubulin levels C) FLAG tagged 
full length NOK expressing cells were lysed in the 1% Triton X-100 containing lysis buffer 
and following western blotting, the inducibilty of the cells was determined by probing the 
membrane with a FLAG antibody. Alpha tubulin was used to analyse the loading. Epitope 
tagged NOK expression was induced by Tetracycline (Tet).  
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5.3 Epitope-tagged NOK co-localises adjacent to mitotic 
chromatin 
Following the generation of human cell lines expressing tagged-NOK, it was 
important to try to identify its cellular localization, and try to help correlate this with 
its function. Amino acid analysis suggested that NOK has a putative transmembrane 
domain between amino acids 26 and 48 (Figure 5.1). However the reported 
localization of NOK differs throughout the literature, with EGFP-tagged NOK 
reported to be found in the cytosol (Liu et al., 2004), whilst HA-tagged NOK 
localizes to endosomal compartments (Ding et al., 2012).  HeLa Flp-In T-REx cells 
that expressed Myc-tagged full length NOK were therefore stained with DAPI, a 
fluorescent stain that binds to DNA and highlights the nucleus, allowing the visual 
differentiation of mitotic cells from cells in interphase by virtue of the chromosomal 
condensation that occurs in mitotic cells.  Myc- tagged NOK was fluorescently 
stained with an anti-Myc epitope antibody and visualized with a corresponding 
secondary antibody conjugated to a fluorophore. As shown in Figure 5.4A, intense 
fluorescence was observed surrounding the mitotic chromatin of Tet-treated cells, 
whereas no signal was observed for Tet-negative cells. A similar pattern of staining 
was observed for cells probed with an anti-Lamin B1 antibody (Figure 5.4B).  Lamin 
B1 usually lines the inner nuclear envelope, but in mitotic cells Lamin B1 is cleaved 
(Chandler et al., 1997), which facilitates mitotic progression by dissolution of the 
nuclear envelope and allowing the mitotic spindle to access the condensed chromatin 
(Burke, 2001). 
5.4  Myc tagged NOK expression increases in mitosis 
To evaluate if there was any change to the levels of expressed tagged NOK 
during mitosis, HeLa Flp-In T-REx cells were treated with Nocodazole, which 
arrested the cell cycle during mitosis due to its ability to depolymerise the mitotic 
spindle and activate the spindle assembly checkpoint (SAC) (Jordan et al., 1992). 
Nocodazole-treated and control cells were harvested (adherent and non-adherent 
mitotic cells) in both Tet positive and untreated populations, resolved by SDS-PAGE 
on a 15% gel and then immobilized on a membrane that was excised at ~50 kDa and 
~25 kDa. The 50 kDa-25 kDa section was probed with an anti-Myc antibody, which 
detected Myc-tagged NOK in Tet-exposed cells, with a more intense signal observed 
in nocodazole-treated cells (Figure 5.5). Alpha tubulin was used as a loading control 
and the increased level of phosphorylated Histone H3 in nocodazole treated cells 
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confirmed that cells were enriched in the mitotic phase of the cell cycle, when this 
Histone mark is maximal (Ota et al., 2002). 
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Figure 5.4 Intense NOK staining is observed surrounding mitotic chromatin.   HeLa 
Flp-In T-REx cells were transfected with Myc-tagged full length NOK. The cells in the top 
panels of both A and B were cultured in media that was supplemented with Tetracycline. 
Nuclear chromatin was stained with DAPI.  Cells were probed with a primary antibody that 
targeted the A) Myc epitope of Myc tagged NOK, or B) Lamin B1, a resident protein of the 
inner nuclear envelope. The cells were incubated with a secondary Cy3 fluorophore 
conjugated antibody that recognised the primary antibodies. The right hand panel is a 
merged image of the DAPI and Cy3 fluorescence signals. 
 
 237 
 
  
50
37
50
75
+
+
-
+ -
+ -
-
Tet
Noc
20
25
α-myc
α- Alpha Tubulin
α- phospho Histone H3
Myc-NOK
25
Non-specific
Figure 5.5 Western blot analysis of cells arrested in mitosis. HeLa Flp-In T-REx cells 
stably transfected with Myc-tagged full length NOK were treated with tetracycline (Tet) and 
nocodazole (Noc). The lysates were subjected to SDS-PAGE and western blotting. The 
membranes were probed with either an α-Myc (top panel), α-alpha tubulin (middle panel) or 
α-phospho Histone H3 (lower panel) antibody. Myc tagged NOK and non-specific bands 
have been highlighted. 
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5.5 Epitope-tagged NOK stains the ‘nuclear rim’ of HeLa cells  
 In non-mitotic cells that expressed either Myc (Figure 5.6 A) or FLAG-
tagged NOK (Figure 5.6 B), the nuclear rim and organelles surrounding the cytosolic 
side of the nucleus were strongly stained, but notably no fluorescence was detected 
surrounding the nucleus of Tet-negative cells, which indicated that the detected 
signal was NOK-specific. Not all cells showed the same intensity of NOK staining, 
despite all cells being stably transfected in the population. This may indicate that 
cells expressed different levels of NOK at different stages of the cell cycle, the 
intense staining observed around mitotic nuclei and in mitotic lysates (Figures 5.4 
and 5.5) are further examples of this. The observed fluorescent signals for N-
terminal Myc tagged NOK and C-terminal FLAG tagged NOK were similar, which 
demonstrated that subcellular localization is not affected by the presence of the 
epitope tag. 
Further validation that the observed indirect immunofluorescence was of the 
epitope tagged NOK and not non-specific background was obtained by a marked 
decrease in signal in Myc-tagged NOK expressing cells that were treated with a pool 
of NOK targeting siRNA, when compared to the staining of cells transfected with a 
non-coding siRNA control pool or cells treated with the transfection reagent alone 
(Figure 5.7 A). Consistently, siRNA treated Tet-induced cells had a similar level of 
background staining as the uninduced cells. 
In agreement with my immunofluorescence analysis, western blotting also 
showed that Myc-NOK expression decreased when cells were transfected with a 
NOK targeting siRNA pool. In the lysates that had been treated with NOK siRNA, 
no Myc signal was detected at the molecular weight expected for Myc-tagged NOK 
(Figure 5.7 B).  Myc-NOK was still detected in induced lysates treated with the non-
coding siRNA control or the transfection reagent lipofectamine. Myc NOK was 
detected in the Myc tagged NOK control lysate. 
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Figure 5.6 Tagged NOK localises to the nuclear membrane. A, B) The localisation of 
overexpressed NOK was determined by indirect immunofluorescence microscopy. Cells 
were grown on glass coverslips prior to fixing in 3.7 % paraformaldehyde (PFA). The cells 
in the upper panels of A and B were treated with Tet A) NOK overexpression in HeLa Flp-
In T-REx cells was observed with an α-Myc primary antibody and a Cy-3 conjugated 
secondary antibody B) FLAG tagged NOK localisation was determined by probing the 
cells with an α-FLAG primary antibody, which permitted visualisation of the FITC-
conjugated secondary antibody.  
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Figure 5.7 Overexpressed NOK protein levels can be decreased by siRNA Two 
hundred pmoles of an siRNA pool containing equal molar amounts of 4 NOK specific 
siRNAs, and 200 pmoles of a non-coding siRNA pool were transfected  (alongside a 
lipofectamine control) into Myc tagged NOK expressing HeLa Flp-In T-REx cells that were 
grown in dishes containing glass coverslips.  A) After 64 hours, the cells attached to the 
glass coverslips were fixed in 3.7 % PFA and stained with DAPI and α-Myc-Cy3 and 
subjected to immunofluorescence.  B) The cells that had adhered to the plastic dishes 
were harvested in cell lysis buffer containing 1 % Triton X-100. Twenty micrograms of total 
protein was transferred immunoblotted with an α-Myc antibody, and an α-alpha tubulin 
antibody to visualise relative protein loading. 
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5.6 Epitope tagged NOK co-localises with Lamin B1 
In Figure 5.6, along with potential endosomal staining, the edge of the 
nucleus appeared to be highlighted. To determine if NOK localised to the nuclear 
envelope, the cells expressing Myc-tagged NOK were probed with a Lamin B1 
antibody. Lamin B1 is a protein that localizes to the inner nuclear membrane (INM) 
and is a nuclear membrane marker (Bocock et al., 2010, Dreger et al., 2001). 
Colocalisation of Myc tagged NOK and Lamin B1 in non-mitotic cells (Figure 5.8) 
was determined by indirect immunofluorescence, which demonstrated that NOK also 
localized to the nuclear envelope in addition to the perinuclear region of the 
cytoplasm, consistent with a previously reported endosomal expression pattern (Ding 
et al., 2012). 
5.7 A sequence that corresponds to the nuclear localization 
sequence observed in the EGFR family members is also 
conserved in NOK 
To identify any potential nuclear membrane localisation sequences, MUSCLE 
software was used to align NOK with the Nuclear Membrane Localisation Sequence 
of a well known nuclear membrane protein, Human Cytomegalovirus Glycoprotein 
B (Meyer and Radsak, 2000). A region of NOK that aligned to the HCMV 
Glycoprotein B localization sequence was identified, and this included the 
conservation of two positively charged Arg residues, R377 and R379 in human NOK 
(Figure 5.9 A). Interestingly, when either of these Arg residues were mutated in 
Glycoprotein B, its cellular localization was altered dramatically (Meyer and Radsak, 
2000). This sequence has also been identified in other known nuclear membrane 
proteins including the Lamina associated proteins LAP1 and LAP2 and the Lamin B 
receptor protein (Meyer et al., 2002). Other RPTK proteins that translocate into the 
nucleus via the nuclear envelope are members of the EGFR family. EGFR 
translocates through the Nuclear Pore Complexes (NPCs) to the inner nuclear 
membrane (INM) by the action of importin β, before being released into the nucleus 
by the INM localised Sec61β (Wang et al., 2010). Incidentally, as well as sharing the 
tripartite NLS observed in EGFR (Figure 5.9 B), NOK has also recently been shown 
to co-localise with EGFR in membrane-bound vesicles (Ding et al., 2012). The 
EGFR NLS sequence is also conserved in the other 3 family members, ErbB2, 3 and 
4 (Hsu and Hung, 2007, Chen et al., 2005a).  Finally, this signal motif has also been 
identified in the E3 ligase RNF13, which localizes to endosomes and colocalizes 
with Lamin B1 in the inner nuclear membrane (Bocock et al., 2010), and published 
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immunofluorescence staining  resembled the immunofluorescence observed for 
epitope tagged NOK in non-mitotic cells. The RNF13 nuclear membrane localization 
sequence has been identified in RNF13, and is very similar to the EGFR localization 
sequence (Bocock et al., 2011) described above.  The same NOK Arg residues 
(R337 and R379) that aligned to the arginine residues critical for Glycoprotein B 
translocation to the nuclear membrane, also aligned with Arg residues present in the 
conserved NLS sequences of the EGFR family (Figure 5.9 B) and RNF13 (Figure 
5.9 C). In ErbB3 and NOK, the position of this conserved localization sequence is in 
the C-terminal region of the pseudokinase domain (Figure 5.9 D). In EGFR, ErbB2 
and ErbB4 the NLS is located within the juxtamembrane domain (Hsu and Hung, 
2007).   
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Figure 5.8 NOK colocalised with Lamin B1 at the inner nuclear membrane. Stably 
transfected Tet-inducible HeLa Flp-In T-Rex cells that expressed Myc tagged NOK were 
fixed with 3.7% PFA. The cell nuclei were highlighted with DAPI stain, Lamin B1 and a 
FITC conjugated secondary antibodies were used to highlight the nuclear membrane, and 
a Myc antibody with a Cy3 fluoprophore secondary was used to analyse the location of 
Myc-tagged NOK. The individual images were merged using Volocity software 
(Improvision) 
 
Figure 5.9 NOK R377 and 379 align with Arg residues in published nuclear 
membrane localisation sequences. The published localisation sequences of A) 
Glycoprotein B, B) EGFR and C) RNF13 were aligned with NOK using the MUSCLE 
alignment software and NOK R377 and R379 and the corresponding aligned residues 
are highlighted in red boxes. D) The position of these two Arg amino acids in relation to 
the pseudokinase domain of NOK is shown in the cartoon of the full length protein. 
The Myc tag is depicted by the yellow box, and the pseudokinase domain in green. For 
reference the residue numbers corresponding to the domain boundaries are noted 
above the protein. 
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5.8 Evaluating putative NOK nuclear localization sequences 
The importance of the two conserved Arg residues (R377 and R379) for 
NOK subcellular localization in the nuclear envelope was determined by 
immunofluorescence analysis of the point mutants NOK R377A and NOK R379A. 
The localization of HCMV Glycoprotein B to the inner nuclear membrane was 
prevented upon mutation of either of the Arg residues corresponding to NOK 
uncharged Ala residues (Meyer and Radsak, 2000). However, following 
immunofluorescence analysis of the corresponding NOK single point mutants 
(Figure 5.10 A and B), no localization change was observed compared to WT 
(Figure 5.10 C), with the fluorescent signal still detectable around the nuclear 
envelope and the perinuclear region of the Tet-treated cells. Consistently, there was 
no signal observed in the Tet-negative cells. To evaluate the effects of mutating both 
amino acids, doubly-mutated NOK was generated and expressed. As shown in 
Figure 5.11, this double mutant does display a different localization pattern when 
compared to NOK WT, NOK R377A and NOK R379A single point mutants and 
colocalization with the inner nuclear membrane marker Lamin B1 was abolished 
(Figure 5.11 A). Doubly mutated NOK, on the other hand was not observed in 
endosome-like structures and did not colocalize with Lamin B1 (Figure 5.11 B). No 
signal was detected in the cells that were not treated with Tet. The altered 
localisation indicated that the motif in which these residues occur (and that is also 
conserved in the EGFR family of tyrosine kinases), is important for the subcellular 
localisation of NOK. 
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Figure 5.10 Single point mutations to the putative nuclear membrane localisation 
sequence do not alter NOK localisation HeLa Flp-In T-REx cells overexpressing either 
A) NOK R377A. B) NOK R379A or C) NOK WT were fixed in 3.7% PFA. A-C i) DAPI 
stained nuclei. A-C ii) Primary antibody recognises the Myc epitope and the secondary 
antibody was raised against murine proteins and conjugated to a Cy3 fluorophore. A-C iii) 
Merged image of i and ii.   
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Figure 5.11 The localisation of doubly mutated NOK R377A R379A is altered 
compared to WT. A and B) HeLa Flp-In T-Rex cells were transfected with WT Myc-NOK 
whilst C and D) expressed the double mutant  Myc-NOK R377A R379A. A-D i) Nuclei were 
stained with DAPI. A-D ii) The nuclear membrane of the cells was observed by a Lamin B1 
antibody and the FITC conjugated secondary. A-D iii) The Myc epitope of Myc-tagged NOK 
was stained with an anti-Myc antibody and Cy3 fluorophore secondary. A-D iv) Merged 
image of i, ii and iii. A and C) Cells were treated with Tetracycline 
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5.9 A point mutation to the conserved 3 lysine of NOK reduces 
the level of phosphorylated ERK1/2 in cells 
It was first reported in 2001 that nuclear localized EGFR was a functional 
transcription factor that associated with the promoter region of the cyclin D1 gene 
(Lin et al., 2001). Since then nuclear EGFR has also been shown to bind the 
promoter regions of several genes including BCRP, Aurora A and iNOS (Brand et 
al., 2011). To determine the role that NOK plays following its trafficking to the 
nuclear membrane, it was important to assess whether the pseudokinase domain has 
the ability to be catalytically active. 
To determine whether the catalytic domain of NOK might be functionally 
important, the levels of phosphoERK1/2 (active ERK1/2) were analysed following 
overexpression of either NOK, NOK K147M (the ‘catalytic’ lysine analogous to 
Trib2 K90 or PKA K72 mutated to an uncharged residue), or NOK G269D L270F (a 
NOK double mutation termed NOK DFG-in, which reinstates the canonical Mg
2+
 ion 
binding residue and the Phe residue completing the DFG motif). Previous analysis of 
ERK 1/2 phosphorylation showed that the levels correlated with the level of 
overexpression of NOK (Li et al., 2009). However, the level of phosphorylated 
ERK1/2 detected in lysates overexpressing NOK or NOK DFG-in mutant resembled 
the levels observed in the uninduced cell lysates. Lysates that contained NOK 
K147M however, had a reduced level of ERK1/2 phosphorylation, compared to 
NOK and NOK DFG expressing and uninduced lysates.  The levels of total ERK1/2, 
and alpha-tubulin, which was used as a total protein loading control, were very 
similar (Figure 5.12), suggesting that NOK might generate an intracellular signal that 
impinges on ERK activation. 
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Figure 5.12 The levels of phosphoERK are reduced in cells overexpressing NOK 
K147M mutant. HeLa Flp-In T-REx cell lysates containing overexpressed NOK WT, 
K147M and DFG and minus Tet control lysates were resolved by SDS-PAGE. The 
protein was transferred to membrane by western blot and was probed with an αMyc 
antibody (top panel) and Myc-NOK is annotated with an arrow, αpERK 1/2 antibody 
(third panel), α total ERK 1/2 (bottom panel) and α alpha tubulin (bottom panel).  
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5.10 Lack of evidence for in vitro NOK ATP binding or 
autophosphorylation 
In addition to a cellular analysis of NOK, its biochemical functions were also 
examined in vitro using partially-purified recombinant proteins. The potential for 
NOK to demonstrate some (low) kinase activity is high, especially given recent 
findings with related tyrosine kinases such as HER3 and the minor deviations from 
the classical motifs commonly present in active kinases. For example, both Trib2 
(see Chapters 3 and 4) and CASK (Mukherjee et al., 2008) are pseudokinases that 
bind to ATP and autophosphorylate, despite lacking the magnesium coordinating 
Asp residue in the DFG motif canonically observed in kinases. NOK is an example 
of another pseudokinase which lacks this motif but it has not yet been determined 
whether NOK can bind to ATP and if so, whether it is important for its cellular 
function. To determine whether the NOK pseudokinase domain could hydrolyse 
ATP in vitro, I employed biochemical assays that had previously demonstrated the 
catalytic functionality of the pseudokinase Trib2. These studies were performed on a 
NOK transmembrane domain (NOK 98-422) recombinant protein expressed in 
eukaryotic Sf9 cells, and the WT NOK TM pseudokinase was analysed alongside 
two mutant NOK proteins designed to prevent ATP binding (K147M) or re-instate 
activity (DFG-in). 
His-tagged NOK 98-422, NOK K147M 98-422 and NOK DFG-in 98-422 
were affinity purified from Sf9 cell lysates. NOK K147M is the mutation of a lysine 
in the 3 sheet of NOK. This Lys side chain in canonical kinases interacts with the 
phosphates of ATP as it points into the binding pocket (Taylor and Kornev, 2010). 
Upon overexpression of this mutant in HeLa Flp-In T-REx cells, the level of 
phosphorylated ERK 1/2 decreased (Figure 5.12), suggesting that ATP binding 
might be relevant in the cellular environment to NOK signaling. NOK DFG (NOK 
G269D L270F) is a mutant in which the metal binding motif observed in canonical 
kinases has been ‘reinstated’ in an effort to induce metal-ion binding and NOK 
hyperactivation. The residues N-terminal to 98 were not included because the 
presence of the hydrophobic transmembrane domain was predicted to decrease the 
protein solubility, potentially preventing analysis of the kinase under standard assay 
conditions. 
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Following IMAC purification of NOK and NOK mutants, Coomassie 
staining revealed that NOK WT and K147M (along with multiple higher MW 
protein contaminants) had been eluted from the TALON resin, but that NOK DFG-in 
was undetectable (Figure 5.13 A). The eluted fractions were pooled together (Figure 
5.13 B).  The yield of soluble NOK was approximately double that of K147M, 
determined by visual analysis of the Coomassie stained gel, and verified by dye-
binding spectrophotometry.  
The low amount of NOK obtained following IMAC (both K147M and, 
especially, DFG-in) prevented further purification of these preparations, because a 
large amount of each protein was required for comparative biochemical analysis. 
Non-radioactive kinases assays were therefore performed on ~1 g (~30 pmoles) of 
partially purified NOK or NOK K147M in the presence of 1 mM ATP, and either the 
absence of a divalent cation, or the presence of 10 mM Mg
2+,
 or 10 mM Mn
2+
 ions 
for 30 minutes.  Autophosphorylation was assessed by measuring the levels of 
phosphotyrosine (a very specific antibody is commercially available) present in 
NOK by western blot analysis (Figure 5.14 A). Changes to NOK phosphotyrosine 
levels were analysed as a potential marker for autophosphorylation, since the 
catalytic motif of NOK is similar to that of other bona fide tyrosine kinases and 
pseudokinases such as HER3, which are known to autophosphorylate in vitro and 
can be readily detected with this antibody (Figure 5.2).  
In the assays, the amount of His-tagged NOK or His tagged NOK K147M 
was comparable, however to obtain 1 g of NOK K147M, double the amount of 
partially purified preparation was assayed when compared to WT. The amount of 
phosphotyrosine present in both WT and K147M NOK is similar under all 
conditions, even when ATP was absent, which suggests that under these conditions, 
NOK is unlikely to be catalytically active. At higher apparent molecular weights, 
when both ATP and magnesium are present, the levels of phosphorylated tyrosine 
detected was higher for K147M; this was probably due to higher levels of 
background kinases present in this purified preparation compared to that from WT 
assays. 
Similarly, when NOK was assayed with 1 mM 
32
P-ATP labeled in the 
gamma position (~2.2 μCi  [32P]-ATP per assay) (Figure 5.14 B), only K147M was 
detectably phosphorylated, with the highest level of phosphorylation observed when 
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Mg
2+
 ions were added to the reaction mixture.  This was also observed for much 
higher MW proteins present in the preparation, and suggests that NOK K147M 
phosphorylation was caused by non-specific kinase contaminants, which again 
would have formed a larger proportion of the reaction mixture for K147M NOK than 
in the WT assays.  
To try to overcome this issue, and eliminate eukaryotic kinase contamination, 
NOK was next expressed in the same bacterial cell strain used to analyse Trib2 and 
Trib3 (BL21DE3pLysS, Chapter 3).  In order to maximize protein expression, the 
conditions following induction of protein synthesis by IPTG were partially 
optimised. The amount of protein following induction of both His tagged NOK 
(pET-30) and GST-His tagged NOK (pET-41) at either 37°C for 3 hours or 18°C for 
18 hours was determined by Coomassie staining (Figure 5.15). The expressed NOK 
proteins either had the full C terminal domain (98-422), a 7 residue (98-415) C 
terminal domain deletion, which removed an ‘autoinhibitory’ Y residue (417) that 
reduced activation of ERK, STAT1 and STAT3 (Li et al., 2007), or was the NOK 
pseudokinase domain minus the C-terminal tail (NOK 98-400). Whole cell extracts 
of E. coli transformed with NOK were analysed after induction to determine the 
optimal conditions that expressed the most protein prior to purification. Coomassie 
staining of SDS-PAGE resolved extracts indicated that the plasmid construct which 
expressed the greatest amount of NOK was pET-30Ek/LIC (6-His-tagged NOK ~37 
kDa) and the optimum incubation conditions post-IPTG induction were 37°C culture 
for 3 hours. Despite determining the optimum expression conditions of NOK in E. 
coli, it has not been possible to obtain a soluble yield of NOK following lysis and 
IMAC sufficient for in vitro kinase assay analysis, although nanogram amounts of 
NOK can be purified for analysis by western blotting. 
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Figure 5.13 Affinity purification of Sf9-expressed human NOK Following the elution of 
NOK from Sf9 cell lysate A) fractions containing either NOK K147M, WT or DFG were 
resolved by SDS-PAGE and the proteins visualised by Coomassie staining. B) The 
fractions were pooled and dialysed and were subjected to gel electrophoresis along with 4 
g BSA. Following coomassie staining, the Sf9 NOK proteins are visible ~ 37 kDa.
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Figure 5.14 Sf9 expressed NOK proteins do not specifically autophosphorylate A) 
Approximately, 1 μg WT or K147M NOK was assayed in the presence of 1 mM ATP and 
either in the absence or presence of 10 mM MgCl2 or MnCl2 for 30 minutes at 30 °C. 
The level of phosphotyrosine determined by anti-phosphotyrosine was used to identify 
whether NOK was capable of autophosphorylation and A341 lysate was used as an 
anti-phosphotyrosine control. Protein levels were determined by the detected His-signal 
and the His-tagged Mps1 loaded to control for the antibody. B) The assay was repeated 
using radiolabelled 1 mM ATP (~2.2μCi P
32
 per assay). The protein was stained and 
subjected to autoradiography. 
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Figure 5.15 Optimising recombinant NOK expression in E. coli His tagged NOK 98-
400, 98-415 and 98-422 were expressed following the addition of IPTG for either 3 
hours at 37 °C (A) or 18 hours at 18 °C (B). Whole cell protein expression levels were 
compared by coomassie staining the protein following SDS-PAGE analysis of 20 l of 
each sample alongside 4 g BSA.  
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5.11  Discussion 
NOK is a pseudokinase that does not have a conventional DFG motif in any 
of the vertebrate species in which it has been shown to be expressed at the mRNA 
level. Despite similar loss of this motif in the Trib2 and CASK pseudokinase 
domains, both of these proteins have demonstrated the ability to autophosphorylate 
and bind ATP, although this is independent of metal ions (Chapters 3 and 4). It is 
currently unproven whether NOK can bind to ATP, or transfer the gamma phosphate 
to a substrate or itself (e.g. autophosphorylate). A published in vitro kinase assay that 
employed immunoprecipitated NOK to demonstrate autophosphorylation, did not 
experimentally control for the presence of contaminating kinases (Chen et al., 
2005b), although as discussed in Chapter 4, the kinases BUBR1, ILK and Titin were 
previously reported to be catalytically active (based on kinase assay analysis in vitro) 
but it has been subsequently shown, in each of these cases, that they are in fact 
devoid of catalytic activity, with phosphorylation in an in vitro assay being driven by 
a contaminating kinase(s) (Suijkerbuijk et al., 2012, Wickstrom et al., 2010, 
Bogomolovas et al., 2014).  Data presented in this Chapter confirms that partially 
purified NOK is contaminated by at least one, but potentially more, tyrosine kinase 
activities, and it will be interesting to analyze these binding partners more closely, 
especially if they are active members of the EGFR receptor (see below), whose 
activities can easily be inhibited using a panel of tyrosine kinase inhibitors. 
Other features of the NOK pseudokinase domain include sequences within 
the catalytic motif (HxDxAARN) that classifies it as a relative of the tyrosine kinase 
division of protein kinases (Kannan et al., 2007) and a predicted single pass 
transmembrane domain located towards the N terminus of the polypeptide. This 
groups NOK within the Receptor Protein Tyrosine Kinase (RPTK) subfamily, and 
places it as part of a small sub-family of PTK pseudokinases (Lemmon and 
Schlessinger, 2010). Despite the characterization of NOK as an RPTK, it only has 25 
residues N-terminal to the TM domain, which are predicted to be located outside the 
cell. However, no known ligand binding domain is present amongst these residues, 
which have little similarity to other extracellular domains when analyzed by 
bioinformatics BLAST searching. It will be interesting to evaluate the effects of 
deletion of these residues in a cell-based system. Generally, most RPTKs that 
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contain ligand binding ectodomains transduce an extracellular signal across the cell 
membrane into the cytoplasm (Lemmon and Schlessinger, 2010), suggesting that 
NOK might either aid in this process (similar to HER3 pseudokinase and other 
EGFR family members), or fulfill a currently unknown role in signaling. 
NOK has been implicated in various signaling pathways when 
overexpressed, including the PI3K and MAPK pathways (Chen et al., 2005b, Liu et 
al., 2004). Additionally, when NOK was overexpressed in HeLa cells, the level of 
phosphorylated GSK3Ser9 was reported to increase, with phosphorylation at this 
residue inhibiting the tumor suppressive behavior of GSK3 along with increased 
Thr 308 phosphorylation (the ‘PDK1 site’) in AKT, which is a physiological 
upstream GSK3 kinase (Li et al., 2012). A tyrosine residue has also been identified 
in the C-terminal tail of NOK that inhibited the phosphorylation of ERK, STAT1 
and regulated cellular proliferation. When this residue was mutated to a non-
phosphorylatable form (Y417F), the levels of phosphorylated ERK, phosphorylated 
STAT1 and the cellular proliferation of Y417F NOK expressing cells increased (Li 
et al., 2007). 
As its name suggests, high expression of NOK (Novel Oncogene with Kinase 
domain) has been implicated in a variety of cancers and a multitude of studies have 
identified increased levels of NOK mRNA expression in samples, and increased 
NOK mRNA expression could even be detected in early clinical stages of NSCLC 
(Amachika et al., 2007), suggesting some prognostic power for analyzing NOK. 
Increased NOK mRNA expression was also discovered in breast tumor samples, 
where the expression was 6 times higher than in control samples. This study also 
observed that following transfection of NOK targeting siRNA into the breast cancer 
cell line T47D, which was the highest NOK mRNA expressing breast cancer cell line 
tested, growth was inhibited by 50% compared to the controls (Moriai et al., 2006). 
Cell growth was also attenuated in NOK shRNA expressing prostate cancer cells 
(Chung et al., 2009) and NOK mRNA was significantly higher in 80% of leukemia 
patients tested. Following various chemotherapy treatments, the mRNA in all the 
patient samples reduced and following siRNA treatment of K562 cells, growth was 
inhibited by 58% (Kondoh et al., 2009). Immunohistochemical stained ovarian 
tissues showed that the level of NOK expression correlated to the severity of the 
illness. The cells that were most highly stained, and had the highest NOK expression 
 257 
 
were the most malignant, whilst benign tissue stained moderately, and for normal 
tissue, minimal staining was observed (Jackson et al., 2009).  Despite the reported 
link between NOK expression and the development of cancer, the function of NOK 
protein in cells remains very poorly understood. The results presented in this Chapter 
have demonstrated that NOK localizes to the nuclear membrane and shares features 
of the tripartite NLS signal sequence conserved throughout the EGFR family of 
RPTKs and the INM-targeted protein RNF13. Mutations to two amino acids in 
NOK, namely R377 and R379, which align with functionally important Arg residues 
in the localization sequences of Glycoprotein B, EGFR and RNF13, block the 
translocation of NOK to the nuclear membrane. The movement of NOK towards the 
nuclear membrane occurs potentially via an endosomal pathway, where NOK has 
previously been identified to reside along with EGFR (Ding et al., 2012), and 
staining resembled the endosomal staining observed for RNF13, which is also 
trafficked to the nuclear membrane via an endosomal pathway (Bocock et al., 2010, 
Bocock et al., 2011). When NOK co-localized with EGFR in endosomes (Ding et 
al., 2012), no nuclear membrane localization was reported and the speculated fate of 
endosomal EGFR was reported as either recycling back towards the cell membrane 
or trafficking for degradation (Ding et al., 2012). EGFR can also be transported to 
the nucleus in endosomes. During this transportation it remains membrane associated 
because of its transmembrane domain (Wang and Hung, 2012). Interestingly, when 
the transmembrane domain of NOK was removed, the co-localization of NOK with 
the early endosomal marker (EEA) was abrogated (Ding et al., 2012). Lipid-
embedded EGFR interacts with importin and is integrated into the inner nuclear 
membrane (INM). Whilst embedded in the INM it interacts with INM-localized 
Sec61β, which facilitates translocation into the nucleus (Wang et al., 2010). Another 
example of an RPTK pseudokinase that is translocated to the nucleus is PTK7, 
which unlike EGFR, has the transmembrane domain sequence cleaved by -secretase 
prior to nuclear entry (Na et al., 2012). A similar mechanism is also observed for the 
nuclear incorporation of ErbB4, which has a conserved EGFR-like NLS sequence, 
but a different trafficking mechanism (Williams et al., 2004). If NOK was cleaved 
like ErbB4, then the N-terminal Myc tagged transmembrane domain would remain 
embedded in the inner nuclear membrane whilst the released pseudokinase domain 
entered the nucleus undetected by immunofluorescence microscopy. However, by 
studying C-terminal FLAG tagged NOK, the staining resembled Myc tagged NOK, 
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indicating that the protein was unlikely to be cleaved and the peptide remained 
embedded in the inner nuclear membrane, and was not translocated into the nucleus. 
Interestingly the COSMIC database (Catalogue of Somatic Mutations In 
Cancer version 68) contains a reported cancer-associated NOK mutation at R377Q in 
a single large intestine carcinoma sample.  However a mutant at this position 
(R377A) stably overexpressed in HeLa cells did not alter the localization of Myc 
tagged NOK. Instead, a doubly mutated protein, NOK R377A R379A was required 
to alter the observed localization. The majority of NOK mutations listed in the 
COSMIC database have only been observed in one tumor sample, and are therefore 
likely to be very rare, or random mutation events. There are however, four residues 
that are mutated more than once, and all of these are located towards the C-terminus 
of the protein: G313E/V, L316F/P, R336C/H, R411K/T. None of these mutations are 
found in any of the conserved kinase domain motifs that define pseudokinases, 
although both G313E/V and L316F/P are predicted to be located in the relatively 
hydrophobic F helix, which anchors the catalytic and regulatory spines of kinase 
catalytic domains (Taylor and Kornev, 2011). It is therefore interesting to speculate 
that these mutations might affect the overall structural conformation of NOK. L316F 
has been identified in a glioma tumor sample, whilst L316P has been identified in 3 
large intestine carcinomas, and it will be interesting to analyse the localization and 
function of these mutants in cell signaling models. 
Nuclear EGFR can act as a co-transcription factor, where it regulates the 
cyclin D1 promoter (Lin et al., 2001), Aurora A (Hung et al., 2008), c-Myc 
(Jaganathan et al., 2011), iNOS (Lo et al., 2005), B-Myb (Hanada et al., 2006) and 
COX2 (Lo et al., 2010, Brand et al., 2013). Nuclear EGFR has demonstrated the 
ability to increase the stability of PCNA by phosphorylating PCNA Tyr211, 
therefore increasing cell proliferation. Also, EGFR assists the reparation of DNA-
double stand breaks caused by radiation therapy by interacting with DNA-PK and all 
these function together to enhance oncogenic proliferation and led to an increased 
patient mortality with implications in cisplatin treatment, treatment with anti-EGFR 
compounds and radiation resistance (Brand et al., 2013).  Interestingly, following 
treatment of breast cancer cell lines with tamoxifen and raloxifen, NOK mRNA 
expression increased (Kimbro et al., 2008), which raises the interesting possibility 
that NOK could be important in drug resistance in cancers.  
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To determine if small molecule kinase domain targeted therapies could be 
useful for the treatment of NOK overexpressing cancers, the function of the NOK 
ATP binding domain needs to be determined. The majority of the literature focusing 
on NOK mainly reports the NOK mRNA expression levels in different cancers or the 
influence that the overexpression of NOK has upon signaling pathways. One 
example of how the presence of NOK affects a cell signaling pathway is observed 
when NOK binds to AKT, which increases the phosphorylation of AKT Thr308, 
which in turn increases the level of the Ser9 phosphorylated form of GSK3, 
potentially inactivating the tumor suppressing function of this kinase. However, it is 
unclear whether NOK acts catalytically, or as a protein scaffold, perhaps bringing 
GSK3 and AKT into closer proximity (Li et al., 2012). One indication that ATP 
binding by the pseudokinase domain of NOK might be important for its proliferative 
actions was demonstrated by the transfection of 22Rv1 cells (a prostate cancer cell 
line) with either a vector that contained NOK or a vector that contained NOK 
K147R, which like K14M described in this Chapter, represents a subtle mutation to 
the lysine located in the VAIK motif of the N-lobe 3 sheet designed to block ATP 
binding. In canonical kinases this lysine interacts with the ATP - and - phosphates 
and often forms part of the catalytic ‘triad’ stabilizing ATP for hydrolysis.  The 
effects upon proliferation by NOK or NOK K147R overexpression in 22Rv1 cells 
were determined by MTT analysis 48 hours after transfection. Whilst proliferation of 
the NOK overexpressing cells was significantly increased compared to the mock 
transfection control, the cells overexpressing NOK K147R did not demonstrate any 
cell proliferation enhancement (Chung et al., 2009). In partial agreement with this 
finding, overexpression of NOK K147M in HeLa Flp-In T-REx cells reduced the 
levels of phosphorylated ERK 1/2 in cells grown in serum (Figure 5.12) whilst the 
phosphorylation was not altered in the presence of exogenous WT NOK or DFG 
NOK when compared alongside controls. Indeed, there was no observed decrease in 
the levels of phosphorylated ERK 1/2 in the HeLa Flp-In T-REx K147M uninduced 
lysate, indicating that the reduction observed in K147M expressing lysates could be 
an effect of a dominant-negative mutation, potentially suggesting that the integrity of 
the ATP domain is relevant for NOK downstream signalling.   
Finally, two potentially interesting tyrosine residues, Y327 and Y356, are 
located C-terminal to the NOK pseudokinase domain and are conserved in many 
RPTKs including FGFR, PDGFR, Met, Tie1 and Tek. FGFR1 Y701 (corresponding 
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to NOK Y327) and FGFR1 Y724 (NOK Y356) are required for the activation of 
FRS2-mediated ERK pathway amongst others (Chen et al., 2005b), although it has 
been suggested that FGFR1 Y701 is not a phosphorylation site (Foehr et al., 2001). 
Stable BaF3 cells expressing an erythropoietin receptor/NOK hybrid protein 
(EPOR/NOK), or cells that expressed EPOR/NOK Y327F, or EPOR/NOK Y356F 
were analysed for S-phase progression by assessing 
3
H Thymidine incorporation in 
starvation conditions.  The replication of BaF3 cells expressing EPOR/NOK doubled 
after one day of incubation whereas the proliferation of EPOR/NOK Y327F or 
EPOR/NOK Y356F were reduced and comparable with the proliferation rates of 
BaF3 untransfected cells, or BaF3 cells transfected with a control plasmid.  In a 
colony formation assay in soft agar supplemented with starved culture medium, the 
BaF3 cells that expressed EPOR/NOK Y327F or Y356 demonstrated dramatically 
reduced anchorage independent growth capabilities compared to WT EPOR/NOK. 
Nude mice transfected with cells expressing EPOR/NOK showed substantial 
evidence of tumorigenesis and metastasis, with subjects developing enlarged spleens 
and livers as well as evidence of metastatic growth in the liver, kidneys, lungs, 
skeletal muscle and intestines of test subjects. All the metastatic growth stained 
positive for NOK by immunohistochemistry. However, for EPOR/NOK Y327F or 
EPOR/NOK Y356F expressing mice, there was no evidence of metastasis. Despite 
using EPOR/NOK constructs, the results were not dependent upon erythropoietin 
stimulation and the results for EPOR/NOK were consistent with NOK 
overexpressing cells (Chen et al., 2005b).  The results indicated that the two tyrosine 
residues are essential for NOK mediated tumorigenesis. In the same study, it was 
reported that EPOR/NOK increased the levels of phosphorylated ERK, 
phosphorylated AKT and activated STAT5, whilst mutations to the conserved 
tyrosine residues reduced the levels of all these, but it is unknown how these residues 
affect the activation of the downstream pathways; whether NOK acts as a scaffold 
and these tyrosines are docking sites for other signaling proteins or whether they are 
autophosphorylation substrates has yet to be determined (Chen et al., 2005b).   
In this Chapter, I have begun to investigate whether NOK can 
autophosphorylate in vitro after affinity purification from TM Sf9 NOK-expressing 
cell lysates. Autoradiography demonstrates that, surprisingly, the NOK K147M 
mutant incorporated radioactive phosphate from ATP during the assay, however 
contaminating kinases or their substrates was more than likely the cause of this, since 
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the signals were much more intense for Sf9 K147M, and because these assays 
probably contained an increased amount of co-purifying kinase activity when 
compared to WT-NOK. Other groups have published data suggesting that NOK is 
catalytically active (Chen et al., 2005a, Chung et al., 2009). However, they do not 
control for the possibility that the detected signals could be caused by other kinases 
and do not support their data with a NOK mutant that has a reduced ability to 
autophosphorylate, as might be predicted for K147M NOK based on my experience 
with Trib2 and Trib3. For example, it was suggested that recombinant NOK 
phosphorylated a 15 kDa substrate found in 22Rv1 whole cell lysate, although no 
kinase-dead control or loading control was present, and in the control assay which 
contained lysate alone (but did not include recombinant NOK), there was a faint 
band observed at the same MW as the implied ‘NOK substrate’ (Chung et al., 2009).  
Although no signal was observed for Sf9-expressed WT NOK 
autophosphorylation (Figure 5.14), it is not possible to rule out that it is catalytically 
inactive. Indeed, HER3 is a distinct, but NOK-related pseudokinase that has an Asn 
instead of the catalytic Asp in the catalytic motif. It was recently demonstrated that 
HER3 possesses a weak catalytic activity, abrogated by mutation of K723 (the 
residue corresponding to NOK K147), equivalent to approximately 1/1000
th
 the 
specific activity of EGFR (Shi et al., 2010). However, this activity was only 
observed when the intracellular domains of HER3 were artificially clustered onto 
vesicle surfaces by the attachment of nitrilotriacetate-Ni head groups to the lipids. 
These interacted with the His-tag at the N-terminus of the intracellular domain of 
HER3.  Without the clustering no autophosphorylation was apparent (Shi et al., 
2010), and so this approach might be tested using purified NOK in the future.  
It is not known whether NOK can bind to ATP or other ligands. DSF analysis 
has not yet been performed upon recombinant NOK, and had time permitted it would 
have been very interesting to identify whether pure preparations of NOK could bind 
to ATP, thus helping determine whether the ATP binding site of NOK is potentially 
targetable with small molecules.  In Chapter 4, I found that the ATP binding site of 
Trib2 is potentially druggable. If the ATP binding site of NOK is also accessible by 
ATP or analogues, then it would be crucial to observe the cellular effects of NOK 
inhibition by analysis of the downstream signaling pathways such as the MAPK and 
AKT pathways and also analyze the proliferation and transformation capabilities of 
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NOK following therapeutic treatment. It would also be interesting to see if this 
inhibition altered the trafficking of NOK and its cellular localization. Together this 
would reveal whether NOK, which has already demonstrated potential clinical 
relevance as a biomarker linked to the severity of ovarian cancers (Jackson et al., 
2009), might be a novel drug target in some cancers. 
5.12 Conclusion 
Preliminary research discussed in this Chapter, alongside a body of published 
data, has demonstrated that NOK has the properties of an inactive pseudokinase. 
However, as demonstrated by another RPTK pseudokinase HER3, this does not 
definitively mean that it cannot autophosphorylate and performing in vitro kinase 
assays upon recombinant NOK clustered in lipid vesicles could highlight any 
autophosphorylation potential. This work highlights the problems associated with 
performing in vitro kinase assays upon pseudokinases when the correct controls are 
not in place, and it will be important to obtain HER3 kinase as a positive control in 
the future. To determine the accessibility of the NOK pseudokinase domain by ATP 
analogues and therapeutics, it is imperative to employ a ligand binding assay such as 
DSF, which has already proved to be extremely useful in identifying other 
pseudokinases that can bind to ATP, such as Trib2, SgK495 (in Chapter 4), HER3 
(Littlefield et al., 2014, Davis et al., 2011), the JAK pseudokinase domains (Murphy 
et al., 2014b) and the very poorly understood pseudokinase SgK071, which binds to 
ATP but has no known biological function (Murphy et al., 2014b).  
The identification of NOK as a nuclear membrane targeted protein is 
consistent with the presence of a transmembrane domain, and of particular interest 
considering the oncogenic potential that NOK overexpressing cells demonstrate. It is 
perhaps suggestive that it may function as a regulatory partner of other nuclear 
envelope-targeted kinases, perhaps including active kinases such as other members 
of the EGFR family (Lemmon and Schlessinger, 2010). There have been many 
examples of nuclear localized RPTKs that are overexpressed in cancers including 
EGFR (Brand et al., 2011, Brand et al., 2013). It is also important to identify 
whether after NOK translocation to the inner nuclear membrane, it is transported into 
the nucleus, possibly by Sec61, as observed for EGFR (Wang et al., 2010) with 
which it shares the tripartite NLS, even though my current analysis suggests that 
NOK remains embedded in the nuclear envelope. Another novel therapeutic 
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approach for targeting NOK, if the ATP binding site proves not to be suitable for 
small molecule inhibition, would be to identify whether preventing nuclear 
membrane localization affects the transforming and metastatic phenotypes displayed 
by NOK overexpressed cells previously reported (Liu et al., 2004, Chen et al., 
2005b, Chung et al., 2009, Li et al., 2007, Moriai et al., 2006).  
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CHAPTER 6. Future Directions 
The work presented in this Thesis proves that Trib2 has maintained sufficient 
integrity in the pseudokinase domain to facilitate ATP binding and enzymatic 
incorporation of the -phosphate into a protein substrate, Trib2 itself. This behavior 
can be altered by mutation to key residues located throughout the catalytic domain. 
Not only can Trib2 bind to ATP, but the ability of Trib2 to bind to ATP and 
autophosphorylate is severely reduced in the presence of the divalent cations 
magnesium and manganese. This demonstrates that ATP binding by Trib2 occurs via 
a different mechanism than utilized by canonical kinases, which require magnesium 
ions to stabilize the negatively charged ATP in the binding pocket (Nagar, 2007). 
This presents an opportunity that could enable ATP analogues to potentially bind in 
a way that differs to the binding mode in other kinase domains, which could 
minimize off-target effects across the >500 member human kinome. 
ATP binding by Trib2 has, so far, only been determined for bacterial 
recombinant Trib2, and to gain further insight into the function of Trib2 ATP 
binding, the affinity of Trib2 for ATP in a cellular environment needs to be 
examined.  In this thesis, a putative correlation was observed between the ATP 
binding properties of recombinant Trib2, and the expressed levels of induced Trib2 
and Trib2 mutants in human cell lines. The K90M mutant, which had a reduced 
ability to bind to ATP and autophosphorylate in vitro was expressed at a 
significantly lower level in HeLa Flp-In T-REx cells, potentially indicating that 
Trib2 stability and/or turnover in cells is regulated by ATP binding, but this 
suggestion requires further investigation.  
In the future, analysis of Trib2 behavior in neurons and brain tissue would be 
very interesting because compared to other tissues, the level of ‘free’ (not 
coordinated to Mg
2+
) ATP is reported to be relatively high (Taylor et al., 1991). The 
brain (or any cell type where ATP levels are high) could therefore be a potential 
biological site that favors Trib2 autophosphorylation (or phosphorylation of a 
substrate yet to be identified). Intriguingly, analysis of Oncomine data revealed that a 
variety of brain tissue tumours contained highly overexpressed Trib2 mRNA. 
Previous Trib2 analysis has identified that the catalytic domain is important 
for the oncogenicity of Trib2 overexpressing cells, with the complete catalytic 
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domain as well as the COP1 binding domain being a requirement for the  
degradation of the transcription factor C/EBP(Keeshan et al., 2010). A mutation to 
K177 in the Trib2 catalytic motif (K177R) reduced C/EBP degradation and the 
ability of overexpressing colonies to serially replate in comparison to WT (Keeshan 
et al., 2010). Recombinant Trib2 K177A, in which the Lys is changed to an 
uncharged Ala, exhibits a much lower level of autophosphorylation compared to 
WT, and resembles the activity of K90M Trib2. However, whether this is because 
the ability of Trib2 to bind to ATP has been reduced by the mutation, or because the 
mutation impedes the catalytic phospho-transfer remains to be investigated, and DSF 
would be a very useful tool for this. It would also be very interesting to observe the 
levels of C/EBP degradation and the transforming capabilities of cells that 
overexpress Trib2 K90M, which cannot detectably bind to ATP when analysed by 
DSF in vitro. 
In addition, the development of ‘knock-in’ Trib2 mutant mice, especially 
those containing alterations to the critical ATP binding residues, could assist in the 
elucidation of ATP-dependent Trib2 mediated phenotypes in a multicellular 
organism. In addition, a developing technique is the CRISPR/Cas9 system adapted 
from bacteria, which permits genomes with engineered gene insertions to be created 
relatively simply (Wang et al., 2013a) and would allow for the expression of Trib2 
mutated genes. This technique operates by generating specific breaks in the DNA 
using Cas9, which is guided by short RNA sequences that target the region of DNA 
to be mutated. Following this, the donor template (e.g. mutant Trib2 gene flanked by 
long arms of homologous DNA) is homologously recombined into this specific site 
(Rong et al., 2014, Ran et al., 2013, Auer et al., 2014, Hsu et al., 2014). 
Furthermore, this technique also facilitates the deletion of multiple genes 
simultaneously, which would allow for a combination of Trib2, Trib3 and Trib1 
knockout cells or mice to be generated for further analysis of Trib-mediated 
phenotypes (Wang et al., 2013a). 
Further analysis of the ATP binding site in cells could be performed, not by a 
loss-of-function mutation but by targeting the ATP binding site with a small 
molecule modulator/inhibitor, and I have demonstrated in this thesis that the Trib2 
ATP site is accessible to both ATP and inhibitors.  Non-enzymatic assay approaches 
such as DSF, which was adapted for Trib2 analysis in this study, will be crucial for 
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this process. A panel of inhibitors could be tested against Trib2 in a 96-well format 
and binding ‘hits’ isolated for further study. By treating either a cancer model in 
which Trib2 expression causes a phenotype, or by using my Trib2-inducible cell 
lines and intracellular Trib2 ligands, it might be possible to identify phenotypic 
changes caused specifically by binding to Trib2 rather than other kinases present in 
the cells.  
To negate the problem of off-target inhibitory effects that will probably be 
observed when the cells are treated with pan-kinase inhibitors, further manipulation 
of the gatekeeper residue could also be performed with the aim of obtaining an 
analogue sensitive mutant that retains the level of WT catalytic activity, which is 
unfortunately lost when the Trib2 gatekeeper residue is mutated to a Gly or Ala. One 
potential mutation that could be used is F130C, followed by a DSF based screen of 
electrophilic small molecules.  
Structural analysis of Trib2 bound to an inhibitor or ATP would be a very 
insightful, and essential, next step to determine the mechanism of Mg
2+
 independent 
ATP binding. X-ray crystallography and NMR spectroscopy would be obvious 
interesting techniques to use for this. In particular, NMR performed using my 
15
N-
labelled Trib2 preparations (Figure 3.27) would facilitate the analysis of protein 
dynamics in solution so the individual residues that move in relation to ligand 
binding could be ascertained and novel inhibitors modeled to the structure, perhaps 
without crystal artifacts.  
Even if the low levels of Trib2 catalytic activity observed in vitro are not a 
requirement for Trib2 mediated degradation of C/EBP by COP1, binding of an 
inhibitor could prevent the degradation complex from forming, which relies upon the 
presence of the catalytic domain and could still be a potential therapeutic targeting 
site. However, it will be important to carefully analyze whether ligand binding to 
Trib2 inadvertently increases the degradation of C/EBP by allosterically 
stimulating COP1 activity, which would not be a goal for the development of Trib2 
ligands as anti-cancer agents. 
Future analysis of NOK should initially clarify whether the pseudokinase 
domain is catalytically competent to hydrolyze ATP, whether it can solely bind to 
ATP, or neither of these functions. In vitro kinase assays and DSF should be 
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performed in tandem upon pure preparations of NOK and NOK kinase domain 
mutants, including NOK K147M, which when overexpressed, reduced the levels of 
phosphorylated ERK1/2.  
The function of NOK translocation to the nuclear membrane also needs to be 
determined. The stimuli that triggers this trafficking, along with interacting 
substrates at the INM are still unknown, however, previous co-localization with 
EGFR in vesicles has been reported (Ding et al., 2012), indicating they could 
potentially dimerise and NOK could be involved with activation of different 
HER/EGFR members.  
NOK overexpression has been widely reported in the literature, but its 
function is less clear. Following elucidation of its catalytic capabilities and function 
at the INM, it will be important to ascertain whether NOK is a suitable therapeutic 
target. If NOK does bind to ATP then disrupting the binding with an inhibitor and 
analyzing any changes to cell signaling pathways, including the MAPK and AKT 
pathways, would help to indicate if NOK mediated activity had been altered. If NOK 
does not detectably bind to ATP, then another target that could be potentially 
adapted therapeutically is its localization and it would be interesting to observe any 
phenotypic changes that occur when NOK localization is altered, for instance the 
two Arg residues that have been identified in this thesis disrupt the observed nuclear 
membrane association when mutated, but how this affects overall cell signaling 
profile has yet to be ascertained.  
As discussed above, CRISPR/Cas9 technology could be used to engineer a 
variety of Trib2 mutant knock in, or gene deletion situations in mice (or human cell 
lines (Jinek et al., 2013)) and this same procedure could be adapted to NOK quite 
simply, with the only changes required being to the targeting RNA sequences to 
make them specific to the genomic NOK location and to the donor gene insert. This 
could provide information of phenotypes at the level of a multicellular organism 
caused by mutations to the NOK catalytic domain or by altering the NOK cellular 
localization. 
 In this thesis, I have shown that Trib2 is catalytically active in vitro, and that 
NOK localizes to the inner nuclear membrane. However the downstream effects of 
these activities and targeting events have yet to be determined for either protein and 
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further analysis will hopefully reveal whether these cancer-implicated pseudokinases 
could be developed into novel therapeutic targets in the future. 
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Appendix 
 
Table A 
Carcinoma 
Total number of 
samples 
Number 
containing 
mutant Trib2 
Percentage of 
mutated 
samples (%) 
Amino acid 
mutation and 
position 
Endometrium 505 8 1.58 
F129L  
R148I  
R179W  
E222* 
V237M 
R251W 
R286Q 
R291W 
Large intestine 781 10 1.28 
R31K 
E186K 
D211N 
D211N 
R251W 
R286*, 
R290H, 
V314I, 
V332I 
E336D 
Stomach 81 1 1.23 S299L 
Oesophagus 261 2 0.77 
L224V 
F314L 
Skin 334 2 0.60 
P69L 
R142C 
Lung 1397 8 0.57 
G44V 
V58L 
G62E 
S139F 
S227I 
H255R 
L289V 
S313C 
Urinary tract 366 1 0.27 V249M 
Breast 1210 3 0.25 
E150K 
G250E 
R286Q 
Kidney 804 2 0.25 
M334I 
P340R 
Pancreas 905 2 0.22 
K63R, 
R286Q 
Haematopoietic 
and Lymphoid 
1325 1 0.08 S36N 
Table A Analysis of somatic Trib2 mutants identified in the COSMIC database. 
Missense and nonsense somatic Trib2 mutants are listed in the table along with the 
cancerous tissue in which they were identified, the number of samples analysed and the 
percentage of samples that contained a mutated variant of Trib2. The red font highlights the 
residues discussed in section 1.27.  
